

# 2014 - 2015

## Annual Report

70 YEARS



**QIMR Berghofer**  
Medical Research Institute





**QIMR Berghofer**  
Medical Research Institute

# ANNUAL REPORT 2014 - 2015

# TABLE OF CONTENTS

Letter of compliance	2
Research highlights	3
Awards and achievements	5
Message from our patron	6
Chair's report	7
Director's report	8
Our organisation	9
Our governance	10
Our people	19
Our performance	25
Our support	28
Our research achievements	30
Compliance	57
Financial statements	58
Supporting information	96
Awards	96
Invited lectures	98
Patents	113
Grants and funding	115
QIMR Berghofer Fellows	125
Scientific publications	126
Compliance checklist	167
Glossary/Acronyms	169

# LETTER OF COMPLIANCE



**QIMR Berghofer**  
Medical Research Institute

1 September 2015

The Honourable Cameron Dick MP  
Minister for Health and Ambulance Services  
Parliament House  
Brisbane QLD 4000

Dear Minister

I am pleased to present the Annual Report 2014-15 and financial statements for the Council of the Queensland Institute of Medical Research (trading as QIMR Berghofer Medical Research Institute).

I certify that this Annual Report complies with:

- the prescribed requirements of the *Financial Accountability Act 2009* and the *Financial and Performance Management Standard 2009*, and
- the detailed requirements set out in the *Annual report requirements for Queensland Government agencies*.


A checklist outlining the annual reporting requirements can be found on the final pages of this Annual Report or accessed at our website:

[www.qimrberghofer.edu.au/annualreport](http://www.qimrberghofer.edu.au/annualreport)

Yours sincerely

Dr Douglas McTaggart  
Chair  
The Council of the Queensland Institute of Medical Research

300 Herston Road, Herston Q 4006 Australia | QIMR Locked Bag 2000, Royal Brisbane Hospital, Q 4029  
T (617) 3362 0222 F (617) 3362 0111 W [www.qimr.edu.au](http://www.qimr.edu.au)




# RESEARCH HIGHLIGHTS

## CANCER

- Found a new treatment approach that could offer hope to patients with the aggressive blood cancer, acute myeloid leukaemia (AML).
- Completed a Phase I clinical trial for experimental immunotherapy treatment for aggressive brain cancer.
- Changed international practice for the treatment of leukaemia patients undergoing bone marrow transplants through Phase I and II clinical trials.
- Identified a way to prevent bone marrow transplant patients from suffering serious complications.
- Found new markers for melanoma which may allow the disease to be accurately monitored via a routine blood test.
- Determined that sudden 'chromosomal catastrophes' may trigger a third of oesophageal tumours, the fastest rising cancer in Australia.
- Determined more people die from thin melanomas (less than one millimetre) than thick melanomas (greater than four millimetres).
- Used an experimental drug produced from the seeds of a rainforest plant to cure solid cancer tumours in pre-clinical studies.
- Determined that some anti-inflammatory drugs have the potential to prevent squamous cell carcinoma.
- Determined how a single DNA variant increases a woman's risk of developing breast cancer.
- Found that women in rural and remote areas of Australia have a higher risk of dying from ovarian cancer than those in richer, urban areas.
- Discovered a novel family of toxins in the venom of box jellyfish, opening the door for further investigation into the use of the venom in the treatment of cancers.



Professor Geoff Hill (second from left) and Dr Jeannette Young at G20 announcing new bone marrow treatment practices for leukaemia patients.



Dr Steven Lane and cancer biologist Claudia Bruedigam, from QIMR Berghofer's Translational Leukaemia Research Laboratory have found a new treatment approach that could offer hope to patients with the aggressive blood cancer acute myeloid leukaemia (AML).

# INFECTIOUS DISEASES

- Collaborated with the CSIRO on developing a breath test to diagnose malaria.
- Commenced a pre-clinical study of a genetic treatment to permanently suppress HIV.
- Developed a unique methodology for conducting clinical trials for the treatment of malaria.
- Conducted research into the Asian Tiger Mosquito in QIMR Berghofer's state-of-the-art insectary.
- Tested more than 2000 patient samples from Timor L'este for intestinal parasites.

# MENTAL HEALTH AND OTHER COMPLEX DISORDERS

- Developed a method to predict developmental outcomes for pre-term babies.
- Comprehensively mapped the connections in the healthy elderly brain, laying the groundwork for new research into Alzheimer's disease and dementia.
- Identified genes associated with the most common form of glaucoma, the world's leading cause of irreversible blindness.
- Identified five genetic variants that influence the size of structures within the brain.
- Commenced using cutting-edge imaging and information technology to develop a diagnostic test for major depressive disorders.
- Found that hypoglycaemia significantly increases the risk of cardiovascular disease and death in diabetic patients.
- Commenced a two-year trial of a rheumatoid arthritis medication to treat asthma.



Dr Manuel Ferreira and a trial participant at the announcement of new asthma treatment clinical trials.

# AWARDS AND ACHIEVEMENTS

- Announced full ownership of the clinical trial facility, Q-Pharm.
- Six QIMR Berghofer scientists were elected Fellows of the Australian Academy of Health and Medical Sciences. Professors Frank Gannon, Geoff Hill, Rajiv Khanna, Mark Smyth, Nick Martin and Adele Green were inducted into the Academy.
- QIMR Berghofer and QUT entered a collaboration between the organisations. Under the agreement, QUT has access to specialist health and medical research facilities at QIMR Berghofer.
- Dr Andrea Schuessler won the Australian Society for Medical Research Postdoctoral award.
- QIMR Berghofer was granted approval by the Therapeutic Goods Administration (TGA) to manufacture cellular therapies for human use, opening the way for clinical trials of new cancer treatments.
- Professor Nick Martin was elected a Fellow of the American Association for the Advancement of Science (AAAS).
- Senior Scientist Professor Geoff Hill was awarded the Translational Research Institute (TRI) National Prize for research improving health outcomes for patients.
- QIMR Berghofer entered into a major research collaboration with Medicines for Malaria Venture on behalf of the Bill & Melinda Gates Foundation to develop the Human Challenge Malaria Model.



QIMR Berghofer Director and CEO Professor Frank Gannon and QUT Vice-Chancellor Professor Peter Coaldrake sign an MOU at a ceremony at BIO Philadelphia with witnesses including Queensland Premier, the Hon Anastacia Palaszczuk.



Professors Mark Smyth, Rajiv Khanna, Geoff Hill, Frank Gannon and Nick Martin at their induction to the Australian Academy of Health and Medical Sciences in Canberra, March 2015.

# MESSAGE FROM OUR PATRON



GOVERNMENT HOUSE  
QUEENSLAND

## Message from the Governor of Queensland for the QIMR Berghofer Medical Research Institute Annual Report

As Governor of Queensland, Patron of the QIMR Berghofer Medical Research Institute, and former Chair of the QIMR Council, I congratulate the Institute on its 70th anniversary in 2015.

The Institute continues to build on its reputation as a world-renowned medical research hub dedicated to improving the health of communities in Queensland, and much further afield.

While “research” is rightly prominent in the Institute’s title, the organisation’s activities extend to collaborations and alliances with other distinguished institutions, patents, clinical trials and commercialisation. To borrow QIMR Berghofer’s own words, the Institute is committed to taking the research “from the laboratory bench to the hospital bedside”.

The Institute’s achievements in the year under review are a prime illustration of its commitment to that admirable mission.

These include, but are by no means limited to, advances that promise better and more targeted prevention, diagnosis, monitoring and treatment of serious conditions ranging from aggressive breast, ovarian, skin and pancreatic cancers to asthma.

These are outcomes that will affect directly, and for the better, the lives of individuals everywhere. I thank the QIMR Council, the CEO and his highly skilled research and support teams for their dedication and hard work over the past year.

The work of the more than 600 personnel at QIMR Berghofer would not be possible without generous support from governments and from all those organisations and individuals whose time, energy and philanthropy have provided the resources needed for QIMR Berghofer’s work.

As Governor and Patron, I thank all concerned for their roles in supporting the Institute’s impressive work program and achievements over the past twelve months, and in further strengthening the foundations for continued success as this outstanding Queensland institution enters its eighth decade.

A handwritten signature in black ink, reading "Paul de Jersey".

His Excellency the Honourable Paul de Jersey AC  
Governor of Queensland



# CHAIR'S REPORT

It is a great privilege and pleasure to provide my first report as Chairman of QIMR Berghofer as this iconic Queensland institution enters its 70th year of improving health through medical research. From humble beginnings, QIMR Berghofer is now a major medical research institute by world standards and has established an international reputation for research excellence and extraordinary research achievements.

The Institute's work in infectious diseases—the original purpose for which it was established—continues apace. Malaria continues to be a key target for our researchers, who are testing anti-malarial medicines in healthy volunteers. This is important work as this preventable and curable disease kills more than half a million people every year, most of them children.

QIMR Berghofer has also cemented its place as a global leader in the fight against cancer. From a new treatment approach for acute myeloid leukaemia, to cutting-edge work in cancer immunotherapy, and an antibody that could fight an aggressive brain cancer, the Institute's world-class research brings hope for those suffering terrible diseases.

Mental health and complex disorders are growing areas of focus for the Institute. Our scientists are collaborating with colleagues around Australia and overseas to develop diagnostic tools for dementia and major depressive orders. We are researching debilitating illnesses such as asthma and anorexia nervosa. As always, the Institute's research agenda is driven by the needs of the community.

QIMR Berghofer has a unique capability to take its world-leading research findings from the laboratory into medical practice. In the past year the Institute took full ownership of the co-located clinical trial facility Q-Pharm, increasing its stake from the previous 24.5 per cent which will enable even greater opportunities for translation of the Institute's research into the clinic.

Our impressive campus and the research it accommodates have been made possible by the generosity of our many supporters.



Two of these have been honoured in the past year. Legendary American philanthropist Charles 'Chuck' Feeney was awarded Research Australia's Great Australian Philanthropy Award and Toowoomba businessman Clive Berghofer was a finalist for Queensland Senior Australian of the Year. Both are shining examples of the 'giving while you're living' movement making the world a better place by providing great support for medical research.

And while both Mr Feeney's and Mr Berghofer's significant contributions have allowed the Institute to become the organisation it is today, we must thank our legion of donors, event volunteers and supporters who help our researchers do the work that means so much to the wider community and the world. Our supporters are so very vital to our research and are evidence that all contributions, great or small, make a big difference in making our research happen.

**Dr Douglas McTaggart**

**Chair of the Council of the Queensland Institute of Medical Research (QIMR Berghofer)**

# DIRECTOR'S REPORT

QIMR Berghofer's 70th anniversary provides an opportunity not just to reflect on our past, but also on how far we have come. It is without doubt an exciting time at the Institute, which is on the cusp of a new era of discoveries, and opportunities to turn them into therapies and diagnostic tools which will help patients. Our research is producing outcomes which have consequences beyond the laboratory, and we have made great advances in our 'research with consequences' in the past year.

QIMR Berghofer has invested in research and biotechnology facilities to help take discoveries through clinical trials and into clinics. In the past year, the Institute has wholly acquired Q-Pharm Pty Ltd, a clinical trials centre with expertise in first-time-in-human studies. At time of writing 50 trials were underway at Q-Pharm and in collaborating hospitals. Our initial goal was to be engaged in up to 40 trials within five years. It is satisfying to know that we have already exceeded that goal, with many of these clinical trials coming from our own research. Our aim is to increase the number of trials that come from our laboratories while maintaining a high overall involvement in external trials.

The Institute's Q-Gen manufacturing facility gained regulatory approval from the TGA to prepare clinical grade T cell therapies — the first in Australia to do so. The landmark announcement at the Bio International Convention in Philadelphia highlighted QIMR Berghofer as a global leader in the emerging field of immunotherapy. The approval enables the Institute to initiate new clinical trials of innovative cancer therapies.

The 2014 G20 Leaders' Summit in Brisbane also placed QIMR Berghofer on the world stage. Professor Geoff Hill was invited to announce successful clinical trials changing international practice for the treatment of leukaemia patients undergoing bone marrow transplants. The Institute's scientists presented their research at the parallel event, Brisbane Global Café, where I was privileged to co-chair sessions on improving world health for the international audience.



The quality of QIMR Berghofer's research program continues to be recognised by the NHMRC in a very competitive funding environment. Our scientists had a 20 per cent success rate in the latest round of grant applications compared to the national average of 14 per cent. This challenging environment is likely to continue.

The unswerving loyalty of our supporters ensures our scientists are able to proceed with research which would otherwise be delayed or shelved. Chief among them is Toowoomba businessman Clive Berghofer, whose generosity provides a foundation for important and deserving projects that will make a difference to the health of Queenslanders, Australians and people around the world. We are truly grateful to all donors, fundraisers, volunteers and many others who help QIMR Berghofer in so many ways.

**Professor Frank Gannon**

**Director and CEO of QIMR Berghofer**

# OUR ORGANISATION



## ROLE AND MAIN FUNCTION

QIMR Berghofer was established under the *Queensland Institute of Medical Research Act 1945* for the purpose of research into any branch or branches of medical science.

QIMR Berghofer is a world-leading medical research institute. The Institute's research focuses on three areas: cancer; infectious diseases; and mental health/complex disorders. Working in close collaboration with clinicians and other research institutes, our aim is to improve health by developing prevention strategies, new diagnostics and better treatments.

## OPERATING ENVIRONMENT

QIMR Berghofer has demonstrated its ongoing commitment to its role and main focus as defined by the Queensland Institute of Medical Research Act 1945: 'research into any branch or branches of medical science'. Carrying out research into many of the world's most debilitating diseases, many of which impact Queenslanders, QIMR Berghofer has stayed true to its core vision of better health through medical research since the Institute's inception 70 years ago.

QIMR Berghofer is home to more than 600 scientists, students and support staff across six research departments (in over 50 separate laboratories) and a support division.

The Institute supports scientists who perform world-class medical research aimed at improving the health and wellbeing of all people.

Located on the RBWH campus at Herston, Brisbane, QIMR Berghofer's close proximity to the major teaching hospital and the University of Queensland (UQ) Medical School, UQ School of Population Health and Queensland University of Technology, ensures the Institute is ideally placed for clinical research collaborations.



# OUR GOVERNANCE

## COUNCIL PURPOSE AND MEMBERSHIP

In accordance with Part 2, Section 4A of the *Queensland Institute of Medical Research Act 1945*, QIMR Berghofer is controlled and governed by The Council of the Queensland Institute of Medical Research (The Council). Under the Statutory Bodies Financial Arrangements Act 1982, the Council is a statutory body.

## FUNCTIONS OF THE COUNCIL

Under the Act, the functions of the Council of the Queensland Institute of Medical Research are to:

- control and manage the Institute
- raise and accept monies for the purposes of the Institute
- invest monies raised or accepted by the Council for the purposes of the Institute
- invest monies derived from any property or other invested monies of the Council for the purposes of the Institute.

## MEMBERSHIP OF THE COUNCIL

The Council consists of at least seven members, but not more than 11 members, appointed by the Governor in Council.

Under the QIMR Act the Minister for Health is to recommend persons to be appointed as members of the Council. The Minister may have regard to the skills, experience and expertise of a person in any of the following areas:

- corporate governance
- public or academic administration
- health or clinical research
- health ethics
- financial management
- fundraising
- any other area the Minister considers to be relevant to the functions of the Council.

# MEMBERS OF COUNCIL

## Dr Douglas McTaggart

BEC (Hons) (ANU) MA PhD (Chicago) Hon DUniv (QUT) FAICD FAIM

Dr McTaggart was appointed Chair of Council on 27 November 2014.

Dr McTaggart brings strong leadership to the Council, having held various senior positions on industry bodies and public interest groups.

He is a director of the Suncorp Group and Chairman of the Audit Committee, a director of UGL Limited and a member of both the Queensland Council, Australian Institute of Company Directors and the Australian National University Council. In March 2012 he was appointed to the Queensland Government Independent Commission of Audit and Chairman of the Public Service Commission, retiring in 2015. He is a member of the Prime Minister's Expert Advisory Panel for the White Paper on Reform of the Federation and has also served in other advisory roles to government as well as holding positions on, including chairing, various industry representative bodies.

Dr McTaggart has broad experience in financial markets and funds management. He was Chief Executive of QIC Limited for 14 years until his retirement in June 2012. Prior to joining QIC, he was the Under Treasurer and Under Secretary of the Queensland Department of Treasury and had a distinguished academic career as Professor of Economics and Associate Dean at Bond University.

Dr McTaggart also chairs the QIMR Berghofer Investment Committee, the Executive Employment and Remuneration Committee and the Commercialisation Committee and is a member of the Finance and Audit Committee.

## Mr Christopher Coyne

Mr Coyne is Deputy Chair of Council.

Mr Coyne is a solicitor of the Supreme Court of Queensland and an accredited specialist in the field of commercial litigation, specialising in insurance law, health law, corporate governance and risk management. Following his admission as a solicitor in 1979 he practised law in Brisbane and was a partner in the national law firm Clayton Utz from 1984 to 2004.

Mr Coyne now practices on his own account. He is a member of the Council of the Queensland Law Society. Mr Coyne is a director of Lexon Insurance Pty Ltd (Queensland Law Society, Singapore Captive Insurer), a director of the Incorporated Council of Law Reporting for the State of Queensland, past president of the Medico-Legal Society of Queensland and Australian Insurance Law Association and former legal member of the Australian Health Ethics Committee.

Mr Coyne is a member of the QIMR Berghofer Executive Employment and Remuneration Committee and a director of the Q-Pharm Pty Ltd Board (a wholly owned subsidiary of QIMR Berghofer).

## Associate Professor Paula Marilton

MB BS (Hons I) FRACP FRCPA

Associate Professor Marilton is the Head of Leukaemia and Lymphoma Services at the Princess Alexandra Hospital where she is also Deputy Director of Haematology. Her previous appointments include three years at the MD Anderson Cancer Centre in Houston, Texas. She has extensive experience in clinical research, including the role of principal investigator for national multi-centre trials and supervisor of molecular translational research associated with trials. She was the founding Chair of the Australasian Leukaemia and Lymphoma Group (ALLG) Laboratory Science Committee and has established and continues to direct the ALLG Tissue Bank. Her other professional roles include medical advisor and board member of the Leukaemia Foundation, member of government and college advisory committees and several drug advisory boards, as well as a wide range of academic and clinical service roles.

Associate Professor Marilton is a member of the QIMR Berghofer Appointments and Promotions Committee.

## Dr Jeannette Young

PSM MBBS MBA FRACMA FFPH FCHSM (Hon)

Dr Young has been the Chief Health Officer of Queensland since 2005. Previously she worked in a range of positions in hospitals in Queensland and Sydney. She has specialist qualifications as a Fellow of the Royal Australasian College of Medical Administrators and as a Fellow by Distinction of the Faculty of Public Health of the Royal College of Physicians of the United Kingdom. She is an adjunct professor in the Centre for Environment and Population Health at Griffith University and an adjunct professor in the School of Public Health and Social Work at QUT.

Her role includes responsibility for health disaster planning and response; aero-medical retrieval services; licensing of private hospitals and schools of anatomy; and policy regarding research; organ and tissue donation; blood, poisons and medicines; cancer screening; communicable diseases; environmental health; preventive health; and medical workforce planning and leadership.

Dr Young is a member of numerous state and national committees and boards including the NHMRC, the Australian Health Protection Principal Committee, the Jurisdictional Blood Committee, the Organ and Tissue Jurisdictional Advisory Committee, the National Screening Committee and the Queensland Clinical Senate.

Dr Young is a member of the QIMR Berghofer Commercialisation Committee and was a director of the Q-Pharm Pty Ltd Board until 20 March 2015.

## Professor Alan Pettigrew

BSc (Hons) PhD FAICD

Professor Pettigrew is a Fellow of the Australian Institute of Company Directors. He has held senior academic and executive appointments at the Universities of Sydney, Queensland and New South Wales. He was Vice Chancellor and CEO of the University of New England from 2006 to 2009. From 2001 to 2005 Professor Pettigrew was the inaugural CEO of the National Health and Medical Research Council (NHMRC) of Australia.

Professor Pettigrew has served on many Government and other committees, including an advisory committee for the Australian Law Reform Commission (2003-04), the Board of the Australian Universities Quality Agency (AUQA) Ltd (2006-10) and the Cooperative Research Centres Committee (2010-15).

Professor Pettigrew is currently an adjunct professor at the Australian National University and a professorial fellow of the L.H. Martin Institute at the University of Melbourne. He is Chair of the Board of the Western Australian Data Linkage Infrastructure Project, and Chair of the Board of the Illawarra Health and Medical Research Institute. Professor Pettigrew has served as a consultant on projects supported by the World Bank and the OECD, as well as advising on leadership, management and research at a range of Australian universities.

Professor Pettigrew was appointed Chair of the QIMR Berghofer Appointments and Promotions Committee and a member of the Executive Employment and Remuneration Committee on 2 December 2014.

## Emeritus Professor John de Jersey *(from 27 November 2014)*

AM BSc (Hons 1) PhD

Professor de Jersey enjoyed a long career as an academic staff member of the University of Queensland, from 1971 until retirement in 2007. Prior to 1971 he gained his PhD from UQ and undertook research and teaching at the University of Sydney and the Pennsylvania State University. As well as maintaining an active research program funded largely by the Australian Research Council (ARC) and NHMRC, Professor de Jersey served as head of the Department of Biochemistry, head of the School of Molecular and Microbial Sciences and Deputy Dean of the Faculty of Biological and Chemical Sciences. In addition, he served for several years as a member of the UQ Senate elected by the Academic Board. He was actively involved in the Australian Society for Biochemistry and Molecular Biology for many years, serving as President of the Society in 2001-02, and was Secretary-General of the Federation of Asian and Oceanian Societies of Biochemistry and Molecular Biology from 2006-11.

Professor de Jersey has undertaken various research projects in protein chemistry and enzymology and currently is part of a team seeking to develop biotechnological uses for components of Australian snake venoms.

Emeritus Professor de Jersey was appointed a member of the QIMR Berghofer Appointments and Promotions Committee on 2 December 2014.

## Professor John Shine AO *(from 27 November 2014)*

BSc (Hons 1) PhD DSc (Honoris Causa) FAA

Professor Shine was Executive Director of the Garvan Institute of Medical Research from 1990 until the end of 2011 and is Professor of Medicine and Professor of Molecular Biology at the University of NSW and current Chairman of CSL Limited. He is a past Chairman of the NHMRC, past president of the Australian Genome Research Facility, and a Fellow of the Australian Academy of Science. He is an Officer in the Order of Australia and until 2011 was a member of the Prime Minister's Science, Engineering and Innovation Council. As well as Chairman of CSL, he is currently President of the Museum of Applied Arts and Science (Powerhouse Museum and Sydney Observatory).

Professor Shine obtained his PhD from the Australian National University in 1975. From 1975-78 at the University of California, San Francisco, Professor Shine was instrumental in the development of many of the techniques of genetic engineering. He was a central figure in the cloning of the insulin and growth hormone genes and was the first to clone a human gene. He also determined the first sequence responsible for replication of a cancer-causing virus.

In early 1984, Professor Shine was appointed Director of Research of a newly formed biotech company, California Biotechnology Inc. He was appointed President of the company in 1986 and guided it from a staff of some 15 scientists in 1984 to more than 200 in 1987.

In 2010, Professor Shine was awarded the Prime Minister's Prize for Science, the nation's highest scientific award.

Professor Shine is a member of the QIMR Berghofer Appointments and Promotions Committee and the Commercialisation Committee.

## Mr Ian Fraser

BComm FCA FAICD

Ian Fraser is a Chartered Accountant practising as a non-executive company director with more than 45 years' experience as a business and accounting professional, including 10 years as a company director of listed and unlisted public companies and 27 years as a partner with KPMG. He retired as an audit and corporate advisory partner in 2004.

Mr Fraser is Chairman of Asia Pacific Data Centre Trust, a publicly listed real estate investment trust.

Mr Fraser was appointed Chair of the QIMR Berghofer Finance and Audit Committee on 2 December 2014 and is a member of the QIMR Berghofer Investment Committee.

## Mr Michael Sargent *(from 27 November 2014)*

Mr Sargent is a Brisbane-based stockbroker and financial planner with more than 50 years experience with some of the world's leading financial groups.

He began his career with SGIO (now Suncorp), and continued with JB Were and Son, Hall Chadwick Chartered Accountants, the State Bank of South Australia and Wilson HTM, where he was responsible for setting up their money market and fixed interest operations.

Mr Sargent was the State Manager for ANZ Stockbroking and retired as Senior Client Advisor for Morgan Stanley Smith Barney where he oversaw investment in equities and fixed interest and other investment categories. His clients included superannuation funds, institutions and local and overseas private clients.

Mr Sargent was a Fellow of the Certified Practising Accountants (FCPA) and a Fellow of the Securities Institute of Australia (FSIA). He has been an active supporter of the community as a charter member of the Rotary Club of Brisbane-Mid City and Club President and Rotary District Treasurer, board member and former President of the Royal Automobile Club of Queensland, Chairman of RACQ Insurance Ltd and former State President and Australian Vice-President of the Securities Institute.

Mr Sargent is a member of the QIMR Berghofer Finance and Audit Committee, the Investment Committee and the Commercialisation Committee.

## Emeritus Professor Bryan Campbell *(to 26 November 2014)*

AM MD BS FRACP FRACMA

Emeritus Professor Campbell was formerly Chief Health Officer of Queensland and head of The University of Queensland Medical School.

He has been a councillor of the Royal Australasian College of Physicians, the Royal Australian College of Medical Administrators and a member of the NHMRC. He was Deputy Chair of the Australian Health Ethics Committee and a member of the NHMRC Embryo Research Licensing Committee until June 2006.

Until November 2014 Emeritus Professor Campbell was Chair of QIMR Berghofer Finance and Audit Committee and a member of QIMR Berghofer Executive Employment and Remuneration Committee.

Emeritus Professor Campbell retired on 26 November 2014 after 29 years as a member of the QIMR Berghofer Council.

## Distinguished Professor Judith Clements AC *(to 26 November 2014)*

BAppSc MAppSc PhD

Professor Clements has more than 20 years' experience in biomedical research, primarily in the general field of molecular endocrinology. Her areas of expertise include prostate, ovarian and breast cancer, as well as biomarkers for cancer progression, kallikrein proteases and new therapeutic targets.

She is currently Scientific Director of the Australian Prostate Cancer Research Centre Queensland within the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), at the Translational Research Institute on the Princess Alexandra Hospital Biomedical Precinct. She coordinates the Australian Prostate Cancer BioResource, a national tissue bank for prostate cancer research. She is also a NHMRC Principal Research Fellow. In 2007, Professor Clements was awarded the prestigious international Frey-Werle Foundation Gold Medal for her significant contributions to the kallikrein protease field. She was awarded the Queensland Women in Technology Biotech Outstanding Achievement Award for 2012 and the prestigious title of Distinguished Professor at QUT in 2013.

Professor Clements was appointed as a Companion of the Order of Australia in the 2015 Queen's Birthday Honours List for eminent service to the biological sciences and to education, through seminal contributions to improving the understanding of cancers, particularly prostate cancer, as an advocate for the development of biomedical research facilities, and to the training of scientists.

Until November 2014, Professor Clements was Chair of the QIMR Berghofer Appointments and Promotions Committee.

Professor Clements retired on 26 November 2014 after 12 years as a member of the QIMR Berghofer Council.

## Professor Nicholas Fisk *(to 26 November 2014)*

FAHMS MBBS PhD MBA FRANZCOG FRCOG DDU CMFM GAICD

Professor Fisk is Executive Dean of the Faculty of Medicine and Biomedical Sciences at The University of Queensland. He is a board member of the Metro North Hospital and Health Service and of Brisbane Diamantina Health Partners. He practices as a maternal-fetal medicine specialist at the Royal Brisbane and Women's Hospital, and leads a research group in The University of Queensland Centre for Clinical Research (UQCCR).

Between 1992 and 2007, he was Professor of Obstetrics and Fetal Medicine at Imperial College, London and Queen Charlotte's Hospital, London. His main research interests have been in monochorionic placentation and human fetal stem cell biology. He is a Fellow of the Academy of Health and Medical Sciences, a past President of the International Fetal Medicine and Surgery Society, and is a member of several editorial boards including PLoS Medicine.

Professor Fisk stepped down from Council on 26 November 2014.



## Mr Rodney Wylie *(to 26 November 2014)*

OBE BComm BA FCA FAICD

Rodney Wylie is a Brisbane-based chartered accountant with substantial experience in investment, company management and corporate governance across a wide range of organisations, in many cases with national and international activities.

He has been involved through board or council membership in the administration of a number of professional and community not-for-profit groups.

Until 26 November 2014, Mr Wylie chaired QIMR Berghofer's Investment Committee and remains an external member of QIMR Berghofer's Finance and Audit Committee.

Mr Wylie retired from the QIMR Berghofer Council on 26 November 2014.

## Dr John Herron AO *(from 27 November 2014 to 15 April 2015)*

MBBS FRCS FRCSE FRACS FAMA KCHSJ KSG DUniv (Honoris Causa) ACU

Dr Herron was a Senator in the Parliament of Australia for 12 years, including five years as Minister for Aboriginal and Torres Strait Islander Affairs and was Ambassador to Ireland and the Holy See from 2003 to 2005.

Prior to entering Parliament he was a general surgeon for 30 years.

Outside his surgical and political careers, he was an officer in The Royal Australian Army Medical Corps and a Squadron Leader in the Royal Australian Air Force.

He was the 2014 Dame Elisabeth Murdoch Orator for the Australian Drug Foundation and has been awarded the Bancroft Medal of the AMA (Queensland), the Justin Fleming Medal of the Australian Association of Surgeons, a Citation by the Royal Australasian College of Surgeons, the Humanitarian Overseas Service Medal for his work in Rwanda and the Australian Service Medal. He is a Knight Commander of the Holy Sepulchre of Jerusalem and a Papal Knight of St Gregory.

Dr Herron stepped down from Council on 15 April 2015.

## NUMBER OF MEETINGS

Attendance by Members of Council who held office during the 2014-15 financial year are as follows:

Appointed members	Meetings attended
Douglas McTaggart	5 of 5
Bryan Campbell	2 of 3
Judith Clements	2 of 3
Christopher Coyne	8 of 8
John de Jersey	4 of 5
Nicholas Fisk	1 of 3
Ian Fraser	8 of 8
John Herron	1 of 3
Paula Marlton	8 of 8
Alan Pettigrew	8 of 8
Michael Sargent	5 of 5
John Shine	4 of 5
Rodney Wylie	3 of 3
Jeannette Young	4 of 8
<b>Council Secretary</b> Donna Hancock	8 of 8

## REMUNERATION OF COUNCIL

The aggregate remuneration for Council for 2014-15 was \$21 123.

## COMMITTEES TO COUNCIL

### FINANCE AND AUDIT COMMITTEE

The role of the Finance and Audit Committee is to provide independent assurance and assistance to the Council on:

- risk, control and compliance frameworks;
- QIMR Berghofer's external accountability responsibilities as prescribed in the relevant legislation; and
- the appointment of the internal audit function and communications with internal and external auditors.

The Committee is directly responsible and accountable to Council for the exercise of its duties and responsibilities.

The Committee meets quarterly to review business and financial risk, financial operating performance and audit performance. The committee reviews all issues and recommendations arising from internal audit and the Queensland Audit Office, along with agreed management actions implemented to address any issues found.

The Finance and Audit Committee follows its terms of reference and has due regard to Queensland Treasury's *Audit Committee Guidelines*. The Finance and Audit Committee comprises:

- Emeritus Professor Bryan Campbell (*Chair to 26 November 2014*)
- Mr Ian Fraser (*Chair from 2 December 2014*)
- Dr Douglas McTaggart (*from 2 December 2014*)
- Dr John Herron (*2 December 2014 to 15 April 2015*)
- Mr Michael Sargent (*from 2 December 2014*)
- Mr Rodney Wylie (*External member from 2 December 2014*)

### APPOINTMENTS AND PROMOTIONS COMMITTEE

The Appointments and Promotions Committee assists Council with the maintenance of academic standards at QIMR Berghofer by reviewing proposals for the appointment and promotion of Faculty staff. The Committee comprises:

- Distinguished Professor Judith Clements (*Chair to 26 November 2014*)
- Professor Alan Pettigrew (*Chair from 2 December 2014*)
- Emeritus Professor John de Jersey (*from 2 December 2014*)
- Associate Professor Paula Marlton
- Professor John Shine (*from 2 December 2014*)
- Dr Tony Evans, Chairman  
Cancer Therapeutics CRC Pty Ltd
- Professor Joe Trapani, Executive Director Cancer Research, Peter MacCallum Cancer Centre
- Dr Joanne Aitken, Head of Research and Director of Cancer Registries, Cancer Council Queensland
- Professor Alan Cowman, Walter and Eliza Hall Institute of Medical Research
- Professor Bob Graham, Executive Director, Victor Chang Cardiac Research Institute
- Professor Andrew Grulich, The Kirby Institute
- Professor Frank Gannon (ex officio)

### INVESTMENT COMMITTEE

The Investment Committee is responsible for overseeing the investment of Council funds. Committee members are:

- Mr Rodney Wylie (*Chair to 26 November 2014*)
- Dr Douglas McTaggart (*Chair from 2 December 2014*)
- Mr Ian Fraser
- Mr Michael Sargent
- Mr John Allpass

## EXECUTIVE EMPLOYMENT AND REMUNERATION COMMITTEE

The Executive Employment and Remuneration Committee is responsible for reviewing the terms and conditions relating to the appointment and remuneration of senior management. The committee comprises:

- Emeritus Professor Bryan Campbell  
(*Chair to 26 November 2014*)
- Dr Douglas McTaggart (*Chair from 2 December 2014*)
- Mr Christopher Coyne (*from 2 December 2014*)
- Professor Alan Pettigrew (*from 2 December 2014*)

## COMMERCIALISATION COMMITTEE

The Commercialisation Committee advises the Council and management by providing expert opinion on innovation and potential commercialisation opportunities, and monitors progress of key projects. The Committee comprises:

- Dr Douglas McTaggart (Chair)
- Mr Michael Sargent
- Professor John Shine
- Dr Jeannette Young

## THE PHASE II AND III BUILDING PROJECT STEERING COMMITTEE

The Phase II and III Building Project Steering Committee, on behalf of Council, oversaw the completion of the QIMR Berghofer Central construction and the ongoing refurbishment of the Bancroft Centre. The members of the committee are:

- Professor Frank Gannon (Chair)
- Professor Greg Anderson (Deputy Director)
- Mr John Parnell (Project Manager)
- Professor Grant Ramm (Staff Association Representative)
- Ms Donna Hancock (Chief Operating Officer)
- Mr Chris Darbyshire (Project Director)
- Ms Susanne Behrendt (Chief Financial Officer)

## HUMAN RESEARCH ETHICS COMMITTEE

The Human Research Ethics Committee, on behalf of Council, ensures the maintenance of ethical standards in human research and compliance with regulatory guidelines. The Committee comprises:

- Dr Ian Wilkey (Chair)
- Dr Roger Allison
- Ms Madeline Brennan
- Ms Dominique Grigg
- Reverend Deacon Mick Jones
- Dr/Reverend Mervyn Lander
- Professor Barbara Leggett
- Mrs Mary Mackenzie
- Professor Robin Mortimer
- Dr Peter Roeser
- Mr David Russell
- Mr John Stead
- Dr Brett Stringer
- Associate Professor Katharine Trenholme
- Ms Donna Hancock (Advisor)

## ANIMAL ETHICS COMMITTEE

The Animal Ethics Committee, on behalf of Council, ensures the maintenance of ethical standards in animal research and compliance with regulatory guidelines in the use of animals in medical research.



## RISK MANAGEMENT

The review and management of risk at QIMR Berghofer is undertaken by QIMR Berghofer Council through the Finance and Audit Committee. QIMR Berghofer management maintains a register of potential risks applicable to functions of the Institute. A schedule of quarterly reviews incorporates the actions required to improve any identified gaps in controls. Refer to page 16 for members of the Finance and Audit Committee.

## AUDIT

Internal audit is a fundamental part of corporate governance that ensures that QIMR Berghofer operates effectively, efficiently and economically. The Finance and Audit Committee oversees the planning, performance and reporting of the internal auditor.

The role of internal audit is to provide independent, objective assurance and advice designed to assist QIMR Berghofer in accomplishing its objectives by bringing a systematic, disciplined approach to evaluating and improving the appropriateness and effectiveness of risk management and internal control.

The internal audit contractor (KPMG) met with the Finance and Audit Committee at each quarterly committee meeting.

The approach taken to identifying areas of significant risk combines a focus on both cyclical reviews of core business processes as well as reviews of key risk areas. KPMG's integrated governance, risk and controls framework builds on a traditional internal audit model to take a holistic view of QIMR Berghofer's key objectives, risks, controls and supporting structure across the organisation.

In formulating an internal audit plan for presentation to the Finance and Audit Committee for approval, consideration was given to past internal audit findings, recent and forthcoming changes in systems and processes, key business risks and the period since the last internal audit of each core business process. An annual internal audit plan was prepared and presented to the Finance and Audit Committee prior to the commencement of the financial year.

The internal audit function has observed the terms of its charter and has due regard to Queensland Treasury's *Audit Committee Guidelines*.

# OUR PEOPLE

## EXECUTIVE MANAGEMENT

### DIRECTOR AND CEO, PROFESSOR FRANK GANNON

Professor Frank Gannon is QIMR Berghofer's seventh Director and CEO. In this role he is responsible for the work undertaken by the Institute, management of employees and the development of the strategies of the Institute under the overall control of the Council. Professor Frank Gannon joined QIMR Berghofer as Director and CEO in January 2011. Previously, Professor Gannon was the Director General at the Science Foundation Ireland (SFI) from 2007.

From 1994-2007, Professor Gannon was the Executive Director of the European Molecular Biology Organisation (EMBO) and Senior Scientist at the European Molecular Biology Laboratory (EMBL) based in Germany; and Director of the National Diagnostic Centre and Associate Professor in the Department of Microbiology at University College Galway, Ireland (1981-1994).

He obtained a Bachelor of Science from the National University of Ireland, Galway in 1970; a PhD from the University of Leicester, England in 1973; was a post-doctoral fellow at the University of Madison Wisconsin, USA from 1973-1975; and Chargé de Recherche in INSERM at the University of Strasbourg, France from 1975-1981, after which he returned to Galway.

His major research interest is the expression and functional regulation of the oestrogen receptor, which plays a major role in breast and endometrial cancers. These studies have provided leads to novel treatments or therapeutic approaches to these and other cancers.

Professor Gannon has authored more than 200 research articles published in international journals. In addition, from 2000-2008, he contributed a monthly editorial to EMBO Reports of which he was founding Senior Editor. He also writes extensively on diverse topics related to science policy.

Professor Gannon has seven patent applications, four of which are active at present, and was the founder of both Bimini Ltd (1990) and Elara Pharmaceuticals (2006). He was a member of the interim Board of Science Foundation Ireland from 2002-2004 and was elected as a Member of Academia Europea in 2005, Royal Irish Academy in 2007, the Mexican Academy of Medicine in 2008 and The European Academy of Cancer Sciences in 2009. In 2012, Professor Gannon was appointed as a Queensland Academy of Arts and Science Fellow. In 2015, Professor Gannon was made a Fellow of the

Australian Academy of Health and Medical Sciences.


He has been awarded honorary Doctorates by the University of Jozsef Attila, Szeged (Hungary), UQ and Queens University Belfast (Northern Ireland).



He has served on a range of high-level scientific advisory boards at institutes in Norway, Poland, South Africa and Australia and was co-founder of the European Life Sciences Forum (ELSF) and the Initiative for Science Europe (ISE) that played significant roles in the establishment of the European Research Council (ERC).

He was Vice President of the European Heads of Research Council and an advisor to the European Union Commissioner for Research and Innovation prior to his move to Brisbane.

Professor Gannon is also currently serving as a board member of the Australian Association of Medical Research Institutes and is the Chair of Q-Pharm Pty Ltd.

# ORGANISATIONAL CHART





# WORKFORCE PLANNING, ATTRACTION AND RETENTION

Workforce planning initiatives at QIMR Berghofer include:

- Attracting students to medical research and a career at QIMR Berghofer through the Education and Higher Degrees Program;
- Supporting a culture of work/life balance to attract and retain employees;
- Maximising remuneration benefits for employees through highly effective salary packaging options; and,
- Providing childcare arrangements for early year childcare places.

While ongoing resource planning at QIMR Berghofer is challenging because of short-term funding cycles for research employees, QIMR Berghofer's Support Division has planned resourcing and staffing requirements to ensure growth in research staff is effectively supported into the future.

To meet QIMR Berghofer's strategic aim of attracting staff in the areas of molecular and cellular biology, cancer biology, infectious diseases, bioinformatics and systems biology, chemistry, population and clinical sciences, throughout 2014-15 the Institute has continued attracting interest from researchers (seeking employment in Brisbane) from over 30 different countries.

The majority of QIMR Berghofer staff are employed under the *QIMR Enterprise Agreement 2014*, which is complemented by a range of workforce policies that not only support the operation of the Enterprise Agreement and the achievement of strategic objectives, but foster a high performance culture.

## STAFFING

At 30 June 2015, QIMR Berghofer had 569 employees and 162 students. Seventy-two per cent of the Institute's employees are employed on fixed-term contracts as research funding relies on short-term grants.

Historically, QIMR Berghofer has maintained a low rate of voluntary staff turnover; for 2014-15 the voluntary separation rate was 10.35 per cent.

At 30 June 2015, QIMR Berghofer had 55 members of faculty with eight Senior Scientists, 27 Group Leaders and 20 Team Heads. The Institute's career development structure will support the ongoing development of the faculty towards 2019.



# REVIEW OF EQUAL OPPORTUNITIES

QIMR Berghofer has reviewed the guidelines endorsed by the Council of the Australian Academy of Science to ensure that women and men have equal opportunities to pursue a successful career in science.

## WOMEN AT QIMR BERGHOFER

Women play an important role at QIMR Berghofer with 62 per cent of the total workforce and 58 per cent of students being female. Women hold significant senior management roles, such as Chief Operating Officer, Chief Financial Officer, Genetics and Computational Biology Department Coordinator and Biology Department Coordinator. Women also have significant roles in the Support Division, such as Safety Manager, Regulatory Affairs Manager, Animal Facility Manager, and Flow Cytometry Manager.

At QIMR Berghofer:

- women hold 34 per cent of all scientific leadership positions
- 20 per cent of QIMR Berghofer Council is female
- 50 per cent of the Support Management Team is female; this includes the Chief Operating Officer, Chief Financial Officer, and Manager Council Business
- 50 per cent of newly appointed Team Heads are female

## FLEXIBLE WORKING POLICIES

QIMR Berghofer has flexible working hours, job-share and part-time employment options to help staff balance personal lives. Women account for the majority of the 16 per cent of staff with part-time arrangements, including job-share occupants.

## QIMR BERGHOFER CHILDCARE ASSISTANCE

QIMR Berghofer has secured a number of places with a local childcare centre for infants under two years of age to assist employees with young families.

## NURSING MOTHERS

Within the QIMR Berghofer Central building, the Institute has a room specifically designed to cater for nursing mothers.

# INDIGENOUS WORKFORCE DEVELOPMENT INITIATIVES AND HEALTH RESEARCH PROGRAM

During 2014-15, QIMR Berghofer's Aboriginal and Torres Strait Islander Health Research Program made significant advances across the target areas of workforce development, research and communication.

Reflecting the importance of community control, the program's governance model describes a role for internal and external input; namely, a committee of the Institute's lead researchers and an advisory group of experts from the health services, policy development and research sectors.

In addition to formal structures, the program seeks to engage the health services and research sector of regional Queensland. Specifically, consultation and discussion with experts from regional Queensland is undertaken with a view to engaging capable and responsible partners in the development of proposals to undertake research that impacts community-identified health concerns.

In the area of workforce development, QIMR Berghofer provided a paid traineeship to an Indigenous undergraduate biomedical student; recruited a PhD student to undertake seed research in the area of respiratory health; and facilitated a series of lectures and seminars for the Institute's research personnel.

In the area of communication, the Institute delivered lectures to two high schools in Cairns, and is looking to expand in 2015 to four schools in Far North Queensland. As part of The University of Queensland's *InspireU* Science Camps, the Institute supported 16 Indigenous high school students from across regional Queensland to travel to Brisbane to participate in our highly successful *Day in the Life of the Scientist* health science education initiative.

The Institute was a major supporter of Creating Futures 2015, an international gathering of Indigenous and non-Indigenous delegates from across the globe, meeting to discuss the priority needs for people from rural and remote areas in mental health and disability.

The Institute's research portfolio continues to grow, with activity across the scope of concept development and consultation, through to implementation and dissemination of research findings. Areas of current activity include mental health and physical activity; scabies; respiratory health and mosquito control. A significant proportion of the work of the Institute is highly relevant to Indigenous health, a fact evident in that nearly 30 per cent of our work aims to impact health conditions with higher prevalence rates among Indigenous people.

QIMR Berghofer, through its Aboriginal and Torres Strait Islander Health Research Program continues to demonstrate its commitment to improving the health of Indigenous Australians.



*InspireU* Science Camp students participating in QIMR Berghofer's *Day in the Life of the Scientist*.

# OUR PERFORMANCE

## GOVERNMENT OBJECTIVES FOR THE COMMUNITY

QIMR Berghofer aligns research and activities with the Queensland Government's objective of *Creating jobs for a diverse economy*. We directly contribute to the Queensland Government's objectives relating to a stronger public health system by translating the knowledge we produce and discoveries we make into improved clinical practice.

By advancing medical knowledge and improving public health, we also contribute to the Queensland Government's objective of building a safe, connected and caring community. Our work is helping to broaden and deepen Queensland's economic base, especially in the high-value, high-growth health and medical sector.

## STRATEGIC PLAN

QIMR Berghofer's strategic plan informs the Institute's vision to become a world leader in medically relevant research and to transfer this knowledge and understanding to the clinic; achieving better health for the wider community through medical research.

Each objective is supported by at least one of the Institute's values:

- Translation: Bringing research discoveries from the laboratory bench to the hospital bedside
- Scientific quality: Delivering high quality research aimed at preventing and curing disease throughout Queensland, Australia and the world

- Commercial consequence: Connecting with industry to boost health outcomes and economic benefits
- Societal impacts: Demonstrating the value of improving health and quality of life by addressing the major health needs of society
- International reputation: Attracting researchers, funding and collaborators from around the world to cement international recognition
- Community engagement: Engaging with the community about health issues affecting their well-being, through community education and fundraising programs.



Dr Bryan Day presenting at a QIMR Berghofer cancer public forum on cancer in 2014.



The Probus Club of Algester visiting the signal transduction lab as part of their tour of QIMR Berghofer in 2015.

## Increase knowledge and strengthen reputation for scientific excellence

PERFORMANCE MEASURES	OUTCOME
Increase the total number of publications by 5% annually.	In 2014, QIMR Berghofer researchers published 563 papers, a decrease of 9% on the 620 papers published in 2013.
Maintain a five-year growth rate of more than 15% for total citations	For the latest five-year period (2010-14) there were 104 593 citations. For the previous period (2009-13) there were 89 315 citations ( <i>source: Web of Science</i> ).
Increase by 10% annually the number of high impact papers with first or last author papers	QIMR Berghofer produced 35 high impact papers with first or last authors. In 2013, QIMR Berghofer produced 24 high impact papers with first or last authors.
The number of international lectures presented by QIMR Berghofer researchers to grow to 200 by 2019	In 2014-15, QIMR Berghofer researchers delivered 130 lectures at international conferences.
QIMR Berghofer to receive a minimum of five awards annually	In 2014-15, QIMR Berghofer researchers received awards including: <ul style="list-style-type: none"> <li>• Professor Geoff Hill received the TRI National Prize</li> <li>• Professor Adele Green was acknowledged as a Queensland Great</li> <li>• Dr Andrea Schuessler was awarded the Australian Society for Medical Research (ASMR) Postdoctoral Researcher award.</li> </ul>

## Attract and retain high quality researchers

PERFORMANCE MEASURES	OUTCOME
Increase the total number of faculty (senior scientists, group leaders and team heads) to 65 by 2018	Fifty-five members of faculty, with eight senior scientists, 27 group leaders and 20 team heads. The Institute's career development structure will support the ongoing development of the faculty towards 2018.
Increase the number of PhD students to 150 by 2018	At the end of 2014-15, QIMR Berghofer hosted 162 students (up from 143 in 2013-14), 103 of whom were studying for their PhD.

## Maintain a translational focus in research activities through clinical collaborations and clinical trials

PERFORMANCE MEASURES	OUTCOME
Increase the percentage of QIMR Berghofer researchers engaged in collaborations with clinicians to or above 60%	In 2014-15, 78% of QIMR Berghofer's researchers collaborated with clinicians.
Increase the number of active clinical trials to 40 in five years	In 2014-15, QIMR Berghofer started five new clinical trials, which are included in the 50 ongoing clinical trials coordinated by the Institute.

## Increase funding annually

PERFORMANCE MEASURES	OUTCOME
Increase NHMRC grant funding by 5% annually to 2018	In 2014-15, QIMR Berghofer received \$24.865 million from NHMRC for research grants.
Increase the number of successful NHMRC grant applications by 5% annually to 2018	In 2014, QIMR Berghofer secured 31 NHMRC grants. In 2013, QIMR Berghofer also secured 31 NHMRC grants.
Gain 50 fellowships in the five years to 2013-18	In 2014-15, QIMR Berghofer secured four fellowships with the NHMRC, which is a gain of 15 fellowships since 2013.
Sustain or increase the number of Career Development Awards and equivalent (2013-16)	In 2014, QIMR Berghofer was not awarded any Career Development Awards from the NHMRC. This is a decrease on the four gained in 2013.

## Increase engagement with the biotechnology sector

PERFORMANCE MEASURES	OUTCOME
Increase commercial income to \$3 million by 2018	In 2014-15, QIMR Berghofer generated \$3.459 million in commercial income.
Double the number of provisional patents by 2016	In 2014-15, QIMR Berghofer established five provisional patents, which is in addition to the six established in 2013-14.

## Inform and involve the community in research activities at QIMR Berghofer

PERFORMANCE MEASURES	OUTCOME
Sustain or increase the number of community speaking engagements, tour groups and school students who visit QIMR Berghofer's research facilities at Herston	QIMR Berghofer ran 49 tours with more than 1120 visitors. The Institute also hosted four public forums on topics including cancer and infectious diseases, with approximately 250 attendees. This is an increase of 20% in the total number of visitors in 2013-14.
Sustain or increase the number of community speaking engagements by QIMR Berghofer staff	The Institute conducted 54 speaking engagements to more than 2 845 attendees, which is an increase of 10% on the number of attendees in 2013-14.
Increase the number of high schools participating in the High School Lecture Series to 30 by 2018	QIMR Berghofer held four High School Lecture Series (including regional High School Lecture Series) in 2014-15. The Institute hosted to 21 schools and 760 students. This is an increase of 22% on the number of students attending in 2013-14.
Increase the number of schools that visit the Education Laboratory to 50 by 2018	QIMR Berghofer hosted 55 schools in the Education Laboratory in 2014-15. This was an increase of 37.5% on the number of schools attending in 2013-14.
Increase the number of students who visit the Education Laboratory to 1 000 by 2018	1 200 Year 11 and 12 science students participated in the <i>Day in the Life of a Scientist</i> program in the Education Laboratory in 2014-15. The Institute also placed 52 students in the lab work experience program. This was an increase of 23% on the number of students visiting the Education Laboratory in 2013-14.

# OUR SUPPORT

## SUPPORT DIVISION

Dedicated support staff in the areas of Scientific Services, External Relations, Human Resources, Finance and Administration and Research Support and Governance are committed to providing the high level of assistance and behind-the-scenes support required to keep QIMR Berghofer researchers at the forefront of medical research.

The QIMR Berghofer Support Division ensures researchers have the services, resources and equipment required to undertake world-class research.

Always at the forefront of management priorities is securing the funding necessary for researchers to undertake their important work. A high proportion of Support Division management is dedicated to this goal, whether through community fundraising, government relations, funds management, grant applications or commercial agreements.

The Chief Operating Officer and the support team have negotiated and facilitated a number of important research and commercial collaborations for the Institute. This included an agreement with Medicines for Malaria Venture, on behalf of the Bill and Melinda Gates Foundation, in support of clinical trials at QIMR Berghofer for the treatment of malaria, and the agreement with QUT to access the Institute's state-of-the-art facilities.

The Support Division has helped advance QIMR Berghofer's research and role within the community in numerous other ways in 2014-15.

The Division implemented a new sample processing facility in the Scientific Services area which will assist many research groups, especially in the cross-over of large longitudinal epidemiological studies into genetic analysis. Importantly the Institute's cell therapy manufacturing facility, which is managed by the Support team, obtained a TGA licence for the manufacture of T cell therapies. This was a major achievement in the development of a translational pipeline

to take research discoveries to the bedside. The Support Division also facilitated the acquisition of Q-Pharm Pty Ltd, improving the Institute's ability to provide the full spectrum of translational research as well as administering five new clinical trials, translating research into new therapies.

The Support team assists researchers in the provision and maintenance of infrastructure, and over the past year has completed the refurbishment of the Bancroft Centre. This brings to a close the \$179m project to construct the new Central building and refurbish the Bancroft building, all of which has been achieved on time and within budget. Another significant infrastructure development was the procurement of significant pieces of equipment for the ACRF imaging facility — a multiphoton microscope and a spinning disk microscope.

Improved infrastructure was also delivered for the provision of increased data. As methods in research and bioinformatics develop, so too does the demand for information technology resources. To facilitate the exponential increases in scientific data, a hierarchical storage management (HSM) system has been implemented, supporting the activities of researchers while ensuring availability, reliability and integrity of stored data. This HSM solution has revolutionised the data storage capabilities at QIMR Berghofer providing data storage capacity of more than 10 petabytes.

Another focus for the Support Division has been negotiating the QIMR Enterprise Agreement, which was agreed upon in 2014 and ensured suitable conditions for the Institute's staff.

The Support team also continued to develop their relationships with the community and the Institute's supporters, conducting a busy community relations program of tours and speaking engagements, and maintaining ongoing engagement with our dedicated supporters and donors.

## COMMUNITY SUPPORT

The importance of support from community groups, individuals, business and philanthropic trusts remains a constant for QIMR Berghofer. The Institute could not exist without government support. However, for every dollar received in government funding, a further 65 cents must be raised to make research possible. This is a significant amount to be found each financial year and QIMR Berghofer continues to be inspired and encouraged by the level of support received.

Of special note is the Sid Faithfull Fellowship awarded to Dr Bryan Day. This significant donation in support of a three

year research project will enable new research into precision medicine approaches to treat brain cancer. The fellowship was generously made possible by Sid's wife Christine Sadler, and is in memory of Sid who sadly passed away in 2014.

Supporters in the community raise funds for the Institute in a variety of ways. In March 2015, the Institute organised a celebration for two extraordinary young men, Dylan and Lawson Reid, who set off on a daunting two-year round the world trip on motorbikes to raise awareness of major depressive disorder (MDD). The fundraising adventure will honour Dylan and Lawson's sister, who lost her battle with

depression at the age of 27. The brothers have a fundraising target of \$200 000 in support of QIMR Berghofer's leading edge research into MDD, and have raised \$54 000 to date.

Thanks must also go to the Institute's corporate supporters and partners. Special recognition must go to Rio Tinto as sponsors of the Rio Tinto Ride to Conquer Cancer. Rio Tinto has been a magnificent partner for the event, not just in terms of sponsorship, but also as participants. The Rio Tinto staff teams are an impressive presence each year of the Ride and have raised significant funds for cancer research at the Institute.

Thanks again to Australian investment and trustee group Perpetual Ltd, who have consistently supported QIMR Berghofer's researchers over a number of years.

The Institute has been successful in securing funding towards Professor Rajiv Khanna's work in immunotherapy for a Phase I trial to treat multiple sclerosis (funded by MS Queensland) and Associate Professor John Miles' research into venom-based drugs.

These are just a few highlights of numerous ways the Institute has benefited over the past year. QIMR Berghofer looks forward to growing existing relationships and building new ones.

Special thanks and recognition to the Institute's many other major supporters, listed below.

## THANK YOU TO THE FOLLOWING DONORS

Clive Berghofer

A day on the Farm

ALS Limited

Aurizon Pty Ltd

BT Investment Management Pty Ltd

Biniris Pty Ltd

Buck Off Melanoma

Dorothy May Bailey Trust Fund

The Estate of Mr Keith John Boden

The Estate of Mary Swan Crawford

The Estate of Daphne Margaret Dowdle

The GPT Group

Mr Keith Maher

Ms Brenda Middleton

Mr Ivan and Mrs Sandra Mitchell

Mrs Jacqueline Pascual

Queensland Community Foundation

Ms Jean Redman

The Reid Family

Mr Tim Reid and Mrs Kym Reid

Robert George Relf Trust Fund

Rio Tinto

Roycorp Pty Ltd

Ms Christine Sadler

Mrs Maureen Stevenson and Mr Barry Stevenson

Sunsuper Pty Ltd

Supporters of 65 Roses Inc

# OUR RESEARCH ACHIEVEMENTS

## CANCER PROGRAM

COORDINATOR: PROFESSOR GEOFF HILL

The Cancer Program covers a variety of topics, including:

- identification of the genetic, epigenetic and environmental risk factors that underly an individual's risk of cancer
- study of the molecular changes that occur in precursor lesions that can give rise to cancer and those that occur during the formation of a tumour and its subsequent metastasis
- development and testing of novel therapies for cancer in the laboratory and in clinical trials.

The program has a strong focus on skin cancers, including melanoma; hormone-related cancers such as those of the breast, prostate, ovary and endometrium; leukaemia and lymphoma, including exploring the complications that can arise after stem cell transplantation which is used for the treatment of leukaemia; brain tumours; and tumours of the gastrointestinal tract.

Researchers in the Cancer Program have productive local and international collaborations with clinical oncologists, pathologists and biobanks, and many are also leading, or are involved in, large international consortia that have made great advances into the understanding of the genes that predispose individuals to many types of cancer.

## Antigen Presentation and Immunoregulation

**Group Leader: Kelli MacDonald**

Hematopoietic stem cell transplantation (SCT) is the only curative therapy for the majority of cancers of bone marrow origin. The curative property of this procedure relates to the graft-versus-leukaemia (GVL) effect, which eradicates any remaining cancer after SCT.

Unfortunately the success of SCT is significantly limited by three procedural complications: graft-versus-host disease (GVHD), graft failure and infection.

This group's overarching goal is to improve understanding of how these complications arise in order to develop new therapies that can be translated to clinical practice to improve transplant outcome. This year's primary focus was toward increasing understanding of the pathophysiology of chronic GVHD (cGVHD). This occurs to some degree in the majority of transplant patients. It is characterized by fibrosis and is associated with increased morbidity and mortality. Unfortunately, there are no effective therapies for this condition, thus there is a pressing need to identify therapeutic targets for the prevention and treatment of cGVHD.

**Highlights:**

- Demonstrated that granulocyte-colony stimulating factor (G-CSF) mobilisation provides protection against acute GVHD by enhancing the survival of Treg after transplant
- Identified the critical role of autophagy in haematopoietic stem cell mobilisation
- Obtained funding to investigate the mechanism by which macrophages mediate chronic GVHD.



# Bone Marrow Transplantation

## Senior Scientist: Geoff Hill

Cancer Program Coordinator

This laboratory seeks to understand the pathophysiology of GVHD and GVL in preclinical and clinical bone marrow transplantation (BMT). Its work focuses on cellular and cytokine biology in transplantation. The group is increasingly translating findings into patients at the Royal Brisbane and Women's Hospital BMT lab, and enrolled approximately 100 patients into clinical trials last year.

## Highlights:

- Completed Phase II clinical trial of IL-6 inhibition to prevent acute GVHD
- Initiated and carried out recruitment for Phase III clinical trial of IL-6 inhibition to prevent acute GVHD
- Identified the critical role for the IL-6/IL-17 axis in acute lung injury after BMT
- Successfully optimised murine models of cytomegalovirus (CMV) reactivation after BMT.

# Cancer Aetiology and Prevention

## Team Head: Rachel Neale

This group worked primarily on the D-Health Trial and studies of pancreatic cancer. The pancreatic cancer studies have included analysis of case-control data, contributing to an international genome-wide association study (GWAS) and studies of management of patients with pancreatic cancer.

## Highlights:

- Completed recruitment for the D-Health Trial
- Published results from the Queensland Pancreatic Cancer Study
- Published results highlighting the extremely high supportive care needs of patients with pancreatic cancer.

# Cancer and Population Studies

## Senior Scientist: Adele Green

The Cancer and Population Studies group researches the causes, management and prevention of melanoma and other skin cancers in the Queensland population including very high-risk groups.

## Highlights:

- Showed for the first time that people with multiple skin cancers (basal cell or squamous cell carcinomas) tend to develop one type or the other predominantly, rather than a mixture of both. This has implications for understanding their aetiology and for clinical management
- Showed elevated risk of melanoma in patients with HIV infection through a systematic review and meta-analysis of cohort studies
- In collaboration with Cancer Council Queensland, showed that melanoma incidence trends are declining in adolescents and young adults in Queensland
- Revealed the prevalence of supportive care needs, anxiety, depression and quality of life among newly-diagnosed patients with localised invasive cutaneous melanoma in Queensland
- Demonstrated through a systematic review and meta-analysis that aspirin and non-steroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma
- Conducted a substantive review of the evolution of skin cancer awareness campaigns in Australia
- Found an apparent increase in mortality among women who have a melanoma diagnosis during pregnancy through a systematic review of available literature and meta-analysis.

# Cancer Causes and Care

**Team Head: Susan Jordan**

The Cancer Causes and Care group was formed in February 2015. The research focus is to investigate the aetiology of three main cancer types: thyroid, kidney and ovary, and to investigate patterns of care for patients diagnosed with these cancers.

## Highlights:

- Showed that women with ovarian cancer who have reduced chemotherapy dose intensity have poorer survival, and that duration between primary surgery and commencement of chemotherapy is not associated with survival, at least up to five weeks
- Described patient and cancer factors associated with survival in an Australia-wide population-based cohort of women with ovarian cancer. Along with established prognostic factors (stage, subtype), it was also found that survival was somewhat poorer for older women, women from rural and lower socio-economic areas, and those with more co-morbidities
- Continued recruitment and data collection for a large case-control study of thyroid cancer
- Collected patterns of care data on 1021 patients with renal cell carcinoma diagnosed in Queensland in 2012-13
- Formed collaborations with one international and one national group to extend studies in thyroid cancer.

# Cancer Control Group

**Group Leader: David Whiteman**

Department Coordinator, Population Health

The Cancer Control Group conducts research into a number of different cancers, with a view to deriving new knowledge of practical utility for preventing these diseases, or limiting their adverse impacts.

The group has primary strength in epidemiological approaches to the study of cancer and collaborates widely with researchers from across many disciplines to maximise opportunities.

Historically, the focus has been directed towards cancers of two main organ systems: the skin and the gastro-intestinal tract. Recently, members of the group have initiated research projects exploring the causes and impacts of cancers of the head and neck, thyroid and liver. The Cancer Control Group has also partnered with Cancer Council Australia to lead a project quantifying the burden of cancer in Australia attributable to lifestyle factors that are amenable to modification.

## Highlights:

- Demonstrated that more people in Queensland die from thin melanomas (<1mm) than thick melanomas (4+mm)
- Described the incidence of hepatocellular carcinoma in Queensland communities, highlighting the disparities by geographic and social disadvantage
- Measured the prevalence of oral human papilloma virus (HPV) infection in Queensland tertiary students
- Published guidelines for the diagnosis and management of Barrett's oesophagus
- Documented the burden of cancer in Australia that is attributable to modifiable factors
- Initiated collection of DNA samples from the QSkin cohort (n=43 794)
- Demonstrated that risk of Barrett's oesophagus is strongly associated with measures of body fat measures.

# Cancer Drug Mechanism

## Team Head: Glen Boyle

The Cancer Drug Mechanisms team combines expertise in cancer biology with drug studies. Their cancer biology work currently focuses on understanding the development and progression of cancers of the skin and oral cavity. Specifically, the team is investigating the molecular mechanisms involved in the progression and metastasis of melanoma, head and neck cancer, as well as cutaneous squamous cell carcinoma. These molecular mechanisms also impact drug resistance of cancers. The identification and understanding of aberrantly regulated pathways in these cancers is crucial prior to the design or identification of suitable agents to treat the diseases.

## Highlights:

- Found key transcription factors involved in melanoma progression or invasion impact on drug sensitivity
- Identified key processes involved in perineural invasion of squamous cell carcinoma
- Elucidated host versus tumour response following treatment with EBC-46, a novel anticancer agent.

# Cancer Genetics

## Senior Scientist: Georgia Chenevix-Trench

In 2013, this team completed the first analyses of the largest cancer genetics experiment ever undertaken in the world. This originally identified 49 new breast cancer risk loci and nine new ovarian cancer risk loci, but they have recently used meta-analyses to identify 17 more breast and six more ovarian cancer risk loci.

The team has also identified the first genetic locus associated with outcome in breast cancer. They have also used the fine mapping data from this experiment to identify the target genes at two of these loci, on chromosomes 10 and 19. In an extension of the consortia that identified these inherited risk variants to a new focus on tumour biomarkers, they found that progesterone receptor and estrogen receptor are prognostic biomarkers for ovarian cancer.

They have also made considerable progress in uncovering the molecular mechanisms underlying the association between variants in a gene called TTC39 and ovarian cancer outcome. With the Tumour Immunology Group, the team has identified a new prognostic marker for triple-negative breast cancer based on gene expression, and new potential therapeutic targets based on kinome profiling.

## Highlights:

- Detailed functional follow up of a breast cancer susceptibility region which showed for the first time that a gene called nuclear receptor binding factor-2 is a breast cancer risk gene
- Evaluated the usefulness of clinical 'panel testing' to find mutations responsible for breast cancer families
- Clarified the role of rare missense substitutions in breast cancer susceptibility
- Showed that an FDA-approved test for ovarian cancer susceptibility and outcome has no clinical utility
- Found the first gene regions associated with breast cancer outcome
- Predicted breast cancer risk by evaluating many different genetic variants at once
- Refined the risks associated with breast and ovarian cancer by the location of mutations in the BRCA1 and BRCA2 genes
- Identified 17 novel breast, and seven novel ovarian cancer susceptibility regions.

# Cancer Immunoregulation and Immunotherapy

## Team Head: Michele Teng

Immunotherapies targeting immunosuppressive pathways have revolutionised cancer treatment. Therapies, Nivolumab and Ipilimumab in combination against advanced melanoma have produced impressive anti-cancer effects and may result in significant efficacy against multiple cancers.

A key issue of targeting checkpoint receptors, particularly in combination, is the appearance of immune-related adverse events. Furthermore, the dosing and scheduling for checkpoint inhibitors is still to be optimized. While checkpoint inhibitors have been effective in cancers that are T cell rich (melanoma), some cancers are T cell poor (eg. prostate, colorectal). In these cancers, checkpoint inhibitors are generally ineffective, and even in melanoma, a large proportion of patients are non-responsive. Given that myeloid cells are found in varying proportions in most cancer types and known to suppress tumor immunity, this team hypothesise that co-blockade of immunosuppressive pathways mediated by T and myeloid cells will increase anti-tumor efficacy.

The team's aim is to understand the hierarchy of immunosuppressive pathways mediated by lymphoid and myeloid cells in T cell rich and poor cancers and how they are regulated. This allows rational co-targeting of the dominant suppressive pathways specific to that tumor microenvironment to enable optimal release of endogenous anti-tumor effector function.

## Highlights:

- Developed a mouse model that can assess the therapeutic index and immune-related adverse events following pre-clinical combination immunotherapies
- Proposed that cancers should be based on T cell Infiltration and PD-L1 to determine the type of immunotherapies they receive.

# Conjoint Gastroenterology

## Group Leader: Barbara Leggett

The main focus of this group is in understanding the molecular, histological, clinical and epidemiological features of a particular class of colorectal polyps called serrated polyps, as well as the cancers they may develop into. They have presented detailed clinicopathological and molecular assessments of sessile serrated adenomas, traditional serrated adenomas and have described a new subtype called a serrated tubulovillous adenoma. The group is now extending these studies to include genome wide methylation and transcriptome analyses to better describe the molecular events and altered pathways driving progression of these lesions to malignancy.

## Highlights:

- Identified a DNA methylation signature that segregates with mutation of the IDH1 gene, suggesting this mutation contributes to the CpG Island methylator phenotype in a subset of colorectal cancers
- Identified the frequent mutation (96 per cent) of the intestinal stem cell ubiquitin ligase RNF43 in BRAF mutant colorectal cancers that have microsatellite instability and have demonstrated this confers sensitivity to the porcupine inhibitor LGK974
- Further developed and characterised our BRAF mutant murine model which develops widespread intestinal hyperplasia and murine serrated adenomas. The group is now using this model to investigate strategies for chemoprevention.

# Control of Gene Expression

## Group Leader: Frank Gannon

Director and CEO

The focus of this group's research is the mechanistic processes that lead to the expression of genes. The group's specific interests are endometrial and breast cancer and it collaborates with others on a range of gene expression topics.

The group has a growing body of information on the factors that obese individuals secrete from fat and the changes in gene expression that result from this. The expression of genes depends on epigenetic changes at the DNA and histone levels. The group has studied the impact of over-expressing or inhibiting enzymes (G9a and EZH2) that are essential for specific histone modifications. The RNA-Seq data obtained point to some potential targets that influence cell growth and responses of the immune system. The inhibitor of these histone-modifying enzymes is being tested in combination with standard clinical treatments with the aim of achieving reduced growth by cancer-derived cell lines and hence a reduction of side effects from these treatments.

The group's analysis of the level of expression of the enzymes involved in epigenetic changes and a subset of their target genes are providing new insights into predicting clinical outcomes.

## Highlights:

- Defined the genes with expression dependent on epigenetic modifying enzymes
- Defined the factors that are secreted from the fat of obese individuals
- Established a panel of genes that predicts breast cancer outcomes
- Actively partnered in a clinical trial on endometrial cancer treatment
- Showed synergy between different therapeutic treatments useful in breast cancer.

# Drug Discovery Group

## Group Leader: Peter Parsons

A library of plant extracts was screened for growth inhibition specifically of oral cancer cell lines. Several extracts were identified and further screened to profile cell type specificity. Novel synthetic molecules were also evaluated.

The mechanism of action of the novel anti-cancer compound EBC-46 was examined in mouse models of oral cancer and in cultured tumor and normal cells. The importance of the host response, causing hemorrhagic necrosis, was confirmed by the finding that anti-tumor efficacy was poor in a mouse strain with defective innate immune response. In addition, reproducing in culture the high local dose applied by injection into tumors revealed that rapid necrosis occurred that appeared to be independent of PKC.

The excellent healing that follows ablation of tumors by EBC-46 both in mice and in companion animals prompted a project aimed at evaluating PKC-activating chemicals for healing wounds in mice. Initial experiments have been carried out to optimise the treatment regime. Meanwhile, analogues of EBC-46 are being compared in vitro across a range of characteristics relevant to promotion of wound healing.

The group is also using genetic analysis to discover natural genes that protect against skin cancer.

## Highlights:

- Demonstrated anomalous efficacy of EBC-46 in mice, pointing to a host requirement for drug efficacy
- Demonstrated direct PKC-independent necrosis of tumor cells in culture by clinically-relevant levels of EBC-46
- Identified EBC-46 analogues that might adequately test our two-target hypothesis due to their complementary profiles of PKC activation versus direct necrosis
- Discovered a nevus-modifier gene
- Discovered of melanoma onset gene, TGF beta2.

## Functional Genetics

### Team Head: Juliet French

The focus of this team is to understand how inherited and somatic DNA variants are involved in breast cancer risk and development. The main focus is on DNA variants that fall in non-coding regions of the genome which affect regulatory elements and non-coding transcripts such as lncRNAs. The team hopes that understanding the mechanism by which these genetic variants increase breast cancer risk or promote breast cancer progression will uncover novel avenues of breast cancer therapy.

### Highlights:

- Implemented a high throughput method of detecting chromatin interactions called carbon-copy chromosome conformation capture (5C). The high throughput nature of this method means quick target identification.

## Functional Cancer Genomics

### Team Head: Stacey Edwards

This team's research focuses on understanding how genetic variation contributes to breast cancer risk and progression. The team currently leads the functional follow-up of loci identified by GWAS and validated in the world's largest cancer genetics project, the Collaborative Oncological Gene-environment Study (COGS), an international project aimed at defining individual risk of breast cancer. By studying the genetic make-up of nearly 100 000 individuals, the team is able to pinpoint the genetic variants that are the most likely causative variants for breast cancer. The team and collaborators have developed and successfully implemented a functional pipeline to follow-up loci identified by GWAS, which includes fine mapping of GWAS signal(s), prioritisation of functional SNPs by the integration of genetic epidemiological and bioinformatic methods, and in vitro and in vivo experimental verification of predicted molecular mechanisms for identifying the targeted genes.

### Highlights:

- Identified the causal variant, target gene and mechanisms underlying breast cancer risk at 2q35 and demonstrated for the first time that breast cancer risk SNPs can affect chromatin looping structures leading to altered gene expression
- Contributed the functional analysis of the 17q12 endometrial risk locus and showed that the candidate causal variants lie in a silencer element that the minor alleles of SNPs reduced HNF1B gene expression
- Identified the functional variants and target gene underlying the 8q21 association and allergies, suggesting that the risk-associated allele SNPs predisposed to allergic disease by increasing PAG1 expression that may promote B-cell activation and have a pro-inflammatory effect
- Used an LNA (locked nucleic acid)-modified DNA aptamer to target VEGF and inhibit breast cancer cell proliferation. Nucleic acid aptamers are considered promising alternatives for targeted cancer therapy, and several are now FDA approved
- Identified and evaluated SNPs at the 6q25 breast cancer risk locus that predisposed to breast cancer subtypes and alter mammographic density. Findings point to the existence of at least five separate common genetic variants with differing effects on breast tumor development, providing further insights into the biological and clinical importance of the estrogen receptor in establishing breast cancers.

# Genomic Biology

**Team Head: Nicole Cloonan**

Because of their molecular mechanism of action, microRNAs (miRNAs) are excellent markers of stable cellular states and could therefore be excellent markers of biology that underpins drug sensitivity. Unlike whole genome sequencing, miRNA sequencing and computational analysis is inexpensive and requires very little genetic material. miRNAs are also stable compared to longer RNAs and are stable in blood and serum, making them ideal biomarkers. The team's current research focus is determining the relationship between miRNAs and drug sensitivity, with the short-term aim of using these as markers in personalised therapy and the long term aim of using them as adjunct chemosensitizers.

## Highlights:

- Performed miRNA screen for EGFR inhibitors
- Performed miRNA screen for mTOR inhibitors
- Validated miRNAs as sensitizers of EGFRi therapy.

# Gynaecological Cancers Group

**Group Leader: Penny Webb**

Deputy Department Coordinator, Populational Health

This group investigates all aspects of gynaecological cancer from aetiology to diagnosis, patterns of care, quality of life and survival and also contributes to similar studies of other cancer types. A particular focus is on the role of environmental (non-genetic) factors in causing cancer. More recently, the group has extended this to assess how gynaecological cancers are managed in Australia and to investigate the role of lifestyle in determining quality of life and survival after a diagnosis of cancer. Much of this work is conducted within three national population-based studies: the Australian Ovarian Cancer Study (AOCS), the Ovarian Cancer Patterns of Care Study (POCS) and the Australian National Endometrial Cancer Study (ANECS) and within two international consortia: the Ovarian Cancer Association Consortium (OCAC) and the Epidemiology of Endometrial Cancer Consortium (E2C2). The group has also recently completed recruitment for the Ovarian Cancer Prognosis and Lifestyle (OPAL) study which is investigating whether modifiable aspects are associated with outcomes following a diagnosis of ovarian cancer.

## Highlights:

- Found that serum concentrations of 25(OH)D (a marker of vitamin D status) at diagnosis were independently associated with survival among a cohort of ~670 women diagnosed with ovarian cancer
- Completed recruitment for the OPAL study with a total of 960 eligible women consenting to participate
- Contributed to international pooled analyses showing that women who had used intrauterine devices had a lower risk, and women with a history of infertility had a higher risk of endometrial cancer
- Confirmed that lower limb lymphoedema (LLL) is common after endometrial cancer treatment
- Found that one quarter of women with endometrial cancer report unmet supportive care needs several years after their diagnosis and that these women were younger or had advanced disease stage at diagnosis
- Documented survival rates and factors associated with survival in a nationally representative cohort of women diagnosed with ovarian cancer showing that, in addition to clinical prognostic factors, women in regions of lower socioeconomic status and more rural areas appeared to experience have somewhat lower survival rates.

# Immunology in Cancer and Infection

## Senior Scientist: Mark Smyth

Department Coordinator, Immunology

This laboratory is building a detailed picture of how networks of immune cells function to recognise, respond to and destroy tumour cell masses and metastases. The laboratory is interested in defining the importance, timing and nature of the natural immune response to transformation. The lab has been examining the development and heterogeneity of natural killer cells and their potential to prevent tumor spread. The lab has also been assessing the mechanism of action, safety and efficacy of antibodies to existing and new immune checkpoint molecules, alone and in combination. The findings are being used to develop more effective immunotherapies for human cancer, in particular melanoma, breast and prostate cancer, and haematological cancers.

## Highlights:

- Showed that natural killer (NK) T cells play a role in the positive regulation of NLRP3 inflammasome priming by mediating the production of TNF- $\alpha$
- Provided a strong rationale to use A2ARi with anti-PD-1 mAb for the treatment of minimal residual and metastatic disease
- Demonstrated the combination activity of antibodies targeting CTLA-4 and RANK ligand in melanoma in mice and humans
- Showed that additional NK cell-based immunotherapy (by checkpoint blockade or agonists or cytokines) may combine well with BRAF(V600E) inhibitor therapy to promote more durable responses in melanoma
- Proposed a new way to specifically analyze IL-17-producing V $\alpha$ 6/V $\delta$ 1(+) T cells based on the level of CD3 signals
- Demonstrated the ability of IFN- $\gamma$  to directly regulate NK cell effector functions in vivo, alone and in the context of IFN- $\alpha$  $\beta$
- Provided in vivo evidence that CD226 is important for multiple myeloma (MM) immunosurveillance and indicate that specific immune components should be targeted for optimal MM treatment efficacy
- Demonstrated through transcriptional profiling and functional studies that the activating receptor DNAM-1 (CD226) identifies two distinct NK cell functional subsets.

# Leukaemia Foundation Laboratory

## Group Leader: Andrew Boyd

In the past year, the group has completed studies of Eph receptors on leukaemia and normal haematopoiesis. Studies of the same receptors in brain tumours are ongoing, now in collaboration with the Translational Brain Cancer team. In particular these studies are informing the further clinical testing of KB004, a clinical antibody derived from our IIIA4 anti-EphA3 monoclonal antibody. They are also continuing to develop an Eph inhibitor based on a soluble form of EphA4, in collaboration with the Queensland Brain Institute. An optimised inhibitor is now being produced for clinical trials

## Highlights:

- Produced ten primary research papers
- Lodged one new patent
- Continued clinical trial of KB004.



# Medical Genomics

**Team Head: Nicola Waddell**

The Medical Genomics team aims to learn more about how mutations in our DNA lead to diseases such as cancer. Their recent research has used next generation sequence data and computational tools to identify mutations in DNA from hundreds of cancer samples from patients with mesothelioma, oesophageal, melanoma, pancreatic ductal, pancreatic neuroendocrine or ovarian cancers. Cataloguing these mutations enabled identification of the underlying mutational processes and driver mutations in each cancer type. The team has found that different cancers arising in different body locations can have similar mutation processes and therefore may respond to similar treatments. These are important steps towards 'personalised medicine', where the diagnosis, management and treatment of patients is based on their individual genomic data.

## Highlights:

- Completed the analysis of the Australian Pancreatic and Ovarian International Cancer Genome Consortium (ICGC) projects
- Identified different mechanisms that contribute to resistance to therapy in ovarian cancer
- Showed that genomic catastrophes are a common driver of oesophageal cancer
- Identified new driver genes in pancreatic cancer.

# Molecular Cancer Epidemiology

**Group Leader: Amanda Spurdle**

This group focuses on the identification of genetic risk factors for hormonal cancers, and laboratory and statistical methods to identify individuals at high genetic risk of cancer.

Work has also focussed on identifying novel genetic factors associated with modest risk of endometrial cancer, in order to better understand the biology of this disease.

## Highlights:

- Highlighted issues to address for improved specificity of molecular screening for Lynch Syndrome
- Discovered endometrial cancer risk variants at the multicancer TERT locus, supplementing evidence for cancer pleiotropy
- Identified variants that increase HNF1B expression as a causal mechanism that underlies endometrial cancer risk
- Developed refined tumour predictors of BRCA1 and BRCA2 mutation status.

# Oncogenomics

## Senior Scientist: Nick Hayward

The principal focus of the Oncogenomics Group remains the study of melanoma genetics and genomics. The group studies population-based cases of melanoma as well as melanoma families to identify new risk genes underlying susceptibility to this type of cancer. The main approaches to this research are genome-wide association studies (GWAS) and whole genome sequencing.

For both cutaneous and uveal melanoma, the group employs a range of genomics methodologies to identify and characterise the aberrations that lead to melanocytic neoplasia. The group has a particular focus on identification of new drivers of melanoma development as well as mutations that lead to new proteins on the surface of melanoma cells that can be recognised by a patient's immune system. These novel epitopes provide the opportunity for designing individualised vaccines to treat melanoma.

This group has also continued to elucidate the mechanisms underlying lung cancer transformation and has been working with several other groups at the Institute to establish the innovative and powerful Cas9/CRISPR technology for genome editing.

## Highlights:

- Showed that loss of CDKN2A expression in melanoma cell lines correlates with sensitivity to the CDK4 inhibitor PD0332991
- Identified TET2 as a melanoma susceptibility locus
- Demonstrated the effect on melanoma risk of genes previously associated with telomere length
- Reported a recurrent germline BAP1 mutation and extended the BAP1 tumour predisposition spectrum to include basal cell carcinoma
- Contributed to the first whole-genome sequencing study of oesophageal adenocarcinoma
- Showed that BRAF mutation status is an independent prognostic factor for patients with resected stage III melanoma
- Identified mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma
- Conducted a population-based prevalence study of germline BAP1, CDKN2A, and CDK4 mutations in Queensland melanoma cases
- Showed that miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
- Showed that PARP1 polymorphisms play opposing roles in melanoma occurrence and survival
- Used exome sequencing to predict neoantigens in melanoma.

# Personalised Medicine

## Team Head: Fares Al-Ejeh

This team focuses on developing and validating new biomarker tests and new therapeutic targets for personalised and precise management of breast and pancreatic cancers.

## Highlights:

- Invention entered PCT phase concerned with precision oncology approaches for more than 10 cancer types including breast, melanoma, lung and colorectal cancers.

# Signal Transduction

## **Group Leader: Kum Kum Khanna**

Deputy Department Coordinator, Cell and Molecular Biology

This group focuses on the medically important area of understanding the contribution of DNA damage response pathway in normal tissue homeostasis and applying it to understand how its dysregulation can lead to development and progression of cancer and to predict novel therapeutic opportunities for cancer patients.

## **Highlights:**

- Published a comprehensive map of the DNA damage response pathway to harness it to improve therapeutic outcomes
- Discovered a new mechanism that helps cells choose a particular DNA repair pathway (incorrect decision can drive cancer development)
- Discovered essential roles of two DNA repair proteins in the maintenance of normal tissue homeostasis
- Discovered new roles of the cell cycle protein, Cep55, in the regulation of embryonic growth and development
- Developed preclinical novel combination therapy against pancreatic cancer, involving targeted radio-immunotherapy with DNA repair and checkpoint inhibitor
- Identified a mechanism by which FBX031, a tumor suppressor, might lead to increased genomic instability through regulation of DNA replication
- Developed novel therapeutic approaches to treat triple negative breast cancers and also developed gene signatures that predict prognostic outcomes.

# Translational Brain Cancer Research

## **Team Head: Bryan Day**

The Translational Brain Cancer Research Laboratory was newly developed in February 2015. Since then much effort has gone into the establishment of the lab and continuation of previously funded projects obtained by the Team Head. These studies have focused on characterising the function of Eph receptors and also characterising a novel stem cell targeting agent, salinomycin, in brain cancer. In addition, the team has commenced new projects looking at the function of Eph receptors in microglia and how this contributes to the progression of brain cancer, and a novel approach to identify therapy-resistant clones in brain cancer.

## **Highlights:**

- Progressed to Phase I clinical testing of an EphA3 antibody in recurrent glioblastoma
- Identified salinomycin as a novel radiomimetic and stem cell-targeting therapy in brain cancer
- Identified Eph receptor over expression and function in paediatric brain cancer
- Identified metronomic cyclophosphamide as a novel immunotherapy in brain cancer.



## Translational Leukaemia Research

**Team Head: Steven Lane**

This team researches myeloid blood cancers such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and the myeloproliferative neoplasms (MPN). These are very aggressive and rapidly fatal blood cancers that are among the most common types of cancer affecting Australians. The team's efforts are concentrated on understanding how leukaemia stem cells in AML and MPN are able to regenerate leukaemia (or cause relapse in patients), even after cytotoxic chemotherapy. To achieve this, research has focused on generating robust models of leukaemia and dissecting the pathways of self-renewal in leukaemia stem cells and normal blood stem cells.

**Highlights:**

- Identified telomerase as a therapeutic target in AML
- Found the stem cell niche in regenerative medicine.

## Tumour Microenvironment

**Team Head: Andreas Moller**

The Tumour Microenvironment team focuses on developing clinically applicable predictive markers for breast and lung cancer. Using novel technical and conceptual approaches, the team has discovered blood-based methodology to identify patients at risk of metastatic disease progression. This research is being developed to generate novel therapeutic opportunities for metastatic breast and lung cancer patients.

**Highlights:**

- Developed predictive, blood-based signature for patients at risk of developing metastatic lung cancer
- Assessed exosomes as predictive and therapeutic targets in breast cancer and lung cancer.

# INFECTIOUS DISEASES

## COORDINATOR: PROFESSOR JAMES MCCARTHY

The laboratories that contribute to QIMR Berghofer's Infectious Diseases Program study how a range of important pathogenic organisms cause illness, search for better ways to diagnose and treat them, and develop vaccines to prevent infections. A major emphasis is on infections that disproportionately affect people living in the developing world and tropical regions.

Pathogens studied include viruses such as human immunodeficiency virus (HIV), cytomegalovirus, Epstein-Barr virus and mosquito-borne viruses, bacteria such as streptococci and parasites such as malaria, intestinal protozoa, worms and scabies. One laboratory in the program focuses on the application of proteomic technology to biomedical science.

The Program continues to focus on strong collaborations between clinicians and researchers from within QIMR

Berghofer and other institutes, as well as working with pharmaceutical companies to develop patented therapeutic technologies that improve the health of many.

QIMR Berghofer is a founding member of the Queensland Tropical Health Alliance (QTHA), which is designed to enhance collaborations and networking in tropical health issues, and the Australian Infectious Diseases Research Centre (AID), which supports research into diseases such as malaria, dengue fever and schistosomiasis. QIMR Berghofer's collaboration with James Cook University, Griffith University, Queensland University of Technology (QUT) and The University of Queensland (UQ) through the QTHA and through AID brings strength and focus to plans to address serious tropical and infectious disease issues through Queensland, across Australia, and in the Asia-Pacific region.

## Biomarkers and Biology of Infection Related Cancers

### Team Head: Jason Mulvenna

The team is focused on developing novel techniques for the identification of proteins and miRNAs important in the genesis of disease, the most important cancers. The team developed a comprehensive understanding of the protein and miRNA expression present during the liver cancer cholangiocarcinoma as well as the precursor stages of the disease.

The team also investigated the pharmaceutical potential of small proteins from human pathogens and venomous organisms. The team has been developing hookworm peptides as potential immunomodulatory drugs for autoimmune diseases such as coeliac disease and Crohn's disease. The team also characterised the venom proteome of the box jellyfish, *Chironex fleckeri*, and is currently assessing these proteins as pharmaceuticals or as targets for chemical therapies for jellyfish stings.

### Highlights:

- Carried out the transcriptome and proteome of the box jellyfish
- Completed the transcriptome and proteome of irukandji jellyfish
- Identified miRNA biomarkers for cholangiocarcinoma
- Developed the dried-blood spot/FireFly assay to detect miRNA markers of disease
- Described protein dysregulations in inflammation prior to cholangiocarcinoma
- Described proteome of cholangiocarcinoma tumours.

# Cellular Immunology

## Group Leader: Scott Burrows

The main focus of this group has been investigating Epstein-Barr virus (EBV) which causes glandular fever and is associated with certain cancers such as nasopharyngeal carcinoma and a subset of T and NK cell lymphomas. This virus is carried by 90-95 per cent of healthy adults and is kept under control by killer T cells that eliminate virus-infected B cells.

The group has been particularly interested in understanding the role that EBV plays in the development of multiple sclerosis (MS). Earlier studies have shown that MS patients have a deficiency in EBV-specific killer T cells and the group suggested that this could lead to the accumulation of EBV-infected B cells in the brain.

Another focus of investigation has been the human T cell receptor (TCR). This molecule is on the surface of killer T cells and is critical for the recognition of virus-infected cells. The group has been investigating the impact of inherited variation in the genes that encode for the TCR. The group has also been developing novel strategies for immunotherapy for the EBV-associated malignancies. These studies have involved the use of high-affinity TCR molecules that are engineered from natural human TCRs. These will be tested for possible use against EBV-associated malignancies.

## Highlights:

- Showed that a deficiency of 'effector memory' killer T cells is an early and persistent feature of multiple sclerosis
- Showed that killer T cells which control Epstein-Barr virus infection can be auto-reactive with 'self-proteins'
- Identified a small region of Epstein-Barr virus that stimulates a T cell immune response in many people and could be used for vaccine development
- Used Epstein-Barr virus-specific T cells as immunotherapy to treat a patient with multiple sclerosis.

# Clinical Tropical Medicine

## Senior Scientist: James McCarthy

### Infectious Diseases Program Coordinator

The Clinical Tropical Medicine Laboratory investigates how parasites such as the malaria parasite, hookworm, threadworm and scabies cause disease and how they become resistant to drugs used to treat them. The group also identifies new drugs and drug targets, and develops novel diagnostic techniques.

Of particular interest to this group is the application of to apply modern techniques in microbiology, molecular biology and immunology to study clinical problems associated with infectious diseases in tropical environments; drug resistance in a range of parasites, and the development of novel diagnostic techniques.

The major recent focus of the group is to evaluate the activity of experimental antimalarial drugs.

## Highlights:

- Discovered that certain antimalarial drugs likely make people treated with them infectious to mosquitoes
- Tested more than 2,000 patient samples from Timor Leste for intestinal parasites
- Successfully completed a pre-IND with the USA FDA for a genetically modified malaria vaccine
- Discovered that the breath of people with malaria contains chemicals that can be used for diagnosis
- Found that the experimental antimalarial DSM265 has a very promising antimalarial activity.

# HIV Molecular Virology

**Group Leader: David Harrich**

The main focus of this group has been investigating Epstein-Human immunodeficiency virus type 1 (HIV-1) dependency factors (HDFs) which are cellular proteins directly required for HIV-1 replication. HDFs have attracted intense scientific interest as they may provide multiple new targets and strategies for development of anti-HIV agents.

Over the past 10 years, this group has taken innovative approaches to the discovery and analysis of unknown HDFs that may provide avenues towards novel treatment or possibly a cure for HIV/AIDS. To this end, this group reported the identification of two new HDFs, eukaryotic translation elongation factors eEF1A and eEF1G. They showed that both cellular components associated with the HIV reverse transcription complex (RTC), which was required for RTC stability and completion of reverse transcription.

The group has undertaken a detailed biochemical and molecular analysis of the eEF1A:RT interaction with the goal of blocking this protein interaction. Secondly, they invented a modified HIV protein that can block HIV-1 replication. The project has used a gene therapy to treat human immune cells that subsequently become resistant to HIV infection. An animal study is in progress. Finally, the group has shown that some RNA viruses require eEF1A for their replication including RSV and Hendra virus. Exactly how these viruses use eEF1A is under investigation.

## Human Immunity

**Team Head: John Miles**

The Human Immunity team aims to understand the fundamental workings of cellular immunity and then artificially modulate the system through rational vaccine design and therapeutic interventions.

### Highlights:

- Reported that Nullbasic attacks HIV-1 in the cell nucleus by sequestering an import HIV-1 dependency factor called an RNA helicase
- Demonstrated that Nullbasic targets the HIV-1 enzyme reverse transcriptase (RT). The mechanism of action is highly novel where Nullbasic attacks RT inside the virus particle leading to abortive virus replication
- Showed that novel solid material matrices can be embedded with tonofovir and nevirapine for potential enhanced prevention of HIV-1 infection through the vaginal route
- Showed for the first time that a cellular protein called eEF1A plays an important role in RSV replication. A detailed analysis has revealed strategies that may lead to novel antiviral strategies.

### Highlights:

- Characterised antigen specific T cell precursors in human newborns
- Identified unique T cell repertoires between the placenta and peripheral blood
- Identified T cell dysfunction in type 1 diabetes patients
- Identified a unique immune endotype in individuals susceptible to mycobacterium infection
- Identified panels of immune modulating compounds from venom and animal secretions
- Identified panels of anti-cancer compounds from venom.

# Immunology and Infection

## Group Leader: Christian Engwerda

Deputy Coordinator Infectious Diseases Program

The Immunology and Infection group remains focused on understanding host immune responses during malaria and leishmaniasis, two infectious diseases caused by protozoan parasites. Specifically, the team aims to distinguish T cell responses that control parasite growth and protect against re-infection from those that cause tissue damage and resulting disease.

## Highlights:

- Identified Blimp-1 dependent IL-10 production by CD4+ T cells as a critical regulator of TNF-mediated tissue pathology
- Discovered that type I interferons suppress anti-parasitic CD4+ T cell responses in human volunteers infected with *Plasmodium falciparum* and visceral leishmaniasis patients
- Developed an attenuated whole parasite, anti-parasitic vaccine platform to protect against visceral leishmaniasis
- Discovered that IL-17 suppresses early anti-parasitic immunity in the liver during visceral leishmaniasis.

# Inflammation Biology

## Group Leader: Andreas Suhrbier

The Inflammation Biology group continues its research on the arthritis/arthralgia caused by chikungunya virus, with the hope of identifying new drugs and vaccines for this mosquito transmitted disease. The global chikungunya virus epidemic continues to spread, reaching *inter alia* the Caribbean, USA, Papua New Guinea and New Caledonia, with millions of cases reported.

The group's continuing work on SerpinB2 has unravelled how this protein protects against metastasis. SerpinB2 is efficiently secreted via microparticle formation, which explains for the first time how it can reach and inhibit the extracellular protease, urokinase, an enzyme known to be associated with cancer growth and metastasis.

The group is developing a mouse model of HIV called EcoHIV, with the hope that this model will help accelerate the development of new drugs and vaccines for HIV.

The group has begun a collaborative project to develop therapeutics for ebola virus.

The group has also started a project on Sin1 and pancreatic cancer with the hope that this research will improve prognosis and help choose appropriate treatments.

## Highlights:

- Showed that inhibitors of the CCR2/CCL2 pathway exacerbate chikungunya virus arthritis, illustrating that macrophages have a beneficial role in inhibiting influx of highly destructive neutrophils
- Characterised a mouse model of chronic chikungunya virus arthropathy and showed the persistence of viral RNA and protein, and inflammatory responses in joint tissues
- Demonstrated that SerpinB2 is secreted on cancer microparticles and inhibits metastases
- In collaboration with University of Adelaide, used the EcoHIV mouse model of HIV to show protective efficacy of novel HIV vaccines
- In collaboration with UQ, developed a Kunjin replicon vaccine against ebola virus, which protected non-human primates from ebola.



# Malaria Immunology

**Team Head: Ashraful Haque**

This team has focused on understanding immunological mechanisms that either drive or impair adaptive (i.e. T cell-dependent) immunity to blood-stage malaria. The team has sought to characterise how the host immune response can be improved to facilitate more effective control of parasite numbers. In addition, the team has developed novel in vivo methods for determining how parasite numbers may be best controlled. Finally, the team has developed new ways to determine how T helper cells decide upon the developmental fate that they eventually undergo during infection.

## Highlights:

- Demonstrated that a subset of immune cells called CD8-dendritic cells are impaired in their function during experimental blood-stage malaria via signals mediated by type I Interferons
- Developed a novel experimental model of co-infection with malaria parasites and respiratory syncytial virus (RSV)
- Demonstrated that suppression of the immune system during experimental blood-stage malaria operates via the transcription factor interferon regulatory factor (IRF) 7
- Using mathematical modelling and experimental in vivo modelling techniques, showed that parasite growth rates slow in vivo due to combined mechanisms of weak parasite clearance and reduced capacity for parasites to become established inside red blood cells.

# Molecular Immunology

**Team Head: Michelle Wykes**

The team has been investigating the role of checkpoint inhibitors, especially the PD-1 pathway in immunity against malaria, and have identified a novel reagent to initiate immunity. The team now proposes to examine the relevance of its novel findings in patients with cancer.

## Highlights:

- Completed a major study on the role of PD-1 in immunity against malaria
- Filed a patent on the above study.

# Molecular Parasitology

**Senior Scientist: Don McManus**

This laboratory focuses on understanding the biology, immunology and epidemiology of human neural tube defects caused by parasitic worms, particularly the *Schistosoma* bloodflukes (schistosomiasis), the *Echinococcus* (hydatid) tapeworms (echinococcosis), and soil transmitted helminthiasis (STH)—diseases of the world's poorest people.

The team's goal is to translate laboratory results to develop effective public-health interventions and diagnostic procedures against these pathogens, leading to their elimination. This research model has applications that can be used by other researchers working on tropical diseases of poverty. This approach marries laboratory with applied field-research to develop findings into workable and practical control strategies, leading to improved health outcomes.

The lab's research is now at the stage where tools are available to completely eliminate schistosomiasis from Asia. A generic, universal vaccine against the three major human schistosomes may be possible as a result of the lab's vaccine studies and would be a major advance, as no human schistosomiasis vaccine is available currently. Similarly for echinococcosis and STH, integration of current interventions, coupled with the deployment of new approaches including the lab's health education package, can lead to sustainable control in many endemic areas.

## Highlights:

- Completed a four-year cluster-randomised multi-component intervention trial for the elimination of schistosomiasis in the Peoples' Republic of China
- Discovered novel *Schistosoma japonicum* antigens using a targeted protein microarray approach
- Characterised a secretory serine protease inhibitor (SjB6) from *Schistosoma japonicum*
- Carried out genome-wide sequencing of small RNAs revealing a tissue-specific loss of conserved microRNA families in *Echinococcus granulosus*
- Carried out real-time PCR monitoring which demonstrates high human prevalence of *Schistosoma japonicum* in the Philippines with implications for elimination programs
- Carried out multiplex real-time PCR monitoring of intestinal helminths in humans which revealed widespread polyparasitism in Northern Samar, the Philippines
- Showed that suppression of the insulin receptors in adult *Schistosoma japonicum* impacted on parasite growth and development, with further evidence of vaccine potential.

# Molecular Vaccinology

## Group Leader: Denise Doolan

Department Coordinator, Biology

This group conducts basic and translational research in support of the rational development of a malaria vaccine, encompassing core themes of:

- basic research on immune mechanisms with a particular focus on characterising host immunity to the Plasmodium parasite on the molecular level, and defining immunodominance in a complex host-pathogen system
- antigen and epitope discovery from genomic sequence data using protein microarrays and epitope prediction algorithms with biologically relevant laboratory and field specimens
- preclinical research and development of antigen and epitope based molecular vaccine technologies.

## Highlights:

- Refined and optimised an in vitro dendritic cell based assay for screening of small molecules to identify compounds that can specifically inhibit T cell responses (tolerogenic activity) or that can stimulate T cell responses (adjuvant activity)
- Identified a novel subset of human CD4+ T cells of a specific phenotype characterised by high cytotoxic potential and proliferation and low cytokine production that is implicated in control of malaria parasite burden
- Identified a key cytokine promoting the induction of polyfunctional T cells that secrete multiple cytokines in humans
- Identified of a molecular signature of polyfunctional CD4+ T cells in human that is conserved between parasitic and viral infections
- Identified a novel population of liver macrophages that form an immune complex with lymphocytes in the liver very early following Plasmodium blood-stage infection, and that are implicated in blood-stage immunity
- Identified key structural and functional properties of Plasmodium proteins preferentially associated with antibody and T cell reactivity
- Identification of a distinct protein signature which represents a biomarker for risk of nasopharyngeal carcinoma, to identify individuals at increased risk of NPC for targeted intervention to prevent mortality
- Identified a potent Lipid Core Peptide vaccine construct for induction of CD8+ T cells responses.

# Mosquito Control

## Group Leader: Greg Devine

Deputy Department Coordinator, Biology

This group's role is to characterise, monitor and control the entomological determinants of arbovirus and malaria transmission in heterogeneous environments. This includes looking at:

- the impacts of species and strain differences (e.g. vector complexes and insecticide-resistant variants) on vector competence and ecological and behavioural fitness
- the influence of environmental variables on stress, establishment and disease transmission
- novel means of insecticide delivery
- the application of new technologies for monitoring and survey purposes. Much of this work is facilitated by the Institute's unique PC2 and PC3 insectaries.

## Highlights:

- Established colonies of exotic mosquitoes that pose public health risks in Australia and initiation of vector competence experiments that will characterise that risk
- Developed Near Infra Red Spectrometry as a new tool for monitoring vectorial capacity in mosquitoes
- Carried out further field testing of novel means of insecticide application - autodissemination of larvicides and use of volatile pyrethroids
- Developed a cost-benefit analysis of an Aedes albopictus incursion to Australia
- Explored potential new mosquito attractants.

# Protein Discovery Centre

**Group Leader: Jeffrey Gorman**

The QIMR Berghofer Protein Discovery Centre is a state-of-the-art facility recognised as a world leader in the mass spectrometry and proteomics field and is one of the most advanced and best equipped of its kind in Australia. The centre collaborates broadly on both national and international projects. The centre aims to discover the identities of proteins involved in or affected by physiological and disease processes and the ways in which these proteins function and interact and to develop techniques to observe stimulated cells and the reaction within cell proteins.

## Scabies

**Group Leader: Katja Fischer**

Scabies is a disease of major human health significance worldwide, causing substantial morbidity and mortalities as a consequence of complications. Secondary infection of scabies lesions with bacteria such as group A streptococcus and *Staphylococcus aureus* can cause significant sequelae. Available therapies are limited and drug resistance is emerging.

The group's research on molecules that the mite needs to infest the skin (mite intestinal proteases and complement inhibitors) will guide the formulation and testing of novel drugs.

The group undertakes whole genome, transcriptome and proteome analyses of the scabies mite to investigate molecular aspects of the disease pathogenesis and identify targets that could serve in the development of urgently needed treatments and other intervention tools.

The group investigates how scabies mites promote the transmission and/or growth of pathogenic bacteria, and analyse scabies mites for the presence of symbiotic bacteria that may serve as potential targets for novel therapeutics. This will provide improved treatment of affected individuals and their families, thereby reducing the spread of scabies and bacterial infections and their devastating sequelae, particularly in Australian Indigenous communities.

### Highlights:

- Found that metagenome analysis of the internal microflora of scabies mites revealed that they harbour opportunistic pathogens and symbiotic bacteria
- Sequenced the mitochondrial genome of *Sarcoptes scabiei*
- With funds from the Lowitja Institute, developed and delivered a laboratory workshop to two high schools in remote north-west Queensland, followed by a week-long laboratory based work-experience program for selected students.



## Tumour Immunology

**Group Leader: Rajiv Khanna**

Deputy Department Coordinator, Immunology

The major goals of this group are to obtain a deeper understanding of the mechanisms by which the human immune response to viral infections and human cancers may be generated, augmented and applied to the treatment of herpes virus-associated diseases and malignancies. The group has used virus-associated diseases as a model to understand how cellular immune response in humans responds to persistent viral infections.

**Highlights:**

- Successfully completed immunotherapy trial on glioblastoma
- Initiated Phase I clinical trials to assess safety of autologous T cell therapy in solid organ transplant patients
- Successfully completed immunotherapy trial on recurrent nasopharyngeal carcinoma (NPC)
- Progressed development of CMV vaccine.

# MENTAL HEALTH/COMPLEX DISORDERS

COORDINATOR: PROFESSOR MICHAEL BREAKSPEAR

QIMR Berghofer has brought teams from a variety of disciplines together into the Mental Health and Complex Disorders Program.

While the disease focus is broad and multi-system, the program is united by a number of common conceptual and methodological themes. The diseases studied within the program, ranging from schizophrenia and depression to haemochromatosis and migraine, all arise from an interaction of genetic and multi-factorial environmental influences. As highlighted in a number of key strategic reviews, they also represent an enormous burden of illness and unmet research need.

QIMR Berghofer scientists continue to make important breakthroughs in mental health research, from genetics and

epidemiology to brain imaging and computational modelling. Research capabilities, technology opportunities and public awareness of mental health continue to grow, creating a unique opportunity for research at QIMR Berghofer to improve recovery and outcomes for those in the community with mental health disorders.

Technology plays a crucial role in the study of these disorders. QIMR Berghofer is home to a growing number of imaging technologies that enable unprecedented insight into the biology of cells, animals and humans. Cutting edge pre-clinical imaging facilities were recently installed and construction of a major new human imaging facility on the Herston campus is very near to completion. The growth of sequencing technologies that underpin genetic research also continues.

## Asthma Genetics

**Team Head: Manuel Ferreira**

The focus of this team is to identify genetic variants associated with asthma risk using genome-wide association studies (GWAS) and then identify the target genes underlying those associations. At that point the team will seek to identify genes that have therapeutic potential and then validate the therapeutic potential using in vitro and in vivo models. The final step is testing the safety and efficacy of new drugs for asthma in Phase I and II clinical trials.

### Highlights:

- Completed pre-clinical studies of tocilizumab for asthma treatment
- Identified PAG1 as a gene underlying the association between 8q21 variants and asthma risk
- Identified two new asthma risk genes (P2RY13 and P2RY14) using GWAS
- Enrolled 15 patients into our clinical trial of tocilizumab. Two of these have now been randomised to drug/placebo.

# The Clinical Trials and Biostatistics Unit

## Group Leader: Sanjoy Paul

Currently the Clinical Trials and Biostatistics Unit is running seven multicentre and multinational clinical trials in therapeutic areas including critical care, cancer, exercise physiology and geriatric medicine. The group is also leading six clinical, epidemiological and pharmaco-epidemiological studies using data from several clinical trials and primary care-based real world data from the UK and US. These research projects cover three broad areas: clinical studies in the fields of auto-immune and metabolic diseases, methodological and applied studies to identify new 'omics' based biomarkers to understand the progression to diabetes, and pharmaco-epidemiological and methodological studies with large population-level longitudinal data in the fields of diabetes and cardiovascular diseases. In addition, the group is leading a research project to evaluate the cardio-metabolic effects of treatment with GLP-1 receptor agonists in patients with diabetes.

The Clinical Trials Unit has developed facilities to conduct clinical trials to international regulatory and industry standard and is committed to providing training to researchers for efficient conduct of trials, and further develop systems to support efficient clinical reporting to regulatory authorities and end users.

## Highlights:

- Carried out seven ongoing clinical trials, one mechanistic clinical study, one clinical epidemiological study, two pharmaco-epidemiological studies and two statistical methodological studies with research collaborators
- Developed a programme of clinical trials and epidemiological studies with the possible new indication of TCZ in blood cancer, and systemic effects of TCZ and other biologics used for the treatment of rheumatoid arthritis.

# Genetic Epidemiology

## Senior Scientist: Nick Martin

Deputy Program Coordinator,  
Mental Health and Complex Disorders

The group's efforts have been in recruiting a large patient sample of anorexia sufferers and collecting DNA from them to contribute to the international Anorexia Nervosa Genomics Initiative (ANGI). The group also obtained an NHMRC grant to collect DNA from a large sample of depression patients. The group's main analysis effort has been genome-wide association studies (GWAS), as part of an international consortium, which found at least two major genes influencing dizygotic twinning and other important reproductive outcomes.

## Highlights:

- Recruited 1850 anorexia nervosa patients for a genetic study
- Initiated recruitment of 10 000 depression patients for a genetic study
- Found six new genes influencing moliness and melanoma
- Found major genes influencing the size of several brain regions.

# Hepatic Fibrosis

## Group Leader: Grant Ramm

Department Coordinator, Cell and Molecular Biology

The liver is known for its remarkable capacity to regenerate after acute injury, however, chronic liver damage due to constant viral, toxic or carcinogenic injury compromises the regenerative capacity of damaged liver cells. Thus, restitution of liver cell mass relies on the activation and differentiation of liver stem cells into healthy new cells. The extracellular matrix that these new liver cells require to rebuild liver architecture, via wound healing, is produced by liver fibroblasts. Thus, the liver heals itself through an interaction between these two cell types. In chronic liver disease, mortality and morbidity are the results of uncontrolled and inappropriate liver 'wound healing' and regeneration, which can ultimately lead to cirrhosis and liver cancer.

This group's research investigates the interaction between liver progenitor cells and fibroblasts in the iron overload disease hereditary haemochromatosis and in children with obstructive bile duct disease causing cirrhosis of the liver, including cystic fibrosis and biliary atresia. By investigating the mechanisms of cellular interaction, mediators of uncontrolled wound healing and regeneration (disease progression) can be identified which may be detected in the blood permitting development of early diagnostic tests, and may lead to novel therapeutic interventions to halt or reverse the disease process.

## Highlights:

- Identified circulating microRNA signature for the differential diagnosis of liver disease in children with cystic fibrosis
- Demonstrated that iron loading of hepatocytes leading to impaired hepatocyte replication in hereditary haemochromatosis is linked to proliferation of liver progenitor cells and the ductular reaction, with both the presence of the ductular reaction and portal inflammation strongly associated with hepatic fibrosis progression.

# Inflammatory Bowel Disease

## Group Leader: Graham Radford-Smith

The major research focus for this group has been the link between objective and quantitative clinical data and molecular data in subjects with inflammatory bowel disease (Crohn's disease or ulcerative colitis). The group has developed novel systems to extract and analyse longitudinal laboratory data on the group's research subjects and seeks to determine the relationships between specific subgroups within these datasets and both host genome and transcriptome. To this end, the group has generated extensive genotype data on both our Crohn's disease and ulcerative colitis populations, together with a detailed transcriptomic profile of both the small and large bowel. This will improve the group's understanding of intestinal biology in the healthy and inflamed gut, and support the development of novel therapeutic approaches.

## Highlights:

- Successfully applied for two UQ student scholarships
- Completed a major genotype-phenotype study across the International IBD Genetics Consortium — paper accepted by *The Lancet*
- Identified longitudinal laboratory data as highly informative in predicting poor outcomes in patients with Crohn's disease.

# Iron Metabolism

## Group Leader: Greg Anderson

Deputy Director

The Iron Metabolism group focuses on understanding the homeostasis of the essential trace element iron and related metals, the natural history of iron-related disorders and potential therapies for treating them, and mechanisms of liver disease. Specific areas of interest include:

- elucidating the basic mechanisms of intestinal iron absorption and its regulation as increased absorption characterises most iron loading disorders. Emphasis is being placed on the ferroportin/hephaestin iron transport complex and its modulation by the iron regulatory peptide hepcidin.
- exploring novel mechanisms of regulating iron intake in early postnatal life. This work has significant implications for infant nutrition and complementary feeding.
- examining how iron homeostasis is regulated in iron loading anaemias such as thalassaemia. These studies are helping to understand how changes in erythropoiesis regulated body iron intake.
- using novel nanoparticle technology to develop better iron supplements and methods for delivering iron removing agents.
- studying the natural history of the iron loading disorder hereditary haemochromatosis and exploring markers for monitoring the effectiveness of treatment.
- examining how the liver handles manganese and the mechanisms underlying hepatic encephalopathy. The group's work takes a broad approach from basic molecular mechanisms to clinical applications.

## Highlights:

- Showed that the copper-dependent iron oxidase zyklopen plays a role in hair development
- Assessed efficacy and safety of nanoparticulate oral iron supplements in rodent models and humans, including their effects on the gut microbiome
- Defined mechanisms of the erythroid regulation of iron metabolism
- Developed and implemented a novel nanoparticle-based strategy for the delivery of iron chelators
- Demonstrated that GNPAT can act as a modifier of iron loading in hereditary hemochromatosis
- Assessed microbial diversity and how it is influenced by antibiotics in the airways of cystic fibrosis patients.

# Lung Inflammation and Infection

## Team Head: David Reid

A major focus of the Lung Inflammation and Infection team research is to investigate the interaction between bacterial pathogens and the host innate immune response within the lung. Chronic respiratory diseases characterised by infection are very prevalent in Australia and globally. The team is currently studying the role of iron and other biologically active metal ions in promoting bacterial infection in the lungs of patients with the genetic disease cystic fibrosis (CF) and other suppurative lung diseases. To do this, the team is studying bacterial and host immune system interactions *in vivo* using a number of biochemical, molecular and cell imaging methods and also modelling these interactions using mouse models. The team is developing molecules to interfere with bacterial iron acquisition with the goal of developing these as antibiotic adjuncts.

The chelator-antibiotic combinations are highly effective against biofilm dwelling bacteria and a major aim will be to explore this combined approach as a potential intervention directed against a number of multi-drug resistant organisms that are currently extremely difficult to treat.

## Highlights:

- Demonstrated an iron homeostatic abnormality in cultured airway epithelial cells in cystic fibrosis
- Identified innate T lymphocyte abnormalities in cystic fibrosis with implications for other lung diseases characterised by chronic bacterial infection
- Confirmed the disease modulating effect of haemochromatosis gene mutations on the clinical course of cystic fibrosis, which opens the way for screening and intervention.



# Membrane Transport

## Group Leader: Nathan Subramaniam

The major focus of the group's research is aimed at understanding how iron levels are regulated at a cellular, tissue, and body level, the genes involved, their mechanism of action, and the roles these play in various clinical disorders. Excess iron accumulation has been associated with many disorders including liver disease, hepatocellular carcinoma and neurodegenerative disorders. Mutations in the HFE gene are present in 1 in 200 individuals of North European origin and are linked to iron overload and iron deposition in the liver. This is one of the most common genetic disorders in Australia.

A high calorie diet is also a common feature of Western populations and is associated with an increase in the metabolic syndrome. Increasingly the combination of a high fat diet and excess iron has been associated with diabetes and non-alcoholic fatty liver disease. Liver disease is a significant burden on society, affecting many in the prime of their life. Liver fibrosis or scarring of the liver is a response to injury due to many factors including alcohol, viruses, obesity and the metabolic syndrome associated with non-alcoholic fatty-liver disease. Ultimately, the group's research is aimed at identifying means to diagnose, treat and prevent these liver and iron-related disorders.

# Molecular Epidemiology

## Group Leader: Grant Montgomery

Department Coordinator, Genetics and Computational Biology

The Molecular Epidemiology group identifies specific genes and pathways that contribute to risk for common diseases.

The group is a world leader in research on genetic factors increasing risk of endometriosis. It also studies a range of other diseases including inflammatory bowel disease, melanoma, migraine, depression, substance abuse, and asthma. Related projects in systems genetics aim to understand the regulation of gene expression and epigenetic signals to facilitate follow up and interpretation of genetic mapping studies.

The group is continuing to map new risk regions and identify specific genes and pathways in genomic regions associated with disease risk. The laboratory provides the core genotyping facility for the International Endogene Consortium and the Australasian Inflammatory Bowel Disease Consortium and maintains a large sample collection supporting projects in the laboratory and major collaborations with QIMR Berghofer's Statistical Genetics, Genetic Epidemiology, and Oncogenomics laboratories.

## Highlights:

- Identified a variant in the GNPAT gene which is associated with increased iron loading
- Demonstrated that the transferrin receptor 2 gene plays an important role in erythropoiesis
- Showed the IL-22 gene has a role in the hypoferremic response due to inflammation
- Demonstrated that iron depletion results in reduced liver injury in animals fed a high fat diet
- Identified a new signalling molecule involved in the regulation of iron homeostasis.

## Highlights:

- Confirmed a novel association between the IL1A locus and endometriosis risk
- Identified new genetic risk factors for melanoma, age at menarche, obesity, eye diseases, heroin dependence, and brain structure
- Demonstrated that smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease
- Completed the genotyping for 2000 cases and controls for Parkinson's disease
- Demonstrated that stable DNA methylation patterns over time are due to both genetic and environmental factors
- Demonstrated that epigenetic factors can be combined with genetic marker data to help explain variation in complex disease.

## Quantitative Genetics

**Team Head: Sarah Medland**

The Quantitative Genetics Team focuses on the identification of genetic and environmental risk factors influencing a range of health conditions. The major projects focus on:

- mental health: attention deficit hyperactivity disorder, conduct disorder and addiction
- the role of brain structure in dementia and mental health conditions
- reproductive health conditions, including hyperemesis gravidarum.

**Highlights:**

- Identified genetic variants influencing educational attainment
- Identified genetic variants influencing psychiatric conditions
- Identified genetic variants influencing stature and anthropometric traits.

## Statistical Genetics

**Team Head: Stuart MacGregor**

The Statistical Genetics laboratory studies the role that genetic variation plays in determining risk of disease and its risk factors. The laboratory develops and applies statistical genetic methods to gene mapping studies across a wide range of traits and diseases.

The major focus is understanding genetic and epigenetic variation in various cancers. Those studied include melanoma, ovarian cancer, breast cancer and oesophageal cancer. Ultimately this work will lead to better understanding of why particular individuals are affected by cancer or why they respond poorly to cancer treatment.

Another major interest is ophthalmological genetics, with work ongoing to identify the specific genes involved in both eye disease and in underlying quantitative risk factors.

**Highlights:**

- Found that genetic variants which we had previously shown to increase melanoma risk actually had beneficial effects upon outcome (improved survival) among those affected by the disease
- Identified five new loci underlying glaucoma risks
- Identified a protein coding change in the gene WNT10A which doubles the risk of contracting the eye disease keratoconus
- Identified several new loci underlying quantitative trait risk factors for eye disease
- Developed free-to-use user-friendly web accessible software for statistical genetic analysis.

## System Neuroscience

**Group Leader: Michael Breakspear**

Mental Health/Complex Disorders Program Coordinator

Systems Neuroscience is an approach to brain sciences that seeks the fundamental principles of brain organisation, dynamics and function across a hierarchy of spatial and temporal scales. It is a rapidly growing field that differs considerably from the traditional reductionist paradigm in neuroscience that seeks purely sufficient causes for local phenomena. In contrast, systems neuroscience seeks unifying explanations for emergent phenomena.

The work of the group embodies these principles across three broad domains — empirical, computational and clinical neuroscience. The overarching aim is to contribute towards unifying models of brain architecture, dynamics and cognitive (dys)function. These models then inform the design of brain imaging experiments into major mental illnesses.

**Highlights:**

- Developed a novel prognostic marker that predicts neurological and developmental outcomes in preterm and hypoxic newborn neonates. The measure uses EEG to pre-empt cerebral haemorrhage and later crucial developmental milestones in these critically ill neonates. The technique has been patented.
- Developed and employed innovative techniques for quantifying structural and functional brain disturbances. The group used methods to analyse brain imaging data acquired from people with severe mental illness and translated these methods for use in bipolar disorder, major depression, dementia, schizophrenia, perinatal neurology and epilepsy.

# COMPLIANCE

## RISKS

In the highly competitive environment of medical research, QIMR Berghofer faces a number of challenges unique to the grant-based scientific and medical research industry. These include a highly competitive and difficult-to-forecast funding environment, strict compliance and regulatory standards, maintenance of a level of scientific excellence and scientific equipment to stay at the leading edge of research and the ongoing issue of staff retention and recruitment to ensure the best and brightest minds are part of the Institute. QIMR Berghofer's strategic plan takes steps to address these issues from 2014 to 2019.

## ETHICS AND CODE OF CONDUCT

QIMR Berghofer has a Code of Conduct which sets out expected workplace conduct, relationships and behaviour of staff. The Code of Conduct was most recently reviewed in 2011 and updated to reflect changes to the *Public Sector Ethics Act 1994*.

The Code of Conduct aims to foster a safe and productive work environment for all employees and associates of QIMR Berghofer by providing a shared understanding of expected standards of conduct in the workplace.

This Code applies to staff at all times when representing QIMR Berghofer, including (but not limited to) conferences, training events, business trips and work-related social events. It sets out general standards of conduct for all QIMR Berghofer employees whether full-time, part-time or casual.

## WHISTLEBLOWERS PROTECTION ACT 1994

No public interest disclosures were received during the 2014-15 reporting year.

## CARERS ACT 2008

QIMR Berghofer's Human Resource policies are regularly reviewed to ensure that they comply with obligations set out for public authorities under the *Carers Act 2008*. QIMR Berghofer provides access to flexible working arrangements, flexible leave options, a childcare assistance policy, and definitions of a carer compliant with the Act. Employees have access to information regarding benefits and policy on the QIMR Berghofer intranet.

## EXTERNAL SCRUTINY

QIMR Berghofer was not subject to any reports of any parliamentary committees, the Crime and Corruption Commission (formerly known as the Crime and Misconduct Commission) or the Queensland Ombudsman.

## INFORMATION SYSTEMS AND RECORDKEEPING

QIMR Berghofer's recordkeeping aims to streamline and consolidate physical and electronic documents to keep full and accurate records of its activities in accordance with the *Public Records Act 2002*, Information Standard 40 and Information Standard 31. As part of the records management program, the QIMR Recordkeeping Policy 2008 was established and adopted to provide an organisation-wide policy on the management of QIMR Berghofer documents and records, both hardcopy and electronic.

QIMR Berghofer uses the Total Records and Information Management (TRIM) document management system to provide a single, standardised system that promotes file sharing and secures access to the Institute's records. TRIM enables QIMR Berghofer to maximise the value of records with consistent and timely capture. It also improves accessibility, reduces duplication and promotes information-sharing across the organisation.

Records are not disposed of, or archived, unless duly authorised under the *Public Records Act 2002* or by reference to the Retention and Disposal Schedule (RDS) approved by Queensland State Archives (QSA). All QIMR Berghofer records are registered into TRIM before transfer to the off-site storage provider or QSA. All QIMR Berghofer hardcopy records stored off-site are managed under legislatively appropriate risk management standards and guidelines. Work continues on ensuring that all record types are identified, and are managed under the Retention and Disposal Schedule, and that all other legislative and funding body requirements for records management are satisfied.

## OPEN DATA

For information on consultancies and overseas travel for QIMR Berghofer, please visit the Queensland Government Open Data website at <https://data.qld.gov.au>

# FINANCIAL STATEMENTS

## OPERATING RESULT

Total comprehensive income in 2014-15 was \$12.9 million, including a \$17.4 million non-cash gain from asset revaluation mandated by accounting standards. The operating result was a loss of \$4.5 million mainly due to a significant reduction in income from donations and bequests. The Council's financial structure is mainly based on the management of operating and grant funds. Competitive research grant funding spent in the 2014-15 financial year was \$40.6 million (2013-14: \$44.7 million), representing 43% of total income from continuing operations, excluding capital grants. A majority of the Council's core funding is provided as an operating grant from the Department of Health, Queensland (2014-15: \$18.9 million; 2013-14: \$18.9 million). The Council's total funding resources, including amounts under management at 30 June 2015 totalled \$136.3 million (2013-14: \$133.9 million). The increase in funds held during the year was mainly due to the positive performance of financial markets and the related increase in the value of managed funds investments. In 2014-15, the Institute completed the refurbishment of the Bancroft Centre which was the third phase of the Institute's overall construction project fully funded by contributions from the Commonwealth Government (\$110 million), the Queensland State Government (\$35million), and The Atlantic Philanthropies (\$27.5 million).

## CONTENTS

Statement of comprehensive income

Statement of financial position

Statement of changes in equity

Statement of cash flows

Notes to and forming part of the financial statements

Management certificate

Independent auditor's report

## GENERAL INFORMATION

These financial statements are the financial statements of The Council of the Queensland Institute of Medical Research (the Council).

The Council of the Queensland Institute of Medical Research is a Queensland statutory body established under the *Queensland Institute of Medical Research Act 1945*.

The statutory body is controlled by the State of Queensland which is the ultimate parent.

The head office and principal place of business of the statutory body is:

300 Herston Road  
Herston QLD 4006

A description of the nature of the Council's operations and its principal activities is included in the notes to the financial statements.

For information in relation to the Council's financial statements please call +61 7 3362 0222, email [enquiries@qimrberghofer.edu.au](mailto:enquiries@qimrberghofer.edu.au) or visit the internet site [www.qimrberghofer.edu.au](http://www.qimrberghofer.edu.au).

The Council of The Queensland Institute of Medical Research

Statement of comprehensive income for the year ended 30 June 2015

	Notes	2015 \$'000	2014 \$'000
<b>Income from continuing operations</b>			
Grants and other contributions	2	75,950	82,127
User charges and fees	3	4,195	3,926
Other revenue	4	7,018	8,097
Interest		1,221	1,957
Total revenue		<u>88,384</u>	<u>96,107</u>
Gains on sale/revaluation of assets	5	5,181	4,811
<b>Total income from continuing operations</b>		<u><b>93,565</b></u>	<u><b>100,918</b></u>
<b>Expenses from continuing operations</b>			
Employee expenses	6	52,548	50,273
Supplies and services	7	26,731	28,501
Depreciation and amortisation	12,13	11,291	9,404
Other expenses	8	6,811	4,778
Finance costs		674	633
Share of loss of equity accounted investees	22	-	228
<b>Total expenses from continuing operations</b>		<u><b>98,055</b></u>	<u><b>93,817</b></u>
<b>Operating result from continuing operations</b>		<u><b>(4,490)</b></u>	<u><b>7,101</b></u>
<b>Other comprehensive income</b>			
<i>Items that will not be reclassified subsequently to operating result</i>			
Increase in asset revaluation surplus	18	17,410	-
Total items that will not be classified subsequently to operating result		<u>17,410</u>	<u>-</u>
<b>Total other comprehensive income</b>		<u><b>17,410</b></u>	<u><b>-</b></u>
<b>Total comprehensive income</b>		<u><b>12,920</b></u>	<u><b>7,101</b></u>

*The accompanying notes form part of these statements.*

# The Council of The Queensland Institute of Medical Research

## Statement of financial position as at 30 June 2015

	Notes	2015 \$'000	2014 \$'000
<b>Current assets</b>			
Cash and cash equivalents	9	32,388	39,079
Receivables	10	5,246	8,602
Inventories		253	268
Prepayments		808	385
<b>Total current assets</b>		<b>38,695</b>	<b>48,334</b>
<b>Non-current assets</b>			
Other financial assets	11	103,932	94,784
Intangible assets	12	379	465
Property, plant and equipment	13	296,265	284,058
Controlled and jointly controlled entities	22	23	23
<b>Total non-current assets</b>		<b>400,599</b>	<b>379,330</b>
<b>Total assets</b>		<b>439,294</b>	<b>427,664</b>
<b>Current liabilities</b>			
Payables	14	3,476	3,685
Accrued employee benefits	15	4,303	3,856
Non-interest bearing liability	16	-	1,324
Unearned revenue	17	18,957	19,164
<b>Total current liabilities</b>		<b>26,736</b>	<b>28,029</b>
<b>Non-current liabilities</b>			
Accrued employee benefits	15	884	881
<b>Total non-current liabilities</b>		<b>884</b>	<b>881</b>
<b>Total liabilities</b>		<b>27,620</b>	<b>28,910</b>
<b>Net assets</b>		<b>411,674</b>	<b>398,754</b>
<b>Equity</b>			
Accumulated surplus		346,445	350,935
Asset revaluation surplus	18	65,229	47,819
<b>Total equity</b>		<b>411,674</b>	<b>398,754</b>

*The accompanying notes form part of these statements.*

The Council of The Queensland Institute of Medical Research

Statement of changes in equity for the year ended 30 June 2015

	Accumulated surplus	Asset revaluation surplus (note 18)	Total
	\$'000	\$'000	\$'000
<b>Balance as at 1 July 2014</b>	350,935	47,819	398,754
Operating result from continuing operations	(4,490)	-	(4,490)
Other comprehensive income			
Increase in asset revaluation surplus	-	17,410	17,410
<b>Balance as at 30 June 2015</b>	<b>346,445</b>	<b>65,229</b>	<b>411,674</b>
<b>Balance as at 1 July 2013</b>	343,834	47,819	391,653
Operating result from continuing operations	7,101	-	7,101
<b>Balance as at 30 June 2014</b>	<b>350,935</b>	<b>47,819</b>	<b>398,754</b>

*The accompanying notes form part of these statements.*

# The Council of The Queensland Institute of Medical Research

## Statement of cash flows for the year ended 30 June 2015

	Notes	2015 \$'000	2014 \$'000
<b>Cash flows from operating activities</b>			
<b>Inflows:</b>			
Grants and other contributions		77,715	81,849
User charges and fees		6,227	2,871
Other income		1,763	2,224
Interest income		1,221	1,957
GST input tax credits from ATO		2,437	4,605
GST collected from customers		1,839	2,330
<b>Outflows:</b>			
Employee expenses		(51,937)	(50,011)
Supplies and services		(27,348)	(30,402)
Finance costs		(674)	(567)
GST paid to suppliers		(2,893)	(4,952)
GST remitted to ATO		(1,353)	(1,706)
Other		(6,808)	(4,778)
<b>Net cash provided by operating activities</b>	19	<b>189</b>	<b>3,420</b>
<b>Cash flows from investing activities</b>			
<b>Inflows:</b>			
Redemptions of other financial assets		3,036	-
Sale of property, plant and equipment		60	85
<b>Outflows:</b>			
Investments in other financial assets		(2,300)	(5,780)
Acquisition of property, plant and equipment		(6,352)	(21,397)
<b>Net cash used in investing activities</b>		<b>(5,556)</b>	<b>(27,092)</b>
<b>Cash flows from financing activities</b>			
<b>Outflows:</b>			
Non-interest bearing loan redemption		(1,324)	-
<b>Net cash used in financing activities</b>		<b>(1,324)</b>	<b>-</b>
Net decrease in cash and cash equivalents		(6,691)	(23,672)
Cash and cash equivalents at beginning of financial year		39,079	62,751
<b>Cash and cash equivalents at end of financial year</b>	9	<b>32,388</b>	<b>39,079</b>

*The accompanying notes form part of these statements.*



Objectives and principal activities of the Council

Note 1:	Summary of significant accounting policies
Note 2:	Grants and other contributions
Note 3:	User charges and fees
Note 4:	Other revenue
Note 5:	Gains/(losses)
Note 6:	Employee expenses
Note 7:	Supplies and services
Note 8:	Other expenses
Note 9:	Cash and cash equivalents
Note 10:	Receivables
Note 11:	Other financial assets
Note 12:	Intangible assets
Note 13:	Property, plant and equipment
Note 14:	Payables
Note 15:	Accrued employee benefits
Note 16:	Non-interest bearing liability
Note 17:	Unearned revenue
Note 18:	Asset revaluation surplus by class
Note 19:	Reconciliation of operating surplus to net cash from operating activities
Note 20:	Commitments for expenditure
Note 21:	Contingencies
Note 22:	Controlled and jointly controlled entities
Note 23:	Trust transactions and balances
Note 24:	Key management personnel and remuneration
Note 25:	Financial instruments
Note 26:	Events occurring after balance date
Note 27:	Economic dependency
Note 28:	Budget vs actual comparison

### **Objective and principal activities of the Council**

The objective of the Council is to control and manage the operations of the Queensland Institute of Medical Research (the Institute) in accordance with the Queensland Institute of Medical Research Act 1945. The Council has been established to conduct research into all branches of medical science. It operates predominantly in one geographical area, being Queensland, Australia, although it has research collaborations across Australia and overseas.

The majority of the Council's funding is generated from competitive, peer reviewed research grants, commercial and other earned revenue. The Council also receives an annual operational grant from the Department of Health, Queensland (Queensland Health). Further funding is generated from donations, fundraising and investment activities performed under the guidance of the Council. Refer note 27.

### **1. Summary of significant accounting policies**

#### **(a) Statement of compliance**

The Council has prepared this financial report in compliance with section 43 of the *Financial and Performance Management Standard 2009*.

These financial statements are general purpose financial statements, and have been prepared on an accrual basis in accordance with Australian Accounting Standards and Interpretations. In addition, the financial statements comply with Queensland Treasury Minimum Reporting Requirements for the year ended 30 June 2015, and other authoritative pronouncements.

With respect to compliance with Australian Accounting Standards and Interpretations, the Council has applied those requirements applicable to not-for-profit entities, as the Council is a not-for-profit statutory body. Except where stated, the historical cost convention is used.

#### **(b) The reporting entity**

The financial statements include the value of all revenues, expenses, assets, liabilities and equity of the Council.

#### **(c) Controlled and jointly controlled entities**

Controlled entities are all entities over which the Council has the power to govern the financial and operating policies, generally accompanying a shareholding of more than one-half of the voting rights. Any controlled entities that are not considered as material are not consolidated with the Council's financial statements and the amount of the investment is recorded at cost.

During 2014-15 the Council increased its shareholdings in previously jointly controlled entities Q-Pharm Pty Ltd and Vaccine Solutions Pty Ltd to 100% each. As the amount of the investments and the transactions of both entities are not considered material, they are not consolidated within the Council's financial statements. Refer note 22.

#### **(d) Trust transactions and balances**

The Council undertakes certain trustee transactions on behalf of the Cooperative Research Centre Vaccine Technology (CRCVT) and its employees' research activities.

As the Council acts only in a custodial role in respect of these transactions and balances, they are not recognised in the financial statements, but are disclosed in note 23.

#### **(e) Grants and other contributions**

Grants, contributions, donations, bequests, gifts and fundraising that are non-reciprocal in nature are recognised as revenue in the year in which the Council obtains control over them (control is generally obtained at time of receipt). Where grants are received that are reciprocal in nature, revenue is progressively recognised as it is earned according to the terms of the funding agreements.

Contributed assets are recognised at their fair value. Contributions of services are recognised only when a fair value can be determined reliably and the services would be purchased if they had not been donated. Refer note 1 (y).

#### **(f) User charges and fees**

User charges and fees from commercial services and recoveries of expenditure incurred by associated bodies which use the Council's laboratory consumables and services are recognised as revenue when the revenue has been earned and can be measured reliably with a sufficient degree of certainty. This involves either invoicing for related goods/services and/or the recognition of accrued revenue. User charges and fees are controlled by the Council where they can be deployed for the achievement of Council objectives.

**(g) Interest, dividends and distributions**

Revenue for interest on cash and cash equivalents is recognised on an accrual basis. Revenue for dividends and distributions from managed funds classified as financial instruments held at fair value through profit or loss are recognised when the Council's right to receive payment is established.

**(h) Imputation credits**

As an endorsed income tax exempt charity, imputation credits attached to franked dividends received by the Council are refundable and may be claimed retrospectively after the end of the financial year. Imputation credits are brought to account when the right to receive the credits is established.

**(i) Cash and cash equivalents**

For the purposes of the Statement of Financial Position and the Statement of Cash Flows, cash assets include all cash and cheques received but not banked at 30 June as well as deposits at call with financial institutions.

**(j) Receivables**

Trade debtors are recognised at the amounts due at the time of sale or service delivery i.e. the agreed purchase/contract price. Settlement of these amounts is required within 14 days from invoice date.

The collectability of receivables is assessed periodically with provision being made for impairment. Any known bad debts are written-off as at 30 June.

Other debtors generally arise from transactions outside the usual operating activities of the Council and are recognised at their assessed values. Terms are a maximum of 30 days, no interest is charged and no security is obtained.

**(k) Inventories**

Inventories are represented by consumable laboratory supplies valued at the lower of cost and net realisable value.

Cost is assigned on a weighted average basis and includes expenditure incurred in acquiring the inventories and bringing them to their existing condition, except for training costs which are expensed as incurred.

Net realisable value is determined by estimating the selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

No inventory assets have been classified as inventories held for distribution.

**(l) Acquisitions of assets**

Actual cost is used for the initial recording of all non-current physical and intangible asset acquisitions. Cost is determined as the value given as consideration plus costs incidental to the acquisition, including all other costs incurred in getting the assets ready for use. However, any training costs are expensed as incurred.

Where assets are received free of charge from another Queensland Government entity, the acquisition cost is recognised as the gross carrying amount in the books of the transferor immediately prior to the transfer together with any accumulated depreciation.

Assets acquired at no cost or for nominal consideration, other than from an involuntary transfer from another Queensland Government entity, are recognised at their fair value at date of acquisition in accordance with AASB 116 *Property, Plant and Equipment*.

**(m) Property, plant and equipment**

Items of property, plant and equipment with a cost or other value equal to or in excess of the following thresholds are recognised for financial reporting purposes in the year of acquisition:

<b>Class</b>	<b>Threshold</b>
Buildings	\$10,000
Plant and equipment	\$5,000
Other (including heritage & cultural)	\$5,000

Items with a lesser value are expensed in the year of acquisition.

The Council occupies three buildings situated on Crown land reserved and set apart for hospital purposes. The land is under the control of Metro North Hospital & Health Services (Metro North) on behalf of The State of Queensland.

Leases for the land and buildings known as the Bancroft Centre and the Clive Berghofer Cancer Research Centre (CBCRC) exist between the Council and The State of Queensland (represented by Queensland Health), at a nominal rental, terminating on 27 June 2066.

A new lease for the land occupied by the Council is expected to be entered into between the Council and Metro North at nominal rental, terminating on 27 June 2066. Upon commencement of the new lease, the existing leases will be surrendered.

As the buildings are controlled by the Council, these assets are recognised in its financial statements, not in the financial statements of Queensland Health. Any revaluation surpluses or decrements associated with these assets are recognised by the Council. Refer notes 1(n) and 13.

**(n) Valuations and revaluations of non-current physical and intangible assets**

Buildings and heritage & cultural assets are measured at fair value in accordance with AASB 116 *Property, Plant and Equipment*, AASB 13 *Fair Value Measurement* and Queensland Treasury *Non-Current Asset Policies for the Queensland Public Sector*. These assets are reported at their revalued amounts, being the fair value at the date of valuation, less any subsequent accumulated depreciation and impairment losses where applicable.

In respect of these asset classes, the cost of items acquired during the financial year has been judged by management of the Council to materially represent their fair value at the end of the reporting period.

Plant and equipment is measured at cost in accordance with Queensland Treasury *Non-Current Asset Policies*. The carrying amounts for plant and equipment at cost should not materially differ from their fair value.

Property is measured at fair value (refer above) and independently re-valued by an external registered valuer at least once every five years with interim valuations, using appropriate indices, being otherwise performed on an annual basis where there has been a material variation in the index. Where indices are used in the revaluation process the Council ensures that the application of such indices would result in a valid estimation of the asset's fair value at reporting date. Refer to note 13 for details.

The fair values reported by the Council are based on appropriate valuation techniques that maximise the use of available and relevant observable inputs and minimise the use of unobservable inputs. Refer note 1 (o).

Any revaluation increment arising on the revaluation of an asset is credited to the asset revaluation surplus of the appropriate class, except to the extent it reverses a revaluation decrement for the class previously recognised as an expense. A decrease in the carrying amount on revaluation is charged as an expense, to the extent it exceeds the balance, if any, in the revaluation surplus relating to that asset class.

On revaluation, accumulated depreciation is restated proportionately with the change in the carrying amount of the asset and any change in the estimate of remaining useful life.

Separately identified components of assets are measured on the same basis as the assets to which they relate.

Heritage & cultural assets include research library monographs, Australiana and scarce items. They are measured at current replacement costs and are independently re-valued by an external registered valuer at least once every five years.

Materiality concepts (according to the *Framework for the Preparation and Presentation of Financial Statements*) are considered in determining whether the difference between carrying amount and the fair value of an asset is material (in which case revaluation is warranted).

The Council reviewed all fair value methodologies in light of the new principles in AASB 13 and no adjustments were required on the values for property, plant and equipment classes.

**(o) Fair value measurement**

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions (i.e. an exit price) regardless of whether that price is directly derived from observable inputs or estimated using another valuation technique.

Observable inputs are publicly available data that are relevant to the characteristics of the assets/liabilities being valued.

Unobservable inputs are data, assumptions and judgements that are not available publicly, but are relevant to the characteristics of the assets/liabilities being valued. Significant unobservable inputs used by the Council include, but are not limited to, subjective adjustments made to observable data to take account of the characteristics of the Council's assets/liabilities, internal records of recent construction costs (and or estimates of such costs) for assets' characteristics/functionality, and assessments of physical condition and remaining useful life. Unobservable inputs are used to the extent that sufficient relevant and reliable observable inputs are not available for similar assets/liabilities.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

All assets of the Council for which fair value is measured or disclosed in the financial statements are categorised within the following fair value hierarchy, based on the data and assumptions used in the most recent specific appraisals:

level 1 - represents fair value measurements that reflect unadjusted quoted market prices in active markets for identical assets;

level 2 - represents fair value measurements that are substantially derived from inputs (other than quoted prices included within level 1) that are observable either directly or indirectly; and

level 3 - represents fair value measurements that are substantially derived from unobservable inputs.

There were no transfers of assets between fair value hierarchy levels during the current or prior years.

More specific fair value information about the Council's property, plant and equipment is outlined in note 13.

**(p) Intangibles**

Intangible assets with a cost or other acquisition value equal to or greater than \$100,000 are recognised in the Statement of Financial Position; items with a lesser value are expensed. Each intangible asset, less any anticipated residual value, is amortised over its estimated useful life to the Council. The residual value is zero for all the Council's intangible assets.

It has been determined that there is not an active market for any of the Council's intangible assets. As such, the assets are recognised and carried at cost less accumulated amortisation and accumulated impairment losses.

No intangible assets have been classified as held for sale or form part of a disposal group held for sale.

*Purchased software*

The acquisition cost of externally purchased software has been capitalised and is being amortised on a straight-line basis over the period of the expected benefit to the Council, namely 10 years.

*Internally generated software*

Expenditure on research activities relating to internally-generated intangible assets is recognised as an expense in the period in which it is incurred.

Costs associated with the development of computer software have been capitalised and are amortised on a straight line basis over the period of expected benefit to the Council, namely 10 years.

**(q) Depreciation of property, plant and equipment**

Property, plant and equipment is depreciated on a straight-line basis so as to allocate the net cost or re-valued amount of each asset, less its estimated residual value, progressively over its estimated useful life to the Council.

Assets under construction (work-in-progress) are not depreciated until they reach service delivery capacity. Service delivery capacity relates to when construction is complete and the asset is first put to use or is installed ready for use in accordance with its intended application. These assets are then reclassified to the relevant classes within property, plant and equipment.

Any expenditure that increases the originally assessed capacity or service potential of an asset is capitalised and the new depreciable amount is depreciated over the remaining useful life of the asset to the Council.

Heritage & cultural assets include research library monographs, Australiana and scarce items. The service potential of these assets is not expected to diminish with time or use and therefore, they are not depreciated.

For each class of depreciable assets the following depreciation and amortisation rates are used:

<b>Class</b>	<b>Rate</b>
Buildings	2%
Plant and Equipment	5% - 33.3%
Intangible Assets	10%

**(r) Impairment of non-current assets**

All non-current physical and intangible assets are assessed for indicators of impairment on an annual basis. If an indicator of possible impairment exists, the Council determines the asset's recoverable amount. Any amount by which the asset's carrying amount exceeds the recoverable amount is recorded as an impairment loss.

The asset's recoverable amount is determined as the higher of the asset's fair value less costs to sell and depreciated replacement cost.

An impairment loss is recognised immediately in the Statement of Comprehensive Income, unless the asset is carried at a re-valued amount. When the asset is measured at a re-valued amount, the impairment loss is offset against the asset revaluation surplus of the relevant class to the extent available.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised as income, unless the asset is carried at a re-valued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. Refer note 1(n).

**(s) Leases**

Operating lease payments are representative of the pattern of benefits derived from the leased assets and are expensed in the periods in which they are incurred.

**(t) Other financial assets**

Other financial assets held at fair value through profit or loss represent investments in managed funds and shares in listed companies. The investments are stated at current market value at the reporting date. Changes in the market value of these instruments, whether realised or unrealised, are recognised in the Statement of Comprehensive Income. These investments were originally classified at fair value through profit or loss upon initial recognition and the Council manages these investments and makes purchases and sales decisions based on their fair value in accordance with the Council's documented investment strategy.

**(u) Payables**

Trade creditors are recognised upon receipt of the goods or services ordered and are measured at the nominal amount i.e. agreed purchase/contract price, net of applicable trade and other discounts. Amounts owing are unsecured and are generally settled on 30 to 60 day terms.

**(v) Financial instruments**

*Recognition*

Financial assets and financial liabilities are recognised in the Statement of Financial Position when the Council becomes party to the contractual provisions of the financial instrument.

*Classification*

Financial instruments are classified and measured as follows:

- i. Cash and cash equivalents - held at fair value through profit or loss
- ii. Receivables - held at amortised cost
- iii. Other financial assets - held at fair value through profit or loss
- iv. Payables - held at amortised cost

The Council does not enter into transactions for speculative purposes, nor for hedging.

All other disclosures relating to the measurement and financial risk management of financial instruments held by the Council are included in note 25.

**(w) Employee benefits**

Employer superannuation contributions, annual leave expense and long service leave levies are regarded as employee benefits.

Workers' compensation insurance is a consequence of employing employees, but is not counted in an employee's total remuneration package. It is not an employee benefit and is recognised separately as employee related expenses.

*Wages, salaries, annual leave and sick leave*

Accruals for wages, salaries and annual leave expense due but unpaid at reporting date are recognised in the Statement of Financial Position at the current salary rates.

For unpaid entitlements expected to be paid within 12 months, the liabilities are recognised at their undiscounted values. Entitlements not expected to be paid within 12 months are classified as non-current liabilities and recognised also at their undiscounted values.

As sick leave is non-vesting, an expense is recognised for this leave as it is taken. Prior history indicates that on average, sick leave taken each reporting period is less than the existing accumulated entitlements and thus no liability for unused sick leave entitlements is recognised.

*Long service leave*

Under the Queensland Government's long service leave scheme, a levy is made on the statutory body to cover the cost of employees' long service leave. The levies are expensed in the period in which they are payable. Amounts paid to employees for long service leave are claimed from the scheme quarterly in arrears.

No provision for long service leave is recognised in the Council's financial statements, the liability being held on a whole-of-government basis and reported in those financial statements pursuant to AASB 1049 *Whole of Government and General Government Sector Financial Reporting*.

#### *Superannuation*

Employer superannuation contributions are paid to QSuper, the superannuation scheme for Queensland Government employees, at rates determined by the Treasurer on the advice of the State Actuary. Contributions are expensed in the period in which they are paid or payable. The Council's obligation is limited to its contribution to QSuper.

#### *Key management personnel and remuneration*

Key management personnel and remuneration disclosures are made in accordance with section 5 of the Financial Reporting Requirements for Queensland Government Agencies issued by Queensland Treasury. Refer note 24 for the disclosures on key management personnel and remuneration.

#### **(x) Insurance**

The Council's non-current physical assets and other risks are insured through the Queensland Government Insurance Fund (QGIF), premiums being paid on a risk assessment basis. In addition, the Council has policies with private insurance companies to cover risks not included by QGIF.

The Council also pays premiums to WorkCover Queensland and inter-state QBE in respect of its obligations for employee compensation. These costs are reported in note 6.

#### **(y) Services received free of charge or for nominal value**

Contributions of services are recognised only if the services would have been purchased if they had not been donated and their fair value can be measured reliably. Where this is the case, an equal amount is recognised as revenue and an expense.

#### **(z) Taxation**

The Council is a State body as defined under the *Income Tax Assessment Act 1936* and is exempt from Commonwealth taxation with the exception of Fringe Benefits Tax (FBT) and Goods and Services Tax (GST). FBT and GST are the only taxes accounted for by the Council. GST credits receivable from, and GST payable to the ATO, are recognised. Refer note 10.

#### **(aa) Issuance of financial statements**

The financial statements are authorised for issue by the Chair of Council, Director & Chief Executive Officer and Secretary at the date of signing the Management Certificate.

#### **(ab) Accounting estimates and judgements**

The preparation of financial statements necessarily requires the determination and use of certain critical accounting estimates, assumptions, and management judgements that have the potential to cause a material adjustment to the carrying amounts of assets and liabilities within the next financial year. Such estimates, judgements and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in future periods as relevant.

Estimates and assumptions that have a potential significant effect are outlined in the following financial statement notes:

- Useful lives of intangibles and property, plant and equipment - notes 1(p) and (q)
- Valuation of property, plant and equipment - notes 1(n) and 13

#### **(ac) Other presentation matters**

Currency and rounding - Amounts included in the financial statements are in Australian dollars and have been rounded to the nearest \$1,000 or, where that amount is \$500 or less, to zero, unless disclosure of the full amount is specifically required.

Comparatives - Comparative information has been restated where necessary to be consistent with disclosures in the current reporting period.

Current/non-current classification - Assets and liabilities are classified as either 'current' or 'non-current' in the Statement of Financial Position and associated notes. Assets are classified as 'current' where their carrying amount is expected to be realised within 12 months after the reporting date. Liabilities are classified as 'current' when they are due to be settled within 12 months after the reporting date, or the Council does not have an unconditional right to defer settlement to beyond 12 months after the reporting date. All other assets and liabilities are classified as non-current.

**(ad) New and revised accounting standards**

The Council did not voluntarily change any of its accounting policies during 2014-15. The Council has reviewed all new and revised accounting standards applicable for the current year and an assessment of those standards that materially impact on the Council is outlined below. The new standard which has the most significant impact on the Council's financial statements is AASB 1055 *Budgetary Reporting*.

AASB 1055 *Budgetary Reporting* applies for reporting periods beginning on or after 1 July 2014. In response to this new standard, the Council has included in these financial statements a comprehensive new note 'Budget vs Actual Comparison' (refer note 28). This note discloses Council's budgeted figures for 2014-15 compared to actual results, with explanations of major variances, in respect of Council's Statement of Comprehensive Income, Statement of Financial Position and Statement of Cash Flows.

Of the new/revised standards applicable from future financial years, the most significant potential impacts would arise from AASB 10 *Consolidated Financial Statements*. AASB 10 redefines and clarifies the concept of control of another entity, and is the basis for determining which entities should be consolidated into an entity's financial statements. The Council has reviewed the nature of its relationship with Q-Pharm Pty Ltd, Vaccine Solutions Pty Ltd and other entities that the Council is connected with, to determine the impact of AASB 10. It has concluded that it will continue to have control over Q-Pharm Pty Ltd and Vaccine Solutions Pty Ltd based on 100% ownership and will not have any control over any additional entities. On that basis, AASB 10 itself has no substantive impact on the Council's financial statements. However, the new AASB 12 requires a range of particular details to be disclosed in respect of controlled entities, so note 22 Controlled Entities now contains further information that is relevant to Q-Pharm Pty Ltd and Vaccine Solutions Pty Ltd and the Council's relationship with these companies. The Council will continue to review annually its relationships with other entities to identify any further application of AASB 10's principles.

The Council is not permitted to early adopt a new or amended accounting standard ahead of the specified commencement date unless approval is obtained from the Queensland Treasury. Consequently, the Council has not applied any Australian Accounting Standards and Interpretations that have been issued but are not yet effective. The Council applies standards and interpretations in accordance with their respective commencement dates.

At the date of authorisation of the financial report, significant impacts of new or amended Australian Accounting Standards with future commencement dates are as set out below.

AASB 9 *Financial Instruments* and AASB 2010-7 *Amendments to Australian Accounting Standards arising from AASB 9 (December 2010)* [AASB 1, 3, 4, 5, 7, 101, 102, 108, 112, 118, 120, 121, 127, 128, 131, 132, 136, 137, 139, 1023 & 1038 and Interpretations 2, 5, 10, 12, 19 & 127] will become effective for reporting periods beginning on or after 1 January 2018. The main impacts of these standards on the Council are that they will change the requirements for the classification, measurement and disclosures associated with financial assets. The Council has reviewed the application of AASB 9 and does not expect that these will have any significant impact on valuations or disclosures.

AASB 2015-7 *Amendments to Australian Accounting Standards – Fair Value Disclosures of Not-for-Profit Public Sector Entities* amends AASB 13 *Fair Value Measurement* effective from annual reporting periods beginning on or after 1 July 2016. The amendments provide relief from certain disclosures about fair values categorised as level 3 under the fair value hierarchy (refer note 1(o)). Accordingly, the following disclosures for level 3 fair values in note 13 will no longer be required:

- the disaggregation of certain gains/losses on assets reflected in the operating result;
- quantitative information about the significant unobservable inputs used in the fair value measurement; and
- a description of the sensitivity of the fair value measurement to changes in the unobservable inputs.

As the amending standard was released in early July 2015, the Council has early adopted this relief in these financial statements.

AASB 15 *Revenue from Contracts with Customers* will become effective from reporting periods beginning on or after 1 January 2017. This standard contains detailed requirements for the accounting for certain types of revenue from customers. Depending on specific contractual terms, the new requirements may potentially result in a change in the timing of the recognition of revenue, such that some revenue may need to be deferred to later reporting periods if Council has received the cash but not yet met its associated obligations (such amounts would be reported as a liability (unearned revenue) in the meantime). The Council is yet to complete its analysis of current revenue recognition, but at this stage does not expect a significant impact on its present accounting practices.

From reporting periods beginning on or after 1 July 2016, the Council will need to comply with the requirements of AASB 124 *Related Party Disclosures*. This accounting standard requires a range of disclosures about the remuneration of key management personnel, transactions with related parties/entities, and relationships between parent and controlled entities. The Council already discloses information about the remuneration expenses for key management personnel (refer note 24) in compliance with requirements from Queensland Treasury. Therefore, the most significant implications of AASB 124 for the Council's financial statements will be the disclosures to be made about transactions with related parties, including transactions with key management personnel or close members of their families.

All other Australian accounting standards and interpretations with future commencement dates are either not applicable to the Council's activities, or have no material impact on the Council.



	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>2. Grants and other contributions</b>		
Grants - National Health & Medical Research Council	24,859	26,365
Grants - Queensland Health	18,864	18,864
Grants - Other	12,902	15,019
Grants - NHMRC overheads support funding (IRIISS)	4,211	3,861
Grants - Australian Cancer Research Foundation (ACRF)	1,850	750
Grants - Australian Research Council	1,734	231
Grants - Bioplatforms Australia	1,161	1,698
Grants - Cancer Council Queensland	1,342	1,399
Donations and bequests	9,027	13,940
<b>Total</b>	<b>75,950</b>	<b>82,127</b>
<b>3. User charges and fees</b>		
Commercial and contract research	3,459	2,845
Sundry tenants recoveries	420	548
Rent	316	533
<b>Total</b>	<b>4,195</b>	<b>3,926</b>
<b>4. Other revenue</b>		
Reimbursements	2,323	1,268
Investment distributions	4,416	6,272
Other	279	325
Gain on early settlement of borrowings	-	232
<b>Total</b>	<b>7,018</b>	<b>8,097</b>
<b>5. Gains/(losses) on sale/revaluation of assets</b>		
Net gain on market value of other financial assets	5,432	4,924
Net loss on disposal of property, plant and equipment	(254)	(113)
Net gain on sale of shares - US listed entities	3	-
<b>Total</b>	<b>5,181</b>	<b>4,811</b>
The Council holds financial assets including managed funds and listed shares. Refer notes 11 and 25.		
<b>6. Employee expenses</b>		
<b>Employee benefits</b>		
Wages and salaries	41,063	39,218
Employer superannuation contributions *	6,056	5,759
Annual leave expense *	3,887	3,781
Long service leave levy *	890	843
Other employee benefits	333	314
	<u>52,229</u>	<u>49,915</u>
<b>Employee related expenses</b>		
Fringe benefits tax expense	151	184
Workers' compensation premium *	94	89
Other employee related expenses	74	85
	<u>319</u>	<u>358</u>
<b>Total</b>	<b>52,548</b>	<b>50,273</b>
* Refer note 1(w)		

The number of employees including full-time, part-time and casual employees measured on a full-time equivalent basis is:

502

494

	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>7. Supplies and services</b>		
Supplies and consumables	19,455	20,359
Consultants and contractors	4,657	5,298
Travel	1,592	1,452
Minor equipment and software purchases	980	1,355
Rent	47	37
<b>Total</b>	<b>26,731</b>	<b>28,501</b>

<b>8. Other expenses</b>		
Scientific collaboration distributions	5,912	3,787
Insurance	449	485
Audit fees - external *	130	88
Audit & other fees - internal	110	144
Legal expenses	201	213
Net loss on foreign exchange transactions	8	61
Other	1	-
<b>Total</b>	<b>6,811</b>	<b>4,778</b>

\* Total external audit fees to be paid to the Queensland Audit Office relating to the 2014-15 financial year are expected to be \$65,000 (2014: \$65,000). Amounts relating to the 2014-15 financial year and not yet invoiced as at 30 June 2015 have been accrued. There are no non-audit services included in this amount.

<b>9. Cash and cash equivalents</b>		
Imprest accounts	1	1
Cash at bank	5,503	602
Term deposits	26,884	38,476
<b>Total</b>	<b>32,388</b>	<b>39,079</b>

The Council's cash and cash equivalents include \$18.9m (2014: \$19.1m) in research grant funding and \$1.2m (2014: \$3.4m) in capital grant funding received but not yet spent. The reduction in cash and cash equivalents was due to continued expenditure on the refurbishment of the Bancroft Centre and a number of major building maintenance works in 2014-15. The balance of the capital grant funding on deposit has reduced in line with this expenditure.

<b>10. Receivables</b>		
Trade debtors	3,257	5,288
NHMRC grants	-	1,972
Accrued interest	288	140
GST receivable	82	114
Long service leave reimbursements	120	281
Other	1,499	807
<b>Total</b>	<b>5,246</b>	<b>8,602</b>

	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>11. Other financial assets</b>		
<i>Other financial assets at fair value through profit or loss:</i>		
Managed funds investments	103,932	94,757
Shares - US listed entities *	-	27
<b>Total</b>	<b><u>103,932</u></b>	<b><u>94,784</u></b>

\* As at 30 June 2014 the Council held shares in Sequenom Inc. All these shares were sold on 20 April 2015. Refer note 5.

**12. Intangible assets**

Software purchased:		
At cost	679	679
Less: Accumulated amortisation	<u>(382)</u>	<u>(314)</u>
	<u>297</u>	<u>365</u>
Software internally generated:		
At cost	172	172
Less: Accumulated amortisation	<u>(90)</u>	<u>(72)</u>
	<u>82</u>	<u>100</u>
<b>Total</b>	<b><u>379</u></b>	<b><u>465</u></b>

The Council also controls a number of significant software assets that are not recognised as assets because they do not meet AASB 138 recognition criteria.

12. Intangible assets (cont'd)

Intangibles reconciliation	Software internally generated		Software purchased		Total
	2015 \$'000	2015 \$'000	2015 \$'000	2015 \$'000	2015 \$'000
Carrying amount at 1 July 2014	100		365		465
Acquisitions	-		-		-
Disposals	-		-		-
Transfers between classes	-		-		-
Amortisation	(18)		(68)		(86)
<b>Carrying amount at 30 June 2015</b>	<b>82</b>		<b>297</b>		<b>379</b>
Intangibles reconciliation	Software internally generated		Software purchased		Total
	2014 \$'000	2014 \$'000	2014 \$'000	2014 \$'000	2014 \$'000
Carrying amount at 1 July 2013	118		433		551
Acquisitions	-		-		-
Disposals	-		-		-
Transfers between classes	-		-		-
Amortisation	(18)		(68)		(86)
<b>Carrying amount at 30 June 2014</b>	<b>100</b>		<b>365</b>		<b>465</b>

	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>13. Property, plant and equipment</b>		
Buildings: At fair value		
Gross	327,880	259,187
Less: Accumulated depreciation	<u>(58,189)</u>	<u>(47,905)</u>
	<b>269,691</b>	<b>211,282</b>
Heritage & cultural assets: At fair value		
Gross	<u>104</u>	<u>104</u>
	<b>104</b>	<b>104</b>
Plant & equipment: At cost		
Gross	54,190	55,151
Less: Accumulated depreciation	<u>(28,856)</u>	<u>(29,172)</u>
	<b>25,334</b>	<b>25,979</b>
Work in progress: At cost *	<u>1,136</u>	<u>46,693</u>
	<b>1,136</b>	<b>46,693</b>
<b>Total</b>	<b><u>296,265</u></b>	<b><u>284,058</u></b>

\* The refurbishment of the Bancroft Centre was completed in July 2014. Since then a number of major building maintenance works have been undertaken some of which are still in progress as at 30 June 2015.

The Council's three buildings have been revalued at 30 June 2015 to reflect a 6.9% increase in the Queensland Government's 'Asset revaluation index - non-residential construction' resulting in a net revaluation increment of \$17.410m. The increment has been included in the Statement of Comprehensive Income and transferred to the asset revaluation surplus.

#### **Buildings - Bancroft Centre and the Clive Berghofer Cancer Research Centre (CBCRC)**

The purpose-built research facilities operated by the Council known as the Bancroft Centre and the Clive Berghofer Cancer Research Centre (CBCRC) situated in Herston were valued at 30 June 2013 by the independent valuer Damien Hirst BSc(QS)(Hons) AAIQS from the firm Davis Langdon. As there is no active market for research facilities, the basis of the valuation is the depreciated replacement cost (DRC) (level 3 categorisation used), calculated as replacement cost *less* cost to bring asset to current standards *less* accumulated depreciation of the expired useful life of the building. The depreciated replacement cost was based on a combination of internal records of the original cost of the specialised fitouts, adjusted for more contemporary design/construction approaches, and published construction rates for various standard components of buildings. Significant judgement is also used to assess the remaining service potential of the facilities, given local climatic and environmental conditions and records of the current condition of the facilities.

##### **(i) Replacement cost**

The methodology applied by the valuer is a financial simulation in lieu of market value as these assets cannot be bought and sold on the open market. A replacement cost is estimated by creating a cost plan (cost estimate) of the asset through the measurement of key quantities such as: Gross Floor Area (GFA), number of floors/lifts/staircases and girth/height of the building.

The model developed by the valuer creates an elemental cost plan using these quantities and the model includes multiple building types and is based on the valuer's experience of the cost of managing construction contracts.

The cost model is updated each year and tests are done to compare the model outputs on actual recent projects to ensure it produces a true representation of the cost of replacement. The costs are at Brisbane prices and published location indices are used to adjust the pricing to suit local market conditions. Live project costs from across the State are also assessed to inform current market changes that may influence the published factors.

The valuer's key assumption on the replacement cost is that their estimate is based on replacing the current function of the building with a building of the same form. This assumption has a significant impact if an asset's function changes.

### 13. Property, plant & equipment (cont'd)

#### (ii) Cost to bring to current standards

The 'cost to bring to current standards' is the estimated cost of refurbishing the asset to bring it to current standards. For each of the five condition ratings the estimate is based on professional opinion as well as having regard to historical project costs.

In assessing the cost to bring to current standard a condition rating is applied based upon the following information:

- Visual inspection of the asset
- Asset condition data provided by the Institute's Building Services Manager
- Verbal guidance from the Building Services Manager
- Previous reports and inspection photographs if available (to show the change in condition over time).

Category	Condition	Criteria
1	Very good condition	Only normal maintenance required
2	Minor defects only	Minor maintenance required
3	Maintenance required to return to accepted level of service	Significant maintenance required (up to 50% of capital replacement cost)
4	Requires renewal	Complete renewal of the internal fit out and engineering services required (up to 70% of capital replacement cost)
5	Asset unserviceable	Complete asset replacement required

These condition ratings are linked to the cost to bring to current standards.

The standard life of a mixed laboratory/office building is generally 50 years. Estimates of remaining life are based on the assumption that the asset remains in its current function and will be maintained.

Buildings have been valued on the basis that there is no residual value.

An internal valuation was carried out at 30 June 2015 using the Queensland Treasury approved '*Asset revaluation index for non-residential construction in QLD*'. This index is published by the Australian Bureau of Statistics and measures changes over time in the prices of new construction outputs for the eight Australian capital cities.

The valuation basis is at basic prices excluding Goods and Services Tax (GST) and any subsidies. The price of a building is defined as excluding the price of land, site works, external services (such as drainage, water and electricity connection) and design.

The movement in the price of buildings is being measured using a component cost method. In this method, buildings are regarded as a set of standardised homogenous components. The price movement of a whole structure is effectively derived by measuring the price movements of its components. The component prices are as close as possible to market prices; that is, they reflect not only labour, material and plant input costs, but also subcontractors' margin.

At 30 June 2015 the change in the index since the last valuation using indexation was material (6.9%) and consequently the carrying values of these buildings were adjusted to reflect current fair value. The revaluation of the Bancroft Centre and the CBCRC resulted in an increment net of accumulated depreciation of \$8.807m.

#### Buildings - QIMR Berghofer Central

The recently constructed purpose-built research facility operated by the Council known as QIMR Berghofer Central situated in Herston was stated at cost at 30 June 2012. Due to there not being an active market for such facilities fair value is measured based on a level 3 categorisation. Since 2012 annual internal valuations have been carried out using internal expert opinions and the Queensland Treasury approved '*Asset revaluation index for non-residential construction in QLD*' as outlined above.

At 30 June 2015 the change in the index since the last valuation using indexation was material (6.9%) and consequently the carrying value of this building was adjusted to reflect current fair value. The revaluation of QIMR Berghofer Central resulted in an increment net of accumulated depreciation of \$8.603m.

#### Heritage & cultural assets

Heritage & cultural assets consisting of research library monographs, Australiana and scarce items have been included at current replacement cost as assessed by the Approved Commonwealth Valuer (Books) Jörn Harbeck as at 18 April 2012. Council has no indication that there has been a significant change in the fair value since the last valuation.

13. Property, plant & equipment (cont'd)

Property, plant & equipment reconciliation  
(including fair value level. Refer note 1 (o))

	Buildings	Heritage & cultural	Plant & equipment	Work in progress	Total
	Level 3 (Research Facilities)	Level 3			
	2015 \$'000	2015 \$'000	2015 \$'000	2015 \$'000	2015 \$'000
Carrying amount at 1 July 2014	211,282	104	25,979	46,693	284,058
Acquisitions	-	-	5,124	1,998	7,122
Disposals	-	-	(1,120)	-	(1,120)
Transfers between classes	47,555	-	-	(47,555)	-
Revaluation increments	21,138	-	-	-	21,138
Accumulated depreciation revaluation adjustment	(3,728)	-	-	-	(3,728)
Depreciation	(6,556)	-	(4,649)	-	(11,205)
<b>Carrying amount at 30 June 2015</b>	<b>269,691</b>	<b>104</b>	<b>25,334</b>	<b>1,136</b>	<b>296,265</b>

	Buildings	Heritage & cultural	Plant & equipment	Work in progress	Total
	Level 3 (Research Facilities)	Level 3			
	2014 \$'000	2014 \$'000	2014 \$'000	2014 \$'000	2014 \$'000
Carrying amount at 1 July 2013	216,465	104	24,177	31,431	272,177
Acquisitions	-	-	6,135	15,262	21,397
Disposals	-	-	(198)	-	(198)
Transfers between classes	-	-	-	-	-
Revaluation increments	-	-	-	-	-
Accumulated depreciation revaluation adjustment	-	-	-	-	-
Depreciation	(5,183)	-	(4,135)	-	(9,318)
<b>Carrying amount at 30 June 2014</b>	<b>211,282</b>	<b>104</b>	<b>25,979</b>	<b>46,693</b>	<b>284,058</b>

The Council has plant & equipment with an acquisition cost of \$8.6 million (2014: \$10.8 million) and a written down value of zero still being used in the provision of services. The Council intends to retire these assets over the next five years.

	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>14. Payables</b>		
Trade creditors	1,586	1,435
Accrued wages	410	184
Other	1,480	2,066
<b>Total</b>	<b><u>3,476</u></b>	<b><u>3,685</u></b>
<b>15. Accrued employee benefits</b>		
<b>Current</b>		
Long service leave levy payable	231	220
Annual leave entitlements payable	3,370	3,071
Other	702	565
<b>Total</b>	<b><u>4,303</u></b>	<b><u>3,856</u></b>
<b>Non current</b>		
Annual leave entitlements payable	884	881
<b>Total</b>	<b><u>884</u></b>	<b><u>881</u></b>
<b>16. Non-interest bearing liability</b>		
<b>Current</b>		
Loan	-	1,324
<b>Total</b>	<b><u>-</u></b>	<b><u>1,324</u></b>

The Council had an interest free loan of \$3.3m under the Queensland Tropical Health Alliance (QTHA). In 2014-15 the loan was repaid in full at a 10% discount on the present value, being the repayment amount of \$1.324m. The loan was provided by the Queensland State Government and sub-contracted to the Council through the James Cook University. No assets were pledged as security for the liability. No interest was capitalised during the current or comparative reporting periods. There were no defaults or breaches of the loan agreement during the period.

**17. Unearned revenue**

Unearned revenue	18,957	19,164
	<b><u>18,957</u></b>	<b><u>19,164</u></b>

	<b>Grants b/f</b>	<b>Grants</b>	<b>Grant</b>	<b>Grants c/f</b>
	<b>1 July 2014</b>	<b>received</b>	<b>expenditure</b>	<b>30 June 2015</b>
National Health & Medical Research Council	7,333	24,865	(24,858)	7,340
Australian Research Council	934	1,518	(1,734)	718
Bioplatfroms Australia	900	593	(1,161)	332
Cancer Council Qld	195	1,338	(1,342)	191
Other granting bodies	9,444	12,050	(11,463)	10,031
Other commercial funding bodies	358	-	(13)	345
	<b><u>19,164</u></b>	<b><u>40,364</u></b>	<b><u>(40,571)</u></b>	<b><u>18,957</u></b>



**17. Unearned revenue (cont'd)**

	<b>Grants b/f 1 July 2013</b>	<b>Grants received</b>	<b>Grant expenditure</b>	<b>Grants c/f 30 June 2014</b>
National Health & Medical Research Council	7,964	25,734	(26,365)	7,333
Australian Research Council	1,204	2,045	(2,315)	934
Bioplatforms Australia	364	2,234	(1,698)	900
Cancer Council Qld	109	1,485	(1,399)	195
Other granting bodies	9,238	13,126	(12,920)	9,444
Other commercial funding bodies	381	-	(23)	358
	<b>19,260</b>	<b>44,624</b>	<b>(44,720)</b>	<b>19,164</b>

**18. Asset revaluation surplus by class**

	<b>Buildings \$'000</b>	<b>Heritage &amp; cultural \$'000</b>	<b>Total \$'000</b>
Balance at 1 July 2014	47,815	4	47,819
Revaluation increments *	17,410	-	17,410
<b>Balance at 30 June 2015</b>	<b>65,225</b>	<b>4</b>	<b>65,229</b>

	<b>Buildings \$'000</b>	<b>Heritage &amp; cultural \$'000</b>	<b>Total \$'000</b>
Balance at 1 July 2013	47,815	4	47,819
Revaluation increments *	-	-	-
<b>Balance at 30 June 2014</b>	<b>47,815</b>	<b>4</b>	<b>47,819</b>

\* Further details are presented in notes 1(n) and 13.

	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>19. Reconciliation of operating surplus to net cash from operating activities</b>		
Operating (deficit)/surplus	(4,490)	7,101
Depreciation and amortisation expense	11,291	9,404
Loss on sale of property, plant and equipment	254	113
Net gain on market value of other financial assets	(5,432)	(4,924)
Net gain on sale of shares	(3)	-
Investment distributions other financial assets	(4,416)	(6,272)
Gain on early settlement of borrowings	-	(232)
Interest borrowings	-	67
Change in assets and liabilities:		
(Increase)/decrease in receivables	3,358	(488)
(Increase)/decrease in inventories	15	5
(Increase)/decrease in prepayments	(423)	659
Increase/(decrease) in accounts payable	(209)	(2,566)
Increase/(decrease) in accrued employee benefits	450	421
Increase/(decrease) in unearned revenue	(206)	(96)
(Increase)/decrease in investments accounted for using equity method	-	228
<b>Net cash from operating activities</b>	<b>189</b>	<b>3,420</b>

**20. Commitments for expenditure**

**(a) Non-cancellable operating leases**

Commitments under operating leases at reporting date are inclusive of anticipated GST and are payable as follows:

Payable:

Not later than one year	11	41
Later than one year and not later than five years	3	13
Later than five years	-	-
<b>Total</b>	<b>14</b>	<b>54</b>

Operating leases have renewal options, however, no leases have escalation clauses other than in the event of payment default.

No lease arrangements create restrictions on other financing transactions.

	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>20. Commitments for expenditure (cont'd)</b>		
<b>(b) Capital expenditure commitments</b>		
Bancroft Centre building maintenance works	305	704
Other capital commitments	1,243	971
	<u>1,548</u>	<u>1,675</u>

The finalisation of the Bancroft Centre building maintenance works represents 20% of capital expenditure commitments (2014 finalisation of Bancroft Centre refurbishment: 42%). The values shown are based on the committed contract value inclusive of anticipated GST.

Payable:

Not later than one year	1,548	1,675
Later than one year and not later than five years	-	-
Later than five years	-	-
<b>Total</b>	<u>1,548</u>	<u>1,675</u>

**(c) Other expenditure commitments**

Other expenditure committed at the end of the period but not recognised in the accounts is as follows:

Payable:

Not later than one year	2,860	888
Later than one year and not later than five years	-	-
Later than five years	-	-
<b>Total</b>	<u>2,860</u>	<u>888</u>

**21. Contingencies**

**(a) Contingent assets**

*Contributions to Queensland Community Foundation*

The QIMR Trust established a fund with the Queensland Community Foundation (QCF) for the purpose to generate future income and donations. This fund was transferred to Council upon abolition of the Trust on 1 February 2011. All contributions made to this named fund within QCF are held in trust and invested in perpetuity with net income distributed to the Council at the discretion of the Trustee in accordance with the Queensland Community Fund Declaration of Trust. The available balance of this fund was \$2.064m at 30 June 2015 comprising total assets of \$2.082m and total liabilities of \$0.018m (net assets 2014: \$1.971m) of which \$0.01m was contributed by the former QIMR Trust. The Council expects that earnings from the 2014-15 financial year will be brought to account during the financial year ending 30 June 2016.

**(b) Contingent liabilities**

There were no known contingent liabilities at 30 June 2015.

## 22. Controlled and jointly controlled entities

### (a) Q-Pharm Pty Ltd

Q-Pharm Pty Ltd is a clinical trial company. The Council increased its shareholding in Q-Pharm Pty Ltd by acquiring the remaining issued shares from the other three shareholders in August 2014. As at 30 June 2015 the Council holds 100% of the shares of Q-Pharm Pty Ltd (2014: 24.5%).

	2015 \$'000	2014 \$'000
<b>Q-Pharm Pty Ltd</b>		
Investment - at cost (2013-14 equity method)	23	23
	<u>23</u>	<u>23</u>
This is a summary of the financial transactions and balances for Q-Pharm Pty Ltd:		
Income	5,146	3,604
Expenses	<u>(4,955)</u>	<u>(4,542)</u>
<b>Net surplus/(deficit)</b>	<u>191</u>	<u>(938)</u>
Current assets	1,231	795
Non-current assets	163	186
Current liabilities	<u>(1,115)</u>	<u>(894)</u>
<b>Net assets</b>	<u>279</u>	<u>87</u>

Q-Pharm Pty Ltd did not have any material contingent liabilities or commitments as at 30 June 2015.

Q-Pharm Pty Ltd's financial statements for the year ended 30 June 2015 were audited by the Auditor-General of Queensland (2014: Mr Terry Murphy CA audited Q-Pharm Pty Ltd). Total external audit fees relating to the 2014-15 financial year are expected to be \$15,500 (2014: \$14,500) and have been accrued. There are no non-audit services included in this amount.

### (b) Vaccine Solutions Pty Ltd

Vaccine Solutions Pty Ltd was established in 1998 to provide clinical trial sponsorship, intellectual property management and commercialisation services to the Cooperative Research Centre for Vaccine Technology (CRCVT). Following the winding up of the CRCVT, Vaccine Solutions manages a number of licensing arrangements for the benefit of the members of CRCVT Trust II. Vaccine Solutions does not own any physical or intellectual property assets on its own and is required to return 97% of all commercial income received from licensing activities to the CRCVT Trust II for distribution to members of that trust. The Council increased its shareholding in Vaccine Solutions Pty Ltd by acquiring the remaining issued shares from the other shareholder CSL Limited in June 2015. As at 30 June 2015 the Council holds 100% of the shares of Vaccine Solutions Pty Ltd (2014: 50%).

This is a summary of the financial transactions and balances for Vaccine Solutions Pty Ltd:

Income	5	7
Expenses	<u>(1)</u>	<u>(4)</u>
<b>Net surplus/(deficit)</b>	<u>4</u>	<u>3</u>
Current assets	29	236
Current liabilities	<u>(10)</u>	<u>(14)</u>
<b>Net assets</b>	<u>19</u>	<u>222</u>

Vaccine Solutions Pty Ltd paid a dividend of \$203,000 in 2014-15 (2013-14: \$0).

Vaccine Solutions Pty Ltd did not have any material contingent liabilities or commitments as at 30 June 2015.

Vaccine Solutions Pty Ltd's was not required to prepare financial statements for the years 30 June 2015 and 30 June 2014, however, the transactions disclosed above have been reviewed by audit.

### (c) Q-Gen Pty Ltd

During the 2004-05 financial year, the Institute incorporated a wholly owned subsidiary, Q-Gen Pty Ltd. The operations of Q-Gen Pty Ltd were wound up as at 30 June 2009 with activities of the entity being taken over by the Institute. The entity still exists as a shelf company but is dormant.

**23. Trust transactions and balances**

**(a) Trust II for the CRC for Vaccine Technology (CRCVT Trust II)**

The Council is the Trustee of the CRC for Vaccine Technology Trust II (CRCVT Trust II), a trust responsible for managing patent families and licensing arrangements on behalf of the participants in the CRCVT since winding up in June 2006. Income received from licensing arrangements is distributed to the members in the trust according to their participating share in the CRCVT as of June 2006. The members of the CRCVT Trust II are: The Council of the Queensland Institute of Medical Research, CSIRO, CSL Limited, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Monash University, Australian Red Cross Blood Service and La Trobe University.

As the Council performs only a custodial role in respect of these transactions and balances, they are not recognised in the financial statements but are disclosed in this note for the information of users.

	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
This is a summary of the financial transactions and balances for CRC for Vaccine Technology Trust II		
Income	7	11
Expenses	<u>(69)</u>	<u>(60)</u>
<b>Trust net surplus/(deficit) before distributions</b>	<b><u>(62)</u></b>	<b><u>(49)</u></b>
Cash	227	437
Receivables	<u>-</u>	<u>31</u>
<b>Total assets</b>	<b><u>227</u></b>	<b><u>468</u></b>
Payables	28	16
Beneficiaries entitlements payable	<u>199</u>	<u>452</u>
<b>Total liabilities</b>	<b><u>227</u></b>	<b><u>468</u></b>
<b>Trust net assets</b>	<b><u>-</u></b>	<b><u>-</u></b>

CRCVT Trust II's financial statements for the year ended 30 June 2015 were audited by PKF (2014: PKF). Total external audit fees relating to the 2014-15 financial year are expected to be \$5,000 (2014: \$5,000) and have been accrued. There are no non-audit services included in this amount.

**(b) Employee Research Services**

The Council undertakes a custodial role in respect of transactions and balances relating to Employee Research Services (ERS). They are not recognised in the financial statements but are disclosed in this note for the information of users.

This is a summary of the financial transactions and balances for Employee Research Services

Income	2,463	2,344
Expenses	<u>(2,015)</u>	<u>(1,665)</u>
<b>Increase/(decrease) in net balance</b>	<b><u>448</u></b>	<b><u>679</u></b>
Cash held in short term deposits	<u>3,238</u>	<u>2,790</u>
<b>Total trust assets</b>	<b><u>3,238</u></b>	<b><u>2,790</u></b>

**24. Key management personnel and remuneration**

**(a) Key management personnel**

The following details for key management personnel include those positions that had authority and responsibility for planning, directing and controlling the activities of the Institute during 2014-15. Further information on these positions can be found in the body of the annual report under the section relating to management.

Position	Responsibilities	Current incumbents	
		Contract classification and appointment authority	Term
<b>Council members</b>			
Dr Douglas McTaggart - Chair	The functions of the Council are to: (a) control and manage the Institute; (b) raise and accept moneys for the purposes of the Institute; (c) invest moneys raised and accepted by the Council for the purposes of the Institute; and (d) invest moneys derived from any property or other invested moneys of the Council for the purposes of the Institute.	Appointed by Governor in Council, s10 Queensland Institute of Medical Research Act 1945	27 Nov 2014 to current
Mr Christopher Coyne - Deputy Chair (Acting Chair from 1 Jul 2014 to 26 Nov 2014)			9 Sep 2011 to current
Mr Ian Fraser			9 Aug 2012 to current
Emeritus Prof John de Jersey			27 Nov 2014 to current
Assoc Prof Paula Mariton			9 Sep 2011 to current
Prof Alan Pettigrew			9 Sep 2011 to current
Mr Michael Sargent			27 Nov 2014 to current
Prof John Shine			27 Nov 2014 to current
Dr Jeannette Young <sup>^</sup>			9 Sep 2011 to current
Emeritus Prof Bryan Campbell			9 Sep 2011 to 26 Nov 2014
Dist Prof Judith Clements			9 Sep 2011 to 26 Nov 2014
Prof Nicholas Fisk			9 Sep 2011 to 26 Nov 2014
Dr John Herron			27 Nov 2014 to 15 Apr 2015
Mr Rod Wylie	9 Sep 2011 to 26 Nov 2014		
<b>Director/CEO</b>			
Prof Frank Gannon	The Director is responsible for the work and efficient and effective administration of the Council	Appointed by Governor in Council, s10 Queensland Institute of Medical Research Act 1945	4 Jan 2011 to current

<sup>^</sup> Officer of the public service

**(b) Remuneration**

The Chairperson and members of Council receive sitting fees in line with the 'Remuneration of part-time Chairs and Members of Government Boards, Committees and Statutory Authorities' guideline issued by the Queensland Government. Any member of the Council who is an officer of the public service does not receive fees or allowances for attendance at a meeting of the Council.

The remuneration policy for the Director/CEO is set by Council and approved by the Governor in Council as provided for under the Queensland Institute of Medical Research Act 1945. The remuneration and other terms of employment for the Director/CEO are specified in the employment contract. The contract provides for the provision of other benefits including motor vehicles.

**24. Key management personnel and remuneration (cont'd)**

The remuneration package for the Director/CEO comprises the following components:

- i. Short term employee benefits which include
  - Base – consisting of base salary, allowances and leave entitlements paid and provided for the entire year or for that part of the year during which the Director/CEO occupied the specified position. Amounts disclosed equal the amount expensed in the Statement of Comprehensive Income.
  - Non-monetary benefits – consisting of provision of living-away-from-home-allowance, travel, vehicle and other minor benefits together with fringe benefits tax applicable to these benefits.
- ii. Long term employee benefits include long service leave accrued.
- iii. Post employment benefits include superannuation contributions.
- iv. Termination benefits are not provided for within the Director/CEO's contract of employment. The contract of employment provides only for notice periods or payment in lieu of notice on termination, regardless of the reason for termination.
- v. There are no performance bonuses paid or payable to the Director/CEO.

Total remuneration is calculated on a 'total cost' basis and includes the base and non-monetary benefits, long term employee benefits and post employment benefits. No termination benefits have been paid during either financial years.

**1 July 2014 - 30 June 2015**

Position	Short term employee benefits		Long term employee benefits	Post-employment benefits	Total remuneration
	Base \$'000	Non-monetary benefits \$'000	\$'000	\$'000	\$'000
Chair of Council (1)	-	-	-	-	-
Council Members (11)	21	-	-	-	21
Director/CEO	601	154	15	35	805
<b>Total</b>	<b>622</b>	<b>154</b>	<b>15</b>	<b>35</b>	<b>826</b>

**1 July 2013 - 30 June 2014**

Position	Short term employee benefits		Long term employee benefits	Post-employment benefits	Total remuneration
	Base \$'000	Non-monetary benefits \$'000	\$'000	\$'000	\$'000
Chair of Council (1)	-	-	-	-	-
Council Members (10)	14	-	-	-	14
Director/CEO	566	185	14	32	797
<b>Total</b>	<b>580</b>	<b>185</b>	<b>14</b>	<b>32</b>	<b>811</b>

The table above includes \$102,000 in fringe benefits tax paid by Council in 2014-15 in relation to key management remuneration (2014: \$116,000).

**25. Financial instruments**

**(a) Categorisation of financial instruments**

The Council has the following categories of financial assets and financial liabilities:

Category	Notes	2015 \$'000	2014 \$'000
<b>Financial assets</b>			
Cash and cash equivalents	9	32,388	39,079
Receivables	10	5,246	8,602
Managed funds investments and US listed shares	11	103,932	94,784
		<b>141,566</b>	<b>142,465</b>

	Notes	2015 \$'000	2014 \$'000
<b>25. Financial instruments (cont'd)</b>			
<b>Financial liabilities</b>			
Financial liabilities measured at amortised cost:			
Payables	14	3,476	3,685
Non-interest bearing liability	16	-	1,324
		<u>3,476</u>	<u>5,009</u>

**(b) Financial risk management**

The Council's activities expose it to a variety of financial risks-credit risk, liquidity risk market risk and interest rate risk.

Financial risk management is implemented pursuant to Government and Council policy. These policies focus on the unpredictability of financial markets and seek to minimise potential adverse effects on the financial performance of the Council.

All financial risk is managed by the Institute under policies approved by the Council. The Council provides written principles for overall risk management, as well as policies covering specific areas.

The Council measures risk exposure using a variety of methods as follows:

Risk exposure	Measurement method
Credit risk	Ageing analysis, earnings at risk
Liquidity risk	Sensitivity analysis
Market risk	Interest rate sensitivity analysis

**(i) Credit risk exposure**

Credit risk exposure refers to the situation where the Council may incur financial loss as a result of another party to a financial instrument failing to discharge their obligation.

The maximum exposure to credit risk at balance date in relation to each class of recognised financial assets is the gross carrying amount of those assets inclusive of any provisions for impairment.

The following table represents the Council's maximum exposure to credit risk based on contractual amounts net of any allowances:

Category	Note	2015 \$'000	2014 \$'000
<b>Maximum Exposure to Credit Risk</b>			
<b>Financial assets</b>			
Managed funds investments and US listed shares	11	103,932	94,784
<b>Total</b>		<u>103,932</u>	<u>94,784</u>

The carrying amount of managed funds investments, US listed shares and receivables represents the maximum exposure to credit risk. As such, receivables are not included in the above disclosure.

No collateral is held as security and no credit enhancements relate to financial assets held by the Council.

The Council manages credit risk through the use of a credit management strategy. This strategy aims to reduce the exposure to credit default by ensuring that the Council invests in secure assets and monitors all funds owed on a timely basis. Exposure to credit risk is monitored on an ongoing basis.

No financial assets and financial liabilities have been offset and presented net in the Statement of Financial Position.

The method for calculating any provision for impairment is based on past experience, current and expected changes in economic conditions and changes in client credit ratings. These economic and geographic changes form part of the Council's documented risk analysis assessment in conjunction with historic experience and associated industry data. This analysis has identified that none of the Council's financial assets are impaired and subsequently provisions for impairment have not been raised.

No financial assets have had their terms renegotiated so as to prevent them from being past due or impaired, and are stated at the carrying amounts as indicated.

Ageing of past due but not impaired financial assets is disclosed in the following tables. No financial assets were assessed as being impaired as at 30 June 2015.



**25. Financial instruments (cont'd)**

**2015 Financial assets past due but not impaired**

Note	Not due		Overdue			Total	Not due and
	< 30 days	30-60 days	61-90 days	> 90 days	overdue		
	\$'000	\$'000	\$'000	\$'000	\$'000		
							Total
							\$'000
<b>Financial assets</b>							
Receivables	10	4,200	536	69	441	1,046	5,246
<b>Total</b>		<b>4,200</b>	<b>536</b>	<b>69</b>	<b>441</b>	<b>1,046</b>	<b>5,246</b>

**2014 Financial assets past due but not impaired**

Note	Not due		Overdue			Total	Not due and
	< 30 days	30-60 days	61-90 days	> 90 days	overdue		
	\$'000	\$'000	\$'000	\$'000	\$'000		
							Total
							\$'000
<b>Financial assets</b>							
Receivables	10	6,258	830	444	1,070	2,344	8,602
<b>Total</b>		<b>6,258</b>	<b>830</b>	<b>444</b>	<b>1,070</b>	<b>2,344</b>	<b>8,602</b>

**(ii) Liquidity risk**

Liquidity risk refers to the situation where the Council may encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset.

The only financial liabilities which expose the Council to liquidity risk are payables and non-interest bearing liabilities. All financial liabilities are current in nature and will be due and payable within twelve months. As such no discounting of cash flows has been made to these liabilities in the Statement of Financial Position. Refer notes 14 and 16.

The Council manages liquidity risk through the use of a liquidity management strategy. This strategy aims to reduce the exposure to liquidity risk by ensuring the Council has sufficient funds available to meet employee and supplier obligations as they fall due. This is achieved by ensuring that minimum levels of cash are held within the various bank accounts so as to match the expected duration of the various employee and supplier liabilities.

**(iii) Market risk**

**Market risk refers to the risk of loss arising from movements in market parameters such as exchange rates, interest rates and equity prices.**

The Council does not trade in foreign currency and is not materially exposed to movements in foreign currency exchange rates. It maintains a bank account in Hong Kong with an immaterial cash balance denominated in HK\$ used to fund the operations of a local study.

The Council does not undertake any hedging in relation to interest risk and manages its risk as per the Council's liquidity risk management strategy articulated in the Council's policies. The Council is exposed to movements in interest rate risk through its investment in externally managed funds and its holdings in cash and cash equivalents. An interest rate sensitivity analysis has been carried out and is presented in item (i) below.

The Council is exposed to price risk arising from its managed funds investments. These investments are classified as financial assets at fair value through profit or loss in the Statement of Financial Position. A price risk sensitivity analysis has been carried out and is presented in item (ii) below.

**i. Interest rate sensitivity analysis**

Sensitivity analysis indicates that the impact on the operating result and equity due to interest rate movements is immaterial for the Council. Interest rate movements of +/- 1% would change the operating result and equity by \$0.3 million (2014: \$0.4 million) based on the Council's exposure to interest rate movements mainly attributed to its holdings of term deposits. Refer note 9.

**25. Financial instruments (cont'd)**

**ii. Price risk sensitivity analysis**

The natural unpredictability of investment market performance can impact on the operating result and equity of the Council due to unit/share price movements. Sensitivity analysis indicates that unit/share price movements of +/-5% would change the operating result and equity by \$5.2 million (2014: \$4.7 million) based on the Council's exposure to unit/share price movements attributed to its holdings of managed funds investments. Refer note 11.

**(c) Fair value**

According to the hierarchy in note 1(o), the fair values of each class of asset/liabilities recognised at fair value are as follows:

	2015 Classification according to fair value hierarchy			Total
	Level 1	Level 2	Level 3	
Financial assets	\$'000	\$'000	\$'000	\$'000
Managed funds investments	103,932	-	-	103,932
<b>Total</b>	<b>103,932</b>	<b>-</b>	<b>-</b>	<b>103,932</b>

	2014 Classification according to fair value hierarchy			Total
	Level 1	Level 2	Level 3	
Financial assets	\$'000	\$'000	\$'000	\$'000
Managed funds investments	94,757	-	-	94,757
Shares-US listed entities	27	-	-	27
<b>Total</b>	<b>94,784</b>	<b>-</b>	<b>-</b>	<b>94,784</b>

Note the above table below does not relate to all assets and liabilities recorded at fair value. For the hierarchy of non-current assets measured at fair value refer note 13.

The fair value of trade receivables and payables is assumed to approximate the value of the original transaction, less any provision for impairment.

**26. Events occurring after balance date**

There are no events occurring after balance date having a material impact on the figures reported in these financial statements.

**27. Economic dependency**

The Council's activities are predominantly funded by grants received from a range of funding agencies, the majority of which are Commonwealth and State Government bodies. The ability of the Council to source sufficient grant funding is dependent upon those entities continuing to have the ability to fund research activities and for the Institute to be successful in its funding applications. At balance date the Council had no indication that operational and research funding would not be provided as per the funding agreements. Should unforeseen fluctuations in the amount of available grant funding occur the Council would use its cash assets (refer note 9) and managed funds investments (refer note 11) to cover short term operational cash requirements.

## 28. Budget vs Actual Comparison

Note: A budget vs actual comparison, and explanations of major variances, has not been included for the Statement of Changes in Equity, as major variances relating to that statement have been addressed in explanations of major variances for other statements.

### STATEMENT OF COMPREHENSIVE INCOME

		Original Budget	Actual	Variance	Variance % of budget
	Variance Notes	2015 \$'000	2015 \$'000	\$'000	
<b>Income from continuing operations</b>					
Grants and other contributions	a	85,542	75,950	(9,592)	(11)
User charges and fees	b	5,404	4,195	(1,209)	(22)
Other revenue	c	5,083	7,018	1,935	38
Interest		1,541	1,221	(320)	(21)
<b>Total revenue</b>		<b>97,570</b>	<b>88,384</b>	<b>(9,186)</b>	<b>(9)</b>
Gains/(losses)	d	3,603	5,181	1,578	44
<b>Total income from continuing operations</b>		<b>101,173</b>	<b>93,565</b>	<b>(7,608)</b>	<b>(8)</b>
<b>Expenses from continuing operations</b>					
Employee expenses		51,223	52,548	(1,325)	(3)
Supplies and services	e	30,743	26,731	4,012	13
Depreciation and amortisation		11,382	11,291	91	1
Other expenses		7,338	6,811	527	7
Finance costs		487	674	(187)	(38)
<b>Total expenses from continuing operations</b>		<b>101,173</b>	<b>98,055</b>	<b>3,118</b>	<b>3</b>
<b>Operating result from continuing operations</b>		<b>-</b>	<b>(4,490)</b>	<b>(4,490)</b>	<b>-</b>
<b>Other comprehensive income</b>					
<i>Items that will not be reclassified subsequently to operating result</i>					
Increase in asset revaluation surplus	f	-	17,410	17,410	-
Total items that will not be classified subsequently to operating result		-	17,410	17,410	-
<b>Total other comprehensive income</b>		<b>-</b>	<b>17,410</b>	<b>17,410</b>	<b>-</b>
<b>Total comprehensive income</b>		<b>-</b>	<b>12,920</b>	<b>12,920</b>	<b>-</b>

28. Budget vs Actual Comparison (cont'd)

STATEMENT OF FINANCIAL POSITION

	Variance Notes	Original Budget 2015 \$'000	Actual 2015 \$'000	Variance \$'000	Variance % of budget
<b>Current assets</b>					
Cash and cash equivalents	g	34,794	32,388	(2,406)	(7)
Receivables	h	10,144	5,246	(4,898)	(48)
Inventories		272	253	(19)	(7)
Prepayments		1,045	808	(237)	(23)
<b>Total current assets</b>		<b>46,255</b>	<b>38,695</b>	<b>(7,560)</b>	<b>(16)</b>
<b>Non-current assets</b>					
Other financial assets	i	97,945	103,932	5,987	6
Intangible assets		379	379	(0)	-
Property, plant and equipment	j	281,534	296,265	14,731	5
Investments accounted for using the equity method		251	23	(228)	(91)
<b>Total non-current assets</b>		<b>380,109</b>	<b>400,599</b>	<b>20,490</b>	<b>-</b>
<b>Total assets</b>		<b>426,364</b>	<b>439,294</b>	<b>12,930</b>	<b>3</b>
<b>Current liabilities</b>					
Payables	k	6,979	3,476	3,503	50
Accrued employee benefits		2,910	4,303	(1,393)	(48)
Unearned revenue		19,259	18,957	302	2
<b>Total current liabilities</b>		<b>29,148</b>	<b>26,736</b>	<b>2,412</b>	<b>8</b>
<b>Non-current liabilities</b>					
Accrued employee benefits		869	884	(15)	(2)
<b>Total non-current liabilities</b>		<b>869</b>	<b>884</b>	<b>(15)</b>	<b>(2)</b>
<b>Total liabilities</b>		<b>30,017</b>	<b>27,620</b>	<b>2,397</b>	<b>8</b>
<b>Net assets</b>		<b>396,347</b>	<b>411,674</b>	<b>15,327</b>	<b>4</b>
<b>Equity</b>					
Accumulated surplus		348,529	346,445	(2,084)	(1)
Asset revaluation surplus	j	47,818	65,229	17,411	36
<b>Total equity</b>		<b>396,347</b>	<b>411,674</b>	<b>15,327</b>	<b>4</b>

28. Budget vs Actual Comparison (cont'd)

STATEMENT OF CASH FLOWS

		Original Budget 2015 \$'000	Actual 2015 \$'000	Variance \$'000	Variance % of budget
<b>Cash flows from operating activities</b>					
<b>Inflows:</b>					
Grants and other contributions	l	85,542	77,715	(7,827)	(9)
User charges and fees		5,404	6,227	823	15
Other income		1,480	1,763	283	19
Interest income		1,541	1,221	(320)	(21)
GST input tax credits from ATO		-	2,437	2,437	-
GST collected from customers		-	1,839	1,839	-
<b>Outflows:</b>					
Employee expenses		(51,223)	(51,937)	(714)	1
Supplies and services	m	(36,423)	(27,348)	9,075	(25)
Finance costs		(486)	(674)	(188)	39
GST paid to suppliers		-	(2,893)	(2,893)	-
GST remitted to ATO		-	(1,353)	(1,353)	-
Other		(1,748)	(6,808)	(5,060)	289
<b>Net cash provided by operating activities</b>		<b>4,087</b>	<b>189</b>	<b>(3,898)</b>	<b>(95)</b>
<b>Cash flows from investing activities</b>					
<b>Inflows:</b>					
Redemptions of other financial assets		6,000	3,036	(2,964)	(49)
Sale of property, plant and equipment		-	60	60	-
<b>Outflows:</b>					
Investments in other financial assets		(6,748)	(2,300)	4,448	(66)
Acquisition of property, plant and equipment		(6,435)	(6,352)	83	(1)
<b>Net cash used in investing activities</b>		<b>(7,183)</b>	<b>(5,556)</b>	<b>1,627</b>	<b>(23)</b>
<b>Cash flows from financing activities</b>					
<b>Outflows:</b>					
Non-interest bearing loan redemption	n	-	(1,324)	(1,324)	-
<b>Net cash used in financing activities</b>		<b>-</b>	<b>(1,324)</b>	<b>(1,324)</b>	<b>-</b>
Net decrease in cash and cash equivalents		(3,096)	(6,691)	(3,595)	116
Cash and cash equivalents at beginning of financial year		37,890	39,079	1,189	3
<b>Cash and cash equivalents at end of financial year</b>		<b>34,794</b>	<b>32,388</b>	<b>(2,406)</b>	<b>(7)</b>

## 28. Budget vs Actual Comparison (cont'd)

### Explanation of Major Variances

The following explanations are in relation to the 2014-15 budget which was approved by the Council on 25 March 2014.

#### Statement of Comprehensive Income

- a. Amounts of competitive research grant funding distributed to the Institute by the National Health and Medical Research Council and other funding agencies did not increase as expected. This further impacted on income from grant administration and fees paid to QIMR Berghofer as the grant administering institute. In addition, amounts of donation and bequest income received by the Institute in 2014-15 were about \$4m lower than budgeted amounts and historic trends.
- b. Due to the ongoing major building maintenance works in the Bancroft Centre, anticipated occupation of lab space did not eventuate until later in 2014-15. User fees and charges reflect lower usage due to later occupation.
- c. Managed funds investments achieved higher returns than budgeted in the first part of 2014-15 reflecting a strong performance of financial markets with a total overall return of 9.4% compared to a budgeted return of 8%.
- d. Gains on sale/revaluation of assets include increases in the market value of QIMR Berghofer's managed funds investments reflecting a stronger than budgeted performance of financial markets in 2014-15. Also refer note i below.
- e. Supplies and services costs in 2014-15 were lower than budget due to successful cost saving initiatives and lower than expected competitive research grant funding being available for research activities.
- f. This variance relates to an increase in the fair value of Council's buildings and the related revaluation increase of \$17.4m which was not budgeted based on historic experience. Also refer note j below.

#### Statement of Financial Position

- g. The decrease in the 2014-15 actual cash balance is mainly related to expenditure of project funds for the completion of the Bancroft Centre refurbishment (about \$2m) and ongoing building maintenance works.
- h. Receivables have reduced due to increased monitoring of outstanding invoices and recovery action taken. In addition, the National Health & Medical Research Council brought its monthly payments forward from one month in arrears to payment within the month the grant funds are due. This reduced the receivable balance by about \$2m at balance date.
- i. The market value of Council's managed funds investments reflects a stronger than budgeted performance of financial markets in 2014-15 actual result with a total overall return of 9.4% compared to a budgeted return of 8%.
- j. This variance relates mainly to an increase in the fair value of Council's buildings and the related revaluation increase of \$17.4m which was not budgeted based on historic experience.
- k. Payables were less than budgeted due to capital expenditure invoices being received and paid earlier than expected.

#### Statement of Cash Flows

- l. Amounts of donation and bequest income received by the Institute in 2014-15 were about \$4m lower than budgeted amounts and historic trends.
- m. Supplies and services paid were lower than budget due to less than anticipated accounts payables at end of 2013-14, successful cost saving initiatives and lower than expected competitive research grant funding being available for research activities.
- n. The Council agreed to the State Government's request to repay the loan provided by the State Government in relation to the Queensland Tropical Health Alliance, ahead of its maturity (\$1.3m).

**The Council of The Queensland Institute of Medical Research**

**Certificate of The Council of the Queensland Institute of Medical Research**


These general purpose financial statements have been prepared pursuant to section 62(1) of the *Financial Accountability Act 2009* (the Act), relevant sections of the *Financial and Performance Management Standard 2009* and other prescribed requirements. In accordance with section 62(1)(b) of the Act we certify that in our opinion:

- a. the prescribed requirements for establishing and keeping the accounts have been complied with in all material respects; and
- b. the statements have been drawn up to present a true and fair view, in accordance with prescribed accounting standards, of the transactions of The Council of the Queensland Institute of Medical Research for the financial year ended 30 June 2015 and of the financial position of the Council at the end of that year; and
- c. these assertions are based on an appropriate system of internal controls and risk management processes being effective, in all material aspects, with respect to the financial reporting throughout the reporting period.

Dated at Brisbane this 28th day of August 2015



**Dr Douglas McTaggart**  
Chair of Council



**Professor Frank Gannon**  
Director & Chief Executive Officer



**Donna Hancock**  
Secretary

## INDEPENDENT AUDITOR'S REPORT

To the Council of the Queensland Institute of Medical Research

### Report on the Financial Report

I have audited the accompanying financial report of the Council of the Queensland Institute of Medical Research, which comprises the statement of financial position as at 30 June 2015, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and certificates given by the Chair, the Director and Chief Executive Officer and Secretary.

#### *The Council's Responsibility for the Financial Report*

The Council is responsible for the preparation of the financial report that gives a true and fair view in accordance with prescribed accounting requirements identified in the *Financial Accountability Act 2009* and the *Financial and Performance Management Standard 2009*, including compliance with Australian Accounting Standards. The Council's responsibility also includes such internal control as the Council determines is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

#### *Auditor's Responsibility*

My responsibility is to express an opinion on the financial report based on the audit. The audit was conducted in accordance with the *Auditor-General of Queensland Auditing Standards*, which incorporate the Australian Auditing Standards. Those standards require compliance with relevant ethical requirements relating to audit engagements and that the audit is planned and performed to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control, other than in expressing an opinion on compliance with prescribed requirements. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Council as well as evaluating the overall presentation of the financial report including any mandatory financial reporting requirements approved by the Treasurer for application in Queensland.

I believe that the audit evidence obtained is sufficient and appropriate to provide a basis for my audit opinion.



### *Independence*

The *Auditor-General Act 2009* promotes the independence of the Auditor-General and all authorised auditors. The Auditor-General is the auditor of all Queensland public sector entities and can be removed only by Parliament.

The Auditor-General may conduct an audit in any way considered appropriate and is not subject to direction by any person about the way in which audit powers are to be exercised. The Auditor-General has for the purposes of conducting an audit, access to all documents and property and can report to Parliament matters which in the Auditor-General's opinion are significant.

### *Opinion*

In accordance with s.40 of the *Auditor-General Act 2009* –

- (a) I have received all the information and explanations which I have required; and
- (b) in my opinion –
  - (i) the prescribed requirements in relation to the establishment and keeping of accounts have been complied with in all material respects; and
  - (ii) the financial report presents a true and fair view, in accordance with the prescribed accounting standards, of the transactions of the Council of the Queensland Institute of Medical Research for the financial year 1 July 2014 to 30 June 2015 and of the financial position as at the end of that year.

### **Other Matters - Electronic Presentation of the Audited Financial Report**

Those viewing an electronic presentation of these financial statements should note that audit does not provide assurance on the integrity of the information presented electronically and does not provide an opinion on any information which may be hyperlinked to or from the financial statements. If users of the financial statements are concerned with the inherent risks arising from electronic presentation of information, they are advised to refer to the printed copy of the audited financial statements to confirm the accuracy of this electronically presented information.



D J OLIVE CPA  
as Delegate of the Auditor-General of Queensland



Queensland Audit Office  
Brisbane

# SUPPORTING INFORMATION

## AWARDS

RESEARCHER	AWARDING ORGANISATION	AWARD NAME
Lauren Aoude	University of Queensland	Dean's Award for Outstanding Research Higher Degree Thesis
Jasmine Akter	University of Queensland	International Postgraduate Award
Scott Bell	Thoracic Society of Australia and New Zealand	TSANZ Research Medal
	Prince Charles Hospital	Best published paper
Mark Bettington	Gastroenterology Society of Australia	Poster of Merit
Sumudu Britton	NHMRC	Postgraduate Medical Scholarship
Julie Burel	ASI	Student Travel Award
	Australian Society for Parasitology	Student Travel Award
	American Association of Immunologists (AAI)	Trainee Abstract Award
Yi Chieh Lim	COGNO	Best Oral Presentation
Lucia Colodro Conde	International Society for Psychiatric Genetics	Travel Award
Ashraful Haque	AIDRC	Seed Fund Award
Karina DeSousa	OzEMalaR	Australia Europe Malaria Research Cooperative Travel Award
	Australian Society of Parasitology	Travel Award
	University of Queensland	UQ International Postgraduate Research Scholarship
	University of Queensland	University of Queensland Centennial Scholarship
Chelsea Edwards	University of Queensland	Australian Postgraduate Award
Shin Foong Ngiow	ASMR	Runner-Up Postdoctoral Researcher Award
Adele Green	Queensland Government	Queensland Great award
Leonardo Gollo	Organisation for Computational Neurosciences	Travel Award
David Harrich	NHMRC	Outstanding Contribution Honour Roll 2014
Geoff Hill	Translational Research Institute	Translational Research Institute National Research Prize
Joshua Horne-Debets	Australasian Society of Immunology (ASI)	Travel Award
Kylie James	OzeMalar	Travel Award
	EMBL	Travel Award
Murugan Kalimutho	CASS Foundation	Travel Award
Yan Lu	Biometals 2014 (9th International Biometals Symposium)	Poster Award for Postdoctoral Trainees
Louise Marquart	Statistical Modelling Society	Travel grant
	University of Queensland	International Travel Award
Nick Martin	American Association for Advancement of Science	Fellow
	Australian Academy of Health and Medical Science	Fellow
Marcela Montes De Oca	Brisbane Immunology Group	Peter Doherty Medal

## Awards continued

RESEARCHER	AWARDING ORGANISATION	AWARD NAME
Sarah Medland	Royal Netherlands Academy of Arts and Sciences	Emerging research leader Visiting Professorship
Susanna Ng	Griffith University	University Medal
	Griffith University	International Postgraduate Research Scholarship
Antonia Pritchard	Australian Academy of Science	Travel Award
Carla Proietti	Australian Society of Parasitology	Travel Award
Melinda Protani	University of Queensland	Dean's Award for Outstanding Research Higher Degree Thesis
Eva Putz	Erwin Schroedinger Fellowship of the Austrian Science Fund	Postdoctoral Scholarship
Grant Ramm	The American Association for the Study of Liver Diseases (AASLD)	Fellow of the AASLD (FAASLD)
Daniel Rawle	University of Queensland	Australian Postgraduate Award
Andrea Schuessler	ASMR	ASMR Postdoctoral Award
	ASMR	Postgraduate Division Awards finalist
Ismail Sebina	Walter and Eliza Hall Institute	Conference Travel Award
Maggy Sikulu	American Society for Tropical Medicine and Hygiene	Travel Award
	International Conference on Near Infrared Spectroscopy	John Shenk Travel Award
Jacinta Simmons	Cancer Council Queensland	Travel Award
Daniel Smith	Thoracic Society of Australia and New Zealand	Best Oral Presentation CF Special Interest Group
Mitchell Stark	AACR and Society for Melanoma Research	Travel Award
	ASMR	Health and Medical Research Award Finalist
Anna Tai	Thoracic Society of Australia and New Zealand	TSANZ Vertex Cystic Fibrosis Research Award
Jill Ulrich	Florida Mosquito Control Association	T Wainwright Miller, Jr. FMCA Scholarship
Ting Wei	Journal of Virological Methods	Outstanding Contribution in Reviewing
Vicki Whitehall	Gastroenterology Society of Australia	Poster of Merit
	Royal Brisbane and Women's Hospital	RBWH Healthcare Symposium Basic Science Oral Presentation
Arabella Young	ASMR	Runner-Up Postgraduate Researcher Award

# INVITED LECTURES

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Greg Anderson	Absorbing and recycling iron: Links between ferroportin and iron oxidases	Australia	Sydney	International Conference on Heme Oxygenases, Iron Metabolism and Free Radicals
	The interactions between iron and other metals	Indonesia	Jakarta	4th Asia Pacific Iron Academy - Bringing Science to the Clinical Practices
	Mice as models of human trace element physiology and disease	China	Hangzhou	Second Chinese Trace Elements Conference
	Linking iron homeostasis to human disease: Lessons from the hepcidin-ferroportin axis	Australia	Gold Coast	7th Asian Biological Inorganic Chemistry Conference
	The role of the copper-dependent ferroxidases hephaestin and ceruloplasmin in body iron homeostasis	Australia	Melbourne	Annual Meeting of the Society for Free Radical Research (Australasia)
Annika Antonsson	Human papillomavirus infection in head and neck cancer	Australia	Sydney	Frontiers 2014
	Oral HPV infection and HPV in head and neck cancer	Australia	Brisbane	Princess Alexandra Hospital Head and Neck Meeting
Eva Baxter	Investigating the mechanisms underlying the link between obesity and endometrial cancer	Australia	Gold Coast	ANZGOG Annual Scientific Meeting
Scott Bell	Challenges of Adult Cystic Fibrosis Care	Sweden	Gothenburg	European Cystic Fibrosis Conference
	Pro/Con Debate - The airways should be sterile (Con)	Sweden	Gothenburg	European Cystic Fibrosis Conference
	Cystic Fibrosis - 2014	Australia	Coolum	TSANZ (Queensland Branch), Winter Meeting
	Diseases of ageing in the general population and Cystic FibrosisTR	Belgium	Brussels	European Cystic Fibrosis Conference
	Review the Data for the Effects of Therapeutic Cystic FibrosisTR Modulation on Disease Progression	Belgium	Brussels	European Cystic Fibrosis Conference
	Pseudomonas aeruginosa - where does it come from?	Australia	Gold Coast	TSANZ Annual Scientific Meeting
Michael Breakspear	Neuropsychiatric diseases as disorders of brain connectivity	Australia	Kingscliff	From Cape to Coast: The Diverse Landscape of Psychiatry in Queensland
	Large Scale: Model Inversion and DCM on Large Data" and Dysfunction and Disorders	China	Shanghai	Computational and Cognitive Neuroscience Summer School (East China Normal University)
	The Dynamic Brain	Australia	Brisbane	12th International Conference on Cognitive Neuroscience
	Dwelling in the rich club: Connectomic determinants of brain dynamics	Canada	Halifax	19th International Conference on Biomagnetism
	Meet the Fokkers: Modelling large-scale brain dynamics	Germany	Bavaria	Max Planck UCL Symposium and Advanced Course on Computational Psychiatry and Ageing Research

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Michael Breakspear	Mental Health: An Economic Priority	Australia	Brisbane	Brisbane Global Cafe
	Source-Resolved Connectivity Analysis	United States	California	Brain Connectivity Workshop 2015
	Dynamic Connectivity of Agency	United States	California	Brain Connectivity Workshop 2015
	Brain Waves	United States	Honolulu	21st Annual Meeting for the Organization of Human Brain Mapping
	Introduction to Computational Neuroscience	United States	Honolulu	21st Annual Meeting for the Organization of Human Brain Mapping
Julie Burel	A dichotomy in microRNAs and cellular immune responses to experimental blood stage malaria infection in humans revealed by systems immunology	United States	New Orleans	American Association of Immunologists (AAI) Annual Meeting
	Molecular profile of polyfunctional T cells during <i>Plasmodium falciparum</i> infection in humans	Australia	Canberra	50th Australian Society for Parasitology Annual Conference
	Dichotomy in cellular immune responses to experimental <i>Plasmodium falciparum</i> infection in humans	Australia	Wollongong	ASI Annual Conference
Scott Burrows	T cell cross-reactivity between an Epstein-Barr virus epitope and an abundant self-peptide presented by HLA-B*18:01+ cells	Switzerland	Davos	World Immune Regulation Meeting IX
Georgia Chenevix-Trench	Breast cancer susceptibility: From GWAS hit to target gene	Australia	Sydney	International Breast Cancer Conference
	New insights on breast cancer aetiology from genome-wide association studies	Denmark	Vejle	12th Danish Congress for Clinical Biochemistry
	Breast cancer susceptibility: what can genome wide association studies tell us about the pathways to cancer and opportunities for novel risk reduction medications	Australia	Brisbane	University of Queensland School of Pharmacy
	Breast cancer susceptibility: what can genome wide association studies tell us about the pathways to cancer and opportunities for novel risk reduction medications	Australia	Gold Coast	Griffith Health Institute
	Finding the target gene(s) from genome-wide association study 'hits' – challenges and surprises	Australia	Brisbane	Queensland University of Technology
Paul Clark	Australian Gastroenterology Week	Australia	Geelong	Melbourne Liver Group Meeting
Nicole Cloonan	Navigating the miRNA minefield	Australia	Perth	EMBL PhD Symposium
	MicroRNAs. Sequencing, analysis ... and then what?	Australia	Brisbane	IMB Winter School
	MicroRNAs as pathway profiling tools	Australia	Sydney	CMRI Seminar Series

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Jonathan Darbro	Metofluthrin emanators reduce Aedes aegypti survival and biting intensity: results of field trials in Cairns, Australia	Australia	Perth	Mosquito Control Association of Australia
	A cost-benefit analysis of illustrative Aedes albopictus eradication and management plans in Brisbane, Queensland	Australia	Perth	Mosquito Control Association of Australia
Karina DeSousa	A genome-wide approach to immunodominance	Australia	Canberra	50th Australian Society of Parasitology (ASP) Annual Conference
Greg Devine	Negative cross resistance: a practicable means of restoring pyrethroid-susceptibility to vectors of malaria	United States	New Orleans	American Society of Tropical Medicine and Hygiene
Denise Doolan	Molecular profiling of adaptive immunity to Plasmodium infection in humans using systems immunology	Mexico	Mexico City	13th International Congress of Parasitology
	EBV Protein Array Platform to Screen for EBV Antibodies Associated with NPC and other EBV-Associated Disorders	Indonesia	Yogyakarta	7th Nasopharyngeal Carcinoma Biannual Symposium
	Molecular profiling of immunity to malaria using systems immunology and genome-based technological advances	Singapore	Singapore	2nd Annual Microbiology and Infectious Diseases Asia Congress
	Translating genomic sequence data into effective public health interventions	Australia	Cairns	Australian Institute of Tropical Medicine and Health
	Protein microarray platform for identifying biomarkers of endemic Burkitt Lymphoma	Kenya	Kisumu	African Organization for Research and Training in Cancer International Conference
	Immunodominance and vaccine development: new insights from proteome-wide profiling of T cell and antibody responses to malaria	United States	New Orleans	63rd Annual American Society of Tropical Medicine and Hygiene Conference
	Understanding our DNA: The impact and ethical considerations of the sequencing technology revolution	Australia	Gold Coast	Bond University, Bioethics Grand Rounds
Stacey Edwards	Multiple variants in regulatory regions of the 6q25.1 (ESR1) breast cancer risk locus target ESR1, RMND1/c6orf211 and CCDC170	Australia	Kingscliff	Familial Aspects of Cancer Conference
	Beyond GWAS: Illuminating the Dark Road from Association to Function	Australia	Sydney	Victor Chang Cardiac Research Institute
	5C: a high-throughput method to identify target genes of regulatory elements at GWAS loci	Belgium	Leuven	Breast Cancer Association Consortium Conference
	Multiple variants in regulatory regions of the 6q25.1 (ESR1) breast cancer risk locus target ESR1, RMND1/c6orf211 and CCDC170	Belgium	Leuven	Breast Cancer Association Consortium Conference
	Genome-wide association study identifies PSIP1 associated with progression-free survival in epithelial ovarian cancer	Australia	Brisbane	RCOG World Congress 2015

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Stacey Edwards	Beyond GWAS: Illuminating the Dark Road from Association to Function	Australia	Melbourne	La Trobe University
	Beyond GWAS: cis-regulatory variation as a key mechanism underlying breast cancer risk	United Kingdom	Cambridge	Cancer Research UK Cambridge Institute
Christian Engwerda	Immunity to malaria	United States	Woods Hole, MA	Biology of Parasitism course
	Immunity to malaria	Australia	Brisbane	University of Queensland
	Immunity to parasites	Australia	Brisbane	Winter advanced immunology course - University of Queensland
Katja Fischer	Microbiome profiling in a porcine model of scabies mite infection to understand host-parasite-pathogen interactions	Australia	Melbourne	Australian Society for Microbiology Annual Scientific Meeting
David Frazer	Erythroid regulation of iron homeostasis	Australia	Gold Coast	7th Asian Biological Inorganic Chemistry Conference
	Hepcidin and the regulation of iron homeostasis	Australia	Bowral	Gastroenterological Society of Australia Hepatology and Gastrointestinal Research Workshop
Juliet French	Beyond GWAS: Long-Range Gene Regulation as a Common Mechanism Underlying GWAS	Australia	Brisbane	UQ Centre for Clinical Research
	Determining the influence of long non-coding RNAs on breast cancer risk at 11q13	United Kingdom	Cambridge	Cancer Research UK Cambridge Institute
	Finding novel lncRNAs at Breast Cancer Risk Loci	Belgium	Leuven	Breast Cancer Association Consortium
	Functional characterisation of the MAP3K1 Breast Cancer Risk Locus	Belgium	Leuven	Breast Cancer Association Consortium Meeting
	Finding Novel lncRNAs at Breast Cancer Risk Loci	Portugal	Porto	Breast Cancer Association Consortium Meeting
Frank Gannon	I came to Galway to study Bio, and you would never believe what happened	Ireland	Galway	NUI Galway Biochemistry 50 Year Anniversary Symposium
	Is Translational just a buzz word?	Australia	Sydney	The Future of Medical Research Conference
	The estrogen receptor and me	Australia	Sydney	Garvan Institute 2014 Leaders in Science and Medicine Seminar Series
	New insights - better cure?	Hong Kong	Hong Kong	EMBO Conference on Stem Cells and Epigenetics in Cancer
	Millis Oration: The connection between medical research and business	Australia	Gold Coast	AusBiotech National Conference
	Molecular understanding of obesity related carcinogenesis – endometrial cancer as a disease model	Australia	Brisbane	Brisbane Gynaecological Cancer Research Symposium
	Placing Brisbane at the forefront of cancer translational research	Australia	Brisbane	Brisbane Cancer Conference
	Advances in medical research over the past 75 years	Australia	Brisbane	South Brisbane Rotary Club
	Gene regulation	Australia	Perth	Science on the Swan
Expression in different contexts	Australia	Brisbane	QUT School of Biomedical Sciences Seminar series	

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Geoffrey Gobert	Improving praziquantel efficacy against schistosomes by disrupting calcium homeostasis	Australia	Canberra	Australian Society for Parasitology Annual Conference
Leonardo Gollo	Computational Models of Perceptual Uncertainty and Decision Making	Australia	Brisbane	ICON 2014
Catherine Gordon	High prevalence of <i>Schistosoma japonicum</i> in humans and bovines from Northern Samar, the Philippines	United States	New Orleans	The American Society of Tropical Medicine and Hygiene
Catherine Gordon	Multiplex real-time PCR monitoring of intestinal helminths in humans reveals widespread polyparasitism in Northern Samar, the Philippines	New Zealand	Auckland	Australian Society for Parasitology Annual Meeting
Adele Green	Photoageing and its preventability with regular sunscreen use	Singapore	Singapore	Sun Protection and Anti-ageing Conference
	A Global Picture of Skin Cancer	United Kingdom	Edinburgh	XV World Congress on Cancers of the Skin
	Skin Cancer: the Scope of the Problem	Sweden	Stockholm	Department Surgery, Karolinska Institute
	Diagnosis, initial treatment and supportive care needs of adults with localised melanoma in Queensland: The Primary Melanoma Project	Australia	Perth	2nd National SKMRC Melanoma Conference
	New Insights into the Role of Ultraviolet Radiation in Melanoma	United States	Philadelphia	AACR Annual Conference
	Ultraviolet radiation as a cause of Melanoma	Norway	Oslo	Cancer Registry of Norway
Camille Guillerey	Immunosurveillance and therapy of multiple myeloma is CD226-dependent	Australia	Surfers Paradise	Brisbane Immunology Group Annual Retreat
	DNAM-1 controls immune responses against multiple myeloma	Australia	Melbourne	1st Australian Innate Lymphocyte Symposium
Fernando Guimaraes	Understanding natural killer (NK) cell-mediated control of tumor metastasis	Australia	Sydney	2nd Cure Cancer Australia Symposium
	IFN- $\gamma$ and TGF- $\beta$ , cytokines that shape NK cell function and development	Australia	Sydney	Centenary Institute, University of Sydney
	New insights into the role of NK cell in tumors and inflammatory disorders	Australia	Gold Coast	Australasian Society of Cytometry (ASC), Annual Meeting
	Controlling septic shock — will NK cells hold the key?	Australia	Brisbane	23rd Annual RBWH Healthcare Symposium
	NK cells require IFN type III for in vivo effector functions	Australia	Wollongong	Young Investigator Forum of the Australasian Society of Immunology (ASI), Annual Meeting
Janelle Hancock	High-throughput shRNA screen for novel regulator of dormancy in breast cancer	Australia	Brisbane	Innovations in Cell Engineering – From Gene to Protein symposium
David Harrich	eEF1A is a critical co-factor of HIV-1 reverse transcription complex	Australia	Lorne	Lorne Infection and Immunity Meeting
	The eukaryotic translation elongation factor 1A is an important HIV-1 reverse transcriptase binding protein and a possible target for antiviral therapy	United States	Cold Spring Harbor	Cold Spring Harbor Retroviruses Meeting



## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
David Harrich	Inhibiting HIV-1 reverse transcription by targeting the reverse transcription complex	United States	Chicago	Retroviruses and New Drugs
	A gene therapy approach to treat HIV/AIDS	Australia	Brisbane	Australasian Genetics Society
	Inhibiting HIV-1 reverse transcription by targeting the reverse transcription complex	Australia	Brisbane	Griffith University
Marina Harvie	Creating a Live Attenuated Veterinary Vaccine against Schistosomiasis	New Zealand	Auckland	Australian Society for Parasitology Annual Meeting
Nick Hayward	The genetic architecture of melanoma susceptibility	United States	Philadelphia	AACR Special Conference on Advances in Melanoma: From Biology to Therapy
	The genetic architecture of melanoma susceptibility	Singapore	Singapore	Joint IPCC/SMR meeting
	The Australian Melanoma Genome Project	Australia	Sydney	Garvan Institute Leaders in Science and Society Seminar
	The Australian Melanoma Genome Project	Australia	Lorne	Lorne Cancer Conference
Geoff Hill	BMT and HIV cure	Australia	Melbourne	World HIV Symposium
	Translating transplant immunology from mouse to human	Australia	Sydney	Kirby Institute Seminar
	The addition of IL-6 inhibition to prevent acute GVHD after allogeneic stem cell transplantation; final results of a phase I/II trial	Australia	Perth	Hematology Society of Australia and NZ Annual Meeting
	Cytokine inhibition in transplantation: coming of age	Australia	Brisbane	Stem Cell Symposium
Joshua Horne-Debets	PD-1 drives chronic malaria	Australia	Wollongong	Australasian Society of Immunology
Leon Hugo	Prevalence of Wolbachia infections in native Australian mosquitoes	Australia	Perth	Mosquito Control Association of Australia meeting
	Adult survivorship of the dengue mosquito <i>Aedes aegypti</i> varies seasonally in central Vietnam	Australia	Perth	Mosquito Control Association of Australia
Hongping Jin	Latency-like suppression of HIV-1 gene expression by expression of a transdominant negative tat in Jurkat cells	United States	Palms Springs	West Coast Retroviruses Meeting
Murugan Kalimutho	Targeting aneuploidy in triple-negative breast cancer	Malaysia	Kuala Lumpur	University of Malaya, Department of Internal Medicine lecture
Murugan Kalimutho	Targeting triple-negative breast cancer	Australia	Redcliffe	Zonta Club event
Rajiv Khanna	Immune Therapy for virus-associated human malignancies and post-transplant infectious complications	Australia	Melbourne	7th Australian Health and Medical Research Congress
Rajiv Khanna	Cellular Immune Therapy for virus-associated human malignancies and post-transplant infectious complications	Australia	Melbourne	5th Australasian Vaccines and Immunotherapeutics Development Meeting
	Cytomegalovirus and glioblastoma	Australia	Katoomba	Viruses in May
	Immunology and immunotherapy for nasopharyngeal carcinoma	Indonesia	Yogyakarta	7th Nasopharyngeal Carcinoma Biannual Symposium

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Rajiv Khanna	Clinical Assessment of Autologous Human Cytomegalovirus-specific T-cell Therapy as Consolidative Treatment for Recurrent GBM	United States	Boston	CMV and Cancer
	T cells and the EBV-host balance	United Kingdom	Oxford	EBV 50th Anniversary
	EBV and Multiple Sclerosis	Australia	Sydney	MS ATLAS meeting
Kum Kum Khanna	The mouse orthologue of hSSB1/NABP2 is Essential for Embryogenesis and Genomic Stability	Australia	Hunter Valley, NSW	13th Hunter Cell Biology meeting
	DNA damage repair: from Genome maintenance to therapeutic targets	Australia	Brisbane	Veritel Fellowship Alumni Association Conference
	Translational breast cancer research	Australia	Brisbane	Brisbane Cancer Conference
	Session Chair	Australia	Brisbane	Combio 2014
	DNA damage repair and its connection with breast cancer initiation and progression	Australia	Sydney	Garvan Leaders in Science Seminar Series
	DNA damage repair from Genome maintenance to therapeutic targets	Australia	Lorne	Lorne Cancer Conference
Steven Lane	Telomerase to deplete LSCs in Acute Myeloid Leukemia	United States	San Francisco	American Society of Hematology San Francisco 2014, Workshop on Myeloid Development, invited speaker
	How to get started in research	Australia	Brisbane	AMAQ Junior Doctors Conference
	Translational clinical research	Australia	Brisbane	Australasian Leukaemia Lymphoma Group
	Telomerase inhibitors to treat AML and prevent relapse after chemotherapy	Australia	Sydney	CMRI
	Telomerase inhibitors to treat AML and prevent relapse after chemotherapy	Australia	Brisbane	UQCCR
Jason Lee	Hypoxia-mediated gene repression	Australia	Brisbane	Brisbane Gynaecological Cancer Research Symposium
	Hypoxia-mediated epigenetic reprogramming	Australia	Sydney	Asia Pacific-Korea Conference
	Epigenetic modifying enzymes as drug targets for brain metastasis	Australia	Sydney	Asia Pacific-Korea Conference
	Epigenetic regulation in cancer	Australia	Sydney	Asia Pacific-Korea Conference
	Meta-analysis of breast cancer gene expression data	South Korea	Seoul	Kunkuk University, School of Biotechnology Seminar Series
	Tumour hypoxia and epigenetics	South Korea	Daegu	Keimyung University, School of Medicine Special Seminar Series
	Hypoxia-mediated gene repression	South Korea,	Seoul	Seoul National University, Chromatin Dynamics Research Centre
	Epigenetic regulation in breast cancer	South Korea	Seoul	Korea University, School of Biological Sciences
	Hypoxia-mediated gene repression and its role in cancer metastasis and survival	United Kingdom	Dublin	Keystone Symposia, Hypoxia: From Basic Mechanisms to Therapeutics

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Barbara Leggett	Serrated polyps and colorectal cancer	Australia	Brisbane	Brisbane Cancer Conference
Yuesheng Li	Schistosomiasis elimination: a successful control experience from the Dongting Lake of China.	Mexico	Mexico City	XIII International Congress of Parasitology (ICOPA XIII)
Stacey Llewellyn	Sequenom MassARRAY Platform as a high throughput tool for detection and differentiation of human hookworm species in stool	New Zealand	Auckland	2015 NZSP and ASP Annual Conference
Kelli MacDonald	Autophagy is a Critical Pathway for Regulatory T Cell Survival	Australia	Wollongong	Australasian Society for Immunology
	Macrophages as mediators of fibrosis in chronic liver disease	Australia	Bowral	GESA Hepatology and Gastrointestinal Research Workshop
	Immunotherapy – new trends in Bone Marrow Transplantation	Australia	Canberra	TSANZ
Stuart MacGregor	Issues in human phenomics	Australia	Brisbane	CSIRO Genome to Phenome Symposium
James McCarthy	A Phase I/Ib study to investigate the safety, tolerability and pharmacokinetic profile of DSM265 in healthy subjects and then its antimalarial activity in induced blood stage <i>Plasmodium falciparum</i> infection	United States	New Orleans	ASTMH 63rd Annual Meeting
	Repositioning human challenge studies with potentially deadly infections to develop vaccines and drugs	Australia	Brisbane	Brisbane Global Café
	Human Challenge Studies	Singapore	Singapore	Courage Fund Infectious Diseases Conference
	Towards an Experimental System for Study of Human to Mosquito Transmission of Malaria: Clinical, Parasitologic and Molecular Investigations	Spain	Girona	Gordon Research Conference
	New data from controlled <i>Plasmodium vivax</i> infections in human volunteers	Indonesia	Bali	5th International Conference of Research on Plasmodium vivax Malaria
	The human challenge model: An innovative enabler for malaria drug development	Japan	Tokyo	Malaria R and D in a Time of Global Partnerships
Cameron McDonald	Identification of rare variants using custom AmpliSeq	Australia	Brisbane	Genetic Solutions World Tour
	Identification of rare variants using custom AmpliSeq	New Zealand	Auckland	Genetic Solutions World Tour
	Identification of rare variants using custom AmpliSeq	New Zealand	Dunedin	Genetic Solutions World Tour
Donald McLeod	Year in thyroid - Treatment Advances	Australia	Cairns	RACP Congress
	Thyroid cancer	Australia	streamed online	National Endocrine Trainee Teaching Series
Don McManus	<i>Echinococcus granulosus</i> Genomics: an Opportunity to Improve the Diagnosis of Echinococcosis	France	Besancon	Innovation for the Management of Echinococcosis,
	The insulin receptor: an Achilles heel for schistosome vaccine development	United Kingdom	Cambridge	British Society for Parasitology Spring Meeting,
	A Vaccine for Zoonotic Schistosomiasis	Australia	Brisbane	AID conference, University of Queensland

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Don McManus	Control of Asian Schistosomiasis. (Symposium Chair)	Mexico	Mexico City	XIII International Congress of Parasitology (ICOPA XIII),
	Integrated Control of Asian Schistosomiasis	Mexico	Mexico City	XIII International Congress of Parasitology (ICOPA XIII)
	Farewell to the God of Plague – the Control of Schistosomiasis in Asia	Australia	Brisbane	QUT Special Seminar in Infectious Diseases
	Control of Zoonotic Schistosomiasis in Asia	Indonesia	Bogor	14th Annual Workshop of the Regional Network on Asian Schistosomiasis and Other Helminth Zoonoses (RNAS+)
	Towards the Elimination of Schistosomiasis in Asia	Thailand	Bangkok	Faculty of Tropical Medicine, Mahidol University
	Control of NTDs from Asia through Integrated Control	Thailand	Khon Kaen	Tropical Disease Research Laboratory, Khon Kaen University
	Towards the Elimination of Schistosomiasis from China	Australia	Brisbane	Queensland-China Workshop on Vaccine Development Opportunities
Sarah Medland	Genetic Epidemiology	Australia	Brisbane	Translational Research Institute - Genomics Seminar Series
	Common genetic variants influence human subcortical brain structures	Australia	Brisbane	Australian Neurogenetics Conference
	Genetics of Human Brain Development	Sweden	Uppsala	Swedish Society of Human Genetics
	New Findings from the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium	Denmark	Copenhagen	World Congress of Psychiatric Genetics
	Genomic studies with twins	Australia	Melbourne	Healthier Kids: insights from twin research, Australian Twin Registry
	Using collaboration to advance our understanding of brain structure	Australia	Brisbane	Queensland Brain Institute Seminar Series
	Educational Session – Introduction to Imaging Genetics	United States	Honolulu	Organization for Human Brain Mapping Annual Meeting
	Phasing and imputation (also gave 3 tutorials)	United States	Boulder	The 2015 International Workshop On Statistical Genetic Methods For Human Complex Traits
	Multivariate Analysis (6 hour teaching block)	United Kingdom	London	SGDP MRC Summer School - Institute of Psychiatry, Kings College London
	Common genetic variants influence human subcortical brain structures	United States	San Diego	Behaviour Genetics Association Annual Meeting
Common genetic variants influence human subcortical brain structures (Senior Researcher Award Finalist)	Australia	Brisbane	Australian Society of Medical Research - Queensland Meeting	

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
John Miles	Understanding antigen-driven T cell selection dynamics during Epstein-Barr virus infection	Australia	Brisbane	International Symposium on EBV and Associated Diseases
	The future of prostate cancer therapy	Australia	Brisbane	Prostate Cancer Forum: Raising awareness for men's health chaired by Minister Mark McArdle MP
	Understanding and modulating human T cell function	United Kingdom	Manchester	Paterson Institute for Cancer Research
	Affinity enhanced EBV-specific T cell receptors	United Kingdom	Oxford	Immunocore Labs
	Clonal selection from the human TCR repertoire: emerging patterns from a chaotic morass	United States	West Point	Merck Research Laboratories
	Understanding and modulating human T cell function	Australia	Cairns	Australian Institute of Tropical Health and Medicine, James Cook University
	The length and biophysical properties of the peptide in the MHC groove predicts T cell receptor repertoire formation	Australia	Wollongong	44th Annual Scientific Meeting of the Australasian Society for Immunology
	Future of cancer therapy	Australia	Brisbane	Glass House Cancer Support Group Forum
	Predicting T cell receptor repertoire formation against human pathogens	Australia	Brisbane	5th International Congenital CMV Conference and 15th International CMV/ Betaherpesvirus Workshop
	Understanding and modulating human T cell function	Australia	Sydney	Centenary Institute
	Understanding and modulating human T cell function	Australia	Melbourne	Peter Doherty Institute for Infection and Immunity
Deepak Mittal	Novel combinations for cancer immunotherapy	Italy	Milan	Istituto Clinico Humanitas
Andreas Moller	Breast cancer	France	Paris	Miltenyi Conference
	Breast cancer	Australia	Melbourne	La Trobe University
	Cancer biomarkers	Australia	Cairns	Australasia Extracellular Vesicles Conference
	Breast cancer	Australia	Melbourne	Olivia Newton-John Cancer Research Centre
Grant Montgomery	Interaction of Genetics and Epigenetics	United States	San Francisco	Society for Reproductive Investigation Conference
Jason Mulvenna	Proteomics for CCA	Portugal	Lisbon	International Congress on Analytical Proteomics
Christina Nagle	Gynaecological Cancer research at QIMR Berghofer Medical Research Institute	Australia	Brisbane	Women's Networking Event presented by Marsh Tincknell (Chartered Accountants), for Australia's Biggest Morning Tea
Christina Nagle	The weighty issue of cancer	Australia	Cairns	Regional Queensland High School Health Science Lecture Series
Rachel Neale	Nonmelanoma skin cancer: epidemiology and genetics	Australia	Surfers Paradise	Australasian Skin Cancer College Annual Conference
	Sun exposure and health: harms and benefits	Australia	Perth	Cancer Council Western Australia Update Series

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Rachel Neale	Vitamin D and Health: The need for a large-scale trial	Australia	Perth	Telethon Kids Institute
Katia Nones	Methylation detection in cancer using microarrays	Australia	Brisbane	Brisbane Cancer Conference
Catherine Olsen	The QSkin Sun and Health Study	Australia	Brisbane	University of Queensland
Peter O'Rourke	Statistical issues in research planning	Australia	Brisbane	Annual introduction to research principles and resources courses for health professionals
Michael Parsons	The InSiGHT model: application to BRCA1/2 variant classification by ENIGMA and the BRCA Challenge	United Kingdom	Glasgow	Cancer Genetics Workshop, HVP Satellite meeting to ESHG
Ann-Marie Patch	Detecting Structural Variants in Cancer	Australia	Brisbane	Brisbane Cancer Conference
Sanjoy Paul	Obesity paradox in people with newly diagnosed type 2 diabetes	Australia	Sydney	Australian and New Zealand Obesity Society Annual Scientific Meeting
	Clinical inertia and the associated cardiovascular risk in patients with type 2 diabetes	United Kingdom	Leicester	Leicester Diabetes Centre, University of Leicester
Lawrie Powell	History of the Asia-Pacific Association for the Study of the Liver	Turkey	Istanbul	Annual Meeting of the Asia-Pacific Association for the Study of the Liver
Carla Proietti	T cell and antibody immunomics-based approaches for rationale vaccine design against malaria	Australia	Palm Cove	Australasian Tropical Health Conference
Grant Ramm	Non-invasive Assessment of Liver Disease and Fibrosis in Children with Cystic Fibrosis	Australia	Brisbane	Translational Research Institute's Research Committee Networking Workshop
	Non-invasive assessment of fibrosis in paediatric liver disease	Australia	Brisbane	Asian-Pacific Association for the Study of the Liver (APASL) Conference
Shiwanthi Ranasinghe	Novel tegument expressed Kunitz type protease inhibitor from <i>Schistosoma mansoni</i>	United States	New Orleans	The American Society of Tropical Medicine and Hygiene
	Functional characterization of novel Kunitz type protease inhibitors from <i>Echinococcus</i> and <i>Schistosoma</i>	New Zealand	Auckland	Australian Society for Parasitology Annual Meeting
Simone Reynolds	Pathways to Research Higher Degrees	Australia	Brisbane	University of Queensland Undergraduate Indigenous Students Workshop
Jacinta Simmons	Treatment options for Melanoma	Australia	Brisbane	Australian Dermatology Nurses Annual Scientific Meeting
Mark Smyth	Cancer immunotherapy – a basis for new therapy combinations	United Kingdom	Cambridge	Kymab Scientific Experts Meeting
Mark Smyth	NK cells: checkpoints and interferons in tumor control	Australia	Melbourne	International Cytokine and Interferon Society Symposium
	Cancer immunotherapy – preclinical models and candidate profiling	Austria	Vienna	Boehringer Ingelheim Experts Meeting Symposium

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Mark Smyth	The age of combination cancer immunotherapy	Singapore	Singapore	4th Network of Immunology Frontier Winter School Symposium
	Ashley Dunn Oration	Australia	Lorne	27th Lorne Cancer Conference
	IFN $\gamma$ produced by CTL immunoeffects the cancer genome	United States	Philadelphia	Annual American Association for Cancer Research Symposium
	NK cells: subsets, checkpoints and interferons in tumor control	Canada	Montebello	15th Meeting of the Society for Natural Immunity Symposium
	Cancer immunotherapy – combinations in melanoma	Australia	Sydney	MIA Melanoma Immunotherapy Program
	Cancer immunotherapy – a basis for new cancer therapy combinations	Australia	Melbourne	Sciences of Oncology, Medical Oncology Group of Australia
	Immune checkpoint inhibitors and novel approaches	Australia	Brisbane	Brisbane Cancer Conference
	The age of combination cancer immunotherapy	China	Shanghai	National Key Laboratory of Medical Immunology
	New combinations in cancer immunotherapy	United States	Gaithersburg	Medimmune LLC
Amanda Spurdle	Overview of ENIGMA consortium and intersection of ENIGMA research objectives with the BRCA Challenge project	United States	San Diego	Global Alliance Consortium Meeting
	Updates relating to ENIGMA research projects	Belgium	Leuven	CIMBA Consortium Meeting
	Variant classification in high-risk cancer predisposition genes: the role of international multidisciplinary consortia	Australia	Adelaide	Human Genetics Society of Australia Annual Conference
	ENIGMA Research progress	France	Paris	Global Alliance BRCA Challenge Meeting
	ENIGMA and the BRCA challenge project	Portugal	Porto	CIMBA Consortium Meeting
	Update on the ENIGMA Consortium	Australia	Melbourne	Pathology Update 2015, RCPA Annual Conference
Mitchell Stark	Melanoma-specific microRNAs: Why are they important for targeted therapy and can they be used as disease biomarkers?	Australia	Brisbane	TRI Cancer Seminar Series
	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma	Australia	Brisbane	Brisbane Cancer Conference
Nathan Subramaniam	Identification of the genetic basis of atypical iron disorders through next-generation sequencing	Indonesia	Jakarta	Asia-Pacific Iron Academy (APIA) Conference
	Next-generation sequencing for identification of the genetic basis of atypical iron disorders	Italy	Verona	European Iron Club Meeting

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Andreas Suhrbier	The elusive physiological function of SerpinB2 aka PAI-2	United States	San Diego	Protease Inhibitors in Drug Discovery Conference
	Chikungunya arthritis; viral persistence, chronic immunopathology and interventions	Taiwan	Taipei	United States-Japan Cooperative Medical Sciences Program (CMSP) 17th International Conference on "Emerging Infectious Diseases (EID) in the Pacific Rim"
	Macquarie Island: Penguins, Seals, and Viruses	United States	New York City	Linean Society of New York
	Research Collaboration on Dengue and Other Arboviruses in the Caribbean Workshop	Saint Kitts and Nevis	Basseterre	Ross University School of Veterinary Medicine
	Chikungunya virus; global epidemic, arthritic immunopathology and interventions	Australia	Lorne	5th Lorne Infection and Immunity Conference
Michele Teng	The role of IL23 associated cytokines in tumour immunology	Australia	Melbourne	Australasian Sarcoma Study Group (ASSG) Research Meeting, Melbourne
	The age of combination cancer immunotherapy	Australia	Broadbeach	Australia New Zealand Gynaecological Oncology Group (ANZGOG) Annual Scientific Meeting
Nic Waddell	Cancer Genomics	Australia	Brisbane	Brisbane Cancer Conference
	Mutational processes and therapeutic opportunity in cancer	Australia	Sydney	Children's Medical Research Institute
	Overview of the cancer genome and epigenome	Australia	Sydney	RCPA – short course in Medical Genetics and Genetic Pathology
Graeme Walker	UV tumours in mice	Argentina	Córdoba	16th International Congress on Photobiology
	UV induction of melanomas in mice	Singapore	Singapore	22nd International Pigment Cell Conference
Daniel Wallace	A life of iron – genetics, cells and animal models	Australia	Perth	Curtin University Biomedical Sciences Research Retreat
	Non-HFE haemochromatosis: causes and mechanisms	Australia	Brisbane	Brisbane Inter-Hospital Liver Group Meeting
Daniel Wallace	Mechanisms in non-HFE haemochromatosis	Australia	Gold Coast	Australian Gastroenterology Week
Penny Webb	Diet, lifestyle and cancer: opportunities for prevention	India	Chennai	International Conference on Diet and healthy lifestyle in the prevention and control of non-communicable diseases
	Lifestyle modification including exercise	Australia	Brisbane	Royal College of Obstetrics and Gynaecology World Congress 2015
	Translating epidemiological research in gynaecological cancer into cancer control	Australia	Sydney	Sydney Cancer Conference



## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Kosala Weerakoon	Detection of Cell Free Parasite DNA (Cystic FibrosisPD) in human clinical samples as an improved method of diagnosis and evaluation of <i>Schistosoma japonicum</i> infection	New Zealand	Auckland	Australian Society for Parasitology Annual Meeting
Ting Wei	Seeking Novel Anti-Viral Strategy from Host	China	Beijing	Institute of Animal Husbandry and Veterinary Medicine
Shu Wen Wen	Breast cancer exosomes	United States	Washington	ISEV Meeting
Vicki Whitehall	Serrated Pathway of Colorectal Tumorigenesis	Australia	Brisbane	Brisbane Cancer Conference
David Whiteman	Epidemiology of Barrett's esophagus and cancer	Australia	Brisbane	Asia-Pacific Gastroesophageal Cancer Congress
	The QSkin Study	United States	Washington, DC	US National Cancer Institute Keratinocyte Cancer Consortium Meeting
	Melanoma screening and GWAS 101	Australia	Noosa	UQ Skin Cancer Conference
	QSkin and the Burden of Skin Cancer in Queensland	Australia	Noosa	UQ Skin Cancer Conference
	Reducing sun exposure in the population: is it worth the effort?	United Kingdom	Edinburgh	XV World Congress on Cancers of the Skin
	Collaborative Research: Some personal reflections	Australia	Perth	Collaborative Cancer Research Initiative, Cancer Council Western Australia
	Estimating the burden of cancer in Australia due to modifiable exposures	Australia	Melbourne	UICC World Cancer Congress 2014
	Our changing understanding of melanoma aetiology	Australia	Brisbane	Brisbane Cancer Conference
	Genes, sunlight, phenotype: The multiple causal pathways to melanoma	Canada	Vancouver	23rd World Congress of Dermatology
	Cancer prevention	Australia	Perth	Cancer Council Western Australia - Cancer Update Public Lecture Series
	Melanoma epidemiology: An update on causes, screening, mortality	Australia	Gold Coast	IQ Pathology Histology ALM
Adrian Wiegman	Breast cancer	Australia	Brisbane	Kumon Advanced Student Forum
Michelle Wykes	T cell exhaustion drives chronic malaria	Australia	Canberra	2014 Australian Society of Parasitology Meeting
	The role of programmed cell death 1 during malaria	United States	Boston	Harvard Medical School meeting
Michelle Wykes	Programmed cell death1: A major player in the pathogenesis of chronic malaria	Australia	Gold Coast	2014 Brisbane Immunology Group Meeting
	The role of programmed cell death 1 and its ligands in driving malaria	Australia	Canberra	The John Curtin School of Medical Research Seminar Series
	The role of programmed cell death 1 and its ligands in driving malaria	Australia	Brisbane	The Queensland University of Technology Seminar Series
Hong You	The Insulin receptor: An Achilles' heel for Schistosomes vaccine development	United States	Newport	Gordon Research Conferences, Salve Regina University
	Development of a transmission blocking vaccine against Asian Schistosomiasis	New Zealand	Auckland	2015 NZSP and ASP Annual Conference

## Lectures continued

RESEARCHER	LECTURE TITLE	COUNTRY	CITY	EVENT
Arabella Young	Targeting immunosuppressive adenosine to promote an immune response against cancer	Australia	Brisbane	ASMR Queensland Postgraduate Student Conference
	Targeting immunosuppressive adenosine to promote an immune response against cancer	United States	Boston	Laboratory presentation, Dana Farber Cancer Institute
	Targeting immunosuppressive adenosine to promote an immune response against cancer	United States	Boston	Laboratory presentation, Northeastern University

# PATENTS

## Patent families managed by QIMR Berghofer

Title	Inventor(s)	Application Number
Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens	Michael Good; Mary Stevenson	PCT/AU2004/000870
Cytotoxic T cell epitopes	Denis Moss; Scott Burrows; Rajiv Khanna; Beverley Kerr; Jacqueline Burrows; Andreas Suhrbier	PCT/AU1995/000140
CTL epitopes from EBV	Martina Sherritt; Scott Burrows; Rajiv Khanna	PCT/AU1998/000531
EBV peptide epitopes, polyepitopes and delivery system therefor	Rajiv Khanna; Jaikumar Duraiswamy	PCT/AU2003/001451
Novel hCMV cytotoxic T cell epitopes, polyepitopes, composition comprising same and diagnostic and prophylactic and therapeutics uses therefor	Rajiv Khanna; Rebecca Elkington; Susan Walker	PCT/AU2002/000829
Human cytomegalovirus immunotherapy	Rajiv Khanna	PCT/AU2005/001798
Peptide compounds	Istvan Toth; William Gibbons	PCT/GB1993/001558
Mutant TAT proteins and uses thereof	David Harrich	US13/292425
Improved human herpesvirus immunotherapy	Rajiv Khanna	PCT/AU2013/001216
Immunoreceptor modulation for treating cancer and viral infections	Mark Smyth	PCT/AU2013/001132
Immunoreceptor modulation for treating cancer and viral infections	Mark Smyth	PCT/AU2014/000830

## QIMR Berghofer patent families managed outside QIMR Berghofer

Title	Inventor(s)	Application Number
Receptor ligand system and assay	Andrew Boyd	US 09/104340
Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis	Andrew Boyd	PCT/AU2004/000142
A method of treatment	Andrew Boyd	PCT/AU1999/000931
Melanoma-associated MHC Class 1 Associated oligopeptide and its use	Chris Schmidt	PCT/EP2006/008533
A novel growth factor and a genetic sequence encoding same	Nicholas Hayward	PCT/AU1996/000094
Immunogenic complexes and methods relating thereto	Andreas Suhrbier; John Cooper Cox; Debbie Pauline Drane	PCT/AU0000110

## Patent families resulting from industry sponsored contract research performed at QIMR Berghofer

Title	Inventor(s)	Application Number
Treatment of virally induced lesions	Andreas Suhrbier	PCT/AU2008/000596
Treatment of solid tumours	Andreas Suhrbier	PCT/AU2005/001827
Treatment of prostate cancer	Peter Parsons	PCT/AU2001/000966
Therapeutic agents I	Andreas Suhrbier Peter Parsons	PCT/AU2001/000679
Therapeutic agents II	Andreas Suhrbier Peter Parsons	PCT/AU2001/000680
Therapeutic agents III	Andreas Suhrbier Peter Parsons	PCT/AU2001/000678
Macrocyclic diterpenes for the treatment and prophylaxis of acne vulgaris	Andreas Suhrbier Peter Parsons	US 7838555

## Patents families managed by QIMR Berghofer as trustee for the CRC-Vaccine Technology

Title	Inventor(s)	Application Number
T helper epitopes	David Jackson	PCT/AU2000/000070
Novel immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitope	David Jackson	PCT/AU2003/001019
Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes	David Jackson	PCT/AU2003/001018
Truncated LHRH formulations	David Jackson	PCT/AU2005/001383

## Trade marks managed by QIMR Berghofer

Mark	Status	Australian Trade Mark Number
Queensland Institute of Medical Research	Registered / Protected	1233303
QIMR	Registered / Protected	1233307
Hexagons device	Registered / Protected	1233317
Q-Neuro Systems	Registered / Protected	1512321
QIMR Berghofer	Registered / Protected	1583082
QIMR Berghofer Medical Research Institute	Registered / Protected	1583083

# GRANTS AND FUNDING OVER \$100,000

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
Fares Al-Ejeh	NHMRC	From transcriptome metanalysis to targeted therapies in triple negative breast cancer	AUD	\$468 687	3yrs
Fares Al-Ejeh	ARC	EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers	AUD	\$752 067	3yrs
Greg Anderson	NHMRC	The role of the liver in manganese homeostasis	AUD	\$336 056	2yrs
Greg Anderson	NHMRC	Mechanisms of intestinal and systemic iron homeostasis in early infancy	AUD	\$469 838	2yrs
Greg Anderson	NHMRC	The role of soluble transferrin receptor in the regulation of iron homeostasis	AUD	\$521 219	2yrs
Annika Antonsson	NHMRC	Oral human papillomavirus infection	AUD	\$404 884	3yrs
Jonathan Beesley	NHMRC	Activation of TERT gene expression in breast carcinogenesis	AUD	\$444 196	2yrs
Scott Bell	Cystic Fibrosis Foundation Therapeutics	Airborne transmission of micro-organisms among persons with cystic fibrosis	AUD	\$215 811	2yrs
Andrew Boyd	Cancer Council Queensland	Characterisation of the function and therapeutic potential of EphA2 and EphA3 in prostate cancer	AUD	\$200 000	1yr
Glen Boyle	Cancer Council Queensland	Investigating phenotype plasticity in melanoma progression and drug resistance	AUD	\$200 000	1yr
Glen Boyle	NHMRC	Aberrant transcriptional signalling in the progression and metastasis of melanoma	AUD	\$340 931	2yrs
Glen Boyle	NHMRC	Development of a novel drug for chronic and infected wounds	AUD	\$467 974	2yrs
Michael Breakspear	Perpetual Trustees Australia Limited	Depression, physical activity and metabolic risk: a study of physical and emotional wellbeing in an Indigenous urban setting	AUD	\$131 200	1yr
Michael Breakspear	NHMRC	Depressive and bipolar disorders: Pathophysiology, phenotypes and treatment innovations	AUD	\$275 000	5 yrs
Michael Breakspear	ARC	ARC Centre of Excellence for Integrative Brain Function	AUD	\$557 802	6yrs
Scott Burrows	NHMRC	Development of novel immunotherapeutic approaches for the treatment of Epstein-Barr virus-associated malignancies	AUD	\$367 077	3yrs
Scott Burrows	NHMRC	The role of long peptide epitopes in antiviral CD8+ T cell recognition	AUD	\$419 925	4yrs
Scott Burrows	NHMRC	Investigating how genetic variation in the T cell receptor genes influences the immune system	AUD	\$606 894	3yrs

## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
Georgia Chenevix-Trench	Weekend to End Women's Cancers	Expansion of the Brisbane Breast Bank: a prospective study developing biomarkers of response and recurrence	AUD	\$100 000	1yr
Georgia Chenevix-Trench	National Breast Cancer Foundation	A novel target for prevention and treatment of breast cancer	AUD	\$199 378	1yr
Georgia Chenevix-Trench	Susan G Komen Breast Cancer Foundation	Mutations in genes that modify epigenetic silencing in familial breast cancer	AUD	\$585 000	3 yrs
Georgia Chenevix-Trench	NHMRC	Molecular determinants of susceptibility and progression in breast cancer	AUD	\$1 120 900	5 yrs
Paul Clark	Other	Beyond the Bars- An Integrated Education and Treatment Program to Improve Awareness, Diagnosis, Referral and Treatment of Chronic Hepatitis C infection for Women in Prison	AUD	\$180 654	2 yrs
Nicole Cloonan	ARC	Decoding miRNA regulated genetic circuits.	AUD	\$200 000	4yrs
Nicole Cloonan	Cancer Council Queensland	MicroRNAs and isomiRs as chemosensitizers in Double-stranded Break Repair defective cancer	AUD	\$200 000	1yr
Bryan Day	Other	Cure Brain Cancer Foundation - Brain Cancer Discovery Collaborative Funding (BCDC)	AUD	\$150 000	2 yrs
Bryan Day	Cancer Australia	Eph Receptor Tyrosine Kinases as Targets for Therapy in Paediatric Medulloblastoma	AUD	\$199 718	1yr
Bryan Day	Cancer Council Queensland	Understanding the function of salinomycin as a DNA damaging agent and its relevance as a potential therapeutic agent for the treatment of malignant brain tumours	AUD	\$200 000	1yr
Bryan Day	NHMRC	EphA2 and EphA3 Maintain Tumour Initiating Cells and are Therapeutic Targets in Brain Cancer	AUD	\$593 813	2yrs
Greg Devine	Mosquito and Arbovirus Research Committe	Mosquito and arbovirus research in support of local government	AUD	\$147 000	1 yr
Greg Devine	CSIRO	Release the sterile males: a new direction for mosquito population control	AUD	\$225 000	3 yrs
Greg Devine	US Department of Defense	Optimal deployment of volatile pyrethroids	AUD	\$860 000	3 yrs

## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
Denise Doolan	The Walter and Eliza Hall Institute of Medical Research	Discovery and Validation of Serological markers of recent exposure to <i>P. vivax</i> in (pre-)elimination settings	AUD	\$197 655	2 yrs
Denise Doolan	Bill and Melinda Gates Foundation	Identification of T-cell target antigens after immunization by the Chemo-Prophylaxis and Sporozoites (CPS) regime	USD	\$245 404	2 yrs
Denise Doolan	Department of Innovation, Industry, Science and Research	A unique Australian facility for the identification of pathogen-associated drug and vaccine targets	AUD	\$700 000	3 yrs
Denise Doolan	NHMRC	Understanding Immunodominance in a complex host-pathogen system	AUD	\$864 300	4 yrs
Denise Doolan	National Institutes of Health	Proteome-wide cellular immunity approach to <i>P. falciparum</i> antigen identification	USD	\$2 378 344	5 yrs
Denise Doolan	NHMRC	Tropical Disease - immunity, pathogenesis and vaccine development: global translation Goal: Basic and translational research in support of the development of a malaria vaccine	AUD	\$17 100 585	4 yrs
Ken Dutton-Regester	NHMRC	Understanding drug resistance of targeted BRAF inhibitors in late-stage melanoma	AUD	\$359 866	4yrs
Stacey Edwards	Weekend to End Women's Cancers	Functional evaluation of genetic variants at a locus recently found to predict progression free survival in women with ovarian cancer	AUD	\$110 681	1yr
Stacey Edwards	NHMRC	Functional analysis of breast cancer risk regions	AUD	\$739 285	2yrs
Manuel Ferreira	QIMR Berghofer Near Miss Funding	Functional characterization of the new 8q21 asthma risk locus	AUD	\$100 000	1yr
Katja Fischer	NHMRC	Scabies mite intestinal proteases as targets for novel therapeutics	AUD	\$650 798	2yrs
Katja Fischer	ARC	Molecular approaches to overcome scabies and associated disease	AUD	\$749 908	3yrs
Juliet French	NHMRC	Understanding how DNA variants confer an increased breast cancer risk	AUD	\$485 504	3yrs
Juliet French	ARC/ NHMRC Network	Functional analysis of breast cancer susceptibility regions	AUD	\$586 010	4 yrs
Geoffrey Gobert	NHMRC	Targeting schistosome calcium signalling to improve and broaden praziquantel efficacy	AUD	\$466 513	2yrs
Jeffrey Gorman	Bioplatforms Australia Ltd	Emerging bimolecular platforms and informatics project	AUD	\$300 000	1yr

## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
Jeffrey Gorman	Bioplatforms Australia Ltd	National Collaborative Research Infrastructure Strategy - Subcontract	AUD	\$750 000	2yrs
Fernando Guimaraes	National Breast Cancer Foundation	Which tumor immunosuppressive pathways prevent natural killer control of breast cancer spread and impact on prognosis?	AUD	\$100 000	4yrs
Fernando Guimaraes	Cancer Australia	Targeting suppressive TGFβR and A2AR pathways in natural killer cells: enhancing the innate anti-metastatic response	AUD	\$100 000	1yr
Fernando Guimaraes	NHMRC	Deciphering IFN type III, TGF , IL-10 and adenosine pathways in natural killer cells: enhancing the innate anti-metastatic response against breast cancer progression	AUD	\$309 436	4yrs
Ashrafal Haque	QIMR Berghofer	Investigating the influence of innate immune responses on adaptive immunity during experimental blood-stage malaria	AUD	\$100 000	1yr
Ashrafal Haque	NHMRC	Dissecting the dynamics of malaria infection	AUD	\$111 660	2yrs
David Harrich	NHMRC	Targeting a cellular translation factor affecting RNA	AUD	\$566 226	2yrs
David Harrich	NHMRC	eEF1A1 is critical for HIV-1 reverse transcription and replication	AUD	\$689 143	2yrs
David Harrich	NHMRC	A potent anti-HIV-1 gene therapy agent in a humanised mouse model	AUD	\$1 101 141	3yrs
Andrea Henden	Leukaemia Foundation of Australia	PhD Clinical Scholarship	AUD	\$120 000	2yrs
Geoff Hill	Cancer Council Queensland	Understanding and optimizing Graft-versus-Myeloma effects after BMT	AUD	\$200 000	1yr
Geoff Hill	NHMRC	IL-6 and GVHD	AUD	\$572 562	2yrs
Geoff Hill	NHMRC	Immunoregulation for treatment of disease	AUD	\$1 966 255	4yrs
Susan Jordan	NHMRC	Improving cancer outcomes in understudied cancers by understanding their risk factors and patterns of cancer care	AUD	\$404 884	4yrs
Susan Jordan	NHMRC	Understanding causes of the rising incidence of thyroid cancer – What can mutations in the BRAF oncogene tell us about causes and diagnostic pathways for thyroid cancer?	AUD	\$584 521	3yrs
Murugan Kalimutho	Cancer Council Queensland	Cep55 is a determinant of aneuploidy cell fate in breast cancer	AUD	\$200 000	2yrs
Kum Kum Khanna	Cancer Council Queensland	Role of PC4 in tumorigenesis and metastasis of breast cancer	AUD	\$200 000	2yrs
Kum Kum Khanna	NHMRC	Project grant: Deciphering the overlapping roles of SSB1 and SSB2 in the regulation of haematopoiesis and intestinal homeostasis	AUD	\$958 728	3yrs



## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
Rajiv Khanna	Perpetual Trustees Australia Limited	Adoptive immunotherapy for progressive multiple sclerosis	AUD	\$200 000	2 yrs
Rajiv Khanna	Richard Charles and Esther Yewpick Lee Charitable Foundation	Immunity for metastatic nasopharyngeal carcinoma	AUD	\$290 175	3yrs
Rajiv Khanna	NHMRC	A novel vaccine formulation to prevent birth defects	AUD	\$513 447	3yrs
Rajiv Khanna	NHMRC	Combining immune monitoring and Immunotherapy for infectious complications in solid organ transplant patients	AUD	\$778 166	3yrs
Motoko Koyama	Leukaemia Foundation of Australia	Mechanisms of antigen presentation following bone marrow transplantation	AUD	\$200 000	1yr
Motoko Koyama	NHMRC	The role of gut resident antigen presenting cells in graft-versus-host disease	AUD	\$397 077	2yrs
Steven Lane	Leukaemia Foundation of Queensland	IL17-mediated mobilization of haematopoietic stem and progenitor cells	AUD	\$100 000	1yr
Steven Lane	Cancer Australia	Understanding DNA integrity and telomerase in acute myeloid leukaemia stem cell function	AUD	\$100 000	1yr
Steven Lane	University - South Australia	Targeting the egfr and c-met tyrosine kinase receptors in myeloproliferative neoplasms	AUD	\$240 000	2yrs
Steven Lane	NHMRC	Improving patient outcomes in leukaemia by targeting the cancer-causing cells	AUD	\$283 418	4yrs
Steven Lane	NHMRC	Understanding autophagy in haematopoiesis and leukaemia	AUD	\$484 327	2yrs
Jill Larsen	Cure Cancer Australia	Identification of novel permissive mutations representing acquired vulnerabilities in lung cancer	AUD	\$150 000	2yrs
Penelope Lind	NHMRC	A comprehensive analysis of the role of the alcohol dehydrogenase gene cluster in alcohol-related disorders and oesophageal cancer through deep resequencing	AUD	\$587 109	2yrs
Katie Lineburg	Leukaemia Foundation of Queensland	Cellular and molecular mediators of chronic GVHD	AUD	\$120 000	2yrs
Yi Lu	NHMRC	Investigating the interplay of gene and environment in childhood and adolescent mental health	AUD	\$374 986	3yrs
Kelli MacDonald	Cancer Council Queensland	Investigations of the cellular and molecular mediators of chronic GVHD	AUD	\$200 000	1yr

## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
Kelli MacDonald	NHMRC	The role of autophagy in stem cell transplantation	AUD	\$915 820	4yrs
Stuart Macgregor	NHMRC	Identification of germline variation that predicts progression free survival following chemotherapy for advanced ovarian cancer	AUD	\$613 650	2yrs
Stuart Macgregor	ARC	Drinking from the fire hose - Making sense of high density genetic and genomic data	AUD	\$868 452	3yrs
Nicholas Martin	Young and Well Cooperative Research Centre	Wellbeing and links with sleep-wake patterns in adolescent and young adult twins	AUD	\$300 000	1yr
Nicholas Martin	NHMRC	Expanding the power of genetic analysis of complex traits in multiply phenotyped twin sibships	AUD	\$527 447	1yr
Nicholas Martin	NHMRC	Clinical and neurobiological predictors of onset of major mental disorders and associated functional impairment in adolescent and young twins: A prospective longitudinal study	AUD	\$750 000	4yrs
Nicholas Martin	NHMRC	Exploring modifiable candidate risk factors for mental illness in young adults: Infection, vitamin D and stress	AUD	\$827 611	2yrs
Nicholas Martin	NHMRC	Tackling heterogeneity in the etiology of major depressive disorder	AUD	\$2 445 015	4yrs
James McCarthy	Bill and Melinda Gates Foundation	Identification of individuals with glucose-6-phosphate dehydrogenase deficiency	USD	\$124 850	1yr
James McCarthy	Bill and Melinda Gates Foundation	Support of clinical trial infrastructure	USD	\$9 200 000	4 yrs
Donald McLeod	NHMRC	The causes and treatment of thyroid disease	AUD	\$184 718	3yrs
Sarah Medland	National Institutes of Health	ENIGMA Center for Worldwide Medicine, Imaging and Genomics	USD	\$200 000	4 yrs
Sarah Medland	NHMRC	Investigating the relationship between depression, anxiety and nausea and vomiting during pregnancy: causation or shared liability?	AUD	\$583 467	2yrs
John Miles	Rio Tinto Ride to Conquer Cancer and Weekend to End Women's Cancers	Engineering stronger T cell ligands through organic and synthetic biochemistry	AUD	\$100 000	3yrs

## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
John Miles	Perpetual Trustees Australia Limited	Mining a large venom bank for bioactive compounds that boost vaccine potency	AUD	\$112 361	1yr
John Miles	Prostate Cancer Fund of Australia	Isolating high-avidity prostate cancer-specific T cells using high definition allogenic pulldown	AUD	\$240 000	2yrs
John Miles	Other - International	A new approach to the design and evaluation of T cell vaccines for cancer	AUD	\$443 340	2yrs
John Miles	NHMRC	Tracking the human immune system over years of life	AUD	\$456 413	3yrs
John Miles	NHMRC	A new approach to the design and evaluation of T cell vaccines for cancer and infectious disease	AUD	\$639 492	3yrs
Andreas Moller	NHMRC	Exosomes as mediators of metastasis	AUD	\$398 152	2yrs
Grant Montgomery	NHMRC	Genome-wide analysis of gene coding variants increasing risk of endometriosis	AUD	\$686 071	2yrs
Grant Montgomery	NHMRC	Translating gene discovery into clinical outcomes	AUD	\$739 980	4yrs
Jason Mulvenna	NHMRC	Biomarkers for the progression of cholangiocarcinoma: from risk factors to carcinogenesis	AUD	\$507 347	2yrs
Rachel Neale	NHMRC	D-Health: A randomised trial of vitamin D for prevention of cancer and mortality	AUD	\$2 930 705	4yrs
Dale Nyholt	NHMRC	Genetic biomarkers and molecular pathways for migraine.	AUD	\$268 151	1yr
Dale Nyholt	NHMRC	Identification of novel common genetic risk factors for endometriosis	AUD	\$580 011	1yr
Sanjoy Paul	Queensland Government	Smart Futures Co-Investment Fund (CIF) - Blood Glucose Control Tool	AUD	\$136 983	3yrs
Sanjoy Paul	NHMRC	Whole body vibration for osteoporosis: Shaking up our treatment options	AUD	\$163 240	4yrs
Sanjoy Paul	NHMRC	Sampling antibiotics in renal replacement therapy: a multi-national prospective pharmacokinetic study (SMARRT)	AUD	\$218 482	3yrs
Sanjoy Paul	Federal Government	Translating Health Discovery Project (NCRIS 2013)	AUD	\$297 726	1.5yrs
Sanjoy Paul	NHMRC	The obesity paradox in type 2 diabetes	AUD	\$333 930	3yrs
Sanjoy Paul	Education Investment Fund	TIA-EIF - to fund the creation or development of research infrastructure	AUD	\$589 780	2yrs
Jolieke Van Der Pols	Cancer Council Queensland	Risk factors for sessile serrated adenoma	AUD	\$200 000	2yrs
Graham Radford-Smith	Amgen Inc	Analysis of disease biology in IBD	AUD	\$117 431	1 yr
Grant Ramm	NHMRC	Cellular cross-talk between liver progenitor cells and hepatic stellate cells is required for hepatic fibrogenesis	AUD	\$599 154	3yrs
Grant Ramm	NHMRC	Role of hepatic stellate cell and liver progenitor cell interactions in the regulation of wound healing and liver regeneration	AUD	\$599 682	3yrs

## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
Grant Ramm	NHMRC	Identification of the mechanisms of hepatic fibrogenesis aid in the detection and prediction of clinical outcomes in paediatric cholestatic liver disease	AUD	\$602 877	3yrs
Grant Ramm	NHMRC	Mechanisms of liver scarring in chronic liver disease	AUD	\$664 515	5yrs
Grant Ramm	NHMRC	Ferritin binding and signalling receptors in hepatic fibrogenesis	AUD	\$752 281	3yrs
David Reid	NHMRC	Abnormal lung iron homeostasis in cystic fibrosis	AUD	\$629 661	3yrs
David Reid	NHMRC	Abnormal lung iron homeostasis in cystic fibrosis	AUD	\$1 629 661	3 yrs
Corey Smith	NHMRC	Tracking the impact of superinfection with a common herpes virus on T cell immunity in humans	AUD	\$306 806	3yrs
Corey Smith	NHMRC	The impact of infection with different strains of a common virus on immunity in humans	AUD	\$314 063	3yrs
Mark Smyth	Cancer Council Queensland	A new checkpoint target for cancer immunotherapy	AUD	\$200 000	2yrs
Mark Smyth	Cancer Research Institute	The pre-clinical validation of CD96 as a checkpoint target for cancer immunotherapy	USD	\$200 000	2yrs
Mark Smyth	NHMRC	Returning Applicant to SPRF	AUD	\$795 069	5yrs
Mark Smyth	NHMRC	Development of CD96 antibodies for cancer treatment	AUD	\$796 046	3yrs
Mark Smyth	NHMRC	Development of CD96 antibodies for cancer treatment	AUD	\$796 046	3yrs
Amanda Spurdle	Cancer Council Queensland	Clinical classification of BRCA1/2 gene variants	AUD	\$200 000	1yr
Amanda Spurdle	NHMRC	Genetic studies towards improving cancer diagnosis	AUD	\$739 515	5yrs
Brett Stringer	University - Monash	Development of effective antibody-based therapies for glioma	AUD	\$300 000	3yrs
Nathan Subramaniam	National Institute of Health	Genetic modifiers of iron status in hemochromatosis HFE C282Y homozygotes	USD	\$301 800	3 yrs
Nathan Subramaniam	NHMRC	Understanding how the liver regulates body iron levels	AUD	\$407 402	3 yrs
Nathan Subramaniam	NHMRC	NHMRC Fellowship	AUD	\$584 100	5 yrs
Nathan Subramaniam	NHMRC	Dissecting the TMPRSS6 regulation of iron homeostasis	AUD	\$592 142	3 yrs
Nathan Subramaniam	NHMRC	Delineating the relationship between Iron and peroxisomal disorders: The role of the peroxisomal enzyme GNPAT in iron overload	AUD	\$674 461	4 yrs
Andreas Suhrbier	Australian Centre for HIV and Hepatitis	EcoHIV, a convenient, Biosafety Level 2, mouse model for animal testing of HIV vaccines and anti-retroviral drugs	AUD	\$165 000	1yr

## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
Andreas Suhrbier	Cancer Council Queensland	Regulation of mTORC2 and Ras signalling by Sin1 isoforms in pancreatic cancer	AUD	\$200 000	1yr
Andreas Suhrbier	NHMRC	Regulation of inflammation and coagulation by microparticles containing SerpinB2	AUD	\$573 627	2yrs
Andreas Suhrbier	NHMRC	Improving treatment strategies for chronic alphaviral arthritic diseases	AUD	\$623 475	2yrs
Andreas Suhrbier	NHMRC	Applied inflammation biology	AUD	\$802 610	5yrs
Michele Teng	Cancer Council Queensland	The role of IL-23 associated cytokines in cancer immunology	AUD	\$200 000	1yr
Michele Teng	NHMRC	Combined T cell checkpoint blockade to eradicate established cancer	AUD	\$202 298	1yr
Siok Tey	NHMRC	Cell therapy to prevent and treat graft-versus-host disease after allogeneic haematopoietic stem cell transplantation	AUD	\$251 694	3yrs
Siok Tey	NHMRC	Inducible caspase 9 suicide gene to improve the safety of donor T cell addback after haploidentical stem cell transplantation	AUD	\$545 681	2yrs
Nic Waddell	NHMRC	Defining the genomic and therapeutic landscape of familial breast cancer	AUD	\$135 223	3yrs
Nic Waddell	NHMRC	Characterising the mutations, signatures, potential new therapeutic targets and biomarkers in malignant mesothelioma using whole genome analysis	AUD	\$1 188 475	3yrs
Graeme Walker	Cancer Council Queensland	In vivo functional analysis of naevus GWAS hits: dissection of the respective roles of the CDKN2A and MTAP genes in naevus susceptibility	AUD	\$199 782	2yrs
Graeme Walker	Cancer Council Queensland	Characterizing a novel naevus modifier gene on murine chromosome 8	AUD	\$200 000	1yr
Graeme Walker	NHMRC	Do 'classical' or 'oxidative' UVR-induced DNA adducts drive melanoma induction after ultraviolet radiation	AUD	\$324 336	2yrs
Graeme Walker	Melanoma Research Alliance	The Tgfb2/Rrp15 locus is an innate modifier of melanoma development	USD	\$337 500	3yrs
Graeme Walker	NHMRC	Systems analysis of epidermal biology and cancer	AUD	\$1 253 838	3yrs
Penny Webb	ANZGOG	Measure of ovarian cancer symptoms and treatment concerns following treatment	AUD	\$120 000	2yrs
Vicki Whitehall	NHMRC	Wnt and MAPK signalling in the determination of colorectal neoplasia pathway	AUD	\$383 447	3yrs
Vicki Whitehall	NHMRC	Kras- and braf-mediated methylation signatures in colorectal cancers and polyps	AUD	\$443 306	3yrs
David Whiteman	NHMRC	Studies in cancer control	AUD	\$727 610	5yrs

## Grants continued

RESEARCHER	GRANT BODY	GRANT PURPOSE/TITLE	CURRENCY	AMOUNT	DURATION
David Whiteman	NHMRC	PROBE-NET: the progression of barrett's oesophagus to cancer network	AUD	\$2 465 841	5yrs
David Whiteman	NHMRC	QSKIN: the genetics of skin cancer	AUD	\$3 309 067	5yrs
David Whiteman	NHMRC	Generating the evidence to control cancer and optimise outcomes	AUD	\$6 288 080	5 yrs
Christina Wong	National Breast Cancer Foundation	Diagnostic and therapeutic approaches against breast cancer metastasis	AUD	\$390 000	3yrs
Margaret Wright	NHMRC	Neurodevelopment during adolescence: a longitudinal imaging study	AUD	\$1 634 767	4yrs
Huiying Zhao	NHMRC	Development and application of novel bioinformatics approaches to identify pathogenetic mechanisms underlying migraine	AUD	\$309 436	3yrs

# QIMR BERGHOFER FELLOWS

NAME	YEAR AWARDED
Macfarlane Burnet	1981
Ralph Doherty	
Frank Fenner	
Eric French	
Abraham Fryberg	
Douglas Lee	
Margaret Macgregor	
Aubrey Pye	
William Reeves	
John Sprent	
Harry Standfast	
George Taylor	
John Tonge	
Carleton Gajdusek	1982
David Henderson	
Owen Powell	
Julie Saroso	
Edwin Westaway	
Vincent Zigas	
Anthony Epstein	1983
Douglas Gordon	
Elizabeth Marks	
Neville Davis	1985
Robert Porter	
Brian Wilson	
Natth Bhamarapravati	1986
Louis Miller	
Eric Saint	
Robert Shope	
Bruce Watson	
The Hon Mike Ahern	1988
Neville McCarthy	
Gustav Nossal	
E D O'Callaghan (posthumous)	
Frank Schofield	
Edward Stewart	1989
Tao Yixun	
Chamlong Harinasuta	1991
Chev Kidson	
Peter Livingstone	
Michael Alpers	1992
Rod Wylie	
Graham Mitchell	1993
Mervyn Eadie	1994
Bryan Emmerson	
Ian Wilkey	

NAME	YEAR AWARDED
Ted Brown	1995
Peter Doherty	1997
Paul Korner	
Stephen Lynch	
Michael O'Rourke	1998
Michael Barry	1999
Kay Ellem	
Ian Taylor	
Lawrie Powell	2000
Tom Veivers	
Phillip Desbrow	2001
William O'Sullivan	
Diana Cavaye	2002
Mary Dunne	
Clive Berghofer	2003
Bryan Campbell	
Sam Coco	
Peter Wills	2004
John Kerr	2005
Paul Wright	
David Lyons	2006
Ian Goddard	2007
Helen Luckoff	
John Garnsey	2008
Graham Brown	
Robert MacLennan	
Peter Brooks	2009
Peter Roeser	
David Alcorn	2011
Michael Good	
John Hay	2012
Christine Rzepczyk	2013
Jim Aylward	
Bruce Phillips	
Judith Clements	2014

# SCIENTIFIC PUBLICATIONS

**Adams R. L., Cheung C., Banh R., Saal R., Cross D., Gill D., Self M., Klein K. and Mollee P.** Prognostic value of ZAP 70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry.

*CYTOMETRY. PART B, CLINICAL CYTOMETRY* 2014 [86(2): 80-90]

**Afshar Sterle S., Zotos D., Bernard N. J., Scherger A. K., Rodling L., Alsop A. E., Walker J., Masson F., Belz G. T., Corcoran L. M., O'Reilly L. A., Strasser A., Smyth M. J., Johnstone R., Tarlinton D. M., Nutt S. L. and Kallies A.** Fas ligand mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. *NATURE MEDICINE* 2014 [20(3): 283-90]

**Agarwal D., Pineda S., Michailidou K., Herranz J., Pita G., Moreno L. T., Alonso M. R., Dennis J., Wang Q., Bolla M. K., Meyer K. B., Menendez Rodriguez P., Hardisson D., Mendiola M., Gonzalez Neira A., Lindblom A., Margolin S., Swerdlow A., Ashworth A., Orr N., Jones M., Matsuo K., Ito H., Iwata H., Kondo N., Hartman M., Hui M., Lim W. Y., Iau P. T., Sawyer E., Tomlinson I., Kerin M., Miller N., Kang D., Choi J., Park S. K., Noh D., Hopper J. L., Schmidt D. F., Makalic E., Southey M. C., Teo S. H., Yip C. H., Sivanandan K., Tay W., Brauch H., Bruning T., Hamann U., Dunning A. M., Shah M., Andrulis I. L., Knight J. A., Glendon G., Tchatchou S., Schmidt M. K., Broeks A., Rosenberg E. H., van't Veer L. J., Fasching P. A., Renner S. P., Ekici A. B., Beckmann M. W., Shen C., Hsiung C., Yu J., Hou M., Blot W., Cai Q., Wu A. H., Tseng C., Van Den Berg D., Stram D. O., Cox A., Brock I. W., Reed M. W., Muir K., Lophatananon A., Stewart Brown S., Siriwanarangsana P., Zheng W., Deming Halverson S., Shrubsole M. J., Long J., Shu X., Lu W., Gao Y., Zhang B., Radice P., Peterlongo P., Manoukian S., Mariette F., Sangrajrang S., McKay J., Couch F. J., Toland A. E., Yannoukakos D., Fletcher O., Johnson N., dos Santos Silva I., Peto J., Marme F.,**

**Burwinkel B., Guenel P., Truong T., Sanchez M., Mulot C., Bojesen S. E., Nordestgaard B. G., Flyer H., Brenner H., Dieffenbach A. K., Arndt V., Stegmaier C., Mannermaa A., Kataja V., Kosma V., Hartikainen J. M., Lambrechts D., Yesilyurt B. T., Floris G., Leunen K., Chang Claude J., Rudolph A., Seibold P., Flesch-Janys D., Wang X., Olson J. E., Vachon C., Purrington K., Giles G. G., Severi G., Baglietto L., Haiman C. A., Henderson B. E., Schumacher F., Marchand L. L., Simard J., Dumont M., Goldberg M. S., Labreche F., Winqvist R., Pylkas K., Jukkola Vuorinen A., Grip M., Devilee P., Tollenaar R. A. Seynaeve C., Garcia Closas M., Chanock S. J., Lissowska J., Figueroa J. D., Czene K., Eriksson M., Humphreys K., Darabi H., Hooning M. J., Kriege M., Collee J. M., Tilanus Linthorst M., Li J., Jakubowska A., Lubinski J., Jaworska Bieniek K., Durda K., Nevanlinna H., Muranen T. A., Aittomaki K., Blomqvist C., Bogdanova N., Dork T., Hall P., Chenevix Trench G., Easton D. F., Pharoah P. D., Arias Perez J. I., Zamora P., Benitez J. and Milne R. L.** FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. *BRITISH JOURNAL OF CANCER* 2014 [110(4): 1088-1100]

**Al Olama A. A., Kote Jarai Z., Berndt S. I., Conti D. V., Schumacher F., Han Y., Benlloch S., Hazelett D. J., Wang Z., Saunders E., Leongamornlert D., Lindstrom S., Jugurnauth Little S., Dadaev T., Tymrakiewicz M., Stram D. O., Rand K., Wan P., Stram A., Sheng X., Pooler L. C., Park K., Xia L., Tyrer J., Kolonel L. N., Le Marchand L., Hoover R. N., Machiela M. J., Yeager M., Burdette L., Chung C. C., Hutchinson A., Yu K., Goh C., Ahmed M., Govindasami K., Guy M., Tammela T. L., Auvinen A., Wahlfors T., Schleutker J., Visakorpi T., Leinonen K. A., Xu J., Aly M., Donovan J., Travis R. C., Key T. J., Siddiq A., Canzian F., Khaw K. T., Takahashi A., Kubo M., Pharoah P., Pashayan N., Weischer M.,**

**Nordestgaard B. G., Nielsen S. F., Klarskov P., Roder M. A., Iversen P., Thibodeau S. N., McDonnell S. K., Schaid D. J., Stanford J. L., Kolb S., Holt S., Knudsen B., Coll A. H., Gapstur S. M., Diver W. R., Stevens V. L., Maier C., Luedeke M., Herkommer K., Rinckleb A. E., Strom S. S., Pettaway C., Yeboah E. D., Tettey Y., Biritwum R. B., Adjei A. A., Tay E., Truelove A., Niwa S., Chokkalingam A. P., Cannon Albright L., Cybulski C., Wokolorczyk D., Kluzniak W., Park J., Sellers T., Lin H. Y., Isaacs W. B., Partin A. W., Brenner H., Dieffenbach A. K., Stegmaier C., Chen C., Giovannucci E. L., Ma J., Stampfer M., Penney K. L., Mucci L., John E. M., Ingles S. A., Kittles R. A., Murphy A. B., Pandha H., Michael A., Kierzek A. M., Blot W., Signorello L. B., Zheng W., Albanes D., Virtamo J., Weinstein S., Nemesure B., Carpten J., Leske C., Wu S. Y., Hennis A., Kibel A. S., Rybicki B. A., Neslund Dudas C., Hsing A. W., Chu L., Goodman P. J., Klein E. A., Zheng S. L., Batra J., Clements J., Spurdle A., Teixeira M. R., Paulo P., Maia S., Slavov C., Kaneva R., Mitev V., Witte J. S., Casey G., Gillanders E. M., Seminara D., Riboli E., Hamdy F. C., Coetzee G. A., Li Q., Freedman M. L., Hunter D. J., Muir K., Gronberg H., Neal D. E., Southey M., Giles G. G., Severi G., Cook M. B., Nakagawa H., Wiklund F., Kraft P., Chanock S. J., Henderson B. E., Easton D. F., Eeles R. A. and Haiman C. A.** A meta analysis of 87 040 individuals identifies 23 new susceptibility loci for prostate cancer. *NATURE GENETICS* 2014 [46(10): 1103-9]

**Albrecht E Sillanpää E, Karrasch S, Alves AC, Codd V, Hovatta I, Buxton JL, Nelson CP, Broer L, Hägg S, Mangino M, Willemsen G, Surakka I, Ferreira MA, Amin N, Oostra BA, Bäckmand HM, Peltonen M, Sarna S, Rantanen T, Sipilä S, Korhonen T, Madden PA, Gieger C, Jörres RA, Heinrich J, Behr J, Huber RM, Peters A, Strauch K, Wichmann HE, Waldenberger M, Blakemore AI, de Geus EJ, Nyholt DR, Henders AK, Piirilä PL, Rissanen A, Magnusson**



**PK, Viñuela A, Pietiläinen KH, Martin NG, Pedersen NL, Boomsma DI, Spector TD, van Duijn CM, Kaprio J, Samani NJ, Jarvelin MR, Schulz H.** Telomere length in circulating leukocytes is associated with lung function and disease.

*THE EUROPEAN RESPIRATORY JOURNAL* 2014 [43(4): 983 992]

**Alcock C, Khatun M, Ma J and Hacking C** Elimination of oral contrast in the emergency department: an Australian experience. *JOURNAL OF MEDICAL RADIATION SCIENCES* 2014 [61(S1): 185]

**Al Ejeh Fares, Offenhäuser Carolin, Lim Yi Chieh, Stringer Brett W, Day Bryan W and Boyd Andrew W** Eph family co expression patterns define unique clusters predictive of cancer phenotype. *GROWTH FACTORS* 2014 [32(6): 254 264]

**Al Ejeh Fares, Pajic Marina, Shi Wei, Kalimutho Murugan, Miranda Mariska, Nagrial Adnan M, Chou Angela, Biankin Andrew V, Grimmond Sean M, Brown Michael P and KK Khanna** Gemcitabine and CHK1 inhibition potentiate EGFR directed radioimmunotherapy against pancreatic ductal adenocarcinoma. *CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH* 2014 [20(12): 3187 3197]

**Al Ejeh Fares, Staudacher Alexander H, Smyth Douglas R, Darby Jocelyn M, Denoyer Delphine, Tsopeles Chris, Hicks Rodney J and Brown Michael P** Postchemotherapy and tumor selective targeting with the La specific DAB4 monoclonal antibody relates to apoptotic cell clearance. *JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE* 2014 [55(5): 772 779]

**Al Ejeh F., Simpson P. T., Saunus J. M., Klein K., Kalimutho M., Shi W., Miranda M., Kutasovic J., Raghavendra A., Madore J., Reid L., Krause L., Chenevix Trench G., Lakhani S. R. and Khanna K. K.** Meta analysis of the global gene expression profile of triple negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. *ONCOGENESIS* 2014 [3(4): e124]

**Al Ejeh Fares, Miranda Mariska, Shi Wei, Simpson Peter T, Song Sarah, Vargas Ana Cristina, Saunus Jodi M, Smart Chanel E, Mariasegaram Mythily, Wiegman Adrian P, G Chenevix Trench, SR Lakhani and KK Khanna** Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. *ONCOTARGET* 2014 [5(10): 3145 58]

**Alexander K. A., Flynn R., Lineburg K. E., Kuns R. D., Teal B. E., Olver S. D., Lor M., Raffelt N. C., Koyama M., Leveque L., Le Texier L., Melino M., Markey K. A., Varelias A., Engwerda C., Serody J. S., Janela B., Ginhoux F., Clouston A. D., Blazar B. R., Hill G. R. and MacDonald K. P.** CSF 1 dependant donor derived macrophages mediate chronic graft versus host disease. *THE JOURNAL OF CLINICAL INVESTIGATION* 2014 [124(10): 4266 80]

**Andani R., Robertson I., Macdonald K. P., Durrant S., Hill G. R. and Khosrotehrani K.** Origin of Langerhans cells in normal skin and chronic GVHD after hematopoietic stem cell transplantation. *EXPERIMENTAL DERMATOLOGY* 2014 [23(1): 75 7]

**Antonsson A., Cornford M., Perry S., Davis M., Dunne M. P. and Whiteman D. C.** Prevalence and risk factors for oral HPV infection in young Australians. *PLOS ONE* 2014 [9(3): e91761]

**Anuradha S., Webb P. M., Blomfield P., Brand A. H., Friedlander M., Leung Y., Obermair A., Oehler M. K., Quinn M., Steer C. and Jordan S. J.** Survival of Australian women with invasive epithelial ovarian cancer: a population based study. *THE MEDICAL JOURNAL OF AUSTRALIA* 2014 [201(5): 283 8]

**Aoude L. G., Pritchard A. L., Robles Espinoza C. D., Wadt K., Harland M., Choi J., Gartside M., Quesada V., Johansson P., Palmer J. M., Ramsay A. J., Zhang X., Jones K., Symmons J., Holland E. A., Schmid H., Bonazzi V., Woods S., Dutton Register K., Stark M. S., Snowden H., van Doorn R., Montgomery G. W., Martin N. G., Keane T. M., Lopez Otin C., Gerdes A. M., Olsson H., Ingvar C., Borg A., Gruis N. A., Trent J. M., Jonsson G., Bishop D. T., Mann G. J., Newton Bishop J. A., Brown K. M., Adams D. J. and Hayward N. K.** Nonsense mutations in the shelterin

complex genes ACD and TERF2IP in familial melanoma. *JOURNAL OF THE NATIONAL CANCER INSTITUTE* 2014 [107(2): 408]

**Aoude LG Xu M, Zhao ZZ, Kovacs M, Palmer JM, Johansson P, Symmons J, Trent JM, Martin NG, Montgomery GW, Brown KM, Hayward NK.** Assessment of PALB2 as a Candidate Melanoma Susceptibility Gene. *PLOS ONE* 2014 [9(6): e100683]

**Aquino, K. M. Robinson, P. A. Schira, M. M. Breakspear, M.** Deconvolution of neural dynamics from fMRI data using a spatiotemporal hemodynamic response function. *NEUROIMAGE* 2014 [94: 203 15]

**Ashbrook D. G., Williams R. W., Lu L., Stein J. L., Hibar D. P., Nichols T. E., Medland S. E., Thompson P. M. and Hager R** Joint genetic analysis of hippocampal size in mouse and human identifies a novel gene linked to neurodegenerative disease. *BMC GENOMICS* 2014 [15: 850]

**Aslam M. F., Frazer D. M., Faria N., Bruggraber S. F., Wilkins S. J., Mirciov C., Powell J. J., Anderson G. J. and Pereira D. I.** Ferroportin mediates the intestinal absorption of iron from a nanoparticulate ferritin core mimetic in mice. *FASEB JOURNAL* 2014 [28(8): 3671 8]

**Au Yeung G., Webb P. M., Defazio A., Fereday S., Bressel M. and Mileskin L** Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). *GYNECOLOGIC ONCOLOGY* 2014 [133(1): 16 22]

**\*Badve S. V., \*Paul S. K., Klein K., Clayton P. A., Hawley C. M., Brown F. G., Boudville N., Polkinghorne K. R., McDonald S. P. and Johnson D. W. (\*Joint first authors)** The Association between Body Mass Index and Mortality in Incident Dialysis Patients. *PLOS ONE* 2014 [9(12):]

**Bai Y., Zhang Z., Jin L., Kang H., Zhu Y., Zhang L., Li X., Ma F., Zhao L., Shi B., Li J., McManus D. P., Zhang W. and Wang S.** Genome wide sequencing of small RNAs reveals a tissue specific loss of conserved microRNA families in *Echinococcus granulosus*. *BMC GENOMICS* 2014 [15: 736]

**Barbour A. P., Tang Y. H., Armour N., Dutton Register K., Krause L., Loffler K. A., Lambie D., Burmeister B., Thomas J., Smithers B. M. and Hayward N. K.** BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. *EUROPEAN JOURNAL OF CANCER* 2014 [50(15): 2668 76]

**Barrett J. H., Taylor J. C., Bright C., Harland M., Dunning A. M., Akslen L. A., Andresen P. A., Avril M. F., Azizi E., Bianchi Scarra G., Brossard M., Brown K. M., Debniak T., Elder D. E., Friedman E., Ghorzo P., Gillanders E. M., Gruis N. A., Hansson J., Helsing P., Hocevar M., Hoiom V., Ingvar C., Landi M. T., Lang J., Lathrop G. M., Lubinski J., Mackie R. M., Molven A., Novakovic S., Olsson H., Puig S., Puig Butille J. A., van der Stoep N., van Doorn R., van Workum W., Goldstein A. M., Kanetsky P. A., Pharoah P. D., Demenais F., Hayward N. K., Newton Bishop J. A., Bishop D. T., Iles M. M. and Geno M. E. L.** Consortium Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [136(6): 1351 60]

**Baschuk N., Wang N., Watt S. V., Halse H., House C., Bird P. I., Strugnell R., Trapani J. A., Smyth M. J. and Andrews D. M.** NK cell intrinsic regulation of MIP 1alpha by granzyme M. *CELL DEATH & DISEASE* 2014 [5: e1115]

**Baxter E, Windloch K, Gannon F, Lee JS.** Epigenetic regulation in cancer progression. *CELL & BIOSCIENCE* 2014 [4: 45]

**Beesley V. L., Green A. C., Wyld D. K., O'Rourke P., Wockner L. F., deFazio A., Butow P. N., Price M. A., Horwood K. R., Clavarino A. M., Australian Ovarian Cancer Study Group, Australian Ovarian Cancer Study Quality Of Life Study Investigators and Webb P. M.** Quality of life and treatment response among women with platinum resistant versus platinum sensitive ovarian cancer treated for progression: a prospective analysis. *GYNECOLOGIC ONCOLOGY* 2014 [132(1): 130 6]

**Beesley V. L., Smithers B. M., Khosrotehrani K., Khatun M., O'Rourke P., Hughes M. C., Malt M. K., Zonta M. J., Bayley G. J., Barbour A. P., Brown L. J., D'Arcy J., Allan C. P. and Green A. C.** Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. *PSYCHO ONCOLOGY* 2014 [:]

**Beesley V. L., Rowlands I. J., Hayes S. C., Janda M., O'Rourke P., Marquart L., Quinn M. A., Spurdle A. B., Obermair A., Brand A., Oehler M. K., Leung Y., McQuire L. and Webb P. M.** Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema specific supportive care needs in women treated for endometrial cancer. *GYNECOLOGIC ONCOLOGY* 2014 [136(1): 87 93]

**Bell S. C., De Boeck K. and Amaral M. D.** New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. *PHARMACOLOGY & THERAPEUTICS* 2014 [145: 19 34]

**Bell S. C., Heijerman H. and Hartl D.** JCF 2014 and beyond. *JOURNAL OF CYSTIC FIBROSIS : OFFICIAL JOURNAL OF THE EUROPEAN CYSTIC FIBROSIS SOCIETY* 2014 [13(6): 610 11]

**Bell SC, Reid DW.** Challenges of the care of adults with cystic fibrosis. *EUROPEAN RESPIRATORY MONOGRAPH* 2014 [64(In Press): 287 304]

**Benevento Marco, Tonge Peter D, Puri Mira C, Hussein Samer MI, Cloonan Nicole, Wood David L, Grimmond Sean M, Nagy Andras, Munoz Javier and Heck Albert JR** Proteome adaptation in cell reprogramming proceeds via distinct transcriptional networks. *NATURE COMMUNICATIONS* 2014 [5: 5613]

**Benyamin B Pourcain B, Davis OS, Davies G, Hansell NK, Brion MJ, Kirkpatrick RM, Cents RA, Franic S, Miller MB, Haworth CM, Meaburn E, Price TS, Evans DM, Timpson N, Kemp J, Ring S, McArdle W, Medland SE, Yang J, Harris SE, Liewald DC, Scheet P, Xiao X, Hudziak JJ, de Geus EJ; Wellcome Trust Case Control Consortium 2 (WTCCC2),**

**Jaddoe VW, Starr JM, Verhulst FC, Pennell C, Tiemeier H, Iacono WG, Palmer LJ, Montgomery GW, Martin NG, Boomsma DI, Posthuma D, McGue M, Wright MJ, Davey Smith G, Deary IJ, Plomin R, Visscher PM.** Childhood intelligence is heritable, highly polygenic and associated with FNBP1L. *MOLECULAR PSYCHIATRY* 2014 [19(2): 253 258]

**Benyamin B Esko T, Ried JS, Radhakrishnan A, Vermeulen SH, Traglia M, Gögele M, Anderson D, Broer L, Podmore C, Luan J, Kutalik Z, Sanna S, van der Meer P, Tanaka T, Wang F, Westra HJ, Franke L, Mihailov E, Milani L, Hälldin J, Winkelmann J, Meitinger T, Thiery J, Peters A, Waldenberger M, Rendon A, Jolley J, Sambrook J, Kiemeny LA, Sweep FC, Sala CF, Schwenbacher C, Pichler I, Hui J, Demirkan A, Isaacs A, Amin N, Steri M, Waeber G, Verweij N, Powell JE, Nyholt DR, Heath AC, Madden PA, Visscher PM, Wright MJ, Montgomery GW, Martin NG, Hernandez D, Bandinelli S, van der Harst P, Uda M, Vollenweider P, Scott RA, Langenberg C, Wareham NJ; InterAct Consortium, van Duijn C, Beilby J, Pramstaller PP, Hicks AA, Ouwehand WH, Oexle K, Gieger C, Metspalu A, Camaschella C, Toniolo D, Swinkels DW, Whitfield JB.** Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. *NATURE COMMUNICATIONS* 2014 [5: 4926]

**Bettington M., Walker N., Rosty C., Brown I., Clouston A., Wockner L., Whitehall V. and Leggett B.** Critical appraisal of the diagnosis of the sessile serrated adenoma. *THE AMERICAN JOURNAL OF SURGICAL PATHOLOGY* 2014 [38(2): 158 66]

**Bian, M.L., Haigh, O., Munster, D., Harris, M., Cotterill, A., Miles, J.J. and Vuckovic, S.** Reactivated CD4+ Tm cells of children with T1D children and siblings display an exaggerated effector phenotype with heightened sensitivity to activation induced cell death. *DIABETES*. 2015 [:]

**Bieri FA, Li YS, Yuan LP, He YK, Gray DJ, Williams GM, McManus DP.** School based health education targeting intestinal worms further support for integrated control. *PLOS NEGL TROP DIS*. 8(3):E2621. DOI: 10.1371/JOURNAL.PNTD.0002621 2014 [8(3): e2621]

**Bird C. H., Christensen M. E., Mangan M. S., Prakash M. D., Sedelies K. A., Smyth M. J., Harper I., Waterhouse N. J. and Bird P. I.** The granzyme B Serpinb9 axis controls the fate of lymphocytes after lysosomal stress. *CELL DEATH AND DIFFERENTIATION* 2014 [21(6): 876 87]

**Blake S. J. and Teng M. W.** Role of IL 17 and IL 22 in autoimmunity and cancer. *ACTAS SERMO SIFILIOGRAFICAS* 2014 [105: 41 50]

**Block M. S., Charbonneau B., Vierkant R. A., Fogarty Z., Bamlet W. R., Pharoah P. D., Rossing M. A., Cramer D., Pearce C. L., Schildkraut J., Menon U., Kjaer S. K., Levine D. A., Gronwald J., Culver H. A., Whittemore A. S., Karlan B. Y., Lambrechts D., Wentzensen N., Kupryjanczyk J., Chang Claude J., Bandera E. V., Hogdall E., Heitz F., Kaye S. B., Fasching P. A., Campbell I., Goodman M. T., Pejovic T., Bean Y. T., Hays L. E., Lurie G., Eccles D., Hein A., Beckmann M. W., Ekici A. B., Paul J., Brown R., Flanagan J. M., Harter P., du Bois A., Schwaab I., Hogdall C. K., Lundvall L., Olson S. H., Orlow I., Paddock L. E., Rudolph A., Eilber U., Dansonka Mieszkowska A., Rzepecka I. K., Ziolkowska Seta I., Brinton L. A., Yang H., Garcia Closas M., Despierre E., Lambrechts S., Vergote I., Walsh C. S., Lester J., Sieh W., McGuire V., Rothstein J. H., Ziogas A., Lubinski J., Cybulski C., Menkiszak J., Jensen A., Gayther S. A., Ramus S. J., Gentry Maharaj A., Berchuck A., Wu A. H., Pike M. C., Van Den Berg D., Terry K. L., Vitonis A. F., Ramirez S. M., Rider D. N., Knutson K. L., Sellers T. A., Phelan C. M., Doherty J. A., Johnatty S. E., deFazio A., Song H., Tyrer J., Kalli K. R., Fridley B. L., Cunningham J. M. and Goode E. L.** Variation in NF kappaB signaling pathways and survival in invasive epithelial ovarian cancer. *CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION : A PUBLICATION OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, COSPONSORED BY THE AMERICAN SOCIETY OF PREVENTIVE ONCOLOGY* 2014 [23(7): 1421 7]

**Blokland GA McMahon KL, Thompson PM, Hickie IB, Martin NG, de Zubicaray GI, Wright MJ.** Genetic effects on the cerebellar role in working memory: Same brain, different genes? *NEUROIMAGE* 2014 [86: 392 403]

**Bolderson E., Petermann E., Croft L., Suraweera A., Pandita R. K., Pandita T. K., Helleday T., Khanna K. K.\* and Richard D. J.\*** Joint Last author. Human single stranded DNA binding protein 1 (hSSB1/NABP2) is required for the stability and repair of stalled replication forks. *NUCLEIC ACIDS RESEARCH* 2014 [42(10): 6326 36]

**Bond C. E., Nancarrow D. J., Wockner L. F., Wallace L., Montgomery G. W., Leggett B. A. and Whitehall V. L.** Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability. *PLOS ONE* 2014 [9(3): e91739]

**Bosetti C., Rosato V., Li D., Silverman D., Petersen G. M., Bracci P. M., Neale R. E., Muscat J., Anderson K., Gallinger S., Olson S. H., Miller A. B., Bas Bueno de Mesquita H., Scelo G., Janout V., Holcatova I., Laggiou P., Serraino D., Lucenteforte E., Fabianova E., Ghadirian P., Baghurst P. A., Zatonski W., Foretova L., Fontham E., Bamlet W. R., Holly E. A., Negri E., Hassan M., Prizment A., Cotterchio M., Cleary S., Kurtz R. C., Maisonneuve P., Trichopoulos D., Polesel J., Duell E. J., Boffetta P. and La Vecchia C.** Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case Control Consortium. *ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO* 2014 [25(10): 2065 72]

**Bosserhoff A. K., Ellmann L., Quast A. S., Eberle J., Boyle G. M. and Kuphal S.** Loss of T cadherin (CDH 13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma. *MOLECULAR CARCINOGENESIS* 2014 [53(8): 635 47]

**Boufana B., Lett W. S., Lahmar S., Buishi I., Bodell A. J., Varcasia A., Casulli A., Beeching N. J., Campbell F., Terlizzo M., McManus D. P. and Craig P. S.** *Echinococcus equinus* and *Echinococcus granulosus sensu*

*stricto* from the United Kingdom: genetic diversity and haplotypic variation. *INT J PARASITOL* 2014 [45(2 3): 161 6]

**BOYD, AW, Bartlett, PF, Lackmann, M.** Therapeutic targeting of Eph receptors and their ligands. *NAT REV DRUG DISCOVERY* 2,013 [13: 39 62]

**Boyle M. P., Bell S. C., Konstan M. W., McColley S. A., Rowe S. M., Rietschel E., Huang X., Waltz D., Patel N. R., Rodman D. and group V. X.** Study A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. *THE LANCET. RESPIRATORY MEDICINE* 2014 [2(7): 527 38]

**Boyle G. M., D'Souza M. M., Pierce C. J., Adams R. A., Cantor A. S., Johns J. P., Maslovskaya L., Gordon V. A., Reddell P. W. and Parsons P. G.** Intra lesional injection of the novel PKC activator EBC 46 rapidly ablates tumors in mouse models. *PLOS ONE* 2014 [9(10): e108887]

**Bradbury R, Reid DW, Champion AC.** Urease Production as a Marker of Virulence in *Pseudomonas aeruginosa*. *BR J BIOMED SCI.* 2014 [71(4): 175 7]

**Brennan R.M, Burrows J.M, Elliott T, Neller M.A, Gras S, Rossjohn J, Miles J.J and Burrows S.R.** Missense single nucleotide polymorphisms in the human T cell receptor loci control variable gene usage in the T cell repertoire. *BR J HAEMATOL.* 2014 [166(1): 148 52]

**Brennan D. J., Hackethal A., Metcalf A. M., Coward J., Ferguson K., Oehler M. K., Quinn M. A., Janda M., Leung Y., Freemantle M., Group Anecs, Webb P. M., Spurdle A. B. and Obermair A.** Serum HE4 as a prognostic marker in endometrial cancer a population based study. *GYNECOLOGIC ONCOLOGY* 2014 [132(1): 159 65]

**Brinkman DL, Konstantakopoulos N McInerney BV, Mulvenna J, Seymour JE Isbister GK Hodgson WC.** *Chironex fleckeri* (box jellyfish) venom proteins: expansion of a cnidarian toxin family that elicits variable cytolytic and cardiovascular effects. *J BIOL CHEM.* 2014 [289(8): 4798 812]

**Brown T, Ross L, Jones L, Hughes B and Banks M.** Nutrition outcomes following implementation of validated swallowing and nutrition guidelines for patients with head and neck cancer. *SUPPORTIVE CARE IN CANCER* 2014 [22(9): 2381 91]

**Bruedigam C., Bagger F. O., Heidel F. H., Paine Kuhn C., Guignes S., Song A., Austin R., Vu T., Lee E., Riyat S., Moore A. S., Lock R. B., Bullinger L., Hill G. R., Armstrong S. A., Williams D. A. and Lane S. W.** Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. *CELL STEM CELL* 2014 [15(6): 775 90]

**Buas M. F., Levine D. M., Makar K. W., Utsugi H., Onstad L., Li X., Galipeau P. C., Shaheen N. J., Hardie L. J., Romero Y., Bernstein L., Gammon M. D., Casson A. G., Bird N. C., Risch H. A., Ye W., Liu G., Corley D. A., Blount P. L., Fitzgerald R. C., Whiteman D. C., Wu A. H., Reid B. J. and Vaughan T. L.** Integrative post genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. *CARCINOGENESIS* 2014 [35(12): 2740 7]

**Buchanan D. D., Rosty C., Clendenning M., Spurdle A. B. and Win A. K.** Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome). *THE APPLICATION OF CLINICAL GENETICS* 2014 [7: 183 93]

**Buchanan D. D., Tan Y. Y., Walsh M. D., Clendenning M., Metcalf A. M., Ferguson K., Arnold S. T., Thompson B. A., Lose F. A., Parsons M. T., Walters R. J., Pearson S. A., Cummings M., Oehler M. K., Blomfield P. B., Quinn M. A., Kirk J. A., Stewart C. J., Obermair A., Young J. P., Webb P. M. and Spurdle A. B.** Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population level germline mismatch repair gene mutation testing. *JOURNAL OF CLINICAL ONCOLOGY: OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY* 2014 [32(2): 90 100]

**Bunn P. T., Stanley A. C., de Labastida Rivera F., Mulherin A., Sheel M., Alexander C. E., Faleiro R. J., Amante F. H., Montes De Oca M., Best S. E., James K. R., Kaye P. M., Haque A. and Engwerda C. R.** Tissue requirements for establishing long term CD4+ T cell mediated immunity following *Leishmania donovani* infection. *JOURNAL OF IMMUNOLOGY* 2014 [192(8): 3709 18]

**Butow P. N., Price M. A., Bell M. L., Webb P. M., deFazio A., Australian Ovarian Cancer Study Group, Australian Ovarian Cancer Study Quality Of Life Study Investigators and Friedlander M.** Caring for women with ovarian cancer in the last year of life: a longitudinal study of caregiver quality of life, distress and unmet needs. *GYNECOLOGIC ONCOLOGY* 2014 [132(3): 690 7]

**Byrne EM, Carrillo Roa T, Penninx BW, Sallis HM, Viktorin A, Chapman B, Henders AK; Psychiatric Genomic Consortium Major Depressive Disorder Working Group, Pergadia ML, Heath AC, Madden PA, Sullivan PF, Boschloo L, van Grootheest G, McMahon G, Lawlor DA, Landén M, Lichtenstein P, Magnusson PK, Evans DM, Montgomery GW, Boomsma DI, Martin NG, Meltzer Brody S, Wray NR.** Applying polygenic risk scores to postpartum depression. *ARCHIVES OF WOMEN'S MENTAL HEALTH* 2014 [17(6): 519 528]

**Byrne EM, Heath AC, Madden PA, Pergadia ML, Hickie IB, Montgomery GW, Martin NG, Wray NR.** Testing the role of circadian genes in conferring risk for psychiatric disorders. *AMERICAN JOURNAL OF MEDICAL GENETICS. PART B, NEUROPSYCHIATRIC GENETICS* 2014 [165(3): 254 260]

**Campbell, S. J., Savage, G. B., Gray, D. J., Atkinson, J. A., Soares Magalhaes, R. J. Nery, S. V. McCarthy, J. S. Velleman, Y. Wicken, J. H., Traub, R. J., Williams, G. M., Andrews, R. M. Clements, A. C.** Water, Sanitation, and Hygiene (WASH): a critical component for sustainable soil transmitted helminth and schistosomiasis control. *PLOS NEGL TROP DIS* 2015 [8(4): e2651]

**Candido dos Reis F. J., Song H., Goode E. L., Cunningham J. M., Fridley B. L., Larson M. C., Alsop K., Dicks E., Harrington P., Ramus S. J., de Fazio A., Mitchell G., Fereday S., Bolton K. L., Gourley C., Michie C., Karlan B., Lester J., Walsh C., Cass I., Olsson H., Gore M., Benitez J. J., Garcia M. J., Andrusis I., Mulligan A. M., Glendon G., Blanco I., Lazaro C., Whittemore A. S., McGuire V., Sieh W., Montagna M., Alducci E., Sadetzki S., Chetrit A., Kwong A., Kjaer S. K., Jensen A., Hogdall E., Neuhausen S., Nussbaum R., Daly M., Greene M. H., Mai P. L., Loud J. T., Moysich K., Toland A. E., Lambrechts D., Ellis S., Frost D., Brenton J. D., Tischkowitz M., Easton D. F., Antoniou A., Chenevix Trench G., Gayther S. A., Bowtell D. and Pharoah P. D.** Germline mutation in BRCA1 or BRCA2 and ten year survival for women diagnosed with epithelial ovarian cancer. *CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH* 2014 [21(3): 652 7]

**Carvajal Carmona L. G., O'Mara T. A., Painter J. N., Lose F. A., Dennis J., Michailidou K., Tyrer J. P., Ahmed S., Ferguson K., Healey C. S., Pooley K., Beesley J., Cheng T., Jones A., Howarth K., Martin L., Gorman M., Hodgson S., Wentzensen N., Fasching P. A., Hein A., Beckmann M. W., Renner S. P., Dork T., Hillemanns P., Durst M., Runnebaum I., Lambrechts D., Coenegrachts L., Schrauwen S., Amant F., Winterhoff B., Dowdy S. C., Goode E. L., Teoman A., Salvesen H. B., Trovik J., Njolstad T. S., Werner H. M., Scott R. J., Ashton K., Proietto T., Otton G., Wersall O., Mints M., Tham E., Hall P., Czene K., Liu J., Li J., Hopper J. L., Southey M. C., Ekici A. B., Ruebner M., Johnson N., Peto J., Burwinkel B., Marme F., Brenner H., Dieffenbach A. K., Meindl A., Brauch H., Lindblom A., Depreeuw J., Moisse M., Chang Claude J., Rudolph A., Couch F. J., Olson J. E., Giles G. G., Bruinsma F., Cunningham J. M., Fridley B. L., Borresen Dale A. L., Kristensen V. N., Cox A., Swerdlow A. J., Orr N., Bolla M. K., Wang Q., Weber R. P., Chen Z., Shah M., Pharoah P. D., Dunning A. M., Tomlinson I., Easton D. F., Spurdle A. B. and Thompson D. J.** Candidate locus analysis of the TERT CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants

associated with endometrial cancer risk. *HUMAN GENETICS* 2014 [134(2): 231 45]

**Chachay V. S., Macdonald G. A., Martin J. H., Whitehead J. P., O'Moore Sullivan T. M., Lee P., Franklin M., Klein K., Taylor P. J., Ferguson M., Coombes J. S., Thomas G. P., Cowin G. J., Kirkpatrick C. M., Prins J. B. and Hickman I. J.** Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY* 2014 [12(12): 2092 2103]

**Chai E, Ferguson B, Prow T, Soyer P, Walker G** Three dimensional modelling for estimation of nevus count and probability of nevus melanoma progression in a murine model. *PIGMENT CELL MELANOMA RES.* 2014 [227(2): 317 9]

**Chan R. J., Webster J., Chung B., Marquart L., Ahmed M. and Garantziotis S.** Prevention and treatment of acute radiation induced skin reactions: a systematic review and meta analysis of randomized controlled trials. *BMC CANCER* 2014 [14: 53]

**Chan C. J., Martinet L., Gilfillan S., Souza Fonseca Guimaraes F., Chow M. T., Town L., Ritchie D. S., Colonna M., Andrews D. M. and Smyth M. J.** The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. *NATURE IMMUNOLOGY* 2014 [15(5): 431 8]

**Chan C. J., Smyth M. J. and Martinet L.** Molecular mechanisms of natural killer cell activation in response to cellular stress. *CELL DEATH AND DIFFERENTIATION* 2,014 [21(1): 5 14]

**Chausis S, Smout M, Wilson D, Loukas A, Mulvenna J, Seymour J.** Rapid short term and gradual permanent cardiotoxic effects of vertebrate toxins from Chironex fleckeri (Australian box jellyfish) venom. *TOXICON* 2,014 [80(1): 17 26]

**Charbonneau B., Moysich K. B., Kalli K. R., Oberg A. L., Vierkant R. A., Fogarty Z. C., Block M. S., Maurer M. J., Goergen K. M., Fridley B. L., Cunningham J. M., Rider D. N., Preston C., Hartmann L. C., Lawrenson K., Wang C., Tyrer J., Song H., deFazio A., Johnatty S. E., Doherty J. A., Phelan C. M., Sellers T. A., Ramirez S. M., Vitonis A. F.,**

**Terry K. L., Van Den Berg D., Pike M. C., Wu A. H., Berchuck A., Gentry Maharaj A., Ramus S. J., Diergaarde B., Shen H., Jensen A., Menkiszak J., Cybulski C., Lubilski J., Ziogas A., Rothstein J. H., McGuire V., Sieh W., Lester J., Walsh C., Vergote I., Lambrechts S., Despierre E., Garcia Closas M., Yang H., Brinton L. A., Spiewankiewicz B., Rzepecka I. K., Dansonka Mieszkowska A., Seibold P., Rudolph A., Paddock L. E., Orlow I., Lundvall L., Olson S. H., Hogdall C. K., Schwaab I., du Bois A., Harter P., Flanagan J. M., Brown R., Paul J., Ekici A. B., Beckmann M. W., Hein A., Eccles D., Lurie G., Hays L. E., Bean Y. T., Pejovic T., Goodman M. T., Campbell I., Fasching P. A., Konecny G., Kaye S. B., Heitz F., Hogdall E., Bandera E. V., Chang Claude J., Kupryjanczyk J., Wentzensen N., Lambrechts D., Karlan B. Y., Whittemore A. S., Culver H. A., Gronwald J., Levine D. A., Kjaer S. K., Menon U., Schildkraut J. M., Pearce C. L., Cramer D. W., Rossing M. A., Chenevix Trench G., Pharoah P. D., Gayther S. A., Ness R. B., Odunsi K., Sucheston L. E., Knutson K. L. and Goode E. L.** Large scale evaluation of common variation in regulatory T cell related genes and ovarian cancer outcome. *CANCER IMMUNOLOGY RESEARCH* 2014 [2(4): 332 40]

**Charmsaz, S, Beckett, K, Smith, FM, Bruedigam, C, Moore, AS, Al Ejeh, F, Lane, SW, BOYD, AW.** EphA2 is a therapy target in EphA2 positive but is not essential for normal or leukemic hematopoiesis. *PLOS ONE* 2015 [10(6): 768-9]

**Chen G. B., Lee S. H., Brion M. J., Montgomery G. W., Wray N. R., Radford Smith G. L., Visscher P. M. and International I. B. D.** Genetics Consortium Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. *HUMAN MOLECULAR GENETICS* 2014 [23(17): 4710 4720]

**Chow M. T., Duret H., Andrews D. M., Faveeuw C., Moller A., Smyth M. J. and Paget C.** Type I NKT cell mediated TNF alpha is a positive regulator of NLRP3 inflammasome priming. *EUROPEAN JOURNAL OF IMMUNOLOGY* 2014 [44(7): 2111 20]

**Chuah C., Jones M. K., Burke M. L., McManus D. P., Owen H. C. and Gobert G. N.** Defining a pro-inflammatory neutrophil phenotype in response to schistosome eggs. *CELL MICROBIOL* 2014 [16(11): 1666 77]

**Chuah C, Jones MK, Burke ML, McManus DP, Gobert GN.** Cellular and chemokine mediated regulation in schistosome induced hepatic pathology. *TRENDS PARASITOL.* 2015 [30(3): 141 50.]

**Chung Li Ping, Baltic Svetlana, Ferreira Manuel, Temple Suzanna, Waterer Grant and Thompson Philip J.** Beta2 Adrenergic Receptor (ADRB beta) Haplotype Pair (2/4) Is Associated with Severe Asthma. *PLOS ONE* 2014 [9(4): e93695]

**Clancy Jennifer L, Patel Hardip R, Hussein Samer MI, Tonge Peter D, Cloonan Nicole, Corso Andrew J, Li Mira, Lee Dong Sung, Shin Jong Yeon, Wong Justin JL, C Bailey, M Benevento, J Munoz, A Chuah, D Wood, JE Rasko, AJ Heck, SM Grimmond, IM Rogers, JS Seo, CA Wells, MC Puri, A Nagy and T Preiss** Small RNA changes en route to distinct cellular states of induced pluripotency. *NATURE COMMUNICATIONS* 2014 [5:5522]

**Clark Paul J, Thompson Alexander J, Patel Keyur, Muir Andrew J and Volk Michael L.** Trends in hepatitis C treatment uptake in the United States. *HEPATOLOGY* 2014 [60(2): 768 769]

**Cleary E., Barnes T. S., Xu Y., Zhao H., Clements A. C., Gray D. J., McManus D. P., Atkinson J. A., Williams G. M. and Yang Y.** Impact of "Grain to Green" Programme on echinococcosis infection in Ningxia Hui Autonomous Region of China. *VET PARASITOL* 2014 [205(3 4): 523 31]

**Colodro Conde L Zhu G, Power RA, Henders A, Heath AC, Madden PA, Montgomery GW, Medland S, Ordonana JR, Martin NG.** A Twin Study of Breastfeeding With a Preliminary Genome-Wide Association Scan. *TWIN RESEARCH AND HUMAN GENETICS : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR TWIN STUDIES* 2014 [18(1): 61 72]

**Cook M. B., Corley D. A., Murray L. J., Liao L. M., Kamangar F., Ye W., Gammon M. D., Risch H. A., Casson A. G., Freedman N. D., Chow W. H., Wu A. H., Bernstein L., Nyren O., Pandeya N., Whiteman D. C. and Vaughan T. L.** Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). *PLOS ONE* 2014 [9(7): e103508]

**Couvy Duchesne B Blokland GA, Hickie IB, Thompson PM, Martin NG, de Zubicaray GI, McMahon KL, Wright MJ.** Heritability of head motion during resting state functional MRI in 462 healthy twins. *NEUROIMAGE* 2014 [102: 424 434]

**Croese J., Giacomini P., Navarro S., Clouston A., McCann L., Dougall A., Ferreira I., Susianto A., O'Rourke P., Howlett M., McCarthy J., Engwerda C., Jones D. and Loukas A.** Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. *THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY* 2014 [135(2): 508 516]

**Crowe E., Pandeya N., Brotherton J. M., Dobson A. J., Kisely S., Lambert S. B. and Whiteman D. C.** Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case control study nested within a population based screening programme in Australia. *BMJ* 2014 [348: g1458]

**Cuellar Flores I., Sanchez Lopez M. P., Liminana Gras R. M. and Colodro Conde L.** The GHQ 12 for the assessment of psychological distress of family caregivers. *BEHAVIORAL MEDICINE (WASHINGTON, D.C.)* 2014 [40(2): 65 70]

**Cummings M. C., Simpson P. T., Reid L. E., Jayanthan J., Skerman J., Song S., McCart Reed A. E., Kutasovic J. R., Morey A. L., Marquart L., O'Rourke P. and Lakhani S. R.** Metastatic progression of breast cancer: insights from 50 years of autopsies. *THE JOURNAL OF PATHOLOGY* 2014 [232(1): 23 31]

**Curley C., Hill G. R., McLean A. and Kennedy G. A.** Immunotherapy following relapse of acute leukaemia after T cell

replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft versus host disease. *INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY* 2014 [36(2): 197 204]

**Patricia Ellen Dale, Jon Knight, Lachlan Francis Griffin, John Beidler, Ron Brockmeyer, Doug Carlson, David Cox, Jim David, Vincent Encomio, Grant Gilmore, Paul Haydt, Robin Lewis, James McNelly, Sheila M O'Connell, Bruce Perry, Jorge Rey, John Tucker** Multi agency perspectives on managing mangrove wetlands and the mosquitoes they produce. *JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION* 2014 [30(2): 106 115]

**Dale P. E. R, Knight, J. M., Dwyer P. G.** Mangrove rehabilitation: a review focusing on ecological and institutional issues. *WETLANDS ECOLOGY AND MANAGEMENT* 2014 [22(6): 587 604]

**D'Ambrosio Roberta, Aghemo Alessio, De Francesco Raffaele, Rumi Maria Grazia, Galmozzi Enrico, De Nicola Stella, Cheroni Cristina, Clark Paul J, Ronchi Guido and Lampertico Pietro.** The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES* 2014 [15(5): 7213 7224]

**Dang N., Sivakumaran H., Harrich D., Shaw P. N. and Coombes A. G.** Evaluation of Polycaprolactone Matrices for Sustained Vaginal Delivery of Nevirapine in the Prevention of Heterosexual HIV Transmission. *JOURNAL OF PHARMACEUTICAL SCIENCES* 2014 [103(7): 2107 15]

**Dang N. T., Sivakumaran H., Harrich D., Shaw P. N., Davis Poynter N. and Coombes A. G.** Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route. *EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS: OFFICIAL JOURNAL OF ARBEITSGEMEINSCHAFT FUR PHARMAZEUTISCHE VERFAHRENSTECHNIK E.V* 2014 [88(2): 406 14]

**Dave K. A., Norris E. L., Bukreyev A. A., Headlam M. J., Buchholz U. J., Singh T., Collins P. L. and Gorman J. J.** A comprehensive proteomic view of responses of A549 type II alveolar epithelial cells to human respiratory syncytial virus infection. *MOLECULAR & CELLULAR PROTEOMICS : MCP* 2014 [13(12): 3250 69]

**Davies MN Krause L, Bell JT, Gao F, Ward KJ, Wu H, Lu H, Liu Y, Tsai PC, Collier DA, Murphy T, Dempster E, Mill J, Battle A, Mostafavi S, Zhu X, Henders A, Byrne E, Wray NR, Martin NG, Spector TD, Wang J.** Hypermethylation in the ZBTB20 gene is associated with major depressive disorder. *GENOME BIOLOGY* 2014 [15(4): R56]

**Day BW, Stringer BW and Boyd AW.** Eph Receptors as Therapeutic Targets in Glioblastoma. *BRITISH JOURNAL OF CANCER* 2014 [111(7): 1255 61]

**De Boeck K., Castellani C., Elborn J. S. and Board Ecfs.** Medical consensus, guidelines, and position papers: a policy for the ECFS. *JOURNAL OF CYSTIC FIBROSIS : OFFICIAL JOURNAL OF THE EUROPEAN CYSTIC FIBROSIS SOCIETY* 2014 [13(5): 495 8]

**de Andrade L. F., Smyth M. J. and Martinet L.** DNAM 1 control of natural killer cells functions through nectin and nectin like proteins. *IMMUNOLOGY AND CELL BIOLOGY* 2014 [92(3): 237 44]

**De Alwis D Agrawal A, Reiersen AM, Constantino JN, Henders A, Martin NG, Lynskey MT.** ADHD symptoms, autistic traits, and substance use and misuse in adult Australian twins. *JOURNAL OF STUDIES ON ALCOHOL AND DRUGS* 2014 [75(2): 211 221]

**Dennis EL Jahanshad N, McMahon KL, de Zubicaray GI, Martin NG, Hickie IB, Toga AW, Wright MJ, Thompson PM.** Development of insula connectivity between ages 12 and 30 revealed by high angular resolution diffusion imaging. *HUMAN BRAIN MAPPING* 2014 [35(4): 1790 1800]

**Dennis EL, Jahanshad N, Braskie MN, Warstadt NM, Hibar DP, Kohannim O, Nir TM, McMahon KL, de Zubicaray GI, Montgomery GW, Martin NG, Toga AW, Wright MJ, Thompson PM.**

Obesity gene NEGR1 associated with white matter integrity in healthy young adults. *NEUROIMAGE* 2014 [102: 548 557]

**Deutsch AR Slutske WS, Heath AC, Madden PA, Martin NG.** Substance Use and Sexual Intercourse Onsets in Adolescence: A Genetically Informative Discordant Twin Design. *JOURNAL OF ADOLESCENT HEALTH* 2014 [54(1): 114-116]

**Devaud C., Westwood J. A., Teng M. W., John L. B., Yong C. S., Duong C. P., Smyth M. J., Darcy P. K. and Kershaw M. H.** Differential potency of regulatory T cell mediated immunosuppression in kidney tumors compared to subcutaneous tumors. *ONCOIMMUNOLOGY* 2014 [3(11): e963395]

**Devaud C., Westwood J. A., John L. B., Flynn J. K., Paquet Fifield S., Duong C. P., Yong C. S., Pegram H. J., Stacker S. A., Achen M. G., Stewart T. J., Snyder L. A., Teng M. W., Smyth M. J., Darcy P. K. and Kershaw M. H.** Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. *MOLECULAR THERAPY* 2014 [22(1): 18 27]

**Dixon S. C., Ibiebele T. I., Protani M. M., Beesley J., deFazio A., Crandon A. J., Gard G. B., Rome R. M., Webb P. M., Nagle C. M. and Australian Ovarian Cancer Study Group** Dietary folate and related micronutrients, folate metabolising genes, and ovarian cancer survival. *GYNECOLOGIC ONCOLOGY* 2014 [132(3): 566 72]

**Dolton G, Lissina A, Skowera A, Ladell K, Tungatt K, Jones E, Kronenberg Versteeg D, Akpovwa H, Pentier J.M, Holland C.J, Godkin A.J, Cole D.K, Neller M.A, Miles J.J, Price D.A, Peakman M and Sewell A.K.** Comparison of peptide major histocompatibility complex tetramers and dextramers for the identification of antigen specific T cells. *CLIN EXP IMMUNOL*. 2014

**Doolan, D. L. Apte, S. H. Proietti, C.** Genome based vaccine design: the promise for malaria and other infectious diseases. *INT J PARASITOL* 2014 [44(12): 901 13]

**Dubovsky J. A., Flynn R., Du J., Harrington B. K., Zhong Y., Kaffenberger B., Yang C., Towns W. H., Lehman A., Johnson A. J., Muthusamy N., Devine S. M., Jaglowski S., Serody J. S., Murphy W. J., Munn D. H., Luznik L., Hill G. R., Wong H. K., MacDonald K. K., Maillard I., Koreth J., Elias L., Cutler C., Soiffer R. J., Antin J. H., Ritz J., Panoskaltzis Mortari A., Byrd J. C. and Blazar B. R.** Ibrutinib treatment ameliorates murine chronic graft versus host disease. *THE JOURNAL OF CLINICAL INVESTIGATION* 2014 [124(11): 4867 76]

**Dumenil T. D., Wockner L. F., Bettington M., McKeone D. M., Klein K., Bowdler L. M., Montgomery G. W., Leggett B. A. and Whitehall V. L.** Genome wide DNA methylation analysis of formalin fixed paraffin embedded colorectal cancer tissue. *GENES, CHROMOSOMES & CANCER* 2014 [53(7): 537 48]

**Dwyer B. J., Olynyk J. K., Ramm G. A. and Tirnitz Parker J. E.** TWEAK and LTbeta Signaling during Chronic Liver Disease. *FRONTIERS IN IMMUNOLOGY* 2014 [5: 39]

**Earp M. A., Kelemen L. E., Magliocco A. M., Swenerton K. D., Chenevix Trench G., Lu Y., Hein A., Ekici A. B., Beckmann M. W., Fasching P. A., Lambrechts D., Despierre E., Vergote I., Lambrechts S., Doherty J. A., Rossing M. A., Chang Claude J., Rudolph A., Friel G., Moysich K. B., Odunsi K., Sucheston Campbell L., Lurie G., Goodman M. T., Carney M. E., Thompson P. J., Runnebaum I. B., Durst M., Hillemanns P., Dork T., Antonenkova N., Bogdanova N., Leminen A., Nevanlinna H., Pelttari L. M., Butzow R., Bunker C. H., Modugno F., Edwards R. P., Ness R. B., du Bois A., Heitz F., Schwaab I., Harter P., Karlan B. Y., Walsh C., Lester J., Jensen A., Kjaer S. K., Hogdall C. K., Hogdall E., Lundvall L., Sellers T. A., Fridley B. L., Goode E. L., Cunningham J. M., Vierkant R. A., Giles G. G., Baglietto L., Severi G., Southey M. C., Liang D., Wu X.,**

**Lu K., Hildebrandt M. A., Levine D. A., Bisogna M., Schildkraut J. M., Iversen E. S., Weber R. P., Berchuck A., Cramer D. W., Terry K. L., Poole E. M., Tworoger S. S., Bandera E. V., Chandran U., Orlow I., Olson S. H., Wik E., Salvesen H. B., Bjorge L., Halle M. K., van Altena A. M., Aben K. K., Kiemeny L. A., Massuger L. F., Pejovic T., Bean Y. T., Cybulski C., Gronwald J., Lubinski J., Wentzensen N., Brinton L. A., Lissowska J., Garcia Closas M., Dicks E., Dennis J., Easton D. F., Song H., Tyrer J. P., Pharoah P. D., Eccles D., Campbell I. G., Whittemore A. S., McGuire V., Sieh W., Rothstein J. H., Flanagan J. M., Paul J., Brown R., Phelan C. M., Risch H. A., McLaughlin J. R., Narod S. A., Ziogas A., Anton Culver H., Gentry Maharaj A., Menon U., Gayther S. A., Ramus S. J., Wu A. H., Pearce C. L., Pike M. C., Dansonka Mieszkowska A., Rzepecka I. K., Szafron L. M., Kupryjanczyk J., Cook L. S., Le N. D. and Brooks Wilson A.** Genome wide association study of subtype specific epithelial ovarian cancer risk alleles using pooled DNA. *HUMAN GENETICS* 2014 [133(5): 481 97]

**Ebejer J. L., Medland S. E., van der Werf J., M J. Wright, Henders A. K., Gillespie N. A., Hickie I. B., Martin N. G. and Duffy D. L.** Contrast effects and sex influence maternal and self report dimensional measures of attention deficit hyperactivity disorder. *BEHAVIOR GENETICS* 2014 [45(1): 35 50]

**Edwards SL, Poongavanam V, Kanwar JR, Roy K, Hillman KM, Prasad N, Leth Larsen R, Petersen M, Marusic M, Plavec J, Wengel, Veedu RN** Target VEGF with LNA stabilized G rich oligonucleotide for efficient breast cancer inhibition. *CHEMICAL COMMUNICATIONS* 2015 [51: 9499 9502]

**Edwards C. L., Best S. E., Gun S. Y., Claser C., James K. R., de Oca M. M., Sebina I., Rivera Fde L., Amante F. H., Hertzog P. J., Engwerda C. R., Renia L. and Haque A.** Spatiotemporal requirements for IRF7 in mediating type I IFN dependent susceptibility to blood stage Plasmodium infection. *EUROPEAN JOURNAL OF IMMUNOLOGY* 2014 [45(1): 130 41]

**Ehnavall, A. Mitchell, P. B. Hadzi Pavlovic, D. Parker, G. Frankland, A. Loo, C. Breakspear, M. Wright, A. Roberts, G. Lau, P. Perich, T.** Rejection sensitivity and pain in bipolar versus unipolar depression. *BIPOLAR DISORD* 2014 [16(2): 190 8]

**Engwerda C. R., Ng S. S. and Bunn P. T.** The Regulation of CD4(+) T Cell Responses during Protozoan Infections. *FRONTIERS IN IMMUNOLOGY* 2014 [5: 498]

**Eskandari S, Stephenson RJ, Fuaad AA, Apte SH, Doolan DL, Toth I.** Synthesis and characterisation of self assembled and self adjuvanting asymmetric multi epitope lipopeptides of ovalbumin. *CHEMISTRY* 2014 [21(3): 1251 61]

**Evangelou E, Kerkhof HJ, Styrkarsdottir U, Ntzani EE, Bos SD, Esko T, Evans DS, Metrustry S, Panoutsopoulou K, Ramos YF, Thorleifsson G, Tsilidis KK, arcOGEN Consortium, Arden N, Aslam N, Bellamy N, Birrell F, Blanco FJ, Carr A, Chapman K, Day Williams AG, Deloukas P, Doherty M, Engstrom G, Helgadottir HT, Hofman A, Ingvarsson T, Jonsson H, Keis A, Keurentjes JC, Kloppenburg M, Lind PA, McCaskie A, Martin NG, Milani L, Montgomery GW, Nelissen RG, Nevitt MC, Nilsson PM, Ollier WE, Parimi N, Rai A, Ralston SH, Reed MR, Riancho JA, Rivadeneira F, Rodriguez Fontenla C, Southam L, Thorsteinsdottir U, Tsezou A, Wallis GA, Wilkinson JM, Gonzalez A, Lane NE, Lohmander LS, Loughlin J, Metspalu A, Uitterlinden AG, Jonsdottir I, Stefansson K, Slagboom PE, Zeggini E, Meulenbelt I, Ioannidis JP, Spector TD, van Meurs JB, Valdes AM.** A meta analysis of genome wide association studies identifies novel variants associated with osteoarthritis of the hip. *ANNALS OF THE RHEUMATIC DISEASES* 2014 [73(12): 2130 2136]

**Fagan K. J., Irvine K. M., McWhinney B. C., Fletcher L. M., Horsfall L. U., Johnson L., O'Rourke P., Martin J., Scott I., Pretorius C. J., Ungerer J. P. and Powell E. E.** Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. *BMC GASTROENTEROLOGY* 2014 [14: 97]

**Fagan K. J., Zhao E. Y., Horsfall L. U., Ruffin B. J., Kruger M. S., McPhail S. M., O'Rourke P., Ballard E., Irvine K. M. and Powell E. E.** Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change? *INTERNAL MEDICINE JOURNAL* 2014 [44(9): 865 72]

**Faleiro R. J., Kumar R., Hafner L. M. and Engwerda C. R.** Immune regulation during chronic visceral leishmaniasis. *PLOS NEGLECTED TROPICAL DISEASES* 2014 [8(7): e2914]

**Fan J., Niu S., Dong A., Shi J., Wu H. J., Fine D. H., Tian Y., Zhou C., Liu X., Sun T., Anderson G. J., Ferrari M., Nie G., Hu Y. and Zhao Y.** Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids. *NANOMEDICINE* 2014 [10(5): 879 88]

**Fasching P. A., Konecny G. E. and Spurdle A. B.** Biomarkers in women's cancers, gynecology, and obstetrics. *BIOMED RESEARCH INTERNATIONAL* 2014 [2014: 602340]

**Felix A. S., Gaudet M. M., Vecchia C. L., Nagle C. M., Shu X. O., Weiderpass E., Adami H. O., Beresford S., Bernstein L., Chen C., Cook L. S., De Vivo I., Doherty J. A., Friedenreich C. M., Gapstur S. M., Hill D., Horn Ross P. L., Lacey J. V., Levi F., Liang X., Lu L., Magliocco A., McCann S. E., Negri E., Olson S. H., Palmer J. R., Patel A. V., Petruzella S., Prescott J., Risch H. A., Rosenberg L., Sherman M. E., Spurdle A. B., Webb P. M., Wise L. A., Xiang Y. B., Xu W., Yang H. P., Yu H., Zeleniuch Jacquotte A. and Brinton L. A.** Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [136(5): E410 22]

**Ferguson B, Ram R, Handoko HY, Mukhopadhyay P, Soyer P, Muller, K, Morahan G, Walker GJ.** (2014). Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression. *ONCOGENE*. 34(22):2879 86 2014

**Fernando WC, Miranda MS, Worthley DL, Togashi K, Watters DJ, Leggett BA, Spring KJ.** The CIMP Phenotype in BRAF Mutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort. *GASTROENTEROLOGY RESEARCH AND PRACTICE* 2014 [2014: 374926]

**Ferrari de Andrade L., Ngiow S. F., Stannard K., Rusakiewicz S., Kalimutho M., Khanna K. K., Tey S. K., Takeda K., Zitvogel L., Martinet L. and Smyth M. J.** Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E mutant metastatic melanoma. *CANCER RESEARCH* 2014 [74(24): 7298 308]

**Ferreira MA Matheson MC, Tang CS, Granell R, Ang W, Hui J, Kiefer AK, Duffy DL, Baltic S, Danoy P, Bui M, Price L, Sly PD, Eriksson N, Madden PA, Abramson MJ, Holt PG, Heath AC, Hunter M, Musk B, Robertson CF, Le Souëf P, Montgomery GW, Henderson AJ, Tung JY, Dharmage SC, Brown MA, James A, Thompson PJ, Pennell C, Martin NG, Evans DM, Hinds DA, Hopper JL; the Australian Asthma Genetics Consortium Collaborators.** Genome wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype. *THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY* 2014 [133(6): 1564 1571]

**Ferreira Manuel A. R.** Improving the Power to Detect Risk Variants for Allergic Disease by Defining Case Control Status Based on Both Asthma and Hay Fever. *TWIN RESEARCH AND HUMAN GENETICS : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR TWIN STUDIES* 2014 [17(6): 505 511]

**Ferry O. R., Duffy D. L. and Ferreira M. A.** Early life environmental predictors of asthma age of onset. *IMMUNITY, INFLAMMATION AND DISEASE* 2014 [2(3): 141 51]

**Few LR Grant JD, Trull TJ, Statham DJ, Martin NG, Lynskey MT, Agrawal A.** Genetic variation in personality traits explains genetic overlap between borderline personality features and substance use disorders. *ADDICTION*. 2014 [109(12): 2118 2127]



**Fisher O. M., Levert Mignon A. J., Lord S. J., Botelho N. K., Freeman A. K., Thomas M. L., Falkenback D., Wettstein A., Whiteman D. C., Bobryshev Y. V. and Lord R. V.** High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma. *ANNALS OF SURGICAL ONCOLOGY* 2014 [22(7): 2431 8]

**Flynn R., Du J., Veenstra R. G., Reichenbach D. K., Panoskaltsis Mortari A., Taylor P. A., Freeman G. J., Serody J. S., Murphy W. J., Munn D. H., Sarantopoulos S., Luznik L., Maillard I., Koreth J., Cutler C., Soiffer R. J., Antin J. H., Ritz J., Dubovsky J. A., Byrd J. C., MacDonald K. P., Hill G. R. and Blazar**

**B. R.** Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. *BLOOD* 2014 [123(25): 3988 98]

**Forrest K., O'Rourke P., McCombe P. and Henderson R.** Venous thromboembolism in amyotrophic lateral sclerosis: Should we consider routine prophylactic anticoagulation? *AMYOTROPHIC LATERAL SCLEROSIS & FRONTOTEMPORAL DEGENERATION* 2014 [16(3 4): 280 1]

**France M.W. and Bell S.C.** Gastrointestinal cancers in cystic fibrosis. *CURRENT MEDICAL LITERATURE CYSTIC FIBROSIS* 2014 [4(1): 1 14]

**Frances S. P., Rigby L. M. and Chow W. K.** Comparative laboratory and field evaluation of repellent formulations containing DEET and lemon eucalyptus oil against mosquitoes in Queensland Australia. *JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION* 2014 [30(1): 65 67]

**Frazer D. M. and Anderson G. J.** The regulation of iron transport. *BIOFACTORS* 2014 [40(2): 206 14]

**Fuhrman Luck R. A., Silva M. L., Dong Y., Irving Rodgers H., Stoll T., Hastie M. L., Loessner D., Gorman J. J. and Clements J. A.** Proteomic and other analyses to determine the functional consequences of deregulated kallikrein related peptidase (KLK) expression in prostate and ovarian cancer. *PROTEOMICS. CLINICAL APPLICATIONS* 2014 [8(5 6): 403 15]

**Fuqua B. K., Lu Y., Darshan D., Frazer D. M., Wilkins S. J., Wolkow N., Bell A. G., Hsu J., Yu C. C., Chen H., Dunaief J. L., Anderson G. J. and Vulpe C. D.** The multicopper ferroxidase hephaestin enhances intestinal iron absorption in mice. *PLOS ONE* 2014 [9(6): e98792]

**Galluzzi L., Vacchelli E., Bravo San Pedro J. M., Buque A., Senovilla L., Baracco E. E., Bloy N., Castoldi F., Abastado J. P., Agostinis P., Apte R. N., Aranda F., Ayyoub M., Beckhove P., Blay J. Y., Bracci L., Caignard A., Castelli C., Cavallo F., Celis E., Cerundolo V., Clayton A., Colombo M. P., Coussens L., Dhodapkar M. V., Eggermont A. M., Fearon D. T., Fridman W. H., Fucikova J., Gabrilovich D. I., Galon J., Garg A., Ghiringhelli F., Giaccone G., Gilboa E., Gnjatic S., Hoos A., Hosmalin A., Jager D., Kalinski P., Karre K., Kepp O., Kiessling R., Kirkwood J. M., Klein E., Knuth A., Lewis C. E., Liblau R., Lotze M. T., Lugli E., Mach J. P., Mattei F., Mavilio D., Melero I., Melief C. J., Middendorf E. A., Moretta L., Odunsi A., Okada H., Palucka A. K., Peter M. E., Pienta K. J., Porgador A., Prendergast G. C., Rabinovich G. A., Restifo N. P., Rizvi N., Sautes Fridman C., Schreiber H., Seliger B., Shiku H., Silva Santos B., Smyth M. J., Speiser D. E., Spisek R., Srivastava P. K., Talmadge J. E., Tartour E., Van Der Burg S. H., Van Den Eynde B. J., Vile R., Wagner H., Weber J. S., Whiteside T. L., Wolchok J. D., Zitvogel L., Zou W. and Kroemer G.** Classification of current anticancer immunotherapies. *ONCOTARGET* 2014 [5(24): 12472 508]

**Gao B., Russell A., Beesley J., Chen X. Q., Healey S., Henderson M., Wong M., Emmanuel C., Galletta L., Johnatty S. E., Bowtell D., Haber M., Norris M., Harnett P., Chenevix Trench G., Balleine R. L. and deFazio A.** Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. *SCIENTIFIC REPORTS* 2014 [4: 4669]

**Gargett T., Grubor Bauk B., Garrod T. J., Yu W., Miller D., Major L., Wesselingh S., Suhrbier A. and Gowans E. J.** Induction of antigen positive cell death by the expression of perforin, but not DTa, from a DNA vaccine enhances the immune response. *IMMUNOL CELL BIOL* 2014 [92(4): 359

**Gargett T., Grubor Bauk B., Miller D., Garrod T., Yu S., Wesselingh S., Suhrbier A. and Gowans E. J.** Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. *CLIN TRANSL IMMUNOLOGY* 2014 [3(6): e18]

**Garrod T. J., Gargett T., Yu W., Major L., Burrell C. J., Wesselingh S., Suhrbier A., Grubor Bauk B. and Gowans E. J.** Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. *VIRUS RES* 2014 [192: 25 33]

**Garrod T. J., Grubor Bauk B., Gargett T., Li Y., Miller D. S., Yu W., Major L., Burrell C. J., Wesselingh S., Suhrbier A. and Gowans E. J.** DNA vaccines encoding membrane bound or secreted forms of heat shock protein 70 exhibit improved potency. *EUR J IMMUNOL* 2014 [44(7): 1992 2002]

**Gaze S., Driguez P., Pearson MS, Mendes T, Doolan DL, Trieu A, McManus DP, Gobert GN, Periago MV, Correa Oliveira R, Cardoso FC, Oliveira G, Nakajima R, Jasinskas A, Hung C, Liang L, Pablo J, Bethony JM, Felgner PL, Loukas A.** An immunomics approach to schistosoma antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. *PLOS PATHOGENS* 2014 [10(3): e1004033.]

**Geake J., Tay G., Callaway L. and Bell S.C.** Pregnancy and cystic fibrosis: Approach to contemporary management. *OBSTETRIC MEDICINE* 2014 [7(4): 147 55]

**Gharahkhani P., Burdon K. P., Fogarty R., Sharma S., Hewitt A. W., Martin S., Law M. H., Cremin K., Bailey J. N., Loomis S. J., Pasquale L. R., Haines J. L., Hauser M. A., Viswanathan A. C., McGuffin P., Topouzis F., Foster P. J., Graham S. L., Casson R. J., Chehade M., White A. J., Zhou T., Souzeau E., Landers J., Fitzgerald J. T., Klebe S., Ruddle J. B., Goldberg I., Healey P. R., Wellcome Trust Case Control Consortium, Consortium Neighborhood, Mills R. A., Wang J. J., Montgomery G. W., Martin N. G., Radford Smith G., Whiteman D. C., Brown M. A., Wiggs J. L., Mackey D. A., Mitchell P., MacGregor S. and Craig J. E.** Common variants near

ABCA1, AFAP1 and GMDS confer risk of primary open angle glaucoma. *NATURE GENETICS* 2014 [46(10): 1120 5]

Ghousaini M, Edwards SL, Michailidou K, Nord S, Cowper Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Th Rutgers EJ, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang Claude J, Rudolph A, Seibold P, Flesch Janys D, Peto J, Dos Santos Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Zamora MP, Perez JI, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MW, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DS, Wong TY, Hooning MJ, Martens JW, Collée JM, van Deurzen CH, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart Brown S, Siriwanarangsana P, Hartman M, Miao H, Buhari SA, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D,

Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González Neira A, Pita G, Alonso MR, Alvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PD, Chenevix Trench G, French JD, Easton DF, Dunning AM; Australian Ovarian Cancer Management Group; Australian Ovarian Cancer Management Group. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *NATURE COMMUNICATIONS* 2014 [23(4): 4999]

Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, Carlebur S, O'Reilly M, Betts JA, Hillman KM, Kaufmann S, Beesley J, Canisius S, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Schmidt MK, Broeks A, Hogervorst FB, van der Schoot CE, Muir K, Lophatananon A, Stewart Brown S, Siriwanarangsana P, Fasching PA, Ruebner M, Ekici AB, Beckmann MW, Peto J, dos Santos Silva I, Fletcher O, Johnson N, Pharoah PD, Bolla MK, Wang Q, Dennis J, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Burwinkel B, Marme F, Yang R, Surowy H, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, González Neira A, Benitez J, Zamora MP, Arias Perez JI, Anton Culver H, Neuhausen SL, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Meindl A, Schmutzler RK, Brauch H, Ko YD, Brüning T; GENICA Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Tanaka H, Dörk T, Bogdanova NV, Helbig S, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM; kConFab Investigators, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Lambrechts D, Zhao H, Weltens C, van Limbergen E, Chang Claude J, Flesch Janys D, Rudolph A, Seibold P, Radice P, Peterlongo P, Barile M, Capra F, Couch FJ, Olson JE, Hallberg E, Vachon C, Giles GG, Milne RL, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Teo SH, Yip CH, See MH, Cornes B, Cheng CY, Ikram MK, Kristensen V; Norwegian

Breast Cancer Study, Zheng W, Halverson SL, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, García Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Klevebring D, Darabi H, Eriksson M, Hooning MJ, Hollestelle A, Martens JW, Collée JM, Hall P, Li J, Humphreys K, Shu XO, Lu W, Gao YT, Cai H, Cox A, Cross SS, Reed MW, Blot W, Signorello LB, Cai Q, Shah M, Ghousaini M, Kang D, Choi JY, Park SK, Noh DY, Hartman M, Miao H, Lim WY, Tang A, Hamann U, Torres D, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Olswold C, Slager S, Toland AE, Yannoukakos D, Shen CY, Wu PE, Yu JC, Hou MF, Swerdlow A, Ashworth A, Orr N, Jones M, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Healey CS, Brown MA, Ponder BA, Chenevix Trench G, Thompson DJ, Edwards SL, Easton DF, Dunning AM, French JD. Fine scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *AMERICAN JOURNAL OF HUMAN GENETICS* 2015 [96(1): 5 20]

Gobert G. N., You H. and McManus D. P. Gaining biological perspectives from schistosome genomes. *MOL BIOCHEM PARASITOL* 2014 [196(1): 21 8]  
Gold, M.C, McLaren, J.E, Reistetter, J, Smyk Pearson, S, Ladell, K, Swarbrick, G.M, Yu, Y.Y.L, Hansen, T.H, Lund, O, Nielsen, M, Gerritsen, B, Kesmir, C, Miles, J.J, Lewinsohn, D.A, Price, D.A and Lewinsohn, D.M. MR1 restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. *J. EXP. MED.* 2014 [:]

Gollo, L. L., Mirasso, C., Sporns, O. Breakspear, M. Mechanisms of zero lag synchronization in cortical motifs. *PLOS COMPUT BIOL* 2014 [10(4)::]

Gollo, L. L., Breakspear, M. The frustrated brain: From dynamics on motifs to communities and networks. *PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY: B* 2014 [369(1653): In press]

**Haque A. and Engwerda C.**

Hepatocytes break the silence during liver stage malaria. *NATURE MEDICINE* 2014 [20(1): 17 19]

**Harata Lee Y., Turvey M. E., Brazzatti J. A., Gregor C. E., Brown M. P., Smyth M. J., Comerford I. and McColl S. R.**

The atypical chemokine receptor CXCR2 regulates metastasis of mammary carcinoma via an effect on EMT. *IMMUNOLOGY AND CELL BIOLOGY* 2014 [92(10): 815 24]

**Harding, I. H., Harrison, B. J. Breakspear, M. Pantelis, C., Yucel, M.** Cortical Representations of Cognitive Control and Working Memory Are Dependent Yet Non Interacting. *CEREB CORTEX* 2014 [:]

**Hatemi PK Medland SE, Klemmensen R, Oskarsson S, Littvay L, Dawes CT, Verhulst B, McDermott R, Norgaard AS, Klofstad CA, Christensen K, Johannesson M, Magnusson PK, Eaves LJ, Martin NG.** Genetic influences on political ideologies: twin analyses of 19 measures of political ideologies from five democracies and genome-wide findings from three populations. *BEHAVIOR GENETICS* 2014 [44(3): 282 294]

**Haya N, Baessler K, Christmann Schmid C, de Tayrac R, Dietz V, Guldberg R, Mascarenhas T, Nussler Emil, Ballard E, Ankardal M, Boudemaghe T and Maher C** Prolapse and continence surgery in OECD countries. *INTERNATIONAL UROGYNECOLOGY JOURNAL* 2014 [25: S98 S100]

**He, SZ, Busfield, S, Ritchie, DS, Hertzberg, MS, Durrant, S, Lewis, I, Marlton, P, McLachlan, AJ, Kerridge, I, Bradstock, KF, Kennedy, G, BOYD, AW, Iland, H, Yeadon, TM, S. Banford, S, DeWitte, M, Basser, R, Roberts, AW.** A Phase 1 study of the Safety, Pharmacokinetics, and Anti leukemic Activity of the anti CD123 monoclonal antibody, CSL360, in Relapsed, Refractory or High Risk Acute Myeloid Leukemia. Sept 24: 1 23.. *LEUK LYMPHOMA* 2015 [56: 1406 15]

**Gordon L. G., Beesley V. L., Lynch B. M., Mihala G., McGrath C., Graves N. and Webb P. M.** The return to work experiences of middle aged Australian workers diagnosed with colorectal cancer: a matched cohort study. *BMC PUBLIC HEALTH* 2014 [14: 963]

**Gordon L. G., Mayne G. C., Hirst N. G., Bright T., Whiteman D. C., Australian Cancer Study Clinical Follow Up Study and Watson D. I.** Cost effectiveness of endoscopic surveillance of non dysplastic Barrett's esophagus. *GASTROINTESTINAL ENDOSCOPY* 2014 [79(2): 242 56]

**Gottlieb DJ Hek K, Chen TH, Watson NF, Eiriksdottir G, Byrne EM, Cornelis M, Warby SC, Bandinelli S, Cherkas L, Evans DS, Grabe HJ, Lahti J, Li M, Lehtimäki T, Lumley T, Marcianti KD, Pérusse L, Psaty BM, Robbins J, Tranah GJ, Vink JM, Wilk JB, Stafford JM, Bellis C, Biffar R, Bouchard C, Cade B, Curhan GC, Eriksson JG, Ewert R, Ferrucci L, Fülöp T, Gehrman PR, Goodloe R, Harris TB, Heath AC, Hernandez D, Hofman A, Hottenga JJ, Hunter DJ, Jensen MK, Johnson AD, Kähönen M, Kao L, Kraft P, Larkin EK, Lauderdale DS, Luik AI, Medici M, Montgomery GW, Palotie A, Patel SR, Pistis G, Porcu E, Quaye L, Raitakari O, Redline S, Rimm EB, Rotter JI, Smith AV, Spector TD, Teumer A, Uitterlinden AG, Vohl MC, Widen E, Willemsen G, Young T, Zhang X, Liu Y, Blangero J, Boomsma DI, Gudnason V, Hu F, Mangino M, Martin NG, O'Connor GT, Stone KL, Tanaka T, Viikari J, Gharib SA, Punjabi NM, Räikkönen K, Völzke H, Mignot E, Tiemeier H.** Novel loci associated with usual sleep duration: the CHARGE Consortium Genome Wide Association Study. *MOLECULAR PSYCHIATRY* 2014 [:]

**Gray D. J., Li Y. S., Williams G. M., Zhao Z. Y., Harn D. A., Li S. M., Ren M. Y., Feng Z., Guo F. Y., Guo J. G., Zhou J., Dong Y. L., Li Y., Ross A. G. and McManus D. P.** A multi component integrated approach for the elimination of schistosomiasis in the People's Republic of China: design and baseline results of a four year cluster randomised intervention trial. *INT J PARASITOL* 2014 [44(9): 659 68]

**Gray Jesse M, Harmin David A, Boswell Sarah A, Cloonan Nicole, Mullen Thomas E, Ling Joseph J, Miller Nimrod, Kuersten Scott, Ma Yong Chao, McCarroll Steven A, SM Grimmond and M Springer** SnapShot Seq: a method for extracting genome wide, in vivo mRNA dynamics from a single total RNA sample. *PLOS ONE* 2014 [9(2): e89673]

**Green A. C. and McBride P.** Squamous cell carcinoma of the skin (non metastatic). *BMJ CLINICAL EVIDENCE* 2014 [2014:]

**Green A. C.** Epidemiology of actinic keratoses. *CURRENT PROBLEMS IN DERMATOLOGY* 2014 [46: 1 7]

**Grimwood K., Bell S. C. and Chang A. B.** Antimicrobial treatment of non cystic fibrosis bronchiectasis. *EXPERT REVIEW OF ANTI INFECTIVE THERAPY* 2014 [12(10): 1277 96]

**Gulec S., Anderson G. J. and Collins J. F.** Mechanistic and regulatory aspects of intestinal iron absorption. *AMERICAN JOURNAL OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY* 2014 [307(4): G397 409]

**Hannani D., Locher C., Yamazaki T., Colin Minard V., Vetizou M., Aymeric L., Viaud S., Sanchez D., Smyth M. J., Bruhns P., Kroemer G. and Zitvogel L.** Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. *CELL DEATH AND DIFFERENTIATION* 2014 [21(1): 50 58]

**Hansen A. R., Hughes B. G., Paul S., Steadman P., Sommerville S., Dickinson I. C., Walpole E. T., Thomson D. B., Mar Fan H. G. and Joubert W. L.** Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. *ASIA PACIFIC JOURNAL OF CLINICAL ONCOLOGY* 2014 [:]

**Haque A., Best S. E., Montes de Oca M., James K. R., Ammerdorffer A., Edwards C. L., de Labastida Rivera F., Amante F. H., Bunn P. T., Sheel M., Sebina I., Koyama M., Varelias A., Hertzog P. J., Kalinke U., Gun S. Y., Renia L., Ruedl C., MacDonald K. P., Hill G. R. and Engwerda C. R.** Type I IFN signaling in CD8<sup>+</sup> DCs impairs Th1 dependent malaria immunity. *THE*

Heap G. A., Weedon M. N., Bewshea C. M., Singh A., Chen M., Satchwell J. B., Vivian J. P., So K., Dubois P. C., Andrews J. M., Annesse V., Bampton P., Barnardo M., Bell S., Cole A., Connor S. J., Creed T., Cummings F. R., D'Amato M., Daneshmend T. K., Fedorak R. N., Florin T. H., Gaya D. R., Greig E., Halfvarson J., Hart A., Irving P. M., Jones G., Karban A., Lawrance I. C., Lee J. C., Lees C., Lev Tzion R., Lindsay J., Mansfield J., Mawdsley J., Mazhar Z., Parkes M., Parnell K., Orchard T. R., Radford Smith G., Russell R. K., Reffitt D., Satsangi J., Silverberg M. S., Sturniolo G. C., Tremelling M., Tsianos E. V., van Heel D. A., Walsh A., Watermeyer G., Weersma R. K., Zeissig S., Rossjohn J., Holden A. L., Ahmad T., Int Serious Adverse Events Consort and Grp I. B. D. Pharmacogenetics Study **HLA DQA1 HLA DRB1** variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. *NATURE GENETICS* 2014 [46(10): 1131 1134]

Heath AC Waldron MC, Martin NG, Nelson EC, Bucholz KK, Madden PA. Human Mate Selection and Addiction: a Conceptual Critique. *BEHAVIOR GENETICS* 2014 [44(5): 419 426]

Hedditch E. L., Gao B., Russell A. J., Lu Y., Emmanuel C., Beesley J., Johnatty S. E., Chen X., Harnett P., George J., Australian Ovarian Cancer Study Group, Williams R. T., Flemming C., Lambrechts D., Despierre E., Lambrechts S., Vergote I., Karlan B., Lester J., Orsulic S., Walsh C., Fasching P., Beckmann M. W., Ekici A. B., Hein A., Matsuo K., Hosono S., Nakanishi T., Yatabe Y., Pejovic T., Bean Y., Heitz F., Harter P., du Bois A., Schwaab I., Hogdall E., Kjaer S. K., Jensen A., Hogdall C., Lundvall L., Engelholm S. A., Brown B., Flanagan J., Metcalf M. D., Siddiqui N., Sellers T., Fridley B., Cunningham J., Schildkraut J., Iversen E., Weber R. P., Berchuck A., Goode E., Bowtell D. D., Chenevix Trench G., deFazio A., Norris M. D., MacGregor S., Haber M. and Henderson M. J. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. *JOURNAL OF THE NATIONAL CANCER INSTITUTE* 2014 [106(7):]

Hemani G Shakhbazov K, Westra HJ, Esko T, Henders AK, McRae AF, Yang J, Gibson G, Martin NG, Metspalu A, Franke L, Montgomery GW, Visscher PM, Powell JE: Detection and replication of epistasis influencing transcription in humans. *NATURE* 2014 [508(7495): 249 253]

Hemani G Shakhbazov K, Westra HJ, Esko T, Henders AK, McRae AF, Yang J, Gibson G, Martin NG, Metspalu A, Franke L, Montgomery GW, Visscher PM, Powell JE Hemani et al. Detection and replication of epistasis influencing transcription in humans. *NATURE* 2014 [514(7520): E5 E6]

Hibar DP Stein JL, Jahanshad N, Kohannim O, Hua X, Toga AW, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ. Genome wide interaction analysis reveals replicated epistatic effects on brain structure. *NEUROBIOLOGY OF AGING* 2014 [36: 151 158]

Hill WD Davies G, van de Lagemaat LN, Christoforou A, Marioni RE, Fernandes CP, Liewald DC, Croning MD, Payton A, Craig LC, Whalley LJ, Horan M, Ollier W, Hansell NK, Wright MJ, Martin NG, Montgomery GW, Steen VM, Le Hellard S, Espeseth T, Lundervold AJ, Reinvang I, Starr JM, Pendleton N, Grant SG, Bates TC, Deary IJ: Human cognitive ability is influenced by genetic variation in components of postsynaptic signalling complexes assembled by NMDA receptors and MAGUK proteins. *TRANSLATIONAL PSYCHIATRY* 2014 [4: e341]

Ho M. F., Baker, J. Lee N., Luchavez, J., Arie F., Nhem S., Oyibo W., Bell D., Gonzalez I., Chiodini P., Gatton M. L., Cheng Q., McCarthy J. S. Circulating antibodies against Plasmodium falciparum histidine rich proteins 2 interfere with antigen detection by rapid diagnostic tests. *MALAR J* 2014 [13: 480]

Hoggart CJ Venturini G, Mangino M, Gomez F, Ascari G, Zhao JH, Teumer A, Winkler TW, Tšernikova N, Luan J, Mihailov E, Ehret GB, Zhang W, Lamparter D, Esko T, Macé A, Rieger S, Bochud PY, Barcella M, Dauvilliers Y, Benyamin B, Evans DM, Hayward C, Lopez MF, Franke L, Russo A, Heid IM, Salvi E, Vendantam S, Arking DE, Boerwinkle E, Chambers JC, Fiorito G, Grallert H, Guarrera S,

Homuth G, Huffman JE, Porteous D; Generation Scotland Consortium; LifeLines Cohort study; GIANT Consortium, Moradpour D, Iranzo A, Hebebrand J, Kemp JP, Lammers GJ, Aubert V, Heim MH, Martin NG, Montgomery GW, Peraita Adrados R, Santamaria J, Negro F, Schmidt CO, Scott RA, Spector TD, Strauch K, Völzke H, Wareham NJ, Yuan W, Bell JT, Chakravarti A, Kooner JS, Peters A, Matullo G, Wallaschofski H, Whitfield JB, Paccaud F, Vollenweider P, Bergmann S, Beckmann JS, Tafti M, Hastie ND, Cusi D, Bochud M, Frayling TM, Metspalu A, Jarvelin MR, Scherag A, Smith GD, Borecki IB, Rousson V, Hirschhorn JN, Rivolta C, Loos RJ, Kutalik Z. Novel approach identifies SNPs in SLC2A10 and KCNK9 with evidence for parent of origin effect on body mass index. *PLOS GENETICS* 2014 [10(7): e1004508]

Holmes M. L., Huntington N. D., Thong R. P., Brady J., Hayakawa Y., Andoniou C. E., Fleming P., Shi W., Smyth G. K., Degli Esposti M. A., Belz G. T., Kallies A., Carotta S., Smyth M. J. and Nutt S. L. Peripheral natural killer cell maturation depends on the transcription factor Aiolos. *THE EMBO JOURNAL* 2014 [33(22): 2721 34]

Hosein AN, Lim Yc, Day BW, Stringer B, Rose S, Head R, Cosgrove L, Sminia P, Fay, M, and Martin JH. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. *JOURNAL OF NEUROONCOLOGY* 2015 [122(2): 263 71]

Hughes M. C., Olsen C. M., Williams G. M. and Green A. C. A prospective study of cigarette smoking and basal cell carcinoma. *ARCHIVES OF DERMATOLOGICAL RESEARCH* 2014 [306(9): 851 6]

Hugo Leon E., Jeffery Jason A. L., Trewin Brendan J., Wockner Leesa F., Nguyen Thi Yen, Nguyen Hoang Le, Le Trung Nghia, Hine Emma, Ryan Peter A. and Kay Brian H. Adult Survivorship of the Dengue Mosquito *Aedes aegypti* Varies Seasonally in Central Vietnam. *PLOS NEGLECTED TROPICAL DISEASES* 2014 [8(2): e2669]

Hussein Samer MI, Puri Mira C, Tonge Peter D, Benevento Marco, Corso Andrew J, Clancy Jennifer L, Mosbergen Rowland, Li Mira, Lee Dong Sung, Cloonan Nicole, DL Wood, J Munoz, R Middleton, O Korn, HR Patel, CA White, JY Shin, ME Gauthier, KA Lê Cao, JI Kim, JC Mar, N Shakiba, W Ritchie, JE Rasko, SM Grimmond, PW Zandstra, CA Wells, T Preiss, JS Seo, AJ Heck, IM Rogers and A Nagy Genome wide characterization of the routes to pluripotency. *NATURE* 2014 [516(7530): 198 206]

Hyett, M. Parker, G. Breakspear, M. Bias and discriminability during emotional signal detection in melancholic depression. *BMC PSYCHIATRY* 2014 [14: 122]

Hysi PG Cheng CY, Springelkamp H, Macgregor S, Bailey JN, Wojciechowski R, Vitart V, Nag A, Hewitt AW, Höhn R, Venturini C, Mirshahi A, Ramdas WD, Thorleifsson G, Vithana E, Khor CC, Stefansson AB, Liao J, Haines JL, Amin N, Wang YX, Wild PS, Ozel AB, Li JZ, Fleck BW, Zeller T, Staffieri SE, Teo YY, Cuellar Partida G, Luo X, Allingham RR, Richards JE, Senft A, Karssen LC, Zheng Y, Bellenguez C, Xu L, Iglesias AI, Wilson JF, Kang JH, van Leeuwen EM, Jonsson V, Thorsteinsdottir U, Despriet DD, Ennis S, Moroi SE, Martin NG, Jansonius NM, Yazar S, Tai ES, Amouyel P, Kirwan J, van Koolwijk LM, Hauser MA, Jonasson F, Leo P, Loomis SJ, Fogarty R, Rivadeneira F, Kearns L, Lackner KJ, de Jong PT, Simpson CL, Pennell CE, Oostra BA, Uitterlinden AG, Saw SM, Lotery AJ, Bailey Wilson JE, Hofman A, Vingerling JR, Maubaret C, Pfeiffer N, Wolfs RC, Lemij HG, Young TL, Pasquale LR, Delcourt C, Spector TD, Klaver CC, Small KS, Burdon KP, Stefansson K, Wong TY; BMES GWAS Group; NEIGHBORHOOD Consortium; Wellcome Trust Case Control Consortium 2, Viswanathan A, Mackey DA, Craig JE, Wiggs JL, van Duijn CM, Hammond CJ, Aung T. Genome wide analysis of multi ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. *NATURE GENETICS* 2014 [46(10): 1126 1130]

Iannacone M. R., Youlden D. R., Baade P. D., Aitken J. F. and Green A. C. Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [136(3): 603 9]

Iannacone M. R., Hughes M. C. and Green A. C. Effects of sunscreen on skin cancer and photoaging. *PHOTODERMATOLOGY, PHOTOIMMUNOLOGY & PHOTOMEDICINE* 2014 [30(2 3): 55 61]

Ieguchi, K, Tomita, T, Omori, T, Komatsu, A, Deguchi, A, Masuda, J, Duffy, SD, Coulthard, MG, BOYD, AW, Maru, T. ADAM12 cleaved ephrin A1 causes lung metastasis. *ONCOGENE* 2014 [33: 2127 90]

Iles M. M., Bishop D. T., Taylor J. C., Hayward N. K., Brossard M., Cust A. E., Dunning A. M., Lee J. E., Moses E. K., Akslen L. A., Investigators Amfs, Andresen P. A., Avril M. F., Azizi E., Scarra G. B., Brown K. M., Debniak T., Elder D. E., Friedman E., Ghiorzo P., Gillanders E. M., Goldstein A. M., Gruis N. A., Hansson J., Harland M., Helsing P., Hocevar M., Hoiom V., investigators I. B. D., Ingvar C., Kanetsky P. A., Landi M. T., Lang J., Lathrop G. M., Lubinski J., Mackie R. M., Martin N. G., Molven A., Montgomery G. W., Novakovic S., Olsson H., Puig S., Puig Butille J. A., Qmega, Investigators Qtwin, Radford Smith G. L., Randerson Moor J., Group S. D. H. Study, van der Stoep N., van Doorn R., Whiteman D. C., MacGregor S., Pooley K. A., Ward S. V., Mann G. J., Amos C. I., Pharoah P. D., Demenais F., Law M. H., Newton Bishop J. A., Barrett J. H. and Geno M. E. L. Consortium. The effect on melanoma risk of genes previously associated with telomere length. *JOURNAL OF THE NATIONAL CANCER INSTITUTE* 2014 [106(10)]

Inobaya M. T., Olveda R. M., Tallo V., McManus D. P., Williams G. M., Harn D. A., Li Y., Chau T. N., Olveda D. U. and Ross A. G. Schistosomiasis mass drug administration in the Philippines: lessons learnt and the global implications. *MICROBES INFECT* 2014 [17(1): 6 15]

Irwin J., Ferguson E., Simms L., Hanigan K. and Radford Smith G. Consistently high C reactive protein and platelet count are associated with development of perianal fistulae in patients with Crohn's disease. *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY* 2014 [29: 110 110]

Irwin J., Ferguson E., Simms L., Hanigan K. and Radford Smith G. Consistently low haemoglobin level, low albumin level and high platelet count are associated with subsequent objective poor outcome in patients with Crohn's disease. *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY* 2014 [29: 110 111]

Iyer, K. K. Roberts, J. A., Metsaranta, M. Finnigan, S. Breakspear, M., Vanhatalo, S. Novel features of early burst suppression predict outcome after birth asphyxia. *ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY* 2014 [1(3): 209 14]

Jackson K., Mollee P., Morris K., Butler J., Jackson D., Kruger P., Klein K. and Kennedy G. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. *LEUKEMIA & LYMPHOMA* 2014 [55(1): 97 104]

Jacobsen KK Nievergelt CM, Zayats T, Greenwood TA, Anttila V, Akiskal HS, BiGS Consortium, IHG Consortium, BiGS Consortium Co Authors include:, IHG Consortium Co Authors include:, Haavik J, Bernt Fasmer O, Kelsoe JR, Johansson S, Oedegaard KJ, BiGS Consortium Co Authors include IHG Consortium Genome wide association study identifies variants in NBEA associated with migraine in bipolar disorder. *JOURNAL OF AFFECTIVE DISORDERS* 2014 [172C: 453 461]

Jagirdar K Smit DJ, Ainger SA, Lee KJ, Brown DL, Chapman B, Zhao ZZ, Montgomery GW, Martin NG, Stow JL, Duffy DL, Sturm RA. Molecular analysis of common polymorphisms within the human Tyrosinase locus and genetic association with pigmentation traits. *PIGMENT CELL & MELANOMA RESEARCH* 2014 [27(4): 552 564]

**Janda M., Youl P., Neale R., Aitken J., Whiteman D., Gordon L. and Baade P.** Clinical skin examination outcomes after a video based behavioral intervention: analysis from a randomized clinical trial. *JAMA DERMATOLOGY* 2014 [150(4): 372 9]

**Jia X, Kwon S, Wang CI, Huang YH Chan LY, Tan CC, Rosengren KJ, Mulvenna JP, Schroeder CI Craik DJ.** Semiozymatic cyclization of disulfide rich peptides using Sortase A. *J BIOL CHEM.* 2014 [289(10)]

**Jia X, Schulte L, Loukas A, Pickering D, Pearson M, Mobli M, Jones A, Rosengren KJ, Daly NL Gobert GN, Jones MK, Craik D.J., Mulvenna J.** Solution structure, membrane interactions, and protein binding partners of the tetraspanin Sm TSP 2, a vaccine antigen from the human blood fluke *Schistosoma mansoni*. *J BIOL CHEM* 2014 [289(10): 7151 63]

**Johansson Pegah, Jeffery Jessie, Al Eje Fares, Schulz Renée B, Callen David F, Kumar Raman and Khanna Kum Kum.** SCF FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re replication. *JOURNAL OF BIOLOGICAL CHEMISTRY* 2014 [289(26): 18514 18525]

**Johnson N., Dudbridge F., Orr N., Gibson L., Jones M. E., Schoemaker M. J., Folkard E. J., Haynes B. P., Hopper J. L., Southey M. C., Dite G. S., Apicella C., Schmidt M. K., Broeks A., Van T. Veer L. J., Atsma F., Muir K., Lophatananon A., Fasching P. A., Beckmann M. W., Ekici A. B., Renner S. P., Sawyer E., Tomlinson I., Kerin M., Miller N., Burwinkel B., Marme F., Schneeweiss A., Sohn C., Guenel P., Truong T., Cordina E., Menegaux F., Bojesen S. E., Nordestgaard B. G., Flyger H., Milne R., Zamora M. P., Arias Perez J. I., Benitez J., Bernstein L., Anton Culver H., Ziogas A., Clarke Dur C., Brenner H., Muller H., Arndt V., Dieffenbach A. K., Meindl A., Heil J., Bartram C. R., Schmutzler R. K., Brauch H., Justenhoven C., Ko Y. D., Nevanlinna H., Muranen T. A., Aittomaki K., Blomqvist C., Matsuo K., Dork T., Bogdanova N. V., Antonenkova N. N., Lindblom A., Mannermaa A., Kataja V., Kosma V. M., Hartikainen J. M., Chenevix Trench G., Beesley J., Wu A. H., Van den Berg D., Tseng C. C., Lambrechts**

**D., Smeets D., Neven P., Wildiers H., Chang Claude J., Rudolph A., Nickels S., Flesch Janys D., Radice P., Peterlongo P., Bonanni B., Pensotti V., Couch F. J., Olson J. E., Wang X., Fredericksen Z., Pankratz V. S., Giles G. G., Severi G., Baglietto L., Haiman C., Simard J., Goldberg M. S., Labreche F., Dumont M., Soucy P., Teo S., Yip C. H., Phuah S. Y., Cornes B. K., Kristensen V. N., Grenaker Alnaes G., Borresen Dale A. L., Zheng W., Winqvist R., Pylkas K., Jukkola Vuorinen A., Grip M., Andrulis I. L., Knight J. A., Glendon G., Mulligan A. M., Devillee P., Figueroa J., Chanock S. J., Lissowska J., Sherman M. E., Hall P., Schoof N., Hooning M., Hollestelle A., Oldenburg R. A., Tilanus Linthorst M., Liu J., Cox A., Brock I. W., Reed M. W., Cross S. S., Blot W., Signorello L. B., Pharoah P. D., Dunning A. M., Shah M., Kang D., Noh D. Y., Park S. K., Choi J. Y., Hartman, M., Miao H., Lim W. Y., Tang A., Hamann U., Forsti A., Rudiger T., Ulmer H. U., Jakubowska A., Lubinski J., Jaworska Bieniek K., Durda K., Sangrajrang S., Gaborieau V., Brennan P., McKay J., Slager S., Toland A. E., Vachon C., Yannoukakos D., Shen C. Y., Yu J. C., Huang C. S., Hou M. F., Gonzalez Neira A., Tessier D. C., Vincent D., Bacot F., Luccarini C., Dennis J., Michailidou K., Bolla M. K., Wang J., Easton D. F., Garcia Closas M., Dowsett M., Ashworth A., Swerdlow A. J., Peto J., Dos Santos Silva I. and Fletcher O.** Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case control study. *BREAST CANCER RESEARCH : BCR* 2014 [16(3): R51]

**Joubert D. A., Blasdel K. R., Audsley M. D., Trinidad L., Monaghan P., Dave K. A., Lieu K. G., Amos Ritchie R., Jans D. A., Moseley G. W., Gorman J. J. and Walker P. J.** Bovine ephemeral fever rhabdovirus alpha1 protein has viroporin like properties and binds importin beta1 and importin 7. *JOURNAL OF VIROLOGY* 2014 [88(3): 1591 603]

**Julsgaard M., Christensen L. A., Gibson P. R., Fallingborg J., Geary R., Walsh A., Kjeldsen J., Connell W., Sparrow M. P., Radford Smith G., Andrews J. M., Connor S. J., Lawrence I., Wildt S., Moore G. T., Svenningsen L., Rosella O., Grosen A. and Bell S. J.** Adalimumab and Infliximab levels in neonates correlate with duration

of treatment in pregnancy (ERA study). *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY* 2014 [29: 117 118]

**Kansara M., Teng M. W., Smyth M. J. and Thomas D. M.** Translational biology of osteosarcoma. *NATURE REVIEWS. CANCER* 2014 [14(11): 722 35]

**Karcher NR Slutske WS, Kerns JG, Piasecki TM, Martin NG:** Sex Differences in Magical Ideation: A Community Based Twin Study. *PERSONALITY DISORDERS* 2014 [5(2): 212 219]

**Karl Friston, Michael Breakspear, Gustavo Deco.** Critical Slowing and Perception. *CRITICALITY IN NEURAL SYSTEMS* 2014 [Book Chapter:]

**Karttunen S., Duffield M., Scrimgeour N. R., Squires L., Lim W. L., Dallas M. L., Scragg J. L., Chicher J., Dave K. A., Whitelaw M. L., Peers C., Gorman J. J., Gleadle J. M., Rychkov G. Y. and Peet D. J.** Oxygen dependent hydroxylation by FIH regulates the TRPV3 ion channel. *JOURNAL OF CELL SCIENCE* 2014 [128(2): 225 31]

**Katja Fischer and Shelley Walton** Parasitic mites of medical and veterinary importance – is there a common research agenda?. *INTERNATIONAL JOURNAL FOR PARASITOLOGY* 2014 [44: 955 967]

**Keim U., van der Pols J. C., Williams G. M. and Green A. C.** Exclusive development of a single type of keratinocyte skin cancer: evidence from an Australian population based cohort study. *THE JOURNAL OF INVESTIGATIVE DERMATOLOGY* 2014 [135(3): 728 33]

**Kelemen L. E., Terry K. L., Goodman M. T., Webb P. M., Bandera E. V., McGuire V., Rossing M. A., Wang Q., Dicks E., Tyrer J. P., Song H., Kupryjanczyk J., Dansonka Mieszkowska A., Plisiecka Halasa J., Timorek A., Menon U., Gentry Maharaj A., Gayther S. A., Ramus S. J., Narod S. A., Risch H. A., McLaughlin J. R., Siddiqui N., Glasspool R., Paul J., Carty K., Gronwald J., Lubinski J., Jakubowska A., Cybulski C., Kiemeny L. A., Massuger L. F., van Altena A. M., Aben K. K., Olson S. H., Orlow I., Cramer D. W., Levine D. A., Bisogna M., Giles G. G., Southey M. C., Bruinsma F., Kjaer S. K., Hogdall E., Jensen A., Hogdall C. K., Lundvall**

- L., Engelholm S. A., Heitz F., du Bois A., Harter P., Schwaab I., Butzow R., Nevanlinna H., Pelttari L. M., Leminen A., Thompson P. J., Lurie G., Wilkens L. R., Lambrechts D., Van Nieuwenhuysen E., Lambrechts S., Vergote I., Beesley J., Investigators Aocs Study Group/ACS, Fasching P. A., Beckmann M. W., Hein A., Ekici A. B., Doherty J. A., Wu A. H., Pearce C. L., Pike M. C., Stram D., Chang Claude J., Rudolph A., Dork T., Durst M., Hillemanns P., Runnebaum I. B., Bogdanova N., Antonenkova N., Odunsi K., Edwards R. P., Kelley J. L., Modugno F., Ness R. B., Karlan B. Y., Walsh C., Lester J., Orsulic S., Fridley B. L., Vierkant R. A., Cunningham J. M., Wu X., Lu K., Liang D., Hildebrandt M. A., Weber R. P., Iversen E. S., Tworoger S. S., Poole E. M., Salvesen H. B., Krakstad C., Borge L., Tangen I. L., Pejovic T., Bean Y., Kellar M., Wentzensen N., Brinton L. A., Lissowska J., Garcia Closas M., Campbell I. G., Eccles D., Whittemore A. S., Sieh W., Rothstein J. H., Anton Culver H., Ziogas A., Phelan C. M., Moysich K. B., Goode E. L., Schildkraut J. M., Berchuck A., Pharoah P. D., Sellers T. A., Brooks Wilson A., Cook L. S. and Le N. D. Consortium analysis of gene and gene folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. *MOLECULAR NUTRITION & FOOD RESEARCH* 2014 [58(10): 2023 35]
- Kendall B. J., Macdonald G. A., Prins J. B., O'Brien S., Whiteman D. C.** Total body fat and the risk of Barrett's oesophagus: a bioelectrical impedance study. *CANCER EPIDEMIOLOGY* 2014 [38(3): 266 72]
- Kennedy G. A., Varelias A., Vuckovic S., Le Texier L., Gartlan K. H., Zhang P., Thomas G., Anderson L., Boyle G., Cloonan N., Leach J., Sturgeon E., Avery J., Olver S. D., Lor M., Misra A. K., Hutchins C., Morton A. J., Durrant STs, Subramoniapillai E., Butler J. P., Curley C. I., MacDonald K. P., Tey S. K. and Hill G. R.** Addition of interleukin 6 inhibition with tocilizumab to standard graft versus host disease prophylaxis after allogeneic stem cell transplantation: a phase 1/2 trial. *THE LANCET. ONCOLOGY* 2014 [15(13): 1451 9]
- Kepp O., Senovilla L., Vitale I., Vacchelli E., Adjemian S., Agostinis P., Apetoh L., Aranda F., Barnaba V., Bloy N., Bracci L., Breckpot K., Brough D., Buque A., Castro M. G., Cirone M., Colombo M. I., Cremer I., Demaria S., Dini L., Eliopoulos A. G., Faggioni A., Formenti S. C., Fucikova J., Gabriele L., Gaipi U. S., Galon J., Garg A., Ghiringhelli F., Giese N. A., Guo Z. S., Hemminki A., Herrmann M., Hodge J. W., Holdenrieder S., Honeychurch J., Hu H. M., Huang X., Illidge T. M., Kono K., Korbelik M., Krysko D. V., Loi S., Lowenstein P. R., Lugli E., Ma Y., Madeo F., Manfredi A. A., Martins I., Mavilio D., Menger L., Merendino N., Michaud M., Mignot G., Mossman K. L., Multhoff G., Oehler R., Palombo F., Panaretakis T., Pol J., Proietti E., Ricci J. E., Riganti C., Rovere Querini P., Rubartelli A., Sistigu A., Smyth M. J., Sonnemann J., Spisek R., Stagg J., Sukkurwala A. Q., Tartour E., Thorburn A., Thorne S. H., Vandenabeele P., Velotti F., Workenhe S. T., Yang H., Zong W. X., Zitvogel L., Kroemer G. and Galluzzi L.** Consensus guidelines for the detection of immunogenic cell death. *ONCOIMMUNOLOGY* 2014 [3(9): e955691]
- Khan S., Greco D., Michailidou K., Milne R. L., Muranen T. A., Heikkinen T., Aaltonen K., Dennis J., Bolla M. K., Liu J., Hall P., Irwanto A., Humphreys K., Li J., Czene K., Chang Claude J., Hein R., Rudolph A., Seibold P., Flesch Jany D., Fletcher O., Peto J., dos Santos Silva I., Johnson N., Gibson L., Aitken Z., Hopper J. L., Tsimiklis H., Bui M., Makalic E., Schmidt D. F., Southey M. C., Apicella C., Stone J., Waisfisz Q., Meijers Heijboer H., Adank M. A., van der Luijt R. B., Meindl A., Schmutzler R. K., Muller Myhsok B., Lichtner P., Turnbull C., Rahman N., Chanock S. J., Hunter D. J., Cox A., Cross S. S., Reed M. W., Schmidt M. K., Broeks A., Van't Veer L. J., Hogervorst F. B., Fasching P. A., Schrauder M. G., Ekici A. B., Beckmann M. W., Bojesen S. E., Nordestgaard B. G., Nielsen S. F., Flyger H., Benitez J., Zamora P. M., Perez J. I., Haiman C. A., Henderson B. E., Schumacher F., Le Marchand L., Pharoah P. D., Dunning A. M., Shah M., Luben R., Brown J., Couch F. J., Wang X., Vachon C., Olson J. E., Lambrechts D., Moisse M., Paridaens R., Christiaens M. R., Guenel P., Truong T., Laurent Puig P., Mulot C., Marme F., Burwinkel B., Schneeweiss A., Sohn C., Sawyer E. J., Tomlinson I., Kerin M. J., Miller N., Andrusis I. L., Knight J. A., Tchatchou S., Mulligan A. M., Dork T., Bogdanova N. V., Antonenkova N. N., Anton Culver H., Darabi H., Eriksson M., Garcia Closas M., Figueroa J., Lissowska J., Brinton L., Devilee P., Tollenaar R. A., Seynaeve C., van Asperen C. J., Kristensen V. N., Slager S., Toland A. E., Ambrosone C. B., Yannoukakos D., Lindblom A., Margolin S., Radice P., Peterlongo P., Barile M., Mariani P., Hooning M. J., Martens J. W., Collee J. M., Jager A., Jakubowska A., Lubinski J., Jaworska Bieniek K., Durda K., Giles G. G., McLean C., Brauch H., Bruning T., Ko Y. D., Brenner H., Dieffenbach A. K., Arndt V., Stegmaier C., Swerdlow A., Ashworth A., Orr N., Jones M., Simard J., Goldberg M. S., Labreche F., Dumont M., Winqvist R., Pylkas K., Jukkola Vuorinen A., Grip M., Kataja V., Kosma V. M., Hartikainen J. M., Mannermaa A., Hamann U., Chenevix Trench G., Blomqvist C., Aittomaki K., Easton D. F. and Nevanlinna H.** MicroRNA related polymorphisms and breast cancer risk. *PLOS ONE* 2014 [9(11): e109973]
- Khosrotehrani K., van der Ploeg A. P., Siskind V., Hughes M. C., Wright A., Thomas J., Barbour A., Allan C., Bayley G., Eggermont A., Verhoef C., Smithers B. M. and Green A. C.** Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy. *EUROPEAN JOURNAL OF CANCER* 2014 [50(7): 1301 9]
- Khoury D. S., Cromer D., Best S. E., James K. R., Kim P. S., Engwerda C. R., Haque A. and Davenport M. P.** Effect of mature blood stage Plasmodium parasite sequestration on pathogen biomass in mathematical and in vivo models of malaria. *INFECTION AND IMMUNITY* 2014 [82(1): 212 20]
- Khunti K., Davies M., Majeed A., Thorsted B.L., Wolden M.L., Paul S.K.** Hypoglycemia and risk of cardiovascular disease and all cause mortality in insulin treated people with type 1 and type 2 diabetes: a cohort study. *DIABETES CARE* 2014 [:]
- Kim DJ, Clark PJ, Heimbach J, Rosen C, Sanchez W, Watt K and Charlton MR.** Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. *AMERICAN JOURNAL OF TRANSPLANTATION* 2014 [14(6): 1383 1390]

Kim D. K., Lee J., Kim S. R., Choi D. S., Yoon Y. J., Kim J. H., Go G., Nhung D., Hong K., Jang S. C., Kim S. H., Park K. S., Kim O. Y., Park H. T., Seo J. H., Aikawa E., Baj Krzyworzeka M., van Balkom B. W., Belting M., Blanc L., Bond V., Bongiovanni A., Borrás F. E., Buee L., Buzas E. I., Cheng L., Clayton A., Cocucci E., Dela Cruz C. S., Desiderio D. M., Di Vizio D., Ekstrom K., Falcon Perez J. M., Gardiner C., Giebel B., Greening D. W., Gross J. C., Gupta D., Hendrix A., Hill A. F., Hill M. M., Nolte 't Hoen E., Hwang do W., Inal J., Jagannadham M. V., Jayachandran M., Jee Y. K., Jorgensen M., Kim K. P., Kim Y. K., Kislinger T., Lasser C., Lee D. S., Lee H., van Leeuwen J., Lener T., Liu M. L., Lotvall J., Marcilla A., Mathivanan S., Moller A., Morhayim J., Mullier F., Nazarenko I., Nieuwland R., Nunes D. N., Pang K., Park J., Patel T., Pocsfalvi G., Del Portillo H., Putz U., Ramirez M. I., Rodrigues M. L., Roh T. Y., Royo F., Sahoo S., Schiffelers R., Sharma S., Siljander P., Simpson R. J., Soekmadji C., Stahl P., Stensballe A., Stepien E., Tahara H., Trummer A., Valadi H., Vella L. J., Wai S. N., Witwer K., Yanez Mo M., Youn H., Zeidler R. and **Gho Y. S.** EVpedia: a community web portal for extracellular vesicles research. *BIOINFORMATICS* 2014 [31(6): 933 9]

**Kimlin M. G., Lucas R. M., Harrison S. L., van der Mei I., Armstrong B. K., Whiteman D. C., Krickler A., Nowak M., Brodie A. M. and Sun J.** The contributions of solar ultraviolet radiation exposure and other determinants to serum 25 hydroxyvitamin D concentrations in Australian adults: the AusD Study. *AMERICAN JOURNAL OF EPIDEMIOLOGY* 2014 [179(7): 864 74]

**Knibbs L. D., Johnson G. R., Kidd T. J., Cheney J., Grimwood K., Kattenbelt J. A., O'Rourke P. K., Ramsay K. A., Sly P. D., Wainwright C. E., Wood M. E., Morawska L. and Bell S. C.** Viability of *Pseudomonas aeruginosa* in cough aerosols generated by persons with cystic fibrosis. *THORAX* 2014 [69(8): 740 5]

**Kobel M., Madore J., Ramus S. J., Clarke B. A., Pharoah P. D., Deen S., Bowtell D. D., Odunsi K., Menon U., Morrison C., Lele S., Bshara W., Sucheston L., Beckmann M. W., Hein A., Thiel F. C., Hartmann A., Wachter D. L., Anglesio M. S.,**

**Hogdall E., Jensen A., Hogdall C., Kalli K. R., Fridley B. L., Keeney G. L., Fogarty Z. C., Vierkant R. A., Liu S., Cho S., Nelson G., Ghatage P., Gentry Maharaj A., Gayther S. A., Benjamin E., Widschwendter M., Intermaggio M. P., Rosen B., Bernardini M. Q., Mackay H., Oza A., Shaw P., Jimenez Linan M., Driver K. E., Alsop J., Mack M., Koziak J. M., Steed H., Ewanowich C., DeFazio A., Chenevix Trench G., Fereday S., Gao B., Johnatty S. E., George J., Galletta L., Goode E. L., Kjaer S. K., Huntsman D. G., Fasching P. A., Moysich K. B., Brenton J. D. and Kelemen L. E.** Evidence for a time dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. *BRITISH JOURNAL OF CANCER* 2014 [111(12): 2297 307]

**Kochunov P Jahanshad N, Sprooten E, Nichols TE, Mandl RC, Almasy L, Booth T, Brouwer RM, Curran JE, de Zubicaray GI, Dimitrova R, Duggirala R, Fox PT, Elliot Hong L, Landman BA, Lemaître H, Lopez L, Martin NG, McMahon KL, Mitchell BD, Olvera RL, Peterson CP, Starr JM, Sussmann JE, Toga AW, Wardlaw JM, Wright MJ, Wright SN, Bastin ME, McIntosh AM, Boomsma DI, Kahn RS, den Braber A, de Geus EJ, Deary IJ, Hulshoff Pol HE, Williamson DE, Blangero J, van 't Ent D, Thompson PM, Glahn DC.** Multi site study of additive genetic effects on fractional anisotropy of cerebral white matter: Comparing meta and mega-analytical approaches for data pooling. *NEUROIMAGE* 2014 [95: 136 150]

**Koyama M., Hashimoto D., Nagafuji K., Eto T., Ohno Y., Aoyama K., Iwasaki H., Miyamoto T., Hill G. R., Akashi K. and Teshima T.** Expansion of donor reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced intensity conditioning. *BONE MARROW TRANSPLANTATION* 2014 [49(1): 110 5]

**Kubarych TS Kendler KS, Aggen SH, Estabrook R, Edwards AC, Clark SL, Martin NG, Hickie IB, Neale MC, Gillespie NA.** Comparing Factor, Class, and Mixture Models of Cannabis Initiation and DSM Cannabis Use Disorder Criteria, Including Craving, in the Brisbane Longitudinal Twin Study. *TWIN RESEARCH AND HUMAN GENETICS*

2014 [17(2): 89 98]

**Kuchenbaecker K. B., Neuhausen S. L., Robson M., Barrowdale D., McGuffog L., Mulligan A. M., Andrulis I. L., Spurdle A. B., Schmidt M. K., Schmutzler R. K., Engel C., Wappenschmidt B., Nevanlinna H., Thomassen M., Southey M., Radice P., Ramus S. J., Domchek S. M., Nathanson K. L., Lee A., Healey S., Nussbaum R. L., Rebbeck T. R., Arun B. K., James P., Karlan B. Y., Lester J., Cass I., Terry M. B., Daly M. B., Goldgar D. E., Buys S. S., Janavicius R., Tihomirova L., Tung N., Dorfling C. M., van Rensburg E. J., Steele L., v O. Hansen T., Ejlersen B., Gerdes A. M., Nielsen F. C., Dennis J., Cunningham J., Hart S., Slager S., Osorio A., Benitez J., Duran M., Weitzel J. N., Tafur I., Hander M., Peterlongo P., Manoukian S., Peissel B., Roversi G., Scuvera G., Bonanni B., Mariani P., Volorio S., Dolcetti R., Varesco L., Papi L., Tibiletti M. G., Giannini G., Fostira F., Konstantopoulou I., Garber J., Hamann U., Donaldson A., Brewer C., Foo C., Evans D. G., Frost D., Eccles D., Douglas F., Brady A., Cook J., Tischkowitz M., Adlard J., Barwell J., Ong K. R., Walker L., Izatt L., Side L. E., Kennedy M. J., Rogers M. T., Porteous M. E., Morrison P. J., Platte R., Eeles R., Davidson R., Hodgson S., Ellis S., Godwin A. K., Rhiem K., Meindl A., Ditsch N., Arnold N., Plendl H., Niederacher D., Sutter C., Steinemann D., Bogdanova Markov N., Kast K., Varon Mateeva R., Wang Gohrke S., Gehrig A., Markiefka B., Buecher B., Lefol C., Stoppa Lyonnet D., Rouleau E., Prieur F., Damiola F., Barjhoux L., Faivre L., Longy M., Sevenet N., Sinilnikova O. M., Mazoyer S., Bonadona V., Caux Moncoutier V., Isaacs C., Van Maerken T., Claes K., Piedmonte M., Andrews L., Hays J., Rodriguez G. C., Caldes T., de la Hoya M., Khan S., Hogervorst F. B., Aalfs C. M., de Lange J. L., Meijers Heijboer H. E., van der Hout A. H., Wijnen J. T., van Roozendaal K. E., Mensenkamp A. R., van den Ouweland A. M., van Deurzen C. H., van der Luijt R. B., Olah E., Diez O., Lazaro C., Blanco I., Teule A., Menendez M., Jakubowska A., Lubinski J., Cybulski C., Gronwald J., Jaworska Bieniek K., Durda K., Arason A., Maugard C., Soucy P., Montagna M., Agata S., Teixeira M. R., Olswold C., Lindor N., Pankratz V. S., Hallberg E., Wang X., Szabo**



- C. I., Vijai J., Jacobs L., Corines M., Lincoln A., Berger A., Fink Retter A., Singer C. F., Rappaport C., Kaulich D. G., Pfeiler G., Tea M. K., Phelan C. M., Mai P. L., Greene M. H., Rennert G., Imyanitov E. N., Glendon G., Toland A. E., Bojesen A., Pedersen I. S., Jensen U. B., Caligo M. A., Friedman E., Berger R., Laitman Y., Rantala J., Arver B., Loman N., Borg A., Ehrencrona H., Olopade O. I., Simard J., Easton D. F., Chenevix Trench G., Offit K., Couch F. J. and Antoniou A. C.** Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *BREAST CANCER RESEARCH : BCR* 2014 [16(6): 3416]
- Kumar R. and Engwerda C.** Vaccines to prevent leishmaniasis. *CLINICAL & TRANSLATIONAL IMMUNOLOGY* 2014 [3(3): e13]
- Kuys S. S., Peel N. M., Klein K., Slater A. and Hubbard R. E.** Gait speed in ambulant older people in long term care: a systematic review and meta analysis. *JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION* 2014 [15(3): 194 200]
- Kvaskoff M., Pandeya N., Green A. C., Perry S., Baxter C., Davis M. B., Mortimore R., Westacott L., Wood D., Triscott J., Williamson R. and Whiteman D. C.** Solar elastosis and cutaneous melanoma: a site specific analysis. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [136(12): 2900 11]
- Lahmann P. H., Ibiebele T. I., Webb P. M., Nagle C. M., Whiteman D. C. and Australian Cancer Study** A case control study of glycemic index, glycemic load and dietary fiber intake and risk of adenocarcinomas and squamous cell carcinomas of the esophagus: the Australian Cancer Study. *BMC CANCER* 2014 [14: 877]
- Lane S. W., Williams D. A. and Watt F. M.** Modulating the stem cell niche for tissue regeneration. *NAT BIOTECHNOL* 2014 [32(8): 795 803]
- Lane S. W. and Mullally A.** Hit the spleen, JAK! *BLOOD* 2014 [124(19): 2898 900]
- Lau LS, Fernandez Ruiz D, Mollard V, Sturm A, Neller MA, Cozijnsen A, Gregory JL, Davey GM, Jones CM, Lin YH, Haque A, Engwerda CR, Nie CQ, Hansen DS, Murphy KM, Papenfuss AT, Miles JJ, Burrows SR, de Koning Ward T, McFadden GI, Carbone FR, Crabb BS, Heath WR.** CD8+ T cells from a novel T cell receptor transgenic mouse induce liver stage immunity that can be boosted by blood stage infection in rodent malaria. *PLOS PATHOGENS* 2014 [10(5): e1004135]
- Law M. H., Rowe C. J., Montgomery G. W., Hayward N. K., MacGregor S. and Khosrotehrani K.** PARP1 polymorphisms play opposing roles in melanoma occurrence and survival. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [136(10): 2488 9]
- Lee A. W., Tyrer J. P., Doherty J. A., Stram D. A., Kupryjanczyk J., Dansonka Mieszkowska A., Plisiecka Halasa J., Spiewankiewicz B., Myers E. J., Chenevix Trench G., Fasching P. A., Beckmann M. W., Ekici A. B., Hein A., Vergote I., Van Nieuwenhuysen E., Lambrechts D., Wicklund K. G., Eilber U., Wang Gohrke S., Chang Claude J., Rudolph A., Sucheston Campbell L., Odunsi K., Moysich K. B., Shvetsov Y. B., Thompson P. J., Goodman M. T., Wilkens L. R., Dork T., Hillemanns P., Durst M., Runnebaum I. B., Bogdanova N., Pelttari L. M., Nevanlinna H., Leminen A., Edwards R. P., Kelley J. L., Harter P., Schwaab I., Heitz F., du Bois A., Orsulic S., Lester J., Walsh C., Karlan B. Y., Hogdall E., Kjaer S. K., Jensen A., Vierkant R. A., Cunningham J. M., Goode E. L., Fridley B. L., Southey M. C., Giles G. G., Bruinsma F., Wu X., Hildebrandt M. A., Lu K., Liang D., Bisogna M., Levine D. A., Weber R. P., Schildkraut J. M., Iversen E. S., Berchuck A., Terry K. L., Cramer D. W., Tworoger S. S., Poole E. M., Olson S. H., Orlow I., Bandera E. V., Bjorge L., Tangen I. L., Salvesen H. B., Krakstad C., Massuger L. F., Kiemeny L. A., Aben K. K., van Altena A. M., Bean Y., Pejovic T., Kellar M., Le N. D., Cook L. S., Kelemen L. E., Brooks Wilson A., Lubinski J., Gronwald J., Cybulski C., Jakubowska A., Wentzensen N., Brinton L. A., Lissowska J., Yang H., Nedergaard L., Lundvall L., Hogdall C., Song H., Campbell I. G., Eccles D., Glasspool R., Siddiqui N., Carty K., Paul J., McNeish I. A., Sieh W., McGuire V., Rothstein J. H., Whittemore A. S., McLaughlin J. R., Risch H. A., Phelan C. M., Anton Culver H., Ziogas A., Menon U., Ramus S. J., Gentry Maharaj A., Harrington P., Pike M. C., Modugno F., Rossing M. A., Ness R. B., Pharoah P. D., Stram D. O., Wu A. H. and Pearce C. L.** Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *GYNECOLOGIC ONCOLOGY* 2014 [136(3): 542 8]
- Lee Dong Sung, Shin Jong Yeon, Tonge Peter D, Puri Mira C, Lee Seungbok, Park Hansoo, Lee Won Chul, Hussein Samer MI, Bleazard Thomas, Yun Ji Young, J Kim, M Li, N Cloonan, D Wood, JL Clancy, R Mosbergen, JH Yi, KS Yang, H Kim, H Rhee, CA Wells, T Preiss, SM Grimmond, IM Rogers, A Nagy and JS Seo.** An epigenomic roadmap to induced pluripotency reveals DNA methylation as a reprogramming modulator. *NATURE COMMUNICATIONS* 2014 [5(5619):]
- Lee AJ, Mitchem DG, Wright MJ, Martin NG, Keller MC, Zietsch BP.** Genetic Factors that increase male facial masculinity decrease facial attractiveness of female relatives. *PSYCHOLOGICAL SCIENCE* 2014 [25(2): 476 484]
- Lee, K. T. Muller, D. A. Coffey, J. W. Robinson, K. J. McCarthy, J. S. Kendall, M. A. Corrie, S. R.** Capture of the circulating Plasmodium falciparum biomarker HRP2 in a multiplexed format, via a wearable skin patch. *ANAL CHEM* 2014 [86(20): 10474 83]
- Leimgruber A., Moller A., Everitt S. J., Chabrot M., Ball D. L., Solomon B., MacManus M. and Hicks R. J.** Effect of Platinum Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F FLT PET/CT in Patients with Locally Advanced Non Small Cell Lung Cancer. *JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE* 2014 [55(7): 1075 80]
- Leveck, B. Montresor, A. Albonico, M. Ame, S. M. Behnke, J. M. Bethony, J. M. Noumedem, C. D. Engels, D. Guillard, B. Kotze, A. C. Krolewiecki, A. J. McCarthy, J. S. Mekonnen,**

**Z.Periago, M. V. Sopheak, H. Tchuem Tchuente, L. A. Duong, T. T. Huong, N. T. Zeynudin, A. Vercruyse, J.** Assessment of anthelmintic efficacy of mebendazole in school children in six countries where soil transmitted helminths are endemic. *PLOS NEGL TROP DIS* 2014 [8(10): e3204]

**Leveque L., Hodgson S., Peyton S., Koyama M., MacDonald K. P. and Khosrotehrani K.** Selective organ specific inflammation in offspring harbouring microchimerism from strongly alloreactive mothers. *JOURNAL OF AUTOIMMUNITY* 2014 [50: 51 8]

**Li J., Lindstrom L. S., Foo J. N., Rafiq S., Schmidt M. K., Pharoah P. D., Michailidou K., Dennis J., Bolla M. K., Wang Q., Van 't Veer L. J., Cornelissen S., Rutgers E., Southey M. C., Apicella C., Dite G. S., Hopper J. L., Fasching P. A., Haeberle L., Ekici A. B., Beckmann M. W., Blomqvist C., Muranen T. A., Aittomaki K., Lindblom A., Margolin S., Mannermaa A., Kosma V. M., Hartikainen J. M., Kataja V., Chenevix Trench G., Phillips K. A., McLachlan S. A., Lambrechts D., Thienpont B., Smeets A., Wildiers H., Chang Claude J., Flesch Janys D., Seibold P., Rudolph A., Giles G. G., Baglietto L., Severi G., Haiman C. A., Henderson B. E., Schumacher F., Le Marchand L., Kristensen V., Alnaes G. I., Borresen Dale A. L., Nord S., Winqvist R., Pylkas K., Jukkola Vuorinen A., Grip M., Andrulis I. L., Knight J. A., Glendon G., Tchatchou S., Devilee P., Tollenaar R., Seynaeve C., Hooning M., Kriege M., Hollestelle A., van den Ouweland A., Li Y., Hamann U., Torres D., Ulmer H. U., Rudiger T., Shen C. Y., Hsiung C. N., Wu P. E., Chen S. T., Teo S. H., Taib N. A., Har Yip C., Fuang Ho G., Matsuo K., Ito H., Iwata H., Tajima K., Kang D., Choi J. Y., Park S. K., Yoo K. Y., Maishman T., Tapper W. J., Dunning A., Shah M., Luben R., Brown J., Khor C. C., Eccles D. M., Nevanlinna H., Easton D., Humphreys K., Liu J., Hall P. and Czene K.** 2q36.3 is associated with prognosis for oestrogen receptor negative breast cancer patients treated with chemotherapy. *NATURE COMMUNICATIONS* 2014 [5: 4051]

**Li M Luo XJ, Rietschel M, Lewis CM, Mattheisen M, Müller Myhsok B, Jamain S, Leboyer M, Landén M, Thompson PM, Cichon S, Nöthen MM, Schulze TG, Sullivan**

**PF, Bergen SE, Donohoe G, Morris DW, Hargreaves A, Gill M, Corvin A, Hultman C, Toga AW, Shi L, Lin Q, Shi H, Gan L, Meyer Lindenberg A, Czamara D, Henry C, Etain B, Bis JC, Ikram MA, Fornage M, Debette S, Launer LJ, Seshadri S, Erk S, Walter H, Heinz A, Bellivier F, Stein JL, Medland SE, Arias Vasquez A, Hibar DP, Franke B, Martin NG, Wright MJ; MooDS Bipolar Consortium; The Swedish Bipolar Study Group; The Alzheimer's Disease Neuroimaging Initiative; ENIGMA Consortium; CHARGE Consortium, Su B.** Allelic differences between Europeans and Chinese for CREB1 SNPs and their implications in gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. *MOLECULAR PSYCHIATRY* 2014 [19(4): 452 461]

**Li YS, McManus DP, Lin DD, Williams GM, Harn DA, Ross AG, Feng Z, Gray DJ.** The *Schistosoma japonicum* self cure phenomenon in water buffaloes: potential impact on the control and elimination of schistosomiasis in China. *INT J PARASITOL* 2014 [44(3 4): 167 171]

**Li Q Wojciechowski R, Simpson CL, Hysi PG, Verhoeven VJ, Ikram MK, Hohn R, Vitart V, Hewitt AW, Oexle K, Makela KM, Macgregor S, Pirastu M, Fan Q, Cheng CY, St Pourcain B, McMahon G, Kemp JP, Northstone K, Rahi JS, Cumberland PM, Martin NG, Sanfilippo PG, Lu Y, Wang YX, Hayward C, Polasek O, Campbell H, Bencic G, Wright AF, Wedenoja J, Zeller T, Schillert A, Mirshahi A, Lackner K, Yip SP, Yap MK, Ried JS, Gieger C, Murgia F, Wilson JF, Fleck B, Yazar S, Vingerling JR, Hofman A, Uitterlinden A, Rivadeneira F, Amin N, Karssen L, Oostra BA, Zhou X, Teo YY, Tai ES, Vithana E, Barathi V, Zheng Y, Siantar RG, Neelam K, Shin Y, Lam J, Yonova Doing E, Venturini C, Hosseini SM, Wong HS, Lehtimäki T, Kahonen M, Raitakari O, Timpson NJ, Evans DM, Khor CC, Aung T, Young TL, Mitchell P, Klein B, van Duijn CM, Meitinger T, Jonas JB, Baird PN, Mackey DA, Wong TY, Saw SM, Parssinen O, Stambolian D, Hammond CJ, Klaver CC, Williams C, Paterson AD, Bailey Wilson JE, Guggenheim JA, The CREAM Consortium.** Genome-wide association study for refractive astigmatism reveals genetic co determination with spherical equivalent refractive error: the CREAM

consortium. *HUMAN GENETICS* 2014 [134(2): 131 146]

**Lickliter, JD, Taylor, K, Szer, J, Grigg, A, Arthur, C, Hughes, TP, Durrant, S, Filshie, R, Irving, I, Seldon, M, D'Rozario, J, Rooney, K, Ellacott, J, BOYD, AW, Lynch, K, Bradstock, K.** An imatinib only window followed by imatinib and chemotherapy for Philadelphia chromosome positive acute leukemia: long term results of the CMLALL1 trial. *LEUK LYMPHOMA* 2015 [56: 630 8]

**Liew K. and Radford Smith G.** HLA B27 in Crohn's disease. *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY* 2014 [29: 113 114]

**Ligthart L Hottenga JJ, Lewis CM, Farmer AE, Craig IW, Breen G, Willemsen G, Vink JM, Middeldorp CM, Byrne EM, Heath AC, Madden PA, Pergadia ML, Montgomery GW, Martin NG, Penninx BW, McGuffin P, Boomsma DI, Nyholt DR.** Genetic risk score analysis indicates migraine with and without comorbid depression are genetically different disorders. *HUMAN GENETICS* 2014 [133(2): 173 186]

**Lim YC, Roberts TL, Day BW, Stringer BW, Kozlov S, Fazry S, Bruce ZC, Ensbeys KS, Walker DG, Boyd AW and Lavin MF.** Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells. *MOL ONCOL* 2014 [8(8): 1603 15]

**Lin W. Y., Camp N. J., Ghousaini M., Beesley J., Michailidou K., Hopper J. L., Apicella C., Southey M. C., Stone J., Schmidt M. K., Broeks A., Van't Veer L. J., Th Rutgers E. J., Muir K., Lophatananon A., Stewart Brown S., Siriwanarangsana P., Fasching P. A., Haeberle L., Ekici A. B., Beckmann M. W., Peto J., Dos Santos Silva I., Fletcher O., Johnson N., Bolla M. K., Wang Q., Dennis J., Sawyer E. J., Cheng T., Tomlinson I., Kerin M. J., Miller N., Marme F., Surowy H. M., Burwinkel B., Guenel P., Truong T., Menegaux F., Mulot C., Bojesen S. E., Nordestgaard B. G., Nielsen S. F., Flyger H., Benitez J., Zamora M. P., Arias Perez J. I., Menendez P., Gonzalez Neira A., Pita G., Alonso M. R., Alvarez N., Herrero D., Anton Culver H., Brenner H., Dieffenbach A. K., Arndt V., Stegmaier C., Meindl A., Lichtner P., Schmutzler R. K., Muller Myhsok B., Brauch H.,**

- Bruning T., Ko Y. D., Tessier D. C., Vincent D., Bacot F., Nevanlinna H., Aittomaki K., Blomqvist C., Khan S., Matsuo K., Ito H., Iwata H., Horio A., Bogdanova N. V., Antonenkova N. N., Dork T., Lindblom A., Margolin S., Mannermaa A., Kataja V., Kosma V. M., Hartikainen J. M., Wu A. H., Tseng C. C., Van Den Berg D., Stram D. O., Neven P., Wauters E., Wildiers H., Lambrechts D., Chang Claude J., Rudolph A., Seibold P., Flesch Janys D., Radice P., Peterlongo P., Manoukian S., Bonanni B., Couch F. J., Wang X., Vachon C., Purrington K., Giles G. G., Milne R. L., McLean C., Haiman C. A., Henderson B. E., Schumacher F., Le Marchand L., Simard J., Goldberg M. S., Labreche F., Dumont M., Teo S. H., Yip C. H., Hassan N., Vithana E. N., Kristensen V., Zheng W., Deming Halverson S., Shrubsole M. J., Long J., Winqvist R., Pylkas K., Jukkola Vuorinen A., Kauppila S., Andrulis I. L., Knight J. A., Glendon G., Tchatchou S., Devilee P., Tollenaar R. A., Seynaeve C., Van Asperen C. J., Garcia Closas M., Figueroa J., Lissowska J., Brinton L., Czene K., Darabi H., Eriksson M., Brand J. S., Hooning M. J., Hollestelle A., Van Den Ouweland A. M., Jager A., Li J., Liu J., Humphreys K., Shu X. O., Lu W., Gao Y. T., Cai H., Cross S. S., Reed M. W., Blot W., Signorello L. B., Cai Q., Pharoah P. D., Perkins B., Shah M., Blows F. M., Kang D., Yoo K. Y., Noh D. Y., Hartman M., Miao H., Chia K. S., Putti T. C., Hamann U., Luccarini C., Baynes C., Ahmed S., Maranian M., Healey C. S., Jakubowska A., Lubinski J., Jaworska Bieniek K., Durda K., Sangrajang S., Gaborieau V., Brennan P., McKay J., Slager S., Toland A. E., Yannoukakos D., Shen C. Y., Hsiung C. N., Wu P. E., Ding S. L., Ashworth A., Jones M., Orr N., Swerdlow A. J., Tsimiklis H., Makalic E., Schmidt D. F., Bui Q. M., Chanock S. J., Hunter D. J., Hein R., Dahmen N., Beckmann L., Aaltonen K., Muranen T. A., Heikkinen T., Irwanto A., Rahman N., Turnbull C. A., Waisfisz Q., Meijers Heijboer H. E., Adank M. A., Van Der Luijt R. B., Hall P., Chenevix Trench G., Dunning A., Easton D. F. and Cox A.** Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *HUMAN MOLECULAR GENETICS* 2014 [24(1): 285 98]
- Lin M. H., Sivakumaran H., Jones A., Li D., Harper C., Wei T., Jin H., Rustanti L., Meunier F. A., Spann K. and Harrich D.** A HIV 1 Tat mutant protein disrupts HIV 1 Rev function by targeting the DEAD box RNA helicase DDX1. *RETROVIROLOGY* 2014 [11(1): 121]
- Liu YC, Chen Z, Neller MA, Miles JJ, Purcell AW, McCluskey J, Burrows SR, Rossjohn J, Gras S.** A molecular basis for the interplay between T cells, viral mutants, and human leukocyte antigen micropolymorphism. *J BIOL CHEM.* 2014 [289(24): 16688 98]
- Liu G., Guo S., Anderson G. J., Camaschella C., Han B. and Nie G.** Heterozygous missense mutations in the GLRX5 gene cause sideroblastic anemia in a Chinese patient. *BLOOD* 2014 [124(17): 2750 1]
- Liu T., Chien C. C., Parkinson L. and Thierry B.** Advanced micromachining of concave microwells for long term on chip culture of multicellular tumor spheroids. *ACS APPLIED MATERIALS & INTERFACES* 2014 [6(11): 8090 7]
- Liu T., Kempson I., de Jonge M., Howard D. L. and Thierry B.** Quantitative synchrotron X ray fluorescence study of the penetration of transferrin conjugated gold nanoparticles inside model tumour tissues. *NANOSCALE* 2014 [6(16): 9774 82]
- Liu T., Winter M. and Thierry B.** Quasi spherical microwells on superhydrophobic substrates for long term culture of multicellular spheroids and high throughput assays. *BIOMATERIALS* 2014 [35(23): 6060 8]
- Liu C., Srihari S., Cao K. A., Chenevix Trench G., Simpson P. T., Ragan M. A. and Khanna K. K.** A fine scale dissection of the DNA double strand break repair machinery and its implications for breast cancer therapy. *NUCLEIC ACIDS RESEARCH* 2014 [42(10): 6106 27]
- Liu T., Yang C. T., Dieguez L., Denman J. A. and Thierry B.** Robust and Flexible Fabrication of Chemical Micropatterns for Tumor Spheroid Preparation. *ACS APPLIED MATERIALS AND INTERFACES* 2014 [6(13): 10162 71]
- Liu J., Blake S. J., Smyth M. J. and Teng M. W.** Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. *CLINICAL & TRANSLATIONAL IMMUNOLOGY* 2014 [3(8): e22]
- Liu, X, Walton, S. F, Murray, H. C, King, M, Kelly, A, Holt, D. C, Currie, B. J, McCarthy, J. S, Mounsey, K. E.** Crusted scabies is associated with increased IL 17 secretion by skin T cells. *PARASITE IMMUNOL* 2014 [36(11): 594 604]
- Loehlin JC Martin NG.** The Genetic Correlation Between Procrastination and Impulsivity. *TWIN RESEARCH AND HUMAN GENETICS* 2014 [17(6): 512 515]
- Loi S., Michiels S., Salgado R., Sirtaine N., Jose V., Fumagalli D., Kellokumpu Lehtinen P. L., Bono P., Kataja V., Desmedt C., Piccart M. J., Loibl S., Denkert C., Smyth M. J., Joensuu H. and Sotiriou C.** Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *ANNALS OF ONCOLOGY* 2014 [25(8): 1544 50]
- Long G. V., Fung C., Menzies A. M., Pupo G. M., Carlino M. S., Hyman J., Shahheydari H., Tembe V., Thompson J. F., Saw R. P., Howle J., Hayward N. K., Johansson P., Scolyer R. A., Kefford R. F. and Rizos H.** Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma. *NATURE COMMUNICATIONS* 2014 [5: 5694]
- Loukola A Wedenoja J, Keskitalo Vuokko K, Broms U, Korhonen T, Ripatti S, Sarin AP, Pitkaniemi J, He L, Häppölä A, Heikkilä K, Chou YL, Pergadia ML, Heath AC, Montgomery GW, Martin NG, Madden PA, Kaprio J.** Genome-wide association study on detailed profiles of smoking behavior and nicotine dependence in a twin sample. *MOLECULAR PSYCHIATRY* 2014 [19(5): 615 624]
- Lu Y., Ek W. E., Whiteman D., Vaughan T. L., Spurdle A. B., Easton D. F., Pharoah P. D., Thompson D. J., Dunning A. M., Hayward N. K., Chenevix Trench G., Q Mega, Investigators Amfs, Anecs Search,**

**Ukops Search, Consortium Beacon and Macgregor S.** Most common 'sporadic' cancers have a significant germline genetic component. *HUMAN MOLECULAR GENETICS* 2014 [23(22): 6112 8]

**Lucas R. and Neale R.** What is the optimal level of vitamin D? Separating the evidence from the rhetoric. *AUSTRALIAN FAMILY PHYSICIAN* 2014 [43(3): 119 22]

**Lwetoijera Dickson W., Harris Caroline, Kiware Samson S., Dongus Stefan, Devine Gregor J., McCall Philip J. and Majambere Silas** Increasing role of *Anopheles funestus* and *Anopheles arabiensis* in malaria transmission in the Kilombero Valley, Tanzania. *MALARIA JOURNAL* 2014 [13: 331]

**Lwetoijera Dickson W., Harris Caroline, Kiware Samson S., Killeen Gerry F., Dongus Stefan, Devine Gregor J. and Majambere Silas** Comprehensive Sterilization of Malaria Vectors Using Pyriproxyfen: A Step Closer to Malaria Elimination. *AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE* 2014 [90(5): 852 855]

**Lwetoijera Dickson, Harris Caroline, Kiware Samson, Dongus Stefan, Devine Gregor J., McCall Philip J. and Majambere Silas** Effective auto-dissemination of pyriproxyfen to breeding sites by the exophilic malaria vector *Anopheles arabiensis* in semi field settings in Tanzania. *MALARIA JOURNAL* 2014 [13: 161]

**Ma Y., Mattarollo S. R., Adjemian S., Yang H., Aymeric L., Hannani D., Portela Catani J. P., Duret H., Teng M. W., Kepp O., Wang Y., Sistigu A., Schultze J. L., Stoll G., Galluzzi L., Zitvogel L., Smyth M. J. and Kroemer G.** CCL2/CCR2 dependent recruitment of functional antigen presenting cells into tumors upon chemotherapy. *CANCER RESEARCH* 2014 [74(2): 436 45]

**Macagno M., Bandini S., Stramucci L., Quaglino E., Conti L., Balmas E., Smyth M. J., Lollini P. L., Musiani P., Forni G., Iezzi M. and Cavallo F.** Multiple roles of perforin in hampering ERBB 2 (Her 2/neu) carcinogenesis in transgenic male mice. *JOURNAL OF IMMUNOLOGY* 2014 [192(11): 5434 41]

**MacDonald K. P., Le Texier L., Zhang P., Morris H., Kuns R. D., Lineburg K. E., Leveque L., Don A. L., Markey K. A., Vuckovic S., Bagger F. O., Boyle G. M., Blazar B. R. and Hill G. R.** Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G CSF and IL 10. *JOURNAL OF IMMUNOLOGY* 2014 [192(7): 3180 9]

**Maciejewski DF Creemers HE, Lynskey MT, Madden PA, Heath AC, Statham DJ, Martin NG, Verweij KJ.** Overlapping Genetic and Environmental Influences on Nonsuicidal Self injury and Suicidal Ideation: Different Outcomes, Same Etiology? *JAMA PSYCHIATRY* 2014 [71(6): 699 705]

**Markey K. A., Koyama M., Gartlan K. H., Leveque L., Kuns R. D., Lineburg K. E., Teal B. E., MacDonald K. P. and Hill G. R.** Cross dressing by donor dendritic cells after allogeneic bone marrow transplantation contributes to formation of the immunological synapse and maximizes responses to indirectly presented antigen. *JOURNAL OF IMMUNOLOGY* 2014 [192(11): 5426 33]

**Markey K. A., MacDonald K. P. and Hill G. R.** The biology of graft versus host disease: experimental systems instructing clinical practice. *BLOOD* 2014 [124(3): 354 62]

**Markmiller Sebastian, Cloonan Nicole, Lardelli Rea M, Doggett Karen, Keightley Maria Cristina, Boglev Yeliz, Trotter Andrew J, Ng Annie Y, Wilkins Simon J, Verkade Heather, EA Ober, HA Field, SM Grimmond, GJ Lieschke, DY Stainier and JK Heath.** Minor class splicing shapes the zebrafish transcriptome during development. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA* 2014 [111(8): 3062 3067]

**Martin Hilary C, Wani Shivangi, Steptoe Anita L, Krishnan Keerthana, Nones Katia, Nourbakhsh Ehsan, Vlassov Alexander, Grimmond Sean M and Cloonan Nicole.** Imperfect centered miRNA binding sites are common and can mediate repression of target mRNAs. *GENOME BIOLOGY* 2014 [15(3): R51]

**Maslovskaya L. A., Savchenko A. I., Krenske E. H., Gordon V. A., Reddell P. W., Pierce C. J., Parsons P. G. and Williams C. M.** Croton insularis introduces the seco casbane class with EBC 329 and the first casbane endoperoxide EBC 324. *CHEMICAL COMMUNICATIONS* 2014 [50(82): 12315 7]

**Maslovskaya L. A., Savchenko A. I., Krenske E. H., Pierce C. J., Gordon V. A., Reddell P. W., Parsons P. G. and Williams C. M.** EBC 219: a new diterpene skeleton, crotinsulidane, from the Australian rainforest containing a bridgehead double bond. *ANGEWANDTE CHEMIE* 2014 [53(27): 7006 9]

**Maslovskaya L. A., Savchenko A. I., Pierce C. J., Gordon V. A., Reddell P. W., Parsons P. G. and Williams C. M.** Unprecedented 1,14 seco crotofolanes from Croton insularis: oxidative cleavage of crotofolin C by a putative homo Baeyer Villiger rearrangement. *CHEMISTRY* 2014 [20(44): 14226 30]

**McCarthy, J. S.** Oxantel pamoate albendazole for *Trichuris trichiura* infection. *N ENGL J MED* 2014 [370(20): 1952 3]

**McDonald CJ, Wallace DF, Ostini L, Subramaniam VN.** Parenteral vs. oral iron: influence on hepcidin signaling pathways through analysis of Hfe/Tfr2 null mice. *AM J PHYSIOL GASTROINTEST LIVER PHYSIOL* 2014 [306(2): G132 9]

**McKone E. F., Borowitz D., Drevinek P., Griese M., Konstan M. W., Wainwright C., Ratjen F., Sermet Gaudelus I., Plant B., Munck A., Jiang Y., Gilmartin G., Davies J. C. and V. X. Study Group.** Long term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp CFTR mutation: a phase 3, open label extension study (PERSIST). *THE LANCET. RESPIRATORY MEDICINE* 2014 [2(11): 902 10]

**McLeod D. S.** Thyrotropin in the Development and Management of Differentiated Thyroid Cancer. *ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA* 2014 [43(2): 367 83]

**McLeod D. S., Cooper D. S., Ladenson P. W., Ain K. B., Brierley J. D., Fein H. G., Haugen B. R., Jonklaas**

- J., Magner J., Ross D. S., Skarulis M. C., Steward D. L., Maxon H. R. and Sherman For The National Thyroid Cancer Treatment Cooperative Study Group S. I.** Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. *THYROID* 2014 [24(1): 35 42]
- McLeod D. S., Caturegli P., Cooper D. S., Matos P. G. and Hutfless S.** Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. *JAMA* 2014 [311(15): 1563 5]
- McManus D. P., Bieri F. A., Li Y. S., Williams G. M., Yuan L. P., Henglin Y., Du Z. W., Clements A. C., Steinmann P., Raso G., Yap P., Magalhaes R. J., Stewart D., Ross A. G., Halton K., Zhou X. N., Olveda R. M., Tallo V. and Gray D. J.** Health education and the control of intestinal worm infections in China: a new vision. *PARASIT VECTORS* 2014 [7: 344]
- McManus, D.P.** Immunodiagnosis of sheep infections with *Echinococcus granulosus*: in 35 years where have we come? *PARASITE IMMUNOLOGY*. 2014 [36(3): 125 130]
- McMichael A. J., Leeder S. R., Armstrong B. K., Basten A., Doherty P. C., Douglas R. M., Green A. C., Nossal G. J., Shearman D. J., Stanley F. J., Vimpani G. V. and Wodak A. D.** Open letter to the Hon Tony Abbott MP. *THE MEDICAL JOURNAL OF AUSTRALIA* 2014 [201(5): 252]
- McRae A. F., Powell J. E., Henders A. K., Bowdler L., Hemani G., Shah S., Painter J. N., Martin N. G., Visscher P. M. and Montgomery G. W.** Contribution of genetic variation to transgenerational inheritance of DNA methylation. *GENOME BIOLOGY* 2014 [15(5): R73]
- McWilliam H. E., Driguez P., Piedrafita D., McManus D. P. and Meeusen E. N.** Discovery of novel *Schistosoma japonicum* antigens using a targeted protein microarray approach. *PARASIT VECTORS* 2014 [7: 290]
- Medland S. E., Jahanshad N., Neale B. M. and Thompson P. M.** Whole genome analyses of whole brain data: working within an expanded search space. *NATURE NEUROSCIENCE* 2014 [17(6): 791 800]
- Mehrkanoon, S. Breakspear, M., Britz, J. Boonstra, T. W.** Intrinsic coupling modes in source reconstructed electroencephalography. *BRAIN CONNECT* 2014 [4(10): 812 25]
- Mehrkanoon, S., Breakspear, M. Boonstra, T. W.** The reorganization of corticomuscular coherence during a transition between sensorimotor states. *NEUROIMAGE* 2014 [100: 692 702]
- Meier MH Gillespie NA, Hansell NK, Hewitt AW, Hickie IB, Lu Y, MacGregor S, Medland SE, Sun C, Wong TY, Wright MJ, Zhu G, Martin NG, Mackey DA.** Associations between depression and anxiety symptoms and retinal vessel caliber in adolescents and young adults. *PSYCHOSOMATIC MEDICINE* 2014 [76(9): 732 738]
- Metrustry SJ Edwards MH, Medland SE, Holloway JW, Montgomery GW, Martin NG, Spector TD, Cooper C, Valdes AM.** Variants Close to NTRK2 Gene Are Associated With Birth Weight in Female Twins. *TWIN RESEARCH AND HUMAN GENETICS* 2014 [17(4): 254 261]
- Metrustry S. J., Edwards M. H., Medland S. E., Holloway J. W., Montgomery G. W., Martin N. G., Spector T. D., Cooper C. and Valdes A. M.** Variants close to NTRK2 gene are associated with birth weight in female twins. *TWIN RESEARCH AND HUMAN GENETICS : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR TWIN STUDIES* 2014 [17(4): 254 61]
- Miles, J.J., McCluskey, J., Rossjohn, J. and Gras, S.** Understanding the complexity and malleability of T cell recognition. *IMMUNOL CELL BIOL.* 2015
- Mills NT Wright MJ, Henders AK, Eyles DW, Baune BT, McGrath JJ, Byrne EM, Hansell NK, Birosova E, Scott JG, Martin NG, Montgomery GW, Wray NR, Vinkhuyzen AA.** Heritability of Transforming Growth Factor beta1 and Tumor Necrosis Factor Receptor Type 1 Expression and Vitamin D Levels in Healthy Adolescent Twins. *TWIN RESEARCH AND HUMAN GENETICS : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR TWIN STUDIES* 2014 [18(1): 28 35]
- Milne R. L., Burwinkel B., Michailidou K., Arias Perez J. I., Zamora M. P., Menendez Rodriguez P., Hardisson D., Mendiola M., Gonzalez Neira A., Pita G., Alonso M. R., Dennis J., Wang Q., Bolla M. K., Swerdlow A., Ashworth A., Orr N., Schoemaker M., Ko Y. D., Brauch H., Hamann U., Andrulis I. L., Knight J. A., Glendon G., Tchatchou S., Matsuo K., Ito H., Iwata H., Tajima K., Li J., Brand J. S., Brenner H., Dieffenbach A. K., Arndt V., Stegmaier C., Lambrechts D., Peuteman G., Christiaens M. R., Smeets A., Jakubowska A., Lubinski J., Jaworska Bieniek K., Durda K., Hartman M., Hui M., Yen Lim W., Wan Chan C., Marme F., Yang R., Bugert P., Lindblom A., Margolin S., Garcia Closas M., Chanock S. J., Lissowska J., Figueroa J. D., Bojesen S. E., Nordestgaard B. G., Flyger H., Hoening M. J., Kriege M., van den Ouweland A. M., Koppert L. B., Fletcher O., Johnson N., dos Santos Silva I., Peto J., Zheng W., Deming Halverson S., Shrubsole M. J., Long J., Chang Claude J., Rudolph A., Seibold P., Flesch Janys D., Winqvist R., Pylkas K., Jukkola Vuorinen A., Grip M., Cox A., Cross S. S., Reed M. W., Schmidt M. K., Broeks A., Cornelissen S., Braaf L., Kang D., Choi J. Y., Park S. K., Noh D. Y., Simard J., Dumont M., Goldberg M. S., Labreche F., Fasching P. A., Hein A., Ekici A. B., Beckmann M. W., Radice P., Peterlongo P., Azzollini J., Barile M., Sawyer E., Tomlinson I., Kerin M., Miller N., Hopper J. L., Schmidt D. F., Makalic E., Southey M. C., Hwang Teo S., Har Yip C., Sivanandan K., Tay W. T., Shen C. Y., Hsiung C. N., Yu J. C., Hou M. F., Guenel P., Truong T., Sanchez M., Mulot C., Blot W., Cai Q., Nevanlinna H., Muranen T. A., Aittomaki K., Blomqvist C., Wu A. H., Tseng C. C., Van Den Berg D., Stram D. O., Bogdanova N., Dork T., Muir K., Lophatananon A., Stewart Brown S., Siriwanarangsarn P., Mannermaa A., Kataja V., Kosma V. M., Hartikainen J. M., Shu X. O., Lu W., Gao Y. T., Zhang B., Couch F. J., Toland A. E., Yannoukakos D., Sangrajrang S., McKay J., Wang X., Olson J. E., Vachon C., Purrington K., Severi G., Baglietto L., Haiman C. A., Henderson B. E., Schumacher F., Le Marchand L., Devilee P., Tollenaar R. A., Seynaeve C., Czene K., Eriksson M., Humphreys K., Darabi H., Ahmed S., Shah M., Pharoah P. D., Hall P.,**

**Giles G. G., Benitez J., Dunning A. M., Chenevix Trench G. and Easton D. F.** Common non synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *HUMAN MOLECULAR GENETICS* 2014 [23(22): 6096 111]

**Milne R. L., Herranz J., Michailidou K., Dennis J., Tyrer J. P., Zamora M. P., Arias Perez J. I., Gonzalez Neira A., Pita G., Alonso M. R., Wang Q., Bolla M. K., Czene K., Eriksson M., Humphreys K., Darabi H., Li J., Anton Culver H., Neuhausen S. L., Ziogas A., Clarke C. A., Hopper J. L., Dite G. S., Apicella C., Southey M. C., Chenevix Trench G., Swerdlow A., Ashworth A., Orr N., Schoemaker M., Jakubowska A., Lubinski J., Jaworska Bieniek K., Durda K., Andrulis I. L., Knight J. A., Glendon G., Mulligan A. M., Bojesen S. E., Nordestgaard B. G., Flyger H., Nevanlinna H., Muranen T. A., Aittomaki K., Blomqvist C., Chang Claude J., Rudolph A., Seibold P., Flesch Janys D., Wang X., Olson J. E., Vachon C., Purrington K., Winqvist R., Pylkas K., Jukkola Vuorinen A., Grip M., Dunning A. M., Shah M., Guenel P., Truong T., Sanchez M., Mulot C., Brenner H., Dieffenbach A. K., Arndt V., Stegmaier C., Lindblom A., Margolin S., Hooning M. J., Hollestelle A., Collee J. M., Jager A., Cox A., Brock I. W., Reed M. W., Devilee P., Tollenaar R. A., Seynaeve C., Haiman C. A., Henderson B. E., Schumacher F., Le Marchand L., Simard J., Dumont M., Soucy P., Dork T., Bogdanova N. V., Hamann U., Forsti A., Rudiger T., Ulmer H. U., Fasching P. A., Haberle L., Ekici A. B., Beckmann M. W., Fletcher O., Johnson N., dos Santos Silva I., Peto J., Radice P., Peterlongo P., Peissel B., Mariani P., Giles G. G., Severi G., Baglietto L., Sawyer E., Tomlinson I., Kerin M., Miller N., Marme F., Burwinkel B., Mannermaa A., Kataja V., Kosma V. M., Hartikainen J. M., Lambrechts D., Yesilyurt B. T., Floris G., Leunen K., Alnaes G. G., Kristensen V., Borresen Dale A. L., Garcia Closas M., Chanock S. J., Lissowska J., Figueroa J. D., Schmidt M. K., Broeks A., Verhoef S., Rutgers E. J., Brauch H., Bruning T., Ko Y. D., Couch F. J., Toland A. E., Yannoukakos D., Pharoah P. D., Hall P., Benitez J., Malats N. and Easton D. F. A** Large scale assessment of two way SNP interactions in breast

cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *HUMAN MOLECULAR GENETICS* 2014 [23(7): 1934 46]

**Mina Michael M, Clark Paul J, Beasley Holly M, Herawati Lilie, Butler Tony G and Lloyd Andrew R** Enhancing hepatitis C treatment in the custodial setting: a national roadmap. *MEDICAL JOURNAL OF AUSTRALIA* 2014 [200(1): 15 16]

**Mitchem DG Purkey AM, Grebe NM, Carey G, Garver Apgar CE, Bates TC, Arden R, Hewitt JK, Medland SE, Martin NG, Zietsch BP, Keller MC.** Estimating the sex specific effects of genes on facial attractiveness and sexual dimorphism. *BEHAVIOR GENETICS* 2014 [44(3): 270 281]

**Mittal D., Young A., Stannard K., Yong M., Teng M. W., Allard B., Stagg J. and Smyth M. J.** Antimetastatic effects of blocking PD 1 and the adenosine A2A receptor. *CANCER RESEARCH* 2014 [74(14): 3652 8]

**Mittal D., Gubin M. M., Schreiber R. D. and Smyth M. J.** New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape. *CURRENT OPINION IN IMMUNOLOGY* 2014 [27: 16 25]

**Miura K., Hughes M. C., Green A. C. and van der Pols J. C.** Caffeine intake and risk of basal cell and squamous cell carcinomas of the skin in an 11 year prospective study. *EUROPEAN JOURNAL OF NUTRITION* 2014 [53(2): 511 20]

**Moir Meyer G. L., Pearson J. F., Lose F., Scott R. J., McEvoy M., Attia J., Holliday E. G., Pharoah P. D., Dunning A. M., Thompson D. J., Easton D. F., Spurdle A. B. and Walker L. C.** Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition. *HUMAN GENETICS* 2014 [134(3): 269 78]

**Molassiotis A., Brunton L., Hodgetts J., Green A. C., Beesley V. L., Mulatero C., Newton Bishop J. A. and Lorigan P.** Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. *ANNALS OF ONCOLOGY:*

*OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO* 2014 [25(10): 2052 2058]

**Molehin A. J., Gobert G. N., Driguez P. and McManus D. P.** Functional characterization of Sjb10, an intracellular serpin from *Schistosoma japonicum*. *PARASITOLOGY* 2014 [141(13): 1746 60]

**Molehin A. J., Gobert G. N., Driguez P. and McManus D. P.** Characterisation of a secretory serine protease inhibitor (Sjb6) from *Schistosoma japonicum*. *PARASIT VECTORS* 2014 [7: 330]

**Montgomery G. W., Zondervan K. T. and Nyholt D. R.** The future for genetic studies in reproduction. *MOLECULAR HUMAN REPRODUCTION* 2014 [20(1): 1 14]

**Moore S. P., Green A. C., Bray F., Coory M., Garvey G., Sabesan S. and Valery P. C.** Colorectal cancer among Indigenous and non Indigenous people in Queensland, Australia: Toward survival equality. *ASIA PACIFIC JOURNAL OF CLINICAL ONCOLOGY* 2014 [:]

**Moore S. P., Green A. C., Bray F., Garvey G., Coory M., Martin J. and Valery P. C.** Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non indigenous cancer patients. *BMC CANCER* 2014 [14: 517]

**Moxon JV, Liu D, Moran CS, Crossman DJ, Krishna SM, Yonglithipagon P, Emeto TI, Morris DR, Padula MP, Mulvenna JP, Rush CM, Golledge J.** Proteomic and genomic analyses suggest the association of apolipoprotein C1 with abdominal aortic aneurysm. *PROTEOMICS CLIN APPL.* 2014 OCT;8(9 10):762 72. DOI: 10.1002/PRCA.201300119 2014 [8(9 10):]

**Muhleisen TW Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, Mattheisen M, Forstner AJ, Schumacher J, Breuer R, Meier S, Herms S, Hoffmann P, Lacour A, Witt SH, Reif A, Muller Myhsok B, Lucae S, Maier W, Schwarz M, Vedder H, Kammerer Ciernioch J, Pfennig A, Bauer M, Hautzinger M, Moebus S, Priebe L, Czerski PM, Hauser J, Lissowska J, Szeszenia Dabrowska N, Brennan P, McKay JD, Wright A, Mitchell PB, Fullerton JM, Schofield**

**PR, Montgomery GW, Medland SE, Gordon SD, Martin NG, Krasnow V, Chuchalin A, Babadjanova G, Pantelejeva G, Abramova LI, Tiganov AS, Polonikov A, Khusnutdinova E, Alda M, Grof P, Rouleau GA, Turecki G, Laprise C, Rivas F, Mayoral F, Kogevinas M, Grigoriu Serbanescu M, Propping P, Becker T, Rietschel M, Nothen MM, Cichon S.** Genome wide association study reveals two new risk loci for bipolar disorder. *NATURE COMMUNICATIONS* 2014 [5: 3339]

**Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez Talavera JC, Zeuzem S; EMERGE study group.** A randomized phase 2b study of peginterferon lambda 1a for the treatment of chronic HCV infection. *JOURNAL OF HEPATOLOGY* 2014 [61(6): 1238 46]

**Muranushi C., Olsen C. M., Pandeya N. and Green A. C.** Aspirin and nonsteroidal anti inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta analysis. *THE JOURNAL OF INVESTIGATIVE DERMATOLOGY* 2014 [135(4): 975 83]

**Murat P, Zhong J, Lekieffre L, Cowieson NP, Clancy JL, Preiss T, Balasubramanian S, Khanna R, Tellam J. G** Quadruplexes regulate Epstein Barr virus encoded nuclear antigen 1 mRNA translation. *NATURE CHEM BIOL* 2014 [10(4): 358 364]

**Muzari Odwell M., Adamczyk Rebecca, Davis Joseph, Ritchie Scott and Devine Gregor.** Residual Effectiveness of lambda Cyhalothrin Harbourage Sprays Against Foliage Resting Mosquitoes in North Queensland. *JOURNAL OF MEDICAL ENTOMOLOGY* 2014 [51(2): 444 449]

**Nagore E., Requena C., Traves V., Guillen C., Hayward N. K., Whiteman D. C. and Hacker E.** Prognostic value of BRAF mutations in localized cutaneous melanoma. *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY* 2014 [70(5): 858 62 e1 2]

**Najman JakeM, Khatun Mohsina, Mamun Abdullah, Clavarino Alexandra, Williams GailM, Scott James, O'Callaghan Michael, Hayatbakhsh Reza and Alati Rosa.** Does depression experienced by mothers leads to a decline in marital quality: A 21 year longitudinal study. *SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY* 2014 [49(1): 121 132]

**Nawaratna S. S., Gobert G. N., Willis C., Chuah C., McManus D. P. and Jones M. K.** Transcriptional profiling of the oesophageal gland region of male worms of *Schistosoma mansoni*. *MOL BIOCHEM PARASITOL* 2014 [196(2): 82 9]

**Neale R. E., Clark P. J., Fawcett J., Fritschi L., Nagler B. N., Risch H. A., Walters R. J., Crawford W. J., Webb P. M., Whiteman D. C. and Buchanan D. D.** Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer. *CANCER EPIDEMIOLOGY* 2014 [38(5): 576 82]

**Neill A. S., Ibiebele T. I., Lahmann P. H., Hughes M. C., Nagle C. M., Webb P. M., Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group** Dietary phyto oestrogens and the risk of ovarian and endometrial cancers: findings from two Australian case control studies. *THE BRITISH JOURNAL OF NUTRITION* 2014 [111(8): 1430 40]

**Neller MA, Santner Nanan B, Brennan RM, Hsu P, Joung S, Nanan R, Burrows SR, Miles JJ.** Multivariate Analysis Using High Definition Flow Cytometry Reveals Distinct T Cell Repertoires between the Fetal Maternal Interface and the Peripheral Blood. *FRONT IMMUNOL.* 2014 [5:]

**Neller, M.A., Ladell, K., McLaren, J.E., Matthews, K.K., Gostick, E., Pentier, J.M., Dolton, G., Schauenburg, A.J.A., Koning, D., Costa, A.I.C.A.F., Venturi, V., Smith, C., Khanna, R., Miners, K.L., Clement, M., Wooldridge, L., Cole, D.K., Baarle, D., Sewell, A.K., Burrows, S.R., Price, D.A. and Miles, J.J.** Naive CD8+ Ag specific T cell precursors display structured TCR repertoires and antigen driven selection dynamics. *IMMUNOL CELL BIOL.* 2015

**Nelson E. C., Lynskey M. T., Heath A. C., Wray N., Agrawal A., Shand F. L., Henders A. K., Wallace L., Todorov A. A., Schrage A. J., Madden P. A., Degenhardt L., Martin N. G. and Montgomery G. W.** Association of OPRD1 polymorphisms with heroin dependence in a large case control series. *ADDICTION BIOLOGY* 2014 [19(1): 111 121]

**Nelson EC Heath AC, Lynskey MT, Agrawal A, Henders AK, Bowdler LM, Todorov AA, Madden PA, Moore E, Degenhardt L, Martin NG, Montgomery GW.** PTSD risk associated with a functional DRD2 polymorphism in heroin dependent cases and controls is limited to amphetamine dependent individuals. *ADDICTION BIOLOGY* 2014 [19(4): 700 707]

**Nguyen, V. T. Breakspear, M. Cunnington, R.** Reciprocal interactions of the SMA and cingulate cortex sustain premovement activity for voluntary actions. *J NEUROSCI* 2014 [34(49): 16397 407]

**Ni X. W., McManus D. P., Lou Z. Z., Yang J. F., Yan H. B., Li L., Li H. M., Liu Q. Y., Li C. H., Shi W. G., Fan Y. L., Liu X., Cai J. Z., Lei M. T., Fu B. Q., Yang Y. R. and Jia W. Z.** A comparison of loop mediated isothermal amplification (LAMP) with other surveillance tools for *Echinococcus granulosus* diagnosis in canine definitive hosts. *PLOS ONE* 2014 [9(7): e100877]

**Ni X, McManus DP, Yan H, Yang J, Lou Z, Li H, Li L, Lei M, Cai J, Fan Y, Li C, Liu Q, Shi W, Liu X, Zheng Y, Fu B, Yang Y1, Jia W.** Loop mediated isothermal amplification (LAMP) assay for the identification of *Echinococcus multilocularis* infections in canine definitive hosts. *PARASIT VECTORS* 2014 [7: 254]

**Nivarthi, U.K., Gras, S., Kjer Nielsen, L., Berry, R., Lucet, I.S., Miles, J.J., Tracy, S.L., Purcell, A.W., Bowden, D.S., Hellard, M., Rossjohn, J., McCluskey, J. and Bharadwaj M.** An Extensive Antigenic Footprint Underpins Immunodominant TCR Adaptability against a Hypervariable Viral Determinant. *J IMMUNOL.* 2014 [193(11): 5402 13]

**Noel S. E., Stoneham A. C., Olsen C. M., Rhodes L. E. and Green A. C.** Consumption of omega 3 fatty acids and the risk of skin cancers: a systematic review and meta analysis. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [135(1): 149 56]

**Nones K., Waddell N., Wayte N., Patch A. M., Bailey P., Newell F., Holmes O., Fink J. L., Quinn M. C., Tang Y. H., Lampe G., Quek K., Loffler K. A., Manning S., Idrisoglu S., Miller D., Xu Q., Waddell N., Wilson P. J., Bruxner T. J., Christ A. N., Harliwong I., Nourse C., Nourbakhsh E., Anderson M., Kazakoff S., Leonard C., Wood S., Simpson P. T., Reid L. E., Krause L., Hussey D. J., Watson D. I., Lord R. V., Nancarrow D., Phillips W. A., Gotley D., Smithers B. M., Whiteman D. C., Hayward N. K., Campbell P. J., Pearson J. V., Grimmond S. M. and Barbour A. P.** Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. *NATURE COMMUNICATIONS* 2014 [5: 5224]

**Ogbourne S. M. and Parsons P. G.** The value of nature's natural product library for the discovery of New Chemical Entities: the discovery of ingenol mebutate. *FITOTERAPIA* 2014 [98: 36 44]

**Oh G Wang SC, Pal M, Chen ZF, Khare T, Tochigi M, Ng C, Yang YA, Kwan A, Kaminsky ZA, Mill J, Gunasinghe C, Tackett JL, Gottesman II, Willemsen G, de Geus EJ, Vink JM, Slagboom PE, Wray NR, Heath AC, Montgomery GW, Turecki G, Martin NG, Boomsma DI, McGuffin P, Kustra R, Petronis A.** DNA Modification Study of Major Depressive Disorder: Beyond Locus by Locus Comparisons. *BIOLOGICAL PSYCHIATRY* 2014 [77(3): 246 255]

**Olsen C. M., Knight L. L. and Green A. C.** Risk of melanoma in people with HIV/AIDS in the pre and post HAART eras: a systematic review and meta analysis of cohort studies. *PLOS ONE* 2014 [9(4): e95096]

**Olsen C. M., Williams P. F. and Whiteman D. C.** Turning the tide? Changes in treatment rates for keratinocyte cancers in Australia 2000 through 2011. *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY* 2014 [71(1): 21 6]

**Olsen C. M., Neale R. E., Green A. C., Webb P. M., the QSkin Study, the Epigene Study and Whiteman D. C.** Independent Validation of Six Melanoma Risk Prediction Models. *THE JOURNAL OF INVESTIGATIVE DERMATOLOGY* 2014 [135(5): 1377 84]

**Olveda D. U., Olveda R. M., McManus D. P., Cai P., Chau T. N., Lam A. K., Li Y., Harn D. A., Vinluan M. L. and Ross A. G.** The chronic enteropathogenic disease schistosomiasis. *INT J INFECT DIS* 2014 [28: 193 203]

**Olveda D. U., Olveda R. M., Montes C. J., Chy D., Abellera J. M., 3rd, Cuajunco D., Lam A. K., McManus D. P., Li Y. and Ross A. G.** Clinical management of advanced schistosomiasis: a case of portal vein thrombosis induced splenomegaly requiring surgery. *BMJ CASE REP* 2014 [2014:]

**Olveda DU, Li Y, Olveda RM, Lam AK, McManus DP, Chau TN, Harn DA, Williams GM, Gray DJ, Ross AG8.** Bilharzia in the Philippines: past, present, and future. *INT J INFECT DIS.* 2014 [18: 52 56]

**Osorio A., Milne R. L., Kuchenbaecker K., Vaclova T., Pita G., Alonso R., Peterlongo P., Blanco I., de la Hoya M., Duran M., Diez O., Ramon Y. Cajal T., Konstantopoulou I., Martinez Bouzas C., Andres Conejero R., Soucy P., McGuffog L., Barrowdale D., Lee A., Swe Brca, Arver B., Rantala J., Loman N., Ehrencrona H., Olopade O. I., Beattie M. S., Domchek S. M., Nathanson K., Rebbeck T. R., Arun B. K., Karlan B. Y., Walsh C., Lester J., John E. M., Whittemore A. S., Daly M. B., Southey M., Hopper J., Terry M. B., Buys S. S., Janavicius R., Dorfling C. M., van Rensburg E. J., Steele L., Neuhausen S. L., Ding Y. C., Hansen T. V., Jonson L., Ejlersen B., Gerdes A. M., Infante M., Herraes B., Moreno L. T., Weitzel J. N., Herzog J., Weeman K., Manoukian S., Peissel B., Zaffaroni D., Scuvera G., Bonanni B., Mariette**

**F., Volorio S., Viel A., Varesco L., Papi L., Ottini L., Tibiletti M. G., Radice P., Yannoukakos D., Garber J., Ellis S., Frost D., Platte R., Fineberg E., Evans G., Lalloo F., Izatt L., Eeles R., Adlard J., Davidson R., Cole T., Eccles D., Cook J., Hodgson S., Brewer C., Tischkowitz M., Douglas F., Porteous M., Side L., Walker L., Morrison P., Donaldson A., Kennedy J., Foo C., Godwin A. K., Schmutzler R. K., Wappenschmidt B., Rhiem K., Engel C., Meindl A., Ditsch N., Arnold N., Plendl H. J., Niederacher D., Sutter C., Wang Gohrke S., Steinemann D., Preisler Adams S., Kast K., Varon Mateeva R., Gehrigh A., Stoppa Lyonnet D., Sinilnikova O. M., Mazoyer S., Damiola F., Poppe B., Claes K., Piedmonte M., Tucker K., Backes F., Rodriguez G., Brewster W., Wakeley K., Rutherford T., Caldes T., Nevanlinna H., Aittomaki K., Rookus M. A., van Os T. A., van der Kolk L., de Lange J. L., Meijers Heijboer H. E., van der Hout A. H., van Asperen C. J., Gomez Garcia E. B., Hoogerbrugge N., Collee J. M., van Deurzen C. H., van der Luijt R. B., Devilee P., Hebon, Olah E., Lazaro C., Teule A., Menendez M., Jakubowska A., Cybulski C., Gronwald J., Lubinski J., Durda K., Jaworska Bieniek K., Johannsson O. T., Maugard C., Montagna M., Tognazzo S., Teixeira M. R., Healey S., Investigators K., Olswold C., Guidugli L., Lindor N., Slager S., Szabo C. I., Vijai J., Robson M., Kauff N., Zhang L., Rau Murthy R., Fink Retter A., Singer C. F., Rappaport C., Geschwantler Kaulich D., Pfeiler G., Tea M. K., Berger A., Phelan C. M., Greene M. H., Mai P. L., Lejbkowitz F., Andrulis I., Mulligan A. M., Glendon G., Toland A. E., Bojesen A., Pedersen I. S., Sunde L., Thomassen M., Kruse T. A., Jensen U. B., Friedman E., Laitman Y., Shimon S. P., Simard J., Easton D. F., Offit K., Couch F. J., Chenevix Trench G., Antoniou A. C. and Benitez J.** DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLOS GENETICS* 2014 [10(4): e1004256]

**P. M. SWE, S. L. REYNOLDS & K. FISCHER.** Parasitic scabies mites and associated bacteria joining forces against host complement defence. *PARASITE IMMUNOLOGY* 2014 [36: 585 593]



**Pahau Helen, Brown Matthew A., Paul Sanjoy, Thomas Ranjeny and Videm Vibeke.** Cardiovascular disease is increased prior to onset of rheumatoid arthritis but not osteoarthritis: the population based Nord Trondelag health study (HUNT). *ARTHRITIS RESEARCH & THERAPY* 2014 [16(2): R85]

**Painter JN O'Mara TA, Batra J, Cheng T, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS, Kaufmann S, Hillman KM, Walpole C, Moya L, Pollock P, Jones A, Howarth K, Martin L, Gorman M, Hodgson S; National Study of Endometrial Cancer Genetics Group (NSECG); CHIBCHA Consortium, de Polanco MM, Sans M, Carracedo A, Castellvi Bel S, Rojas Martinez A, Santos E, Teixeira MR, Carvajal Carmona L, Shu XO, Long J, Zheng W, Xiang YB; The Australian National Endometrial Cancer Study Group (ANECs), Montgomery GW, Webb PM, Scott RJ, McEvoy M, Attia J, Holliday E, Martin NG, Nyholt DR, Henders AK, Fasching PA, Hein A, Beckmann MW, Renner SP, Dörk T, Hillemanns P, Dürst M, Runnebaum I, Lambrechts D, Coenegrachts L, Schrauwen S, Amant F, Winterhoff B, Dowdy SC, Goode EL, Teoman A, Salvesen HB, Trovik J, Njolstad TS, Werner HM, Ashton K, Proietto T, Otton G, Tzortzatos G, Mints M, Tham E; RENDOCAS, Hall P, Czene K, Liu J, Li J, Hopper JL, Southey MC; Australian Ovarian Cancer Study (AOCS), Ekici AB, Ruebner M, Johnson N, Peto J, Burwinkel B, Marme F, Brenner H, Dieffenbach AK, Meindl A, Brauch H; The GENICA Network, Lindblom A, Depreeuw J, Moisse M, Chang Claude J, Rudolph A, Couch FJ, Olson JE, Giles GG, Bruinsma F, Cunningham JM, Fridley BL, Børresen Dale AL, Kristensen VN, Cox A, Swerdlow AJ, Orr N, Bolla MK, Wang Q, Weber RP, Chen Z, Shah M, French JD, Pharoah PD, Dunning AM, Tomlinson I, Easton DF, Edwards SL, Thompson DJ, Spurdle AB.** Fine mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. *HUMAN MOLECULAR GENETICS* 2014 [24(5): 1478 1492]

**Painter J. N., Nyholt D. R., Krause L., Zhao Z. Z., Chapman B., Zhang C., Medland S., Martin N. G., Kennedy S., Treloar S., Zondervan K. and**

**Montgomery G. W.** Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis. *FERTILITY AND STERILITY* 2014 [102(2): 496 502]

**Palles C., Chegwiddden L., Li X., Findlay J. M., Farnham G., Castro Giner F., Peppelenbosch M. P., Kovac M., Adams C. L., Prenen H., Briggs S., Harrison R., Sanders S., MacDonald D., Haigh C., Tucker A., Love S., Nanji M., deCaestecker J., Ferry D., Rathbone B., Hapeshi J., Barr H., Moayyedi P., Watson P., Zietek B., Maroo N., Gay L., Underwood T., Boulter L., McMurtry H., Monk D., Patel P., Ragnunath K., Al Dulaimi D., Murray I., Koss K., Veitch A., Trudgill N., Nwokolo C., Rembacken B., Atherfold P., Green E., Ang Y., Kuipers E. J., Chow W., Paterson S., Kadri S., Beales I., Grimley C., Mullins P., Beckett C., Farrant M., Dixon A., Kelly S., Johnson M., Wajed S., Dhar A., Sawyer E., Roylance R., Onstad L., Gammon M. D., Corley D. A., Shaheen N. J., Bird N. C., Hardie L. J., Reid B. J., Ye W., Liu G., Romero Y., Bernstein L., Wu A. H., Casson A. G., Fitzgerald R., Whiteman D. C., Risch H. A., Levine D. M., Vaughan T. L., Verhaar A. P., van den Brande J., Toxopeus E. L., Spaander M. C., Wijnhoven B. P., van der Laan L. J., Krishnadath K., Wijmenga C., Trynka G., McManus R., Reynolds J. V., O'Sullivan J., MacMathuna P., McGarrigle S. A., Kelleher D., Vermeire S., Cleynen I., Bisschops R., Tomlinson I. and Jankowski J.** Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. *GASTROENTEROLOGY* 2014 [148(2): 367 78]

**Palmer E., Newcombe R. G., Green A. C., Kelly C., Noel Gill O., Hall G., Fiander A. N., Pirotte E., Hibbitts S. J., Homer J. and Powell N. G.** Human papillomavirus infection is rare in nonmalignant tonsil tissue in the UK: Implications for tonsil cancer precursor lesions. *INTERNATIONAL JOURNAL OF CANCER* 2014 [135(10): 2437 43]

**Pan W. J., Kock K., Rees W. A., Sullivan B. A., Evangelista C. M., Yen M., Andrews J. M., Radford Smith G. L., Prince P. J., Reynhardt K. O., Doherty D. R., Patel S. K., Krill C. D., Zhou K. F., Shen J., Smith**

**L. E., Gow J. M., Lee J., Treacy A. M., Yu Z. G., Platt V. M. and Borie D. C.** Clinical pharmacology of AMG 181, a gut specific human anti alpha(4) beta(7) monoclonal antibody, for treating inflammatory bowel diseases. *BRITISH JOURNAL OF CLINICAL PHARMACOLOGY* 2014 [78(6): 1315 1333]

**Panizza B., Warren T. A., Solares C. A., Boyle G. M., Lambie D. and Brown I.** Histopathological features of clinical perineural invasion of cutaneous squamous cell carcinoma of the head and neck and the potential implications for treatment. *HEAD & NECK* 2014 [36(11): 1611 8]

**Papier K., Williams G. M., Luceres Catubig R., Ahmed F., Olveda R. M., McManus D. P., Chy D., Chau T. N., Gray D. J. and Ross A. G.** Childhood malnutrition and parasitic helminth interactions. *CLIN INFECT DIS* 2014 [59(2): 234 43]

**Papier K., Ahmed F., Lee P. and Wiseman J.** Stress and dietary behaviour among first year university students in Australia: sex differences. *NUTRITION* 2014 [31(2): 324 30]

**Parnell G. P., Gatt P. N., McKay F. C., Schibeci S., Krupa M., Powell J. E., Visscher P. M., Montgomery G. W., Lechner Scott J., Broadley S., Liddle C., Slee M., Vucic S., Stewart G. J. and Booth D. R.** Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. *MULTIPLE SCLEROSIS* 2014 [20(6): 675 85]

**Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S.** Epigenetic Reprogramming of HOXC10 in Endocrine Resistant Breast Cancer. *SCIENCE TRANSLATIONAL MEDICINE* 2014 [6(229): 229ra41]

**Paul Richard, Sousa Carla, Sakuntabhai Anavaj and Devine Gregor.** Mosquito control might not bolster imperfect dengue vaccines. *LANCET* 2014 [384(9956): 1747 1748]

**Paul Sanjoy, Klein Kerenaftali, Majeed Azeem and Khunti Kamlesh.** Longitudinal profiles of blood pressure, lipids and HbA1c and their association with vascular and mortality risks in patients with T2DM under cardioprotective medications. *DIABETES 2014 [63(Supplement 1): A347]*

**Paul S, Klein K, Shaw J. W and Best J. H.** Glycemic control and long term vascular risks in patients treated with insulin and incretin based therapy. *DIABETES 2014 [63(Supplement 1): A343 A425]*

**Paul, S. K., Maggs, D., Klein, K., Best, J. H.** Dynamic risk factors associated with non severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly. *JOURNAL OF DIABETES 2014 [:]*

**Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, Khanna R.** Epstein Barr virus specific adoptive immunotherapy for progressive multiple sclerosis. *MULT. SCLEROSIS 2014 [20(11): 1541 4]*

**Pender MP, Burrows SR.** Epstein Barr virus and multiple sclerosis: potential opportunities for immunotherapy. *CLIN TRANSL IMMUNOLOGY. 2014 [3(10):]*

**Pender MP, Csurhes PA, Pfluger CM, Burrows SR.** Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis. *MULT SCLER. 2014 [20(14): 1825 32]*

**Pereira D. I., Brugggraber S. F., Faria N., Poots L. K., Tagmount M. A., Aslam M. F., Frazer D. M., Vulpe C. D., Anderson G. J. and Powell J. J.** Nanoparticulate iron(III) oxo hydroxide delivers safe iron that is well absorbed and utilised in humans. *NANOMEDICINE 2014 [10(8): 1877 86]*

**Perry JR Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, He C, Chasman DI, Esko T, Thorleifsson G, Albrecht E, Ang WQ, Corre T, Cousminer DL, Feenstra B, Franceschini N, Ganna A, Johnson AD, Kjellqvist S, Lunetta KL, McMahon G, Nolte IM, Paternoster L, Porcu E, Smith AV, Stolk L, Teumer A, Tšernikova N, Tikkanen E, Ulivi S, Wagner EK, Amin N, Bierut LJ, Byrne**

**EM, Hottenga JJ, Koller DL, Mangino M, Pers TH, Yerges Armstrong LM, Hua Zhao J, Andrusis IL, Anton Culver H, Atsma F, Bandinelli S, Beckmann MW, Benitez J, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Buring JE, Chang Claude J, Chanock S, Chen J, Chenevix Trench G, Collée JM, Couch FJ, Couper D, Coviello AD, Cox A, Czene K, D'adamo AP, Davey Smith G, De Vivo I, Demerath EW, Dennis J, Devilee P, Dieffenbach AK, Dunning AM, Eiriksdottir G, Eriksson JG, Fasching PA, Ferrucci L, Flesch Janys D, Flyger H, Foroud T, Franke L, Garcia ME, Garcia Closas M, Geller F, de Geus EE, Giles GG, Gudbjartsson DF, Gudnason V, Guénel P, Guo S, Hall P, Hamann U, Haring R, Hartman CA, Heath AC, Hofman A, Hooning MJ, Hopper JL, Hu FB, Hunter DJ, Karasik D, Kiel DP, Knight JA, Kosma VM, Kutalik Z, Lai S, Lambrechts D, Lindblom A, Mägi R, Magnusson PK, Mannermaa A, Martin NG, Masson G, McArdle PF, McArdle WL, Melbye M, Michailidou K, Mihailov E, Milani L, Milne RL, Nevanlinna H, Neven P, Nohr EA, Oldehinkel AJ, Oostra BA, Palotie A, Peacock M, Pedersen NL, Peterlongo P, Peto J, Pharoah PD, Postma DS, Pouta A, Pykäs K, Radice P, Ring S, Rivadeneira F, Robino A, Rose LM, Rudolph A, Salomaa V, Sanna S, Schlessinger D, Schmidt MK, Southey MC, Sovio U, Stampfer MJ, Stöckl D, Stortiolo AM, Timpson NJ, Tyrer J, Visser JA, Vollenweider P, Völzke H, Waeber G, Waldenberger M, Wallaschofski H, Wang Q, Willemsen G, Winqvist R, Wolffenbuttel BH, Wright MJ; Australian Ovarian Cancer Study; The GENICA Network; kConFab; The LifeLines Cohort Study; The InterAct Consortium; Early Growth Genetics (EGG) Consortium, Boomsma DI, Econs MJ, Khaw KT, Loos RJ, McCarthy MI, Montgomery GW, Rice JP, Streeten EA, Thorsteinsdottir U, van Duijn CM, Alizadeh BZ, Bergmann S, Boerwinkle E, Boyd HA, Crisponi L, Gasparini P, Gieger C, Harris TB, Ingelsson E, Järvelin MR, Kraft P, Lawlor D, Metspalu A, Pennell CE, Ridker PM, Snieder H, Sørensen TI, Spector TD, Strachan DP, Uitterlinden AG, Wareham NJ, Widen E, Zygumt M, Murray A, Easton DF, Stefansson K, Murabito JM, Ong KK.** Parent of origin specific

allelic associations among 106 genomic loci for age at menarche. *NATURE 2014 [514(7520): 92 97]*

**Perry J. R., Hsu Y. H., Chasman D. I., Johnson A. D., Elks C., Albrecht E., Andrusis I. L., Beesley J., Berenson G. S., Bergmann S., Bojesen S. E., Bolla M. K., Brown J., Buring J. E., Campbell H., Chang Claude J., Chenevix Trench G., Corre T., Couch F. J., Cox A., Czene K., D'Adamo A P., Davies G., Deary I. J., Dennis J., Easton D. F., Engelhardt E. G., Eriksson J. G., Esko T., Fasching P. A., Figueroa J. D., Flyger H., Fraser A., Garcia Closas M., Gasparini P., Gieger C., Giles G., Guenel P., Hagg S., Hall P., Hayward C., Hopper J., Ingelsson E., Kardia S. L., Kasiman K., Knight J. A., Lahti J., Lawlor D. A., Magnusson P. K., Margolin S., Marsh J. A., Metspalu A., Olson J. E., Pennell C. E., Polasek O., Rahman I., Ridker P. M., Robino A., Rudan I., Rudolph A., Salumets A., Schmidt M. K., Schoemaker M. J., Smith E. N., Smith J. A., Southey M., Stockl D., Swerdlow A. J., Thompson D. J., Truong T., Ulivi S., Waldenberger M., Wang Q., Wild S., Wilson J. F., Wright A. F., Zgaga L., Ong K. K., Murabito J. M., Karasik D. and Murray A.** DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. *HUMAN MOLECULAR GENETICS 2014 [23(9): 2490 7]*

**Peterlongo P., Chang Claude J., Moysich K. B., Rudolph A., Schmutzler R. K., Simard J., Soucy P., Eeles R. A., Easton D. F., Hamann U., Wilkening S., Chen B., Rookus M. A., Schmidt M. K., van der Baan F. H., Spurdle A. B., Walker L. C., Lose F., Maia A. T., Montagna M., Matricardi L., Lubinski J., Jakubowska A., Gomez Garcia E. B., Olopade O. I., Nussbaum R. L., Nathanson K. L., Domchek S. M., Rebbeck T. R., Arun B. K., Karlan B. Y., Orsulic S., Lester J., Chung W. K., Miron A., Southey M. C., Goldgar D. E., Buys S. S., Janavicius R., Dorfling C. M., van Rensburg E. J., Ding Y. C., Neuhausen S. L., Hansen T. V., Gerdes A. M., Ejlertsen B., Jonson L., Osorio A., Martinez Bouzas C., Benitez J., Conway E. E., Blazer K. R., Weitzel J. N., Manoukian S., Peissel B., Zaffaroni D., Scuvera G., Barile M., Ficarazzi F., Mariette F., Fortuzzi S., Viel A., Giannini G., Papi**

- L., Martayan A., Tibiletti M. G., Radice P., Vratimos A., Fostira F., Garber J. E., Donaldson A., Brewer C., Foo C., Evans D. G., Frost D., Eccles D., Brady A., Cook J., Tischkowitz M., Adlard J., Barwell J., Walker L., Izatt L., Side L. E., Kennedy M. J., Rogers M. T., Porteous M. E., Morrison P. J., Platte R., Davidson R., Hodgson S. V., Ellis S., Cole T., Godwin A. K., Claes K., Van Maerken T., Meindl A., Gehrig A., Sutter C., Engel C., Niederacher D., Steinemann D., Plendl H., Kast K., Rhiem K., Ditsch N., Arnold N., Varon Mateeva R., Wappenschmidt B., Wang Gohrke S., Bressac de Paillerets B., Buecher B., Delnatte C., Houdayer C., Stoppa Lyonnet D., Damiola F., Coupier I., Barjhoux L., Venat Bouvet L., Golmard L., Boutry Kryza N., Sinilnikova O. M., Caron O., Pujol P., Mazoyer S., Belotti M., Piedmonte M., Friedlander M. L., Rodriguez G. C., Copeland L. J., de la Hoya M., Segura P. P., Nevanlinna H., Aittomaki K., van Os T. A., Meijers Heijboer H. E., van der Hout A. H., Vreeswijk M. P., Hoogerbrugge N., Ausems M. G., van Doorn H. C., Collee J. M., Olah E., Diez O., Blanco I., Lazaro C., Brunet J., Feliubadalo L., Cybulski C., Gronwald J., Durda K., Jaworska Bieniek K., Sukiennicki G., Arason A., Chiquette J., Teixeira M. R., Olswold C., Couch F. J., Lindor N. M., Wang X., Szabo C. I., Offit K., Corines M., Jacobs L., Robson M. E., Zhang L., Joseph V., Berger A., Singer C. F., Rappaport C., Kaulich D. G., Pfeiler G., Tea M. K., Phelan C. M., Greene M. H., Mai P. L., Rennert G., Mulligan A. M., Glendon G., Tchatchou S., Andrulis I. L., Toland A. E., Bojesen A., Pedersen I. S., Thomassen M., Jensen U. B., Laitman Y., Rantala J., von Wachenfeldt A., Ehrencrona H., Askmal M. S., Borg A., Kuchenbaecker K. B., McGuffog L., Barrowdale D., Healey S., Lee A., Pharoah P. D., Chenevix Trench G., Antoniou A. C. and Friedman E. Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION : A PUBLICATION OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, COSPONSORED BY THE AMERICAN SOCIETY OF PREVENTIVE ONCOLOGY* 2014 [24(1): 308 16]
- Peeverill W., Powell L. W. and Skoien R.** Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES* 2014 [15(5): 8591 638]
- Phipps Green A. J., Merriman M. E., Topless R., Altaf S., Montgomery G. W., Franklin C., Jones G. T., van Rij A. M., White D., Stamp L. K., Dalbeth N. and Merriman T. R.** Twenty eight loci that influence serum urate levels: analysis of association with gout. *ANNALS OF THE RHEUMATIC DISEASES* 2014 [:]
- Piper M, Barry G, Harvey TJ, McLeay H, Smith AG, Harris L, Mason S, Stringer BW, Day BW, Wray NR, Gronostajski RM, Bailey TL, Boyd AW, Richards LJ.** NFIB mediated repression of the epigenetic regulator Ezh2 promotes cortical development. *J NEUROSCI* 2014 [34(8): 2921 30]
- Plieskatt J, Rinaldi G, Brindley PJ Jia X, Potriquet J, Bethony J. Mulvenna J** Bioclojure: a functional library for the manipulation of biological sequences. *BIOINFORMATICS* 2014 [30(17): 2537 9]
- Plieskatt JL Rinaldi G, Feng Y, Levine PH, Easley S, Martinez E, Hashmi S, Sadeghi N, Brindley PJ Bethony JM Mulvenna JP.** Methods and matrices: approaches to identifying miRNAs for nasopharyngeal carcinoma. *J TRANSL MED.* 2014 [6(12): 3]
- Plieskatt JL, Feng Y, Rinaldi G, Mulvenna JP, Bethony JM, Brindley PJ1.** Circumventing qPCR inhibition to amplify miRNAs in plasma. *BIOMARK RES* 2014 [2(13)::]
- Plieskatt JL, Rinaldi G, Feng Y, Peng J Yonglithipagon P, Easley S, Laha T, Pairojkul C, Bhudhisawasdi V, Sripa B Brindley PJ, Mulvenna JP, Bethony JM.** Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke *Opisthorchis viverrini*. *J HEPATOL.* 2014 [61(4): 850 8]
- Plug E, Webbink D, Martin NG.** Sexual Orientation, Prejudice and Segregation. *JOURNAL OF LABOR ECONOMICS* 2014 [32(1): 123 159]
- Poo Y. S., Rudd P. A., Gardner J., Wilson J. A., Larcher T., Colle M. A., Le T. T., Nakaya H. I., Warrilow D., Allcock R., Bielefeldt Ohmann H., Schroder W. A., Khromykh A. A., Lopez J. A. and Suhrbier A.** Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. *PLOS NEGL TROP DIS* 2014 [8(12): e3354]
- Poo Y. S., Nakaya H., Gardner J., Larcher T., Schroder W. A., Le T. T., Major L. D. and Suhrbier A.** CCR2 deficiency promotes exacerbated chronic erosive neutrophil dominated chikungunya virus arthritis. *J VIROL* 2014 [88(12): 6862 72]
- Poon I. K., Goodall K. J., Phipps S., Chow J. D., Pagler E. B., Andrews D. M., Conlan C. L., Ryan G. F., White J. A., Wong M. K., Horan C., Matthaei K. I., Smyth M. J. and Hulett M. D.** Mice deficient in heparanase exhibit impaired dendritic cell migration and reduced airway inflammation. *EUROPEAN JOURNAL OF IMMUNOLOGY* 2014 [44(4): 1016 30]
- Powell, T. Y., Boonstra, T. W. Martin, D. M., Loo, C. K., Breakspear, M.** Modulation of cortical activity by transcranial direct current stimulation in patients with affective disorder. *PLOS ONE* 2014 [9(6): e98503]
- Power RA Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, Madden PA, Medland SE, Wray NR, Martin NG.** Genetic predisposition to schizophrenia associated with increased use of cannabis. *MOLECULAR PSYCHIATRY* 2014 [19(11): 1201 1204]
- Prakoso E., Tirnitz Parker J. E., Clouston A. D., Kayali Z., Lee A., Gan E. K., Ramm G. A., Kench J. G., Bowen D. G., Olynyk J. K., McCaughan G. W. and Shackel N. A.** Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation. *LIVER TRANSPLANTATION: OFFICIAL PUBLICATION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES AND THE INTERNATIONAL LIVER TRANSPLANTATION SOCIETY* 2014 [20(12): 1508 19]

**Prasad G Joshi SH, Jahanshad N, Villalon Reina J, Aganj I, Lenglet C, Sapiro G, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Toga AW, Thompson PM.** Automatic Clustering and Population Analysis of White Matter Tracts using Maximum Density Paths. *NEUROIMAGE* 2014 [97C: 284 295]

**Pritchard A. L., White O. J., Burel J. G., Carroll M. L., Phipps S. and Upham J. W.** Asthma is associated with multiple alterations in anti viral innate signalling pathways. *PLOS ONE* 2014 [9(9): e106501]

**Proietti C., Doolan, D. L.** The case for a rational genome based vaccine against malaria. *FRONT MICROBIOL* 2014 [5: 741]

**Purrington K. S., Slettedahl S., Bolla M. K., Michailidou K., Czene K., Nevanlinna H., Bojesen S. E., Andrulis I. L., Cox A., Hall P., Carpenter J., Yannoukakos D., Haiman C. A., Fasching P. A., Mannermaa A., Winqvist R., Brenner H., Lindblom A., Chenevix Trench G., Benitez J., Swerdlow A., Kristensen V., Guenel P., Meindl A., Darabi H., Eriksson M., Fagerholm R., Aittomäki K., Blomqvist C., Nordestgaard B. G., Nielsen S. F., Flyger H., Wang X., Olswood C., Olson J. E., Mulligan A. M., Knight J. A., Tchatchou S., Reed M. W., Cross S. S., Liu J., Li J., Humphreys K., Clarke C., Scott R., Fostira F., Fountzilas G., Konstantopoulou I., Henderson B. E., Schumacher F., Le Marchand L., Ekici A. B., Hartmann A., Beckmann M. W., Hartikainen J. M., Kosma V. M., Kataja V., Jukkola Vuorinen A., Pylkas K., Kauppila S., Dieffenbach A. K., Stegmaier C., Arndt V., Margolin S., Balleine R., Arias Perez J. I., Pilar Zamora M., Menendez P., Ashworth A., Jones M., Orr N., Arveux P., Kerbrat P., Truong T., Bugert P., Toland A. E., Ambrosone C. B., Labreche F., Goldberg M. S., Dumont M., Ziogas A., Lee E., Dite G. S., Apicella C., Southey M. C., Long J., Shrubsole M., Deming Halverson S., Ficarazzi F., Barile M., Peterlongo P., Durda K., Jaworska Bieniek K., Tollenaar R. A., Seynaeve C., Bruning T., Ko Y. D., Van Deurzen C. H., Martens J. W., Krieger M., Figueroa J. D., Chanock S. J., Lissowska J., Tomlinson I., Kerin M. J., Miller N., Schneeweiss A., Tapper W. J., Gerty**

**S. M., Durcan L., McLean C., Milne R. L., Baglietto L., dos Santos Silva I., Fletcher O., Johnson N., Van T. Veer L. J., Cornelissen S., Forsti A., Torres D., Rudiger T., Rudolph A., Flesch Jany D., Nickels S., Weltens C., Floris G., Moisse M., Dennis J., Wang Q., Dunning A. M., Shah M., Brown J., Simard J., Anton Culver H., Neuhausen S. L., Hopper J. L., Bogdanova N., Dork T., Zheng W., Radice P., Jakubowska A., Lubinski J., Devilee P., Brauch H., Hooning M., Garcia Closas M., Sawyer E., Burwinkel B., Marmee F., Eccles D. M., Giles G. G., Peto J., Schmidt M., Broeks A., Hamann U., Chang Claude J., Lambrechts D., Pharoah P. D., Easton D., Pankratz V. S., Slager S., Vachon C. M. and Couch F. J.** Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *HUMAN MOLECULAR GENETICS* 2014 [23(22): 6034 46]

**Purrington KS Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang Claude J, Martin NG, Montgomery GW, Kristensen V, Anton Culver H, Goodfellow P, Tapper WJ, Rafiq S, Gerty SM, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou P, Konstanta I, Kotoula V, Lakis S, Dimopoulos MA, Skarlos D, Pectasides D, Fountzilas G, Beckmann MW, Hein A, Ruebner M, Ekici AB, Hartmann A, Schulz Wendtland R, Renner SP, Janni W, Rack B, Scholz C, Neugebauer J, Andergassen U, Lux MP, Haeberle L, Clarke C, Pathmanathan N, Rudolph A, Flesch Jany D, Nickels S, Olson JE, Ingle JN, Olswood C, Slettedahl S, Eckel Passow JE, Anderson SK, Visscher DW, Cafourek V, Sicotte H, Prodduturi N, Weiderpass E, Bernstein L, Ziogas A, Ivanovich J, Giles GG, Baglietto L, Southey M, Kosma VM, Fischer HP, Network TG, Reed MW, Cross SS, Deming Halverson S, Shrubsole M, Cai Q, Shu XO, Daly M, Weaver J, Ross E, Klemp J, Sharma P, Torres D, Rüdiger T, Wölfing H, Ulmer HU, Försti A, Houry T, Kumar S, Pilarski R, Shapiro CL, Greco D, Heikkilä P, Aittomäki K, Blomqvist C, Irwanto A, Liu J, Pankratz VS, Wang X, Severi G, Mannermaa A, Easton D, Hall P, Brauch H, Cox A, Zheng W, Godwin AK, Hamann U, Ambrosone C, Toland AE, Nevanlinna H, Vachon**

**CM, Couch FJ.** Genome wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple negative breast cancer. *CARCINOGENESIS* 2014 [35(5): 1012 1019]

**Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M, Boyd AW and Rose S.** EphA2 as a Diagnostic Imaging Target in Glioblastoma: A PET/MRI Study. *MOLECULAR IMAGING* 2015 [:] **Puttick, S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M, BOYD AW, Rose S.** EphA2 as a Diagnostic Imaging Target in Glioblastoma: A PET/MRI Study. *MOLECULAR IMAGING* 2015 [in press:]

**Rahman M, Reyner K, Deleyrolle L, Millette S, Azari H, Day BW, Stringer BW, Boyd AW, Johns TG, Blot V, Duggal R, Reynolds B.** Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. 48:25 35; 2015. *ANAT. CELL BIOL.* 2014 [32(6): 254 264]

**Rahmioglu N., Macgregor S., Drong A. W., Hedman A. K., Harris H. R., Randall J. C., Prokopenko I., The International Endogene Consortium The Giant Consortium, Nyholt D. R., Morris A. P., Montgomery G. W., Missmer S. A., Lindgren C. M., Zondervan K. T. and The International Endogene Consortium I. E. C. The Giant Consortium.** Genome wide enrichment analysis between endometriosis and obesity related traits reveals novel susceptibility loci. *HUMAN MOLECULAR GENETICS* 2014 [24(4): 1185 99]

**Rahmioglu N., Nyholt D. R., Morris A. P., Missmer S. A., Montgomery G. W. and Zondervan K. T.** Genetic variants underlying risk of endometriosis: insights from meta analysis of eight genome wide association and replication datasets. *HUMAN REPRODUCTION UPDATE* 2014 [20(5): 702 16]

- Rakic AD, Bertling K, Lim YL, Wilson SJ, Nikolic M, Taimre T, Indjin D, Valavanis A, Linfield EH, Giles Davies A, Walker GJ, Ferguson B, Prow TW, Schaidler H, Soyer HP.** Biomedical applications of terahertz self mixing interferometry. Published in. *TERAHERTZ EMITTERS, RECEIVERS, AND APPLICATIONS V. HTTP://SPIE.ORG/X110285.XML. 2014*
- Ramsbottom K. M., Hawkins E. D., Shimoni R., McGrath M., Chan C. J., Russell S. M., Smyth M. J. and Oliaro J.** Cutting edge: DNAX accessory molecule 1 deficient CD8+ T cells display immunological synapse defects that impair antitumor immunity. *JOURNAL OF IMMUNOLOGY 2014 [192(2): 553 7]*
- Ranzani M., Alifrangis C., Perna D., Dutton Register K., Pritchard A., Wong K., Rashid M., Robles Espinoza C. D., Hayward N. K., McDermott U., Garnett M. and Adams D. J.** BRAF/NRAS wild type melanoma, NF1 status and sensitivity to trametinib. *PIGMENT CELL & MELANOMA RESEARCH 2014 [28(1): 117 9]*
- Rentería ME Hansell NK, Strike LT, McMahon KL, de Zubicaray GI, Hickie IB, Thompson PM, Martin NG, Medland SE, Wright MJ.** Genetic architecture of subcortical brain regions: common and region specific genetic contributions. *GENES, BRAIN, AND BEHAVIOR 2014 [13(8): 821 830]*
- Reynolds HV, Talekar CR, Bellapart J, Leggett BA, Boots RJ.** Copper removal strategies for Wilson's disease crisis in the ICU. *ANAESTH INTENSIVE CARE 2014 [42(2): 253 7]*
- Richmond Rakerd LS Slutske WS, Heath AC, Martin NG.** Genetic and Environmental Influences on the Ages of Drinking and Gambling Initiation: Evidence for Distinct Etiologies and Sex Differences. *ADDICTION 2014 [109(2): 323 331]*
- Rietschel L Zhu G, Kirschbaum C, Strohmaier J, Wust S, Rietschel M, Martin NG.** Perceived Stress has Genetic Influences Distinct from Neuroticism and Depression. *BEHAVIOR GENETICS 2014 [44(6): 639 645]*
- Rietveld C. A., Conley D., Eriksson N., Esko T., Medland S. E., Vinkhuyzen A. A., Yang J., Boardman J. D., Chabris C. F., Dawes C. T., Domingue B. W., Hinds D. A., Johannesson M., Kiefer A. K., Laibson D., Magnusson P. K., Mountain J. L., Oskarsson S., Rostapshova O., Teumer A., Tung J. Y., Visscher P. M., Benjamin D. J., Cesarini D., Koellinger P. D. and Social Science Genetics Association Consortium.** Replicability and robustness of genome-wide association studies for behavioral traits. *PSYCHOLOGICAL SCIENCE 2014 [25(11): 1975 86]*
- Rietveld CA Esko T, Davies G, Pers TH, Turley P, Benyamin B, Chabris CF, Emilsson V, Johnson AD, Lee JJ, de Leeuw C, Marioni RE, Medland SE, Miller MB, Rostapshova O, van der Lee SJ, Vinkhuyzen AA, Amin N, Conley D, Derringer J, van Duijn CM, Fehrmann R, Franke L, Glaeser EL, Hansell NK, Hayward C, Iacono WG, Ibrahim Verbaas C, Jaddoe V, Karjalainen J, Laibson D, Lichtenstein P, Liewald DC, Magnusson PK, Martin NG, McGue M, McMahon G, Pedersen NL, Pinker S, Porteous DJ, Posthuma D, Rivadeneira F, Smith BH, Starr JM, Tiemeier H, Timpson NJ, Trzaskowski M, Uitterlinden AG, Verhulst FC, Ward ME, Wright MJ, Davey Smith G, Deary IJ, Johannesson M, Plomin R, Visscher PM, Benjamin DJ, Cesarini D, Koellinger PD.** Common genetic variants associated with cognitive performance identified using the proxy phenotype method. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2014 [111(38): 13790 13794]*
- Rist, M.J., Twist, K., Croft, N.P., Smith, C., Neller, M.A., Burrows, J.M., Sullivan, L.C., Theodossis, A., Brooks, A.G., Miles, J.J., Purcell, A.W., Rossjohn, J., Gras, S. and Burrows, S.R.** T cell cross reactivity between a highly immunogenic EBV epitope and a self peptide naturally presented by HLA B\*18:01+ cells. *J IMMUNOL. 2015*
- Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J; Australian Liver Association Clinical Research Network.** Distribution of interferon lambda 3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARLOT studies. *J GASTROENTEROL HEPATOL 2014 [29(1): 179 84]*
- Roberts R. L., Wallace M. C., Seinen M. L., Krishnaprasad K., Chew A., Lawrance I., Prosser R., Bampton P., Grafton R., Simms L., Radford Smith G., Andrews J. M. and Barclay M. L.** PACSIN2 Does Not Influence Thiopurine Related Toxicity In Patients With Inflammatory Bowel Disease. *AMERICAN JOURNAL OF GASTROENTEROLOGY 2014 [109(6): 925 927]*
- Roberts J. A., Paul S. K., Akova M., Bassetti M., De Waele J. J., Dimopoulos G., Kaukonen K. M., Koulenti D., Martin C., Montravers P., Rello J., Rhodes A., Starr T., Wallis S. C. and Lipman J.** DALL: defining antibiotic levels in intensive care unit patients: are current beta lactam antibiotic doses sufficient for critically ill patients? *CLINICAL INFECTIOUS DISEASES : AN OFFICIAL PUBLICATION OF THE INFECTIOUS DISEASES SOCIETY OF AMERICA 2014 [58(8): 1072 83]*
- Roberts, J. A. Iyer, K. K. Vanhatalo, S. Breakspear, M.** Critical role for resource constraints in neural models. *FRONT SYST NEUROSCI 2014 [8: 154]*
- Roberts, J. A. Iyer, K. K. Finnigan, S. Vanhatalo, S. Breakspear, M.** Scale free bursting in human cortex following hypoxia at birth. *J NEUROSCI 2014 [34(19): 6557 72]*
- Robinson E. B., Howrigan D., Yang J., Ripke S., Anttila V., Duncan L. E., Jostins L., Barrett J. C., Medland S. E., MacArthur D. G., Breen G., O'Donovan M. C., Wray N. R., Devlin B., Daly M. J., Visscher P. M., Sullivan P. F. and Neale B. M.** Response to 'Predicting the diagnosis of autism spectrum disorder using gene pathway analysis'. *MOLECULAR PSYCHIATRY 2014 [19(8): 859 61]*
- Robles Espinoza CD Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, Palmer JM, Symmons J, Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin NG, Liu JZ, Choi J, Makowski M, Brown KM,**

**Dunning AM, Keane TM, Lopez Otin C, Gruis NA, Hayward NK, Bishop DT, Newton Bishop JA, Adams DJ.** POT1 loss of function variants predispose to familial melanoma. *NATURE GENETICS* 2014 [46(5): 478 481]

**Robles Espinoza C. D., Velasco Herrera Mdel C., Hayward N. K. and Adams D. J.** Telomere regulating genes and the telomere interactome in familial cancers. *MOLECULAR CANCER RESEARCH: 2014* [13(2): 211 22]

**Rodero MP, Handoko HY, Villani RM, Walker GJ, Khosrotehrani K.** Differential effects of ultraviolet irradiation in neonatal versus adult mice are not explained by defective macrophage or neutrophil infiltration. *J INVEST DERMATOL.* 2014 [134(7): 1991 7]

**Rolfe B. E., Blakey I., Squires O., Peng H., Boase N. R., Alexander C., Parsons P. G., Boyle G. M., Whittaker A. K. and Thurecht K. J.** Multimodal polymer nanoparticles with combined 19F magnetic resonance and optical detection for tunable, targeted, multimodal imaging in vivo. *JOURNAL OF THE AMERICAN CHEMICAL SOCIETY* 2014 [136(6): 2413 9]

**Ross A. G., Olveda R. M., Chy D., Olveda D. U., Li Y., Harn D. A., Gray D. J., McManus D. P., Tallo V., Chau T. N. and Williams G. M.** Can mass drug administration lead to the sustainable control of schistosomiasis? *J INFECT DIS* 2014 [211(2): 283 9]

**Ross AG, Olveda RM, Li Y** An audacious goal: the elimination of schistosomiasis in our lifetime through mass drug administration. *LANCET* 2015 [385(9983): 2220 1]

**Rossjohn, J., Gras, S., Miles, J.J., Turner, S.J., Godfrey, D.I. and McCluskey, J.** Antigen Receptor Recognition of Antigen Presenting Molecules. *ANNU REV IMMUNOL.* 2014

**Roussotte FF Jahanshad N, Hibar DP, Sowell ER, Kohannim O, Barysheva M, Hansell NK, McMahon KL, de Zubicaray GI, Montgomery GW, Martin NG, Wright MJ, Toga AW, Jack CR Jr, Weiner MW, Thompson PM, and the ADNI** A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain

volumes: replication in elderly and young populations. *HUMAN BRAIN MAPPING* 2014 [35(4): 1226 1236]

**Rowlands I. J., Beesley V. L., Janda M., Hayes S. C., Obermair A., Quinn M. A., Brand A., Leung Y., McQuire L., Webb P. M. and Australian National Endometrial Cancer Study Group** Quality of life of women with lower limb swelling or lymphedema 3 5years following endometrial cancer. *GYNECOLOGIC ONCOLOGY* 2014 [133(22): 314 8]

**Rowlands IJ Lee C, Beesley VL, Webb PM on behalf of the Australian National Endometrial Cancer Study Group** Predictors of sexual wellbeing after endometrial cancer: Results of a national, self report survey. *SUPPORTIVE CARE IN CANCER : OFFICIAL JOURNAL OF THE MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER* 2014 [22(10): 2715 23]

**Roy, D., Sigala, R., Breakspear, M., McIntosh, A. R., Jirsa, V. K., Deco, G. Ritter, P.** Using the virtual brain to reveal the role of oscillations and plasticity in shaping brain's dynamical landscape. *BRAIN CONNECT* 2014 [4(10): 791 811]

**Rudolph A., Milne R. L., Truong T., Knight J. A., Seibold P., Flesch Janys D., Behrens S., Eilber U., Bolla M. K., Wang Q., Dennis J., Dunning A. M., Shah M., Munday H. R., Darabi H., Eriksson M., Brand J. S., Olson J., Vachon C. M., Hallberg E., Castela J. E., Carracedo A., Torres M., Li J., Humphreys K., Cordina Duverger E., Menegaux F., Flyger H., Nordestgaard B. G., Nielsen S. F., Yesilyurt B. T., Floris G., Leunen K., Engelhardt E. G., Broeks A., Rutgers E. J., Glendon G., Mulligan A. M., Cross S., Reed M., Gonzalez Neira A., Arias Perez J. I., Provenzano E., Apicella C., Southey M. C., Spurdle L., Beckmann M. W., Ekici A. B., Dieffenbach A. K., Arndt V., Stegmaier C., McLean C., Baglietto L., Chanock S. J., Lissowska J., Sherman M. E., Bruning T., Hamann U., Ko Y. D., Orr N., Schoemaker M., Ashworth A., Kosma V. M., Kataja V., Hartikainen J. M., Mannermaa A., Swerdlow A., Giles G. G., Brenner H., Fasching P. A., Chenevix Trench G., Hopper J., Benitez J., Cox A., Andrulis I. L., Lambrechts D., Gago Dominguez M., Couch F., Czene K., Bojesen S. E., Easton D. F., Schmidt M. K., Guenel P., Hall P., Pharoah P. D., Garcia Closas M. and Chang Claude J.** Investigation of gene environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [136(6): E685 96]

**S. E., Easton D. F., Schmidt M. K., Guenel P., Hall P., Pharoah P. D., Garcia Closas M. and Chang Claude J.** An investigation of gene environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [136(6): E685 96]

**Rudolph A., Milne R. L., Truong T., Knight J. A., Seibold P., Flesch Janys D., Behrens S., Eilber U., Bolla M. K., Wang Q., Dennis J., Dunning A. M., Shah M., Munday H. R., Darabi H., Eriksson M., Brand J. S., Olson J., Vachon C. M., Hallberg E., Castela J. E., Carracedo A., Torres M., Li J., Humphreys K., Cordina Duverger E., Menegaux F., Flyger H., Nordestgaard B. G., Nielsen S. F., Yesilyurt B. T., Floris G., Leunen K., Engelhardt E. G., Broeks A., Rutgers E. J., Glendon G., Mulligan A. M., Cross S., Reed M., Gonzalez Neira A., Arias Perez J. I., Provenzano E., Apicella C., Southey M. C., Spurdle A., Haberle L., Beckmann M. W., Ekici A. B., Dieffenbach A. K., Arndt V., Stegmaier C., McLean C., Baglietto L., Chanock S. J., Lissowska J., Sherman M. E., Bruning T., Hamann U., Ko Y. D., Orr N., Schoemaker M., Ashworth A., Kosma V. M., Kataja V., Hartikainen J. M., Mannermaa A., Swerdlow A., Giles G. G., Brenner H., Fasching P. A., Chenevix Trench G., Hopper J., Benitez J., Cox A., Andrulis I. L., Lambrechts D., Gago Dominguez M., Couch F., Czene K., Bojesen S. E., Easton D. F., Schmidt M. K., Guenel P., Hall P., Pharoah P. D., Garcia Closas M. and Chang Claude J.** Investigation of gene environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. *INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER* 2014 [136(6): E685 96]

**Saeid Mehrkanon, Michael Breakspear, Tjeerd W Boonstra** Low dimensional dynamics of resting state cortical activity. *BRAIN TOPOGRAPHY* 2014 [27(3): 338 352]

**Sanfilippo PG, Wilkinson CH, Ruddle JB, Zhu G, Martin NG, Hewitt AW, Mackey DA.** Don't it make your brown eyes blue? A comparison of iris colour across latitude in Australian twins. *CLINICAL AND EXPERIMENTAL OPTOMETRY* 2014 [98(2): 172-176]

**Sapkota Y, Low SK, Attia J, Gordon SD, Henders AK, Holliday EG, MacGregor S, Martin NG, McEvoy M, Morris AP, Takahashi A, Scott RJ, Kubo M, Zondervan KT, Montgomery GW, Nyholt DR.** Association between endometriosis and the interleukin 1A (IL1A) locus. *HUMAN REPRODUCTION* 2014 [30(1): 239-248]

**Sathe P., Delconte R. B., Souza Fonseca Guimaraes F., Seillet C., Chopin M., Vandenberg C. J., Rankin L. C., Mielke L. A., Vikstrom I., Kolesnik T. B., Nicholson S. E., Vivier E., Smyth M. J., Nutt S. L., Glaser S. P., Strasser A., Belz G. T., Carotta S. and Huntington N. D.** Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. *NATURE COMMUNICATIONS* 2014 [5: 4539]

**Savage JE, Slutske WS, Martin NG.** Personality and Gambling Involvement: A Person Centered Approach. *PSYCHOLOGY OF ADDICTIVE BEHAVIORS* 2014 [28(4): 1198-1211]

**Sawyer E., Roylance R., Petridis C., Brook M. N., Nowinski S., Papouli E., Fletcher O., Pinder S., Hanby A., Kohut K., Gorman P., Caneppele M., Peto J., Dos Santos Silva I., Johnson N., Swann R., Dwek M., Perkins K. A., Gillett C., Houlston R., Ross G., De Ieso P., Southey M. C., Hopper J. L., Provenzano E., Apicella C., Wesseling J., Cornelissen S., Keeman R., Fasching P. A., Jud S. M., Ekici A. B., Beckmann M. W., Kerin M. J., Marme F., Schneeweiss A., Sohn C., Burwinkel B., Guenel P., Truong T., Laurent Puig P., Kerbrat P., Bojesen S. E., Nordestgaard B. G., Nielsen S. F., Flyger H., Milne R. L., Perez J. I., Menendez P., Benitez J., Brenner H., Dieffenbach A. K., Arndt V., Stegmaier C., Meindl A., Lichtner P., Schmutzler R. K., Lochmann M., Brauch H., Fischer H. P., Ko Y. D., Nevanlinna H., Muranen T. A., Aittomaki K., Blomqvist C., Bogdanova N. V., Dork T., Lindblom A., Margolin S., Mannermaa A., Kataja V., Kosma V. M., Hartikainen J.**

**M., Chenevix Trench G., Investigators K., Lambrechts D., Weltens C., Van Limbergen E., Hatse S., Chang Claude J., Rudolph A., Seibold P., Flesch Janys D., Radice P., Peterlongo P., Bonanni B., Volorio S., Giles G. G., Severi G., Baglietto L., McLean C. A., Haiman C. A., Henderson B. E., Schumacher F., Le Marchand L., Simard J., Goldberg M. S., Labreche F., Dumont M., Kristensen V., Winqvist R., Pylkas K., Jukkola Vuorinen A., Kauppila S., Andrulis I. L., Knight J. A., Glendon G., Mulligan A. M., Devillee P., Tollenaar R. A., Seynaeve C. M., Kriege M., Figueroa J., Chanock S. J., Sherman M. E., Hooning M. J., Hollestelle A., van den Ouweland A. M., van Deurzen C. H., Li J., Czene K., Humphreys K., Cox A., Cross S. S., Reed M. W., Shah M., Jakubowska A., Lubinski J., Jaworska Bieniek K., Durda K., Swerdlow A., Ashworth A., Orr N., Schoemaker M., Couch F. J., Hallberg E., Gonzalez Neira A., Pita G., Alonso M. R., Tessier D., C., Vincent D., Bacot F., Bolla M. K., Wang Q., Dennis J., Michailidou K., Dunning A. M., Hall P., Easton D., Pharoah P., Schmidt M. K., Tomlinson I. and Garcia Closas M.** Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLOS GENETICS* 2014 [10(4): e1004285]

**Scheltinga F., Shibl R., Green A. C., Ng S. K., Scuffham P. A. and Cameron C. M.** Varying sun protection of young children by migrant and Australian born mothers. *AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH* 2014 [38(6): 513-7]

**Schnoder T. M., Arriba Tutusaus P., Griehl I., Bullinger L., Buschbeck M., Lane S. W., Dohner K., Plass C., Lipka D. B., Heide F. H. and Fischer T.** Epo induced erythroid maturation is dependent on Plogamma1 signaling. *CELL DEATH DIFFER* 2014 [22(6): 974-85]

**Schoeps A., Rudolph A., Seibold P., Dunning A. M., Milne R. L., Bojesen S. E., Swerdlow A., Andrulis I., Brenner H., Behrens S., Orr N., Jones M., Ashworth A., Li J., Cramp H., Connley D., Czene K., Darabi H., Chanock S. J., Lissowska J., Figueroa J. D., Knight J., Glendon G., Mulligan A. M., Dumont M., Severi G., Baglietto L., Olson J., Vachon C., Purrington K., Moisse M., Neven P., Wildiers**

**H., Spurdle A., Kosma V. M., Kataja V., Hartikainen J. M., Hamann U., Ko Y. D., Dieffenbach A. K., Arndt V., Stegmaier C., Malats N., Arias Perez J. I., Benitez J., Flyger H., Nordestgaard B. G., Truong T., Cordina Duverger E., Menegaux F., dos Santos Silva I., Fletcher O., Johnson N., Haberle L., Beckmann M. W., Ekici A. B., Braaf L., Atsma F., van den Broek A. J., Makalic E., Schmidt D. F., Southey M. C., Cox A., Simard J., Giles G. G., Lambrechts D., Mannermaa A., Brauch H., Guenel P., Peto J., Fasching P. A., Hopper J., Flesch Janys D., Couch F., Chenevix Trench G., Pharoah P. D., Garcia Closas M., Schmidt M. K., Hall P., Easton D. F. and Chang Claude J.** Identification of new genetic susceptibility loci for breast cancer through consideration of gene environment interactions. *GENETIC EPIDEMIOLOGY* 2014 [38(1): 84-93]

**Schroder W. A., Major L. D., Le T. T., Gardner J., Sweet M. J., Janciauskiene S. and Suhrbier A.** Tumor cell expressed SerpinB2 is present on microparticles and inhibits metastasis. *CANCER MEDICINE* 2014 [3(3): 500-13]

**Schuessler Andrea, Smith Corey, Beagley Leone, Boyle Glen M, Rehan Sweera, Matthews Katherine, Jones Linda, Crough Tania, Dasari Vijayendra and Klein Kerenaftali** Autologous T cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. *CANCER RESEARCH* 2014 [74(13): 3466-76]

**Schuessler A, Walker DG, Khanna R** Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment. *ONCOIMMUNOLOGY* 2014 [3: e29381]

**Schuessler A, Walker DG, Khanna R.** Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. *FRONT ONCOL.* 2014 [4: 275]

**Schulte A., Pandeya N., Tran B., Fawcett J., Fritschi L., Risch H. A., Webb P. M., Whiteman D. C., Neale R. E. and Queensland Pancreatic Cancer Study Group** Cigarette smoking and pancreatic cancer risk: more to the story than just pack years. *EUROPEAN JOURNAL OF CANCER* 2014 [50(5): 997-1003]

**Schussek, S., Trieu, A., Doolan, D. L.** Genome and proteome wide screening strategies for antigen discovery and immunogen design. *BIOTECHNOL ADV* 2014 [32(2): 403 14]

**Schuster I. S., Wikstrom M. E., Brizard G., Coudert J. D., Estcourt M. J., Manzur M., O'Reilly L. A., Smyth M. J., Trapani J. A., Hill G. R., Andoniou C. E. and Degli Esposti M. A.** TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity. *IMMUNITY* 2014 [41(4): 646 56]

**Sehmer E. A., Hall G. J., Greenberg D. C., O'Hara C., Wallingford S. C., Wright K. A. and Green A. C.** Incidence of glioma in a northwestern region of England, 2006 2010. *NEURO ONCOLOGY* 2014 [16(7): 971 4]

**Seillet C., Huntington N. D., Gangatirkar P., Axelsson E., Minnich M., Brady H. J., Busslinger M., Smyth M. J., Belz G. T. and Carotta S.** Differential requirement for Nfil3 during NK cell development. *JOURNAL OF IMMUNOLOGY* 2014 [192(6): 2667 76]

**Seymour L. A., Nourse J. P., Crooks P., Wockner L., Bird R., Tran H. and Gandhi M. K.** The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. *TISSUE ANTIGENS* 2014 [83(3): 154 60]

**Shah S McRae AF, Marioni RE, Harris SE, Gibson J, Henders AK, Redmond P, Cox SR, Pattie A, Corley J, Murphy L, Martin NG, Montgomery GW, Starr JM, Wray NR, Deary IJ, Visscher PM.** Genetic and environmental exposures constrain epigenetic drift over the human life course. *GENOME RESEARCH* 2014 [24(11): 1725 1733]

**Shan ZY Wright MJ, Thompson PM, McMahon KL, Blokland GG, de Zubicaray GI, Martin NG, Vinkhuyzen AA, Reutens DC.** Modeling of the hemodynamic responses in block design fMRI studies. *JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM* 2014 [34(2): 316 324]

**Shand FL Day C, Rawlinson W, Degenhardt L, Martin NG, Nelson EC.** Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. *AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH* 2014 [38(2): 160 164]

**Shen KK Rose S, Fripp J, McMahon KL, de Zubicaray GI, Martin NG, Thompson PM, Wright MJ, Salvado O.** Investigating brain connectivity heritability in a twin study using diffusion imaging data. *NEUROIMAGE*. 2014 [100: 628 641]

**Sherrard LJ, Tunney MM, Elborn JS** Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. *LANCET* 2014 [384(9944)]

**Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Elborn JS, Tunney MM** Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in *Prevotella* isolated from cystic fibrosis (CF) and non CF patients. *JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY* 2014 [69(10): 2690 8]

**Shore Lorenti C., Brennan S. L., Sanders K. M., Neale R. E., Lucas R. M. and Ebeling P. R.** Shining the light on Sunshine: a systematic review of the influence of sun exposure on type 2 diabetes mellitus related outcomes. *CLINICAL ENDOCRINOLOGY* 2014 [81(6): 799 811]

**Shu Wen Wen, Richard Lobb, Andreas Möller** Exosomes in cancer metastasis: Novel targets for diagnosis and therapy?. *CANCER FORUM* 2014 [38(2): 116]

Shukla SD, Sohal S.S., Mahmood MQ, Reid DW, Muller HK, Walters EH. Airway epithelial platelet activating factor receptor (PAFr) expression is markedly upregulated in Chronic Obstructive Pulmonary Disease. *INTERNATIONAL J OF COPD*. 2014 [13(9): 853 61]

**Sievert W, Leggett BA, Macrae FA.** Investigating iron deficiency anaemia. *MED J AUST* 2014 [200(1): 18]

**Sikulu Maggy T., Majambere Silas, Khatib Bakar O., Ali Abdullah S., Hugo Leon E. and Dowell Floyd E.** Using a Near Infrared Spectrometer to Estimate the Age of Anopheles Mosquitoes Exposed to Pyrethroids. *PLOS ONE* 2014 [9(3): e90657]

**Simerska P., Suksamran T., Ziora Z. M., Rivera Fde L., Engwerda C. and Toth I.** Ovalbumin lipid core peptide vaccines and their CD4(+) and CD8(+) T cell responses. *VACCINE* 2014 [32(37): 4743 50]

**Simmons J. L., Pierce C. J. and Boyle G. M.** Evidence for an alternatively spliced MITF exon 2 variant. *JOURNAL OF INVESTIGATIVE DERMATOLOGY* 2014 [134(4): 1166 8]

**Simpson S Jr, Taylor B, Burrows J, Burrows S, Dwyer DE, Taylor J, Ponsonby AL, Blizzard L, Dwyer T, Pittas F, van der Mei I.** EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. *ACTA NEUROL SCAND*. 2014 [130(5): 328 37]

**Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D. P., Adam J., Vitale I., Goubar A., Baracco E. E., Remedios C., Fend L., Hannani D., Aymeric L., Ma Y., Niso Santano M., Kepp O., Schultze J. L., Tuting T., Belardelli F., Bracci L., La Sorsa V., Ziccheddu G., Sestili P., Urbani F., Delorenzi M., Lacroix Triki M., Quidville V., Conforti R., Spano J. P., Puzstai L., Poirier Colame V., Delalogue S., Penault Llorca F., Ladoire S., Arnould L., Cyrta J., Dessoliers M. C., Eggermont A., Bianchi M. E., Pittet M., Engblom C., Pfirschke C., Preville X., Uze G., Schreiber R. D., Chow M. T., Smyth M. J., Proietti E., Andre F., Kroemer G. and Zitvogel L.** Cancer cell autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. *NATURE MEDICINE* 2014 [20(11): 1301 9]

**Skowera, A., Ladell, K., McLaren, J.E., Dolton, G., Matthews, K.K., Gostick, E., Kronenberg Versteeg, D., Eichmann, M., Knight, R.R., Heck, S., Powrie, J., Bingley, P.J., Dayan, C.M., Miles, J.J., Sewell, A.K., Price, D.A. and Peakman M.**  $\beta$  cell specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. *DIABETES*. 2015 [:]

**Slutske WS Deutsch AR, Richmond Rakerd LS, Chernyavskiy P, Statham DJ, Martin NG.** Test of a Potential Causal Influence of Earlier Age of Gambling Initiation on Gambling Involvement and Disorder: A Multilevel Discordant Twin Design. *PSYCHOLOGY OF ADDICTIVE BEHAVIORS* 2014 [28(4): 1177 1189]

**Slutske WS Piasecki TM, Nathanson L, Statham DJ, Martin NG.** Genetic Influences on Alcohol related Hangover. *ADDICTION* 2014 [109(12): 2027 2034]

Slutske WS Piasecki TM, Deutsch AR,



Statham DJ, Martin NG. Telescoping and Gender Differences in the Time Course of Disordered Gambling: Evidence from a General Population Sample. *ADDICTION* 2014 [110(1): 144 151]

**Smith DJ, Hill G, Bell SC, Reid DW.** Reduced mucosal associated invariant T cells are associated with increased disease severity and *Pseudomonas aeruginosa* infection in cystic fibrosis. *PLOS ONE*. 2014 [8(9): e109891.]

**Smith D. J., Anderson G. J., Bell S. C. and Reid D. W.** Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity. *JOURNAL OF CYSTIC FIBROSIS* 2014 [13(3): 289 95]

**Smith C, Gras S, Brennan RM, Bird NL, Valkenburg SA, Twist KA, Burrows JM, Miles JJ, Chambers D, Bell S, Campbell S, Kedzierska K, Burrows SR, Rossjohn J, Khanna R.** Molecular Imprint of Exposure to Naturally Occurring Genetic Variants of Human Cytomegalovirus on the T cell Repertoire. *SCIENTIFIC REPORTS* 2014 [4: 3993]

**Smith D. J., Hill G. R., Bell S. C. and Reid D. W.** Reduced mucosal associated invariant T cells are associated with increased disease severity and *Pseudomonas aeruginosa* infection in cystic fibrosis. *PLOS ONE* 2014 [9(10): e109891]

**Smith D. J., Badrick A. C., Zakrzewski M., Krause L., Bell S. C., Anderson G. J. and Reid D. W.** Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. *THE EUROPEAN RESPIRATORY JOURNAL* 2014 [44(4): 922 30]

**Smyth A. R., Bell S. C., Bojcin S., Bryon M., Duff A., Flume P., Kashirskaya N., Munck A., Ratjen F., Schwarzenberg S. J., Sermet Gaudelus I., Southern K. W., Taccetti G., Ullrich G., Wolfe S. and European Cystic Fibrosis Society** European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. *JOURNAL OF CYSTIC FIBROSIS : OFFICIAL JOURNAL OF THE EUROPEAN CYSTIC FIBROSIS SOCIETY* 2014 [13 Suppl 1: S23 42]

**Smyth M. J., Ngiew S. F. and Teng M. W.** Targeting regulatory T cells in tumor immunotherapy. *IMMUNOLOGY AND CELL BIOLOGY* 2014 [92(6): 473 4]

**Smyth M. J., Yagita H. and McArthur G. A.** Combination Anti CTLA 4 and Anti RANKL in Metastatic Melanoma. *JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY* 2014

**Smyth M. J. and Teng M. W.** Targeting the IL 12/IL 23 axis: An alternative approach to removing tumor induced immune suppression. *ONCOIMMUNOLOGY* 2014 [3: e28964]

**Soares Magalhaes R. J., Salamat M. S., Leonardo L., Gray D. J., Carabin H., Halton K., McManus D. P., Williams G. M., Rivera P., Sanieel O., Hernandez L., Yakob L., McGarvey S. and Clements A.** Geographical distribution of human *Schistosoma japonicum* infection in The Philippines: tools to support disease control and further elimination. *INT J PARASITOL* 2014 [44(13): 977 84]

**Sohal S.S., Soltani A, Reid DW, Chris Ward, H. Konrad Muller, E. Haydn Walters.** A randomised controlled trial of ICS on markers of EMT in large airways in COPD: an exploratory proof of concept study. *INTERNATIONAL JOURNAL OF COPD* 2014 [5: 533 542.]

**Somerset S. and Papier K.** A food frequency questionnaire validated for estimating dietary flavonoid intake in an Australian population. *NUTRITION AND CANCER* 2014 [66(7): 1200 10]

**Song F Amos CI, Lee JE, Lian CG, Fang S, Liu H, MacGregor S, Iles MM, Lindeman NI, Montgomery GW, Duffy DL, Cust AE, Jenkins MA, Whiteman DC, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Brown KM, Martin NG, Mann GJ, Bishop DT, Newton Bishop JA; the GenoMEL consortium, Kraft P, Qureshi AA, Kanetsky PA, Hayward NK, Hunter DJ, Wei Q, Han J.** Identification of a melanoma susceptibility locus and somatic mutation in TET2. *CARCINOGENESIS* 2014 [35(9): 2097 2101]

**Sotillo J, Sanchez Flores A, Cantacessi C, Harcus Y, Pickering D, Bouchery T, Camberis M, Tang SC, Giacomini P, Mulvenna J, Mitreva M, Berriman M, LeGros G, Maizels RM, Loukas A.** Secreted proteomes of different developmental stages of the gastrointestinal nematode *Nippostrongylus brasiliensis*. *MOL CELL PROTEOMICS* 2014 [13(10): 2736 51]

**Spann K. M., Loh Z., Lynch J. P., Ullah A., Zhang V., Baturcam E., Werder R. B., Khajornjiraphan N., Rudd P., Loo Y. M., Suhrbier A., Gale M., Jr., Upham J. W. and Phipps S.** IRF 3, IRF 7, and IPS 1 promote host defense against acute human metapneumovirus infection in neonatal mice. *AM J PATHOL* 2014 [184(6): 1795 806]

**Speckmann B., Gerloff K., Simms L., Oancea I., Shi W., McGuckin M. A., Radford Smith G. and Khanna K. K.** Selenoprotein S is a marker but not a regulator of endoplasmic reticulum stress in intestinal epithelial cells. *FREE RADICAL BIOLOGY & MEDICINE* 2014 [67: 265 277]

**Springelkamp H., Hohn R., Mishra A., Hysi P. G., Khor C. C., Loomis S. J., Bailey J. N., Gibson J., Thorleifsson G., Janssen S. F., Luo X., Ramdas W. D., Vithana E., Nongpiur M. E., Montgomery G. W., Xu L., Mountain J. E., Gharahkhani P., Lu Y., Amin N., Karssen L. C., Sim K. S., van Leeuwen E. M., Iglesias A. I., Verhoeven V. J., Hauser M. A., Loon S. C., Despriet D. D., Nag A., Venturini C., Sanfilippo P. G., Schillert A., Kang J. H., Landers J., Jonasson F., Cree A. J., van Koolwijk L. M., Rivadeneira F., Souzeau E., Jonsson V., Menon G., Blue Mountains Eye Study Gwas group, Weinreb R. N., de Jong P. T., Oostra B. A., Uitterlinden A. G., Hofman A., Ennis S., Thorsteinsdottir U., Burdon K. P., Consortium Neighborhood, Wellcome Trust Case Control Consortium, Spector T. D., Mirshahi A., Saw S. M., Vingerling J. R., Teo Y. Y., Haines J. L., Wolfs R. C., Lemij H. G., Tai E. S., Jansonius N. M., Jonas J. B., Cheng C. Y., Aung T., Viswanathan A. C., Klaver C. C., Craig J. E., Macgregor S., Mackey D. A., Lotery A. J., Stefansson K., Bergen A. A., Young T. L., Wiggs J. L., Pfeiffer N., Wong T. Y., Pasquale L. R., Hewitt A. W., van Duijn C. M.**

and Hammond C. J. Meta analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. *NATURE COMMUNICATIONS* 2014 [5: 4883]

Spurdle A. B., Couch F. J., Parsons M. T., McGuffog L., Barrowdale D., Bolla M. K., Wang Q., Healey S., Schmutzler R., Wappenschmidt B., Rhiem K., Hahnen E., Engel C., Meindl A., Ditsch N., Arnold N., Plendl H., Niederacher D., Sutter C., Wang Gohrke S., Steinemann D., Preisler Adams S., Kast K., Varon Mateeva R., Ellis S., Frost D., Platte R., Perkins J., Evans D. G., Izatt L., Eeles R., Adlard J., Davidson R., Cole T., Scuvera G., Manoukian S., Bonanni B., Mariette F., Fortuzzi S., Viel A., Pasini B., Papi L., Varesco L., Balleine R., Nathanson K. L., Domchek S. M., Offitt K., Jakubowska A., Lindor N., Thomassen M., Jensen U. B., Rantala J., Borg A., Andrulis I. L., Miron A., Hansen T. V., Caldes T., Neuhausen S. L., Toland A. E., Nevanlinna H., Montagna M., Garber J., Godwin A. K., Osorio A., Factor R. E., Terry M. B., Rebbeck T. R., Karlan B. Y., Southey M., Rashid M. U., Tung N., Pharoah P. D., Blows F. M., Dunning A. M., Provenzano E., Hall P., Czene K., Schmidt M. K., Broeks A., Cornelissen S., Verhoef S., Fasching P. A., Beckmann M. W., Ekici A. B., Slamon D. J., Bojesen S. E., Nordestgaard B. G., Nielsen S. F., Flyger H., Chang Claude J., Flesch Janys D., Rudolph A., Seibold P., Aittomaki K., Muranen T. A., Heikkila P., Blomqvist C., Figueroa J., Chanock S. J., Brinton L., Lissowska J., Olson J. E., Pankratz V. S., John E. M., Whittemore A. S., West D. W., Hamann U., Torres D., Ulmer H. U., Rudiger T., Devilee P., Tollenaar R. A., Seynaeve C., Van Asperen C. J., Eccles D. M., Tapper W. J., Durcan L., Jones L., Peto J., dos Santos Silva I., Fletcher O., Johnson N., Dwek M., Swann R., Bane A. L., Glendon G., Mulligan A. M., Giles G. G., Milne R. L., Baglietto L., McLean C., Carpenter J., Clarke C., Scott R., Brauch H., Bruning T., Ko Y. D., Cox A., Cross S. S., Reed M. W., Lubinski J., Jaworska Bieniek K., Durda K., Gronwald J., Dork T., Bogdanova N., Park Simon T. W., Hillemanns P., Haiman C. A., Henderson B. E., Schumacher F., Le Marchand L., Burwinkel B., Marme F., Surovy H., Yang R., Anton Culver H.,

Ziogas A., Hooning M. J., Collee J. M., Martens J. W., Tilanus Linthorst M. M., Brenner H., Dieffenbach A. K., Arndt V., Stegmaier C., Winqvist R., Pylkas K., Jukkola Vuorinen A., Grip M., Lindblom A., Margolin S., Joseph V., Robson M., Rau Murthy R., Gonzalez Neira A., Arias J. I., Zamora P., Benitez J., Mannermaa A., Kataja V., Kosma V. M., Hartikainen J. M., Peterlongo P., Zaffaroni D., Barile M., Capra F., Radice P., Teo S. H., Easton D. F., Antoniou A. C., Chenevix Trench G. and Goldgar D. E. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *BREAST CANCER RESEARCH: BCR* 2014 [16(6): 3419]

Srihari S., Madhamshettiwar P. B., Song S., Liu C., Simpson P. T., Khanna K. K. and Ragan M. A. Complex based analysis of dysregulated cellular processes in cancer. *BMC SYSTEMS BIOLOGY* 2014 [8 Suppl 4: S1]

Staaf J., Harbst K., Lauss M., Ringner M., Masback A., Howlin J., Jirstrom K., Harland M., Zebary A., Palmer J. M., Ingvar C., Olsson H., Newton Bishop J., Hansson J., Hayward N., Gruis N., Jonsson G. and Melanoma Genetics Consortium Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass. *THE JOURNAL OF INVESTIGATIVE DERMATOLOGY* 2014 [134(12): 3000 3]

Stamatakis Z., Brunton L., Lorigan P., Green A. C., Newton Bishop J. and Molassiotis A. Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. *SUPPORTIVE CARE IN CANCER : OFFICIAL JOURNAL OF THE MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER* 2014 [23(3): 779 89]

Staudacher Alexander H, Al Ejeh Fares, Fraser Cara K, Darby Jocelyn M, Roder David M, Ruskiewicz Andrew, Manavis Jim and Brown Michael P. The La antigen is over expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La specific antibody APOMAB®. *EJNMMI RESEARCH* 2014 [4(1): 1 13]

Steinberg S., de Jong S., Mattheisen M., Costas J., Demontis D., Jamain S., Pietilainen O. P., Lin K., Papiol S., Huttenlocher J., Sigurdsson E., Vassos E., Giegling I., Breuer R., Fraser G., Walker N., Melle I., Djurovic S., Agartz I., Tuulio Henriksson A., Suvisaari J., Lonnqvist J., Paunio T., Olsen L., Hansen T., Ingason A., Pirinen M., Strengman E., Group, Hougaard D. M., Orntoft T., Didriksen M., Hollegaard M. V., Nordentoft M., Abramova L., Kaleda V., Arrojo M., Sanjuan J., Arango C., Etain B., Bellivier F., Meary A., Schurhoff F., Szoke A., Ribolsi M., Magni V., Siracusano A., Sperling S., Rossner M., Christiansen C., Kiemeny L. A., Franke B., van den Berg L. H., Veldink J., Curran S., Bolton P., Poot M., Staal W., Rehnstrom K., Kilpinen H., Freitag C. M., Meyer J., Magnusson P., Saemundsen E., Martsenkovsky I., Bikshaieva I., Martsenkovska I., Vashchenko O., Raleva M., Paketchieva K., Stefanovski B., Durmishi N., Pejovic Milovancevic M., Lecic Tosevski D., Silagadze T., Naneishvili N., Mikeladze N., Surguladze S., Vincent J. B., Farmer A., Mitchell P. B., Wright A., Schofield P. R., Fullerton J. M., Montgomery G. W., Martin N. G., Rubino I. A., van Winkel R., Kenis G., De Hert M., Rethelyi J. M., Bitter I., Terenius L., Jonsson E. G., Bakker S., van Os J., Jablensky A., Leboyer M., Bramon E., Powell J., Murray R., Corvin A., Gill M., Morris D., O'Neill F. A., Kendler K., Riley B., Wellcome Trust Case Control Consortium, Craddock N., Owen M. J., O'Donovan M. C., Thorsteinsdottir U., Kong A., Ehrenreich H., Carracedo A., Golimbet V., Andreassen O. A., Borglum A. D., Mors O., Mortensen P. B., Werge T., Ophoff R. A., Nothen M. M., Rietschel M., Cichon S., Ruggeri M., Tosato S., Palotie A., St Clair D., Rujescu D., Collier D. A., Stefansson H. and Stefansson K. Common variant at 16p11.2 conferring risk of psychosis. *MOLECULAR PSYCHIATRY* 2014 [19(1): 108 114]

Stephenson R., You H., McManus D.P. and Toth I. Schistosome Vaccine Adjuvants in Preclinical and Clinical Research. *VACCINES* 2014 [2(3): 654 685]

**Steve S, Claridge Lee C, Jhaveri Ravi, Swiderska Syn Marzena, Clark Paul, Suzuki Ayako, Pereira Thiago A, Zhiyong Mi, Paul C And Cynthia D** Osteopontin is up regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. *CLINICAL SCIENCE* 2014 [126(12): 845 855]

**Stirzaker C, Zotenko E, Song JZ, Qu W, Nair SS, Locke WJ, Stone A, Armstong NJ, Robinson MD, Dobrovic A, Avery Kiejda KA, Peters KM, French JD, Stein S, Korbie DJ, Trau M, Forbes JF, Scott RJ, Brown MA, Francis GD, Clark SJ.** Methylome sequencing in triple negative breast cancer reveals distinct methylation clusters with prognostic value. *AMERICAN JOURNAL OF HUMAN GENETICS* 2015 [2(6): 5899]

**Subramaniam VN, Wallace DF** Linking hypoxia and iron homeostasis: a 'plate' full of factors. *GUT* 2014 [63(12): 1480 2]

**Sun J., Lucas R. M., Harrison S. L., van der Mei I., Whiteman D. C., Mason R., Nowak M., Brodie A. M. and Kimlin M. G.** Measuring exposure to solar ultraviolet radiation using a dosimetric technique: understanding participant compliance issues. *PHOTOCHEMISTRY AND PHOTOBIOLOGY* 2014 [90(4): 919 24]

**Syrmis M. W., Kidd T. J., Moser R. J., Ramsay K. A., Gibson K. M., Anuj S., Bell S. C., Wainwright C. E., Grimwood K., Nissen M., Sloots T. P. and Whiley D. M.** A comparison of two informative SNP based strategies for typing *Pseudomonas aeruginosa* isolates from patients with cystic fibrosis. *BMC INFECTIOUS DISEASES* 2014 [14: 307]

**Tang YT, Gao X, Rosa BA, Abubucker S Hallsworth Pepin K, Martin J, Tyagi R Heizer E, Zhang X, Bhonagiri Palsikar V, Minx P, Warren WC, Wang Q, Zhan B, Hotez PJ, Sternberg PW, Dougall A Gaze ST, Mulvenna J, Sotillo J, Ranganathan S, Rabelo EM, Wilson RK Felgner PL, Bethony J, Hawdon JM Gasser RB, Loukas A, Mitreva M13.** Genome of the human hookworm *Necator americanus*. *NAT GENET.* 2014 [46(3): 261 9]

**Tavtigan S. V. and Chenevix Trench G.** Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. *BIOMARKERS IN MEDICINE* 2014 [8(4): 589 603]

**Tellam JT, Zhong J, Lekieffre L, Bhat P, Martinez M, Croft NP, Kaplan W, Tellam RL, Khanna R.** mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells. *PLOS PATHOGEN* 2014 [10(10): e1004423]

**Teng M. W. and Smyth M. J.** Cancer. Can cancer trigger autoimmunity? *SCIENCE* 2014 [343(6167): 147 8]

**Tewksbury R., Pearch B., Redmond K., Harper J., Klein K. and Quinn J.** Outcomes of infrapopliteal endoluminal intervention for transatlantic intersociety consensus C and D lesions in patients with critical limb ischaemia. *ANZ JOURNAL OF SURGERY* 2014 [84(11): 866 70]

**The Coffee and Caffeine Genetics Consortium Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, Monda KL, Amin N, Fischer K, Renstrom F, Ngwa JS, Huikari V, Cavadino A, Nolte IM, Teumer A, Yu K, Marques Vidal P, Rawal R, Manichaikul A, Wojczynski MK, Vink JM, Zhao JH, Burlutsky G, Lahti J, Mikkilä V, Lemaitre RN, Eriksson J, Musani SK, Tanaka T, Geller F, Luan J, Hui J, Mägi R, Dimitriou M, Garcia ME, Ho WK, Wright MJ, Rose LM, Magnusson PK, Pedersen NL, Couper D, Oostra BA, Hofman A, Ikram MA, Tiemeier HW, Uitterlinden AG, van Rooij FJ, Barroso I, Johansson I, Xue L, Kaakinen M, Milani L, Power C, Snieder H, Stolk RP, Baumeister SE, Biffar R, Gu F, Bastardot F, Kutalik Z, Jacobs DR Jr, Forouhi NG, Mihailov E, Lind L, Lindgren C, Michaëlsson K, Morris A, Jensen M, Khaw KT, Luben RN, Wang JJ, Männistö S, Perälä MM, Kähönen M, Lehtimäki T, Viikari J, Mozaffarian D, Mukamal K, Psaty BM, Döring A, Heath AC, Montgomery GW, Dahmen N, Carithers T, Tucker KL, Ferrucci L, Boyd HA, Melbye M, Treur JL, Mellström D, Hottenga JJ, Prokopenko I, Tönjes A, Deloukas P, Kanoni S, Lorentzon M, Houston DK, Liu Y, Danesh J, Rasheed A, Mason MA, Zonderman AB, Franke L, Kristal BS; International Parkinson's Disease Genomics Consortium (IPDGC); North American Brain Expression**

**Consortium (NABEC); UK Brain Expression Consortium (UKBEC), Karjalainen J, Reed DR, Westra HJ, Evans MK, Saleheen D, Harris TB, Dedoussis G, Curhan G, Stumvoll M, Beilby J, Pasquale LR, Feenstra B, Bandinelli S, Ordovas JM, Chan AT, Peters U, Ohlsson C, Gieger C, Martin NG, Waldenberger M, Siscovick DS, Raitakari O, Eriksson JG, Mitchell P, Hunter DJ, Kraft P, Rimm EB, Boomsma DI, Borecki IB, Loos RJ, Wareham NJ, Vollenweider P, Caporaso N, Grabe HJ, Neuhauser ML, Wolfenbittel BH, Hu FB, Hyppönen E, Järvelin MR, Cupples LA, Franks PW, Ridker PM, van Duijn CM, Heiss G, Metspalu A, North KE, Ingelsson E, Nettleton JA, van Dam RM, Chasman DI.** Genome-wide meta analysis identifies six novel loci associated with habitual coffee consumption. *MOLECULAR PSYCHIATRY* 2014 [20(5): 647 656]

**Thomas G., Khunti K., Curcin V., Molokhia M., Millett C., Majeed A. and Paul S.** Obesity paradox in people newly diagnosed with type 2 diabetes with and without prior cardiovascular disease. *DIABETES, OBESITY AND METABOLISM* 2014 [16(4): 317 325]

**Thomas G, Klein K and Paul S** Statistical challenges in analysing large longitudinal patient level data: The danger of misleading, clinical inferences with imputed data. *JOURNAL OF THE INDIAN SOCIETY OF AGRICULTURAL STATISTICS* 2014 [68(2): 39 54]

**Thompson B. A., Martins A. and Spurdle A. B.** A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays. *CLINICAL GENETICS* 2014 [87(2): 100 8]

**Thompson PM Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, Toro R, Jahanshad N, Schumann G, Franke B, Wright MJ, Martin NG, Agartz I, Alda M, Alhusaini S, Almasy L, Almeida J, Alpert K, Andreassen NC, Andreassen OA, Apostolova LG, Appel K, Armstrong NJ, Aribisala B, Bastin ME, Bauer M, Bearden CE, Bergmann O, Binder EB, Blangero J, Bockholt HJ, Bøen E, Bois C, Boomsma DI, Booth T, Bowman IJ, Bralten J, Brouwer RM, Brunner HG, Brohawn DG, Buckner RL, Buitelaar J, Bulayeva K, Bustillo JR, Calhoun VD, Cannon DM, Cantor RM, Carless MA, Caseras X, Cavalleri GL,**

Chakravarty MM, Chang KD, Ching CR, Christoforou A, Cichon S, Clark VP, Conrod P, Coppola G, Crespo Facorro B, Curran JE, Czisch M, Deary IJ, de Geus EJ, den Braber A, Delvecchio G, Depondt C, de Haan L, de Zubizaray GI, Dima D, Dimitrova R, Djurovic S, Dong H, Donohoe G, Duggirala R, Dyer TD, Ehrlich S, Ekman CJ, Elvsåshagen T, Emsell L, Erk S, Espeseth T, Fagerness J, Fears S, Fedko I, Fernández G, Fisher SE, Foroud T, Fox PT, Francks C, Frangou S, Frey EM, Frodl T, Frouin V, Garavan H, Giddaluru S, Glahn DC, Godlewska B, Goldstein RZ, Gollub RL, Grabe HJ, Grimm O, Gruber O, Guadalupe T, Gur RE, Gur RC, Göring HH, Hagenaars S, Hajek T, Hall GB, Hall J, Hardy J, Hartman CA, Hass J, Hatton SN, Haukvik UK, Hegenscheid K, Heinz A, Hickie IB, Ho BC, Hoehn D, Hoekstra PJ, Hollinshead M, Holmes AJ, Homuth G, Hoogman M, Hong LE, Hosten N, Hottenga JJ, Hulshoff Pol HE, Hwang KS, Jack CR Jr, Jenkinson M, Johnston C, Jönsson EG, Kahn RS, Kasperaviciute D, Kelly S, Kim S, Kochunov P, Koenders L, Krämer B, Kwok JB, Lagopoulos J, Laje G, Landen M, Landman BA, Lauriello J, Lawrie SM, Lee PH, Le Hellard S, Lemaître H, Leonardo CD, Li CS, Liberg B, Liewald DC, Liu X, Lopez LM, Loth E, Lourdasamy A, Luciano M, Macciardi F, Machielsen MW, Macqueen GM, Malt UF, Mandl R, Manoach DS, Martinot JL, Matarin M, Mather KA, Mattheisen M, Mattingsdal M, Meyer Lindenberg A, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meisenzahl E, Melle I, Milaneschi Y, Mohnke S, Montgomery GW, Morris DW, Moses EK, Mueller BA, Muñoz Maniega S, Mühleisen TW, Müller Myhsok B, Mwangi B, Nauck M, Nho K, Nichols TE, Nilsson LG, Nugent AC, Nyberg L, Olvera RL, Oosterlaan J, Ophoff RA, Pandolfo M, Papalampropoulou Tsiridou M, Pappmeyer M, Paus T, Pausova Z, Pearlson GD, Penninx BW, Peterson CP, Pfennig A, Phillips M, Pike GB, Poline JB, Potkin SG, Pütz B, Ramasamy A, Rasmussen J, Rietschel M, Rijpkema M, Risacher SL, Roffman JL, Roiz Santiañez R, Romanczuk Seiferth N, Rose EJ, Royle NA, Rujescu D, Ryten M, Sachdev PS, Salami A, Satterthwaite TD, Savitz J, Saykin AJ, Scanlon C, Schmaal L, Schnack HG, Schork

AJ, Schulz SC, Schür R, Seidman L, Shen L, Shoemaker JM, Simmons A, Sisodiya SM, Smith C, Smoller JW, Soares JC, Sponheim SR, Sprooten E, Starr JM, Steen VM, Strakowski S, Strike L, Sussmann J, Sämann PG, Teumer A, Toga AW, Tordesillas Gutierrez D, Trabzuni D, Trost S, Turner J, Van den Heuvel M, van der Wee NJ, van Eijk K, van Erp TG, van Haren NE, van 't Ent D, van Tol MJ, Valdés Hernández MC, Veltman DJ, Versace A, Völzke H, Walker R, Walter H, Wang L, Wardlaw JM, Weale ME, Weiner MW, Wen W, Westlye LT, Whalley HC, Whelan CD, White T, Winkler AM, Wittfeld K, Woldehawariat G, Wolf C, Zilles D, Zwiers MP, Thalamuthu A, Schofield PR, Freimer NB, Lawrence NS, Drevets W; the Alzheimer's Disease Neuroimaging Initiative, EPIGEN Consortium, IMAGEN Consortium, Saguenay Youth Study (SYS) Group. The ENIGMA Consortium: large scale collaborative analyses of neuroimaging and genetic data. *BRAIN IMAGING AND BEHAVIOR* 2014 [8(2): 153 182]

Thrift A. P., Shaheen N. J., Gammon M. D., Bernstein L., Reid B. J., Onstad L., Risch H. A., Liu G., Bird N. C., Wu A. H., Corley D. A., Romero Y., Chanock S. J., Chow W. H., Casson A. G., Levine D. M., Zhang R., Ek W. E., MacGregor S., Ye W., Hardie L. J., Vaughan T. L. and Whiteman D. C. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. *JOURNAL OF THE NATIONAL CANCER INSTITUTE* 2014 [106(11):]

Thrift A. P., Risch H. A., Onstad L., Shaheen N. J., Casson A. G., Bernstein L., Corley D. A., Levine D. M., Chow W. H., Reid B. J., Romero Y., Hardie L. J., Liu G., Wu A. H., Bird N. C., Gammon M. D., Ye W., Whiteman D. C. and Vaughan T. L. Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization. *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY: THE OFFICIAL CLINICAL PRACTICE JOURNAL OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION* 2014 [12(10): 1667 76]

Thrift A. P., Cook M. B., Vaughan T. L., Anderson L. A., Murray L. J., Whiteman D. C., Shaheen N. J. and Corley D. A. Alcohol and the risk of Barrett's esophagus: a pooled analysis from the International BEACON Consortium. *THE AMERICAN JOURNAL OF GASTROENTEROLOGY* 2014 [109(10): 1586 94]

Thwaites P., Irwin J., Walker N., McMahon A., Sewell K., Croft A., Clark D., Howlett M. and Radford Smith G. L. Hospitalization and treatment costs for acute, severe, steroid refractory ulcerative colitis: Infliximab beats ciclosporin. *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY* 2014 [29: 123 123]

Tian Y., Li S., Song J., Ji T., Zhu M., Anderson G. J., Wei J. and Nie G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. *BIOMATERIALS* 2014 [35(7): 2383 90]

Tilch E., Seidens T., Cocciardi S., Reid L. E., Byrne D., Simpson P. T., Vargas A. C., Cummings M. C., Fox S. B., Lakhani S. R. and Chenevix Trench G. Mutations in EGFR, BRAF and RAS are rare in triple negative and basal like breast cancers from Caucasian women. *BREAST CANCER RESEARCH AND TREATMENT* 2014 [143(2): 385 92]

Tirnitz Parker J. E., Olynyk J. K. and Ramm G. A. Role of TWEAK in coregulating liver progenitor cell and fibrogenic responses. *HEPATOLOGY* 2014 [59(3): 1198 201]

Tivnan A, Zhao J, Johns TG, Day BW, Stringer B, Boyd A, Tiwari S, Giles KM, Teo C, McDonald KL. The tumour suppressor microRNA, miR 124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. *TUMOUR BIOLOGY* 2014 [35(2):]

Toet H.M., Fischer K., Mounsey, K.E. Sandeman. Auto antibodies to iron binding proteins in pigs infested with *Sarcoptes scabiei*. *VETERINARY PARASITOLOGY* 2014

**Tomimatsu N., Mukherjee B., Catherine Hardebeck M., Ilcheva M., Vanessa Camacho C., Louise Harris J., Porteus M., Llorente B., Khanna K. K. and Burma S.** Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice. *NATURE COMMUNICATIONS* 2014 [5: 3561]

**Tonge Peter D, Corso Andrew J, Monetti Claudio, Hussein Samer MI, Puri Mira C, Michael Iacovos P, Li Mira, Lee Dong Sung, Mar Jessica C, Cloonan Nicole, DL Wood, ME Gauthier, O Korn, JL Clancy, T Preiss, SM Grimmond, JY Shin, JS Seo, CA Wells, IM Rogers and A Nagy** Divergent reprogramming routes lead to alternative stem cell states. *NATURE* 2014 [516(7530): 192 197]

**Trabert B., Ness R. B., Lo Ciganic W. H., Murphy M. A., Goode E. L., Poole E. M., Brinton L. A., Webb P. M., Nagle C. M., Jordan S. J., Australian Ovarian Cancer Study Group Australian Cancer Study, Risch H. A., Rossing M. A., Doherty J. A., Goodman M. T., Lurie G., Kjaer S. K., Hogdall E., Jensen A., Cramer D. W., Terry K. L., Vitonis A., Bandera E. V., Olson S., King M. G., Chandran U., Anton Culver H., Zogas A., Menon U., Gayther S. A., Ramus S. J., Gentry Maharaj A., Wu A. H., Pearce C. L., Pike M. C., Berchuck A., Schildkraut J. M., Wentzensen N. and Ovarian Cancer Association Consortium.** Aspirin nonaspirin nonsteroidal anti inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. *JOURNAL OF THE NATIONAL CANCER INSTITUTE* 2014 [106(2): djt431]

**Tran B., Armstrong B. K., Ebeling P. R., English D. R., Kimlin M. G., van der Pols J. C., Venn A., GebSKI V., Whitman D. C., Webb P. M. and Neale R. E.** Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. *AMERICAN JOURNAL OF CLINICAL NUTRITION* 2014 [99(1): 156 61]

**Travers C., Byrne G. J., Pachana N. A., Klein K. and Gray L. C.** Prospective observational study of dementia in older patients admitted to acute hospitals. *AUSTRALASIAN JOURNAL ON AGEING* 2014 [33(1): 55 8]

**Tribolet L, Cantacessi C, Pickering DA, Navarro S, Doolan DL, Trieu A, Fei H, Chao Y, Hofmann A, Gasser RB, Giacomini PR, Loukas A.** Probing of a human proteome microarray with a recombinant pathogen protein reveals a novel mechanism by which hookworms suppress B cell receptor signaling. *J INFECT DIS* 2014 [211(3): 416 425]

**Tungatt, K., Bianchi, V., Crowther, M.D., Powell, W.E., Schauenburg, A.J., Trimby, A., Donia, M., Miles, J.J., Holland, C.J., Cole, D.K., Godkin, A.J., Peakman, M., Straten, P.T., Svane, I.M., Sewell, A.K. and Dolton, G.** Antibody Stabilization of Peptide MHC Multimers Reveals Functional T Cells Bearing Extremely Low Affinity TCRs. *J IMMUNOL.* 2015 [;]

**Udy A. A., Baptista J. P., Lim N. L., Joynt G. M., Jarrett P., Wockner L., Boots R. J. and Lipman J.** Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations\*. *CRITICAL CARE MEDICINE* 2014 [42(3): 520 7]

**Van Limbergen J., Radford Smith G. and Satsangi J.** Advances in IBD genetics. *NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY* 2014 [11(6): 372 85]

**Van den Berg SM de Moor MH, McGue M, Pettersson E, Terracciano A, Verweij KJ, Amin N, Derringer J, Esko T, Van Grootheest G, Hansell NK, Huffman J, Konte B, Lahti J, Luciano M, Matteson LK, Viktorin A, Wouda J, Agrawal A, Allik J, Bierut L, Broms U, Campbell H, Smith GD, Eriksson JG, Ferrucci L, Franke B, Fox JP, de Geus EJ, Giegling I, Gow AJ, Gruzca R, Hartmann AM, Heath AC, Heikkila K, Iacono WG, Janzing J, Jokela M, Kiemenev L, Lehtimaki T, Madden PA, Magnusson PK, Northstone K, Nutile T, Ouwens KG, Palotie A, Pattie A, Pesonen AK, Polasek O, Pulkkinen L, Pulkki Raback L, Raitakari OT, Realo A, Rose RJ, Ruggiero D, Seppala I, Slutske WS, smyth dc, Sorice R, Starr JM, Sutun AR, Tanaka T, Verhagen J, Vermeulen S, Vuoksimaa E, Widen E, Willemsen G, Wright MJ, Zgaga L, Rujescu D, Metspalu A, Wilson JF, Ciullo M, Hayward C, Rudan I, Deary IJ, Raikonen K, Arias**

**Vasquez A, Costa PT, Keltikangas Jarvinen L, van Duijn CM, Penninx BW, Krueger RF, Evans DM, Kaprio J, Pedersen NL, Martin NG, Boomsma DI.** Harmonization of Neuroticism and Extraversion phenotypes across inventories and cohorts in the Genetics of Personality Consortium: an application of Item Response Theory. *BEHAVIOR GENETICS* 2014 [44(4): 295 313]

**van Dongen Jenny, Jansen Rick, Smit Dirk, Hottenga Joke Jan, Mbarek Hamdi, Willemsen Gonneke, Kluff Cornelis, Penninx Brenda W. J., Ferreira Manuel A., Boomsma Dorret I., de Geus Eco J. C. and Collaborators AAGC.** The Contribution of the Functional IL6R Polymorphism rs2228145, eQTLs and Other Genome Wide SNPs to the Heritability of Plasma sIL 6R Levels. *BEHAVIOR GENETICS* 2014 [44(4): 368 382]

**Vinh T. Nguyen, Michael Breakspear, Ross Cunningham.** Fusing concurrent EEG-fMRI with dynamic causal modeling: application to effective connectivity during face perception. *NEUROIMAGE* 2014 [102(1): 60 70]

**von Scheidt B., Leung P. S., Yong M. C., Zhang Y., Towne J. E., Smyth M. J. and Teng M. W.** Combined anti CD40 and anti IL 23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. *CANCER RESEARCH* 2014 [74(9): 2412 21]

**Wadt K. A., Aoude L. G., Johansson P., Solinas A., Pritchard A., Crainic O., Andersen M. T., Kiilgaard J. F., Heegaard S., Sunde L., Federspiel B., Madore J., Thompson J. F., McCarthy S. W., Goodwin A., Tsao H., Jonsson G., Busam K., Gupta R., Trent J. M., Gerdes A. M., Brown K. M., Scolyer R. A. and Hayward N. K.** A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. *CLINICAL GENETICS* 2014 [;]

**Waldron M Grant JD, Bucholz KK, Lynskey MT, Slutske WS, Glowinski AL, Henders A, Statham DJ, Martin NG, Heath AC.** Parental separation and early substance involvement: Results from children of alcoholic and cannabis dependent twins. *DRUG AND ALCOHOL DEPENDENCE* 2014 [134: 78 84]

**Wallace D. F., Secondes E. S., Rishi G., Ostini L., McDonald C. J., Lane S. W., Vu T., Hooper J. D., Velasco G., Ramsay A. J., Lopez Otin C. and Subramaniam V. N.** A critical role for murine transferrin receptor 2 in erythropoiesis during iron restriction. *BR J HAEMATOL* 2014 [168(6): 891 901]

**Walton A. E., Janda M., Youl P. H., Baade P., Aitken J. F., Whiteman D. C., Gordon L. G. and Neale R. E.** Uptake of skin self examination and clinical examination behavior by outdoor workers. *ARCHIVES OF ENVIRONMENTAL & OCCUPATIONAL HEALTH* 2014 [69(4): 214 22]

**Wang H., Li J., Pu H., Hasan B., Ma J., Jones M. K., Zheng K., Zhang X., Ma H., McManus D. P., Lin R., Wen H. and Zhang W.** Echinococcus granulosus infection reduces airway inflammation of mice likely through enhancing IL 10 and down regulation of IL 5 and IL 17A. *PARASIT VECTORS* 2014 [7: 522]

**Wani Shivangi and Cloonan Nicole.** Profiling direct mRNA microRNA interactions using synthetic biotinylated microRNA duplexes. *BIORXIV* 2014 [: 005439]

**Ward A., Khanna K. K. and Wiegmanns A. P.** Targeting homologous recombination, new pre clinical and clinical therapeutic combinations inhibiting RAD51. *CANCER TREATMENT REVIEWS* 2014 [41(1): 35 45]

**Warren T. A., Panizza B., Porceddu S. V., Gandhi M., Patel P., Wood M., Nagle C. M. and Redmond M.** Outcomes after surgery and postoperative radiotherapy for perineural spread of head and neck cutaneous squamous cell carcinoma. *HEAD & NECK* 2014 [:]

**Warstadt NM Dennis EL, Jahanshad N, Kohannim O, Nir TM, McMahon KL, de Zubicaray GI, Montgomery GW, Henders AK, Martin NG, Whitfield JB, Jack CR Jr, Bernstein MA, Weiner MW, Toga AW, Wright MJ, Thompson PM, Alzheimer's Disease Neuroimaging Initiative (ADNI).** Serum cholesterol and variant in cholesterol related gene CETP predict white matter microstructure. *NEUROBIOLOGY OF AGING* 2014 [35(11): 2504 2013]

**Waterhouse M., Tran B., Armstrong B. K., Baxter C., Ebeling P. R., English D. R., GebSKI V., Hill C., Kimlin M. G., Lucas R. M., Venn A., Webb P. M., Whiteman D. C. and Neale R. E.** Environmental, personal and genetic determinants of response to vitamin D supplementation in older adults. *THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM* 2014 [99(7): E1332 40]

**Wei T., Li D., Marcial D., Khan M., Lin M. H., Snape N., Ghildyal R., Harrich D. and Spann K.** The Eukaryotic Elongation Factor 1A Is Critical for Genome Replication of the Paramyxovirus Respiratory Syncytial Virus. *PLOS ONE* 2014 [9(12): e114447]

**West A. C., Smyth M. J. and Johnstone R. W.** The anticancer effects of HDAC inhibitors require the immune system. *ONCOIMMUNOLOGY* 2014 [3(1): e27414]

**White Michael T., Lwetoijera Dickson, Marshall John, Caron Lormier Geoffrey, Bohan David A., Denholm Ian and Devine Gregor J.** Negative Cross Resistance Mediated by Co Treated Bed Nets: A Potential Means of Restoring Pyrethroid Susceptibility to Malaria Vectors. *PLOS ONE* 2014 [9(5): e95640]

**Whitehall V., Dumenil T., McKeone D., Bond C., Bettington M., Buttenshaw R., Bowdler L., Montgomery G., Wockner L. and Leggett B.** Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. *EPIGENETICS : OFFICIAL JOURNAL OF THE DNA METHYLATION SOCIETY* 2014 [9(11): 1454 60]

**Whiteman D. C., Baade P. D. and Olsen C. M.** More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. *THE JOURNAL OF INVESTIGATIVE DERMATOLOGY* 2014 [135(4): 1190 3]

**Whiteman D. C.** Does a prior diagnosis of Barrett's oesophagus influence risk of dying from oesophageal adenocarcinoma?. *GUT* 2014 [64(1): 5 6]

**Wiegmanns A. P., Al Ejeh F., Chee N., Yap P. Y., Gorski J. J., Da Silva L., Bolderson E., Chenevix Trench G., Anderson R., Simpson P. T., Lakhani S. R. and Khanna K. K.** Rad51 supports triple negative breast cancer metastasis. *ONCOTARGET* 2014 [5(10): 3261 72]

**Wikstrom M. E., Khong A., Fleming P., Kuns R., Hertzog P. J., Frazer I. H., Andoniou C. E., Hill G. R. and Degli Esposti M. A.** The early monocytic response to cytomegalovirus infection is MyD88 dependent but occurs independently of common inflammatory cytokine signals. *EUROPEAN JOURNAL OF IMMUNOLOGY* 2014 [44(2): 409 19]

**Winkler TW Day FR, Croteau Chonka DC, Wood AR, Locke AE, Magi R, Ferreira T, Fall T, Graff M, Justice AE, Luan J, Gustafsson S, Randall JC, Vedantam S, Workalemahu T, Kilpelainen TO, Scherag A, Esko T, Kutalik Z, Heid IM, Loos RJ, Genetic Investigation of Anthropometric Traits (GIANT) Consortium.** Quality control and conduct of genome wide association meta analyses. *NATURE PROTOCOLS* 2014 [9(5): 1192 1212]

**Winter C. D., Whyte T. R., Cardinal J., Rose S. E., O'Rourke P. K. and Kenny R. G.** Elevated plasma S100B levels in high altitude hypobaric hypoxia do not correlate with acute mountain sickness. *NEUROLOGICAL RESEARCH* 2014 [36(9): 779 85]

**Wockner L. F., Noble E. P., Lawford B. R., Young R. M., Morris C. P., Whitehall V. L. and Voisey J.** Genome wide DNA methylation analysis of human brain tissue from schizophrenia patients. *TRANSL PSYCHIATRY* 2014 [4: e339]

**Wood M. J., Gadd V. L., Powell L. W., Ramm G. A. and Clouston A. D.** Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. *HEPATOLOGY* 2014 [59(3): 848 57]

**Wood AR Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, Chu AY, Estrada K, Luan J, Kutalik Z, Amin N, Buchkovich ML, Croteau Chonka DC, Day FR, Duan Y, Fall T, Fehrmann R, Ferreira T, Jackson AU,**

- Karjalainen J, Lo KS, Locke AE, Magi R, Mihailov E, Porcu E, Randall JC, Scherag A, Vinkhuyzen AA, Westra HJ, Winkler TW, Workalemahu T, Zhao JH, Absher D, Albrecht E, Anderson D, Baron J, Beekman M, Demirkan A, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Fraser RM, Goel A, Gong J, Justice AE, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Lui JC, Mangino M, Leach IM, Medina Gomez C, Nalls MA, Nyholt DR, Palmer CD, Pasko D, Pechlivanis S, Prokopenko I, Ried JS, Ripke S, Shungin D, Stancakova A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, van Vliet Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Afzal U, Arnlöv J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Bluher M, Bolton JL, Bottcher Y, Boyd HA, Bruinenberg M, Buckley BM, Buyske S, Caspersen IH, Chines PS, Clarke R, Claudi Boehm S, Cooper M, Daw EW, De Jong PA, Deelen J, Delgado G, Denny JC, Dhonukshe Rutten R, Dimitriou M, Doney AS, Dorr M, Eklund N, Eury E, Folkersen L, Garcia ME, Geller F, Giedraitis V, Go AS, Grallert H, Grammer TB, Grassler J, Gronberg H, de Groot LC, Groves CJ, Haessler J, Hall P, Haller T, Hallmans G, Hannemann A, Hartman CA, Hassinen M, Hayward C, Heard Costa NL, Helmer Q, Hemani G, Henders AK, Hillege HL, Hlatky MA, Hoffmann W, Hoffmann P, Holmen O, Houwing Duistermaat JJ, Illig T, Isaacs A, James AL, Jeff J, Johansen B, Johansson A, Jolley J, Juliusdottir T, Junttila J, Kho AN, Kinnunen L, Klopp N, Kocher T, Kratzer W, Lichtner P, Lind L, Lindstrom J, Lobbens S, Lorentzon M, Lu Y, Lyssenko V, Magnusson PK, Mahajan A, Maillard M, McArdle WL, McKenzie CA, McLachlan S, McLaren PJ, Menni C, Merger S, Milani L, Moayyeri A, Monda KL, Morken MA, Muller G, Muller Nurasyid M, Musk AW, Narisu N, Nauck M, Nolte IM, Nothen MM, Oozageer L, Pilz S, Rayner NW, Renstrom F, Robertson NR, Rose LM, Roussel R, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Schunkert H, Scott RA, Sehmi J, Seufferlein T, Shi J, Silventoinen K, Smit JH, Smith AV, Smolonska J, Stanton AV, Stirrups K, Stott DJ, Stringham HM, Sundstrom J, Swertz MA, Syvanen AC, Tayo BO, Thorleifsson G, Tyrer JP, van Dijk S, van Schoor NM, van der Velde N, van Heemst D, van Oort FV, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Waldenberger M, Wennauer R, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Bergmann S, Biffar R, Blangero J, Boomsma DI, Bornstein SR, Bovet P, Brambilla P, Brown MJ, Campbell H, Caulfield MJ, Chakravarti A, Collins R, Collins FS, Crawford DC, Cupples LA, Danesh J, de Faire U, den Ruijter HM, Erbel R, Erdmann J, Eriksson JG, Farrall M, Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Gansevoort RT, Gejman PV, Gieger C, Golay A, Gottesman O, Gudnason V, Gyllenstein U, Haas DW, Hall AS, Harris TB, Hattersley AT, Heath AC, Hengstenberg C, Hicks AA, Hindorf LA, Hingorani AD, Hofman A, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Jacobs KB, Jarvelin MR, Jousilahti P, Jula AM, Kaprio J, Kastelein JJ, Kayser M, Kee F, Keinänen Kiukaanniemi SM, Kiemenev LA, Kooner JS, Kooperberg C, Koskinen S, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lupoli S, Madden PA, Mannisto S, Manunta P, Marette A, Matise TC, McKnight B, Meitinger T, Moll FL, Montgomery GW, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Ouwehand WH, Pasterkamp G, Peters A, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ritchie M, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Sebert S, Sever P, Shuldiner AR, Sinisalo J, Steinthorsdottir V, Stolk RP, Tardif JC, Tonjes A, Tremblay A, Tremoli E, Virtamo J, Vohl MC, The Electronic Medical Records and Genomics (eMERGE) Consortium, The MIGen Consortium, The PAGE Consortium, The LifeLines Cohort Study, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hayes MG, Hui J, Hunter DJ, Hveem K, Jukema JW, Kaplan RC, Kivimäki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Powell JE, Power C, Quertermous T, Rauramaa R, Reinmaa E, Ridker PM, Rivadeneira F, Rotter JI, Saaristo TE, Saleheen D, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Strauch K, Stumvoll M, Tuomilehto J, Uusitupa M, van der Harst P, Volzke H, Walker M, Wareham NJ, Watkins H, Wichmann HE, Wilson JF, Zanen P, Deloukas P, Heid IM, Lindgren CM, Mohlke KL, Speliotes EK, Thorsteinsdottir U, Barroso I, Fox CS, North KE, Strachan DP, Beckmann JS, Berndt SI, Boehnke M, Borecki IB, McCarthy MI, Metspalu A, Stefansson K, Uitterlinden AG, van Duijn CM, Franke L, Willer CJ, Price AL, Lettre G, Loos RJ, Weedon MN, Ingelsson E, O'Connell JR, Abecasis GR, Chasman DI, Goddard ME, Visscher PM, Hirschhorn JN, Frayling TM. Defining the role of common variation in the genomic and biological architecture of adult human height. *NATURE GENETICS* 2014 [46(11): 1173 1186]
- Wright E. K., Williams J., Andrews J. M., Day A. S., Geary R. B., Bampton P., Moore D., Lemberg D., Ravikumaran R., Wilson J., Lewindon P., Radford Smith G., Rosenbaum J., Catto Smith A., Desmond P. V., Connell W. R., Cameron D., Alex G., Bell S. J. and De Cruz P. Perspectives of paediatric and adult gastroenterologists on transfer and transition care of adolescents with inflammatory bowel disease. *INTERNAL MEDICINE JOURNAL* 2014 [44(5): 490 496]
- Xiang F., Lucas R., Hales S. and Neale R. Incidence of non-melanoma skin cancer in relation to ambient UV radiation in white populations, 1978 2012: empirical relationships. *JAMA DERMATOLOGY* 2014 [150(10): 1063 71]
- Yang Qi, Michael Breakspear, Pulin Ging. Subdiffusive Dynamics of Bump Attractors: Mechanisms and Functional Roles. *NEURAL COMPUTATION* 2015 [27(2): 255 280]

**You H. and McManus D. P.**

Vaccines and diagnostics for zoonotic schistosomiasis japonica. *PARASITOLOGY* 2014 [142(2): 271 89]

**You H., Stephenson R. J., Gobert G. N. and McManus D. P.**

Revisiting glucose uptake and metabolism in schistosomes: new molecular insights for improved schistosomiasis therapies. *FRONT GENET* 2014 [5: 176]

**Young R. J., Waldeck K., Martin C., Foo J. H., Cameron D. P., Kirby L., Do H., Mitchell C., Cullinane C., Liu W., Fox S. B., Dutton Regester K., Hayward N. K., Jene N., Dobrovic A., Pearson R. B., Christensen J. G., Randolph S., McArthur G. A. and Sheppard K. E.**

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. *PIGMENT CELL & MELANOMA RESEARCH* 2014 [27(4): 590 600]

**Young A., Mittal D., Stagg J. and Smyth M. J.**

Targeting cancer derived adenosine: new therapeutic approaches. *CANCER DISCOVERY* 2014 [4(8): 879 88]

**Young A., Mittal D., Stannard K., Yong M., Teng M. W., Allard B., Stagg J., Smyth M. J.** Co blockade of immune checkpoints and adenosine: A receptor suppresses metastasis. *ONCOIMMUNOLOGY* 2014 [3(10):]

**Zafar A., Wu F., Hardy K., Li J., Tu W. J., McCuaig R., Harris J., Khanna K. K., Attema J., Gregory P. A., Goodall G. J., Harrington K., Dahlstrom J. E., Boulding T., Madden R., Tan A., Milburn P. J. and Rao S.** Chromatinized protein kinase C theta directly regulates inducible genes in epithelial to mesenchymal transition and breast cancer stem cells. *MOLECULAR AND CELLULAR BIOLOGY* 2014 [34(16): 2961 80]

**Zalesky A., Fornito A., Cocchi, L.**

**Gollo, L. L. Breakspear, M.** Time resolved resting state brain networks. *PROC NATL ACAD SCI U S A* 2014 [111(28): 10341 6]

**Zhang W., Wang S. and McManus D.**

P. Echinococcus granulosus genomics: a new dawn for improved diagnosis, treatment, and control of echinococcosis. *PARASITE* 2014 [21: 66]

**Zhang W., Zhang Z., Wu W., Shi B., Li J., Zhou X., Wen H. and McManus D. P.**

Epidemiology and control of echinococcosis in central Asia, with particular reference to the People's Republic of China. *ACTA TROP* 2014 [141(Pt B): 235 43]

**Zhao H., Thienpont B., Yesilyurt B. T., Moisse M., Reumers J., Coenegrachts L., Sagaert X., Schrauwen S., Smeets D., Matthijs G., Aerts S., Cools J., Metcalf A., Spurdle A., Amant F. and Lambrechts D.** Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double strand breaks. *ELIFE* 2014 [3: e02725]



# COMPLIANCE CHECKLIST

Summary of requirement	Basis for requirement	Annual report reference	
Letter of compliance	A letter of compliance from the accountable officer or statutory body to the relevant Minister/s	ARRs – section 8	Page 2
Accessibility	Table of contents Glossary	ARRs – section 10.1	Page 1 Page 169
	Public availability	ARRs – section 10.2	Back cover
	Interpreter service statement	Queensland Government Language Services Policy ARRs – section 10.3	Back cover
	Copyright notice	Copyright Act 1968 ARRs – section 10.4	Back cover
	Information Licensing	QGEA – Information Licensing ARRs – section 10.5	n/a
General information	Introductory Information	ARRs – section 11.1	Page 9
	Agency role and main functions	ARRs – section 11.2	Page 9
	Operating environment	ARRs – section 11.3	Page 9
	Machinery of government changes	ARRs – section 11.4	n/a
Non-financial performance	Government's objectives for the community	ARRs – section 12.1	Page 25
	Other whole-of-government plans/specific initiatives	ARRs – section 12.2	n/a
	Agency objectives and performance indicators	ARRs – section 12.3	Page 26
	Agency service areas and service standards	ARRs – section 12.4	*
Financial performance	Summary of financial performance	ARRs – section 13.1	Page 58
Governance – management and structure	Organisational structure	ARRs – section 14.1	Page 20
	Executive management	ARRs – section 14.2	Page 19
	Government bodies (statutory bodies and other entities)	ARRs – section 14.3	n/a
	Public Sector Ethics Act 1994	Public Sector Ethics Act 1994 ARRs – section 14.4	Page 57
Governance – risk management and accountability	Risk management	ARRs – section 15.1	Page 18
	External scrutiny	ARRs – section 15.2	Page 57
	Audit committee	ARRs – section 15.3	Page 16
	Internal audit	ARRs – section 15.4	Page 18
	Information systems and recordkeeping	ARRs – section 15.5	Page 57
Governance – human resources	Workforce planning and performance	ARRs – section 16.1	Page 22
	Early retirement, redundancy and retrenchment	Directive No.11/12 Early Retirement, Redundancy and Retrenchment ARRs – section 16.2	n/a
Open Data	Consultancies	ARRs – section 17 ARRs – section 34.1	Page 57
	Overseas travel	ARRs – section 17 ARRs – section 34.2	Page 57
	Queensland Language Services Policy	ARRs – section 17 ARRs – section 34.3	n/a
	Government bodies	ARRs – section 17 ARRs – section 34.4	n/a

## Compliance checklist continued

Summary of requirement	Basis for requirement	Annual report reference	
Financial statements	Certification of financial statements	FAA – section 62 FPMS – sections 42, 43 and 50 ARRs – section 18.1	Page 93
	Independent Auditors Report	FAA – section 62 FPMS – section 50 ARRs – section 18.2	Page 94
	Remuneration disclosures	Financial Reporting Requirements for Queensland Government Agencies ARRs – section 18.3	Page 84

1. FAA Financial Accountability Act 2009 FPMS *Financial and Performance Management Standard 2009*

2. ARRs *Annual report requirements for Queensland Government agencies*

\*Please note, QIMR Berghofer has not reported on service areas and service standards on their service delivery statement, instead refer to page 26 for performance indicators relevant to QIMR Berghofer's strategic plan.

# GLOSSARY

(Hons)	With Honours degree
AC	Companion of the Order of Australia
AID	Australian Infectious Diseases Research Centre
AMA	Australian Medical Association
AML	Acute myeloid leukaemia
ANZGOG	Australia New Zealand Gynaecological Oncology Group
APC	Antigen presenting cells
APGI	Australian Pancreatic Cancer Genome Initiative
ARC	Australian Research Council
ASHG	American Society for Human Genetics
ASMR	Australian Society for Medical Research
ASMTM	The American Society of Tropical Medicine and Hygiene
ATCM	Australian College of Tropical Medicine
BEACON	Barrett's and Esophageal Adenocarcinoma Consortium
CCQ	Cancer Council Queensland
CF	Cystic fibrosis
CMV	Cytomegalovirus
DNA	Deoxyribonucleic acid
EBV	Epstein-Barr virus
EMBL	European Molecular Biology Laboratory
EMBO	European Molecular Biology Organization
FCA	Fellow of The Institute of Chartered Accountants in Australia
FIMSA	Federation of Immunological Societies of Asia-Oceania
FTE	Full time equivalent
GMP	Good manufacturing practice
GVHD	Graft versus host disease
GVL	Graft versus leukaemia
GWAS	Genome wide association studies
HAA	Haematology Society of Australia and New Zealand, the Australian and New Zealand Society of Blood Transfusion and the Australasian Society of Thrombosis and Haemostasis
HIRF	Herston Imaging Research Facility
HIV	Human immunodeficiency virus
HNSCC	Head and neck: squamous cell carcinoma
HPV	Human Papillomavirus
Hon	Honorary (degree)
ICON	International Conference on Cognitive Neuroscience
IGCS	International Gynecologic Cancer Society (
IHBI	Institute of Health and Biomedical Innovation
IMB	Institute of Molecular Bioscience

JCU	James Cook University
LLB	Bachelor of Laws
MA	Master of Arts
MAICD	Member of the Australian Institute of Company Directors
MBus	Master of Business
MND	Motor Neurone Disease
MPhil	Master of Philosophy
MPN	Myeloproliferative neoplasms
MSc	Master of Science
NCBS	National Centre for Biological Sciences
NCI	National Cancer Institute
NDLR	New Directions in Leukaemia Research
NHMRC	National Health and Medical Research Council
NIH	National Institutes of Health
NPC	Nasopharyngeal Carcinoma
OBE	Order of the British Empire
OCNS	Organization for Computational Neurosciences
OPAL	Ovarian Cancer Prognosis And Lifestyle
PhD	Doctor of Philosophy
QTHA	Queensland Tropical Health Alliance
QUT	Queensland University of Technology
RBWH	Royal Brisbane and Women's Hospital
RNA	Ribonucleic acid
RSV	Respiratory syncytial virus
TPCH	The Prince Charles Hospital
UCSF	University of California (San Francisco)
UQ	The University of Queensland
UQCCR	University of Queensland Centre for Clinical Research
WEHI	Walter and Eliza Hall Institute
WHO	World Health Organization



**QIMR Berghofer**  
Medical Research Institute

Copies of this annual report are available on QIMR Berghofer's website at [www.qimrberghofer.edu.au/annualreport](http://www.qimrberghofer.edu.au/annualreport) and by contacting QIMR Berghofer on (07) 3362 0222, freecall 1800 993 000 or [enquiries@qimrberghofer.edu.au](mailto:enquiries@qimrberghofer.edu.au).

QIMR Berghofer Medical Research Institute  
300 Herston Road, Herston  
Queensland, Australia 4006  
T: +61 7 3362 0222  
F: +61 7 3362 0102  
W: [www.qimrberghofer.edu.au](http://www.qimrberghofer.edu.au)

QIMR Berghofer is committed to providing accessible services to people from culturally and linguistically diverse backgrounds. If you have difficulty in understanding the annual report, you can contact us on (07) 3362 0222 and the Institute will arrange an interpreter to communicate the report to you.  
ISSN 1839 – 1877

© QIMR Berghofer Medical Research Institute 2015

